Studies on cathepsin B of Eimeria tenella and pyroglutamyl peptidase of Leishmania major by Schaeffer, Marie
Studies  on  cathepsin  B  of  Eimeria  tenella  and 
pyroglutamyl  peptidase  of  Leishmania  major 
Marie  Schaeffer 
Division  of  Infection  and  Immunity 
Institute  of  Biomedical  and  Life  Sciences 
This  thesis  is  submitted  for  the  degree  of  Doctor  of  Philosophy 
Faculty  of  Biomedical  and  Life  Sciences 
University  of  Glasgow 
March  2005 Abstract 
Proteolytic  enzymes  play  important  roles  in  parasitic  protozoa,  including 
the  organisms  responsible  for  malaria,  leishmaniasis  and  trypanosomiasis. 
Cysteine  peptidases  have  attracted  particular  attention  over  recent  years  as 
some  have  been  reported  to  play  key  roles  in  host-parasite  interactions  and 
virulence,  and  may  constitute  promising  targets  for  new  selective  inhibitors  and 
anti-parasite  agents. 
The  obligate  intracellular  protozoan  parasite  Eimeria  (mainly  E.  tenella) 
belonging  to  the  subclass  of  Coccidia  (with  other  parasites  such  as  Toxoplasma 
and  Cryptosporidium),  is  responsible  for  coccidiosis,  which  inflicts  a  serious 
economical  burden  to  the  poultry  industry.  Invasion  of  host  cells  by  Smelia 
involves  the  regulated  release  from  specialised  secretory  organelles  forming  the 
apical  complex,  whose  proteins'  maturation,  trafficking  and  secretion  rely  on 
proteolytic  processing.  A  sequence  encoding  a  cathepsin  B-like  cysteine 
peptidase  of  the  clan  CA,  family  C1  was  identified  in  the  genome  database  of  E. 
tenella.  The  sequence  corresponded  to  a  single  copy  gene,  and  did  not  carry  any 
introns. 
The  E  tenella  enzyme,  sharing  42%  identity  with  the  Toxoplasma  gondfi 
toxopain-1,  which  is  reportedly  involved  in  the  invasion  of  host  cells,  was 
expressed  as  a  soluble  inactive  zymogen  in  E.  coli.  Recombinant  cathepsin  B  of 
E.  tenella  was  functionally  expressed  as  a  mature  enzyme  in  the  Pichia  pastoris 
inducible  system  as  a  glycosylated  protein,  but  the  glycosylations  did  not 
apparently  affect  the  enzyme's  activity.  The  biochemical  characteristics  of  the 
recombinant  enzyme  were  consistent  with  what  has  been  reported  in  the 
literature  for  cathepsin  Bs.  The  cathepsin  B  of  E.  tenella  was  detected  in  oocyst 
and  sporozoite  extracts,  and,  more  specifically,  in  microneme  preparations.  In 
the  sexual  stages,  the  enzyme  localised  to  mature  macrogametes  in  discrete 
granules,  the  size  and  location  of  which  suggest  that  they  are  wall-forming 
bodies,  organelles  involved  in  the  oocyst  wall  formation  in  Eimeria.  These  data 
suggest  that  the  cathepsin  B  may  play  roles  in  both  cell  invasion  by  sporozoites 
and  the  formation  of  the  protective  wall  of  the  oocyst. The  genus  Leishmania  belongs  to  the  family  Trypanosomatidae,  which 
includes  the  Trypanosoma  species,  and  is  the  cause  of  leishmaniasis,  which 
affects  2  million  people  and  causes  about  60000  deaths  a  year.  Many  peptidases 
encoded  by  the  Leishmania  genome  are  cysteine  peptidases,  some  of  which 
have  been  identified  as  important  virulence  factors,  and  therefore  potential  drug 
targets.  Pyroglutamyl  peptidases  I  (PPI)  are  cysteine  peptidases  of  the  clan  CF, 
family  C15,  which  hydrolyse  N-terminal  L-pyroglutamate  (pGlu)  residues.  The 
pGlu  modification  is  a  post-transcriptional  modification  catalysed  by  the 
glutaminyl  cyclase  in  human  that  confers  relative  aminopeptidase  resistance  and, 
in  some  cases,  is  essential  to  the  modified  peptides'  activity.  PPIs  have  been 
identified  in  a  variety  of  organisms  but  no  definitive  biological  function  has  been 
attributed  to  them. 
A  single  copy  gene  encoding  a  PPI  was  identified  in  the  genome  database 
of  L.  major.  Active  recombinant  enzyme  was  successfully  produced  in  E  coli, 
and  its  biochemical  properties  coincided  with  those  of  mammalian  PPls.  The 
active  site  catalytic  triad  E101,  C210,  and  H234  (L.  major  PPI  numbering)  was 
confirmed  by  mutagenesis.  The  PPI  activity  was  detected  in  L.  major 
promastigotes,  and  the  enzyme  localised  to  the  parasite  cytoplasm.  PPi  knock- 
out  mutants  were  generated,  and  knock-out  of  the  PPI  activity  did  not  seem  to 
induce  a  phenotype  in  L.  major.  The  parasites  retained  the  properties  in  vivo  and 
in  vitro  of  L.  majorwild  type  cells.  The  over-expression  of  the  active  PPI  in  L. 
major  promastigotes  seemed  to  impair  metacyclogenesis  and  in  vivo  infectivity, 
while  the  over-expression  of  the  C210A  mutant  did  not  have  any  detrimental 
effect.  Susceptibility  to  a  natural  pGlu  modified  anti-microbial  peptide,  gomesin, 
was  tested  on  the  different  cell  lines,  which  were  all  equally  susceptible.  The  data 
suggest  that  pGlu-modified  peptides  in  L.  major  might  be  required  for 
metacyclogenesis  and  modulation  of  the  immune  response  in  the  host. Acknowledgments 
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Chapter  I 
General  introduction 
Proteolytic  enzymes  seem  to  play  important  roles  in  parasitic  protozoa, 
including  the  organisms  responsible  for  malaria,  leishmaniasis  and 
trypanosomiasis.  Cysteine  peptidases  have  attracted  particular  attention  over 
recent  years  and  have  been  the  subject  of  extensive  studies  because  of  their 
importance  in  parasite  survival,  interaction  with  the  host  cells  and  pathogenicity 
(McKerrow,  1993;  Rosenthal,  1999;  Klemba  and  Goldberg,  2002).  Despite  the 
progress  in  combating  infectious  diseases  and  the  constant  search  for  new  drugs 
or  treatments,  some  parasites  still  inflict  a  dramatic  social  and  economical  burden 
to  tropical  or  sub-tropical  regions  of  the  world  (human  and  animal  infections),  as 
well  as  to  developed  societies  (in  particular  with  the  development  of  intensive 
husbandry  of  domestic  animals  enhancing  transmission  of  parasites). 
The  protozoan  parasite  Eimeria  (mainly  E.  tenella),  belonging  to  the 
subclass  of  Coccidia  (with  other  parasites  such  as  Toxoplasma  and 
Cryptosporidium),  is  responsible  for  coccidiosis,  which  is  a  serious  problem  in  the 
poultry  industry.  Worldwide  expenditures  just  for  anti-coccidiodial  drugs  added  to 
feed  is  estimated  to  be  $250  to  $300  millions  annually  and  there  is  a  rising 
problem  of  parasites  becoming  resistant  to  these  coccidiostats 
(www.  antecint.  co.  uk/main/oocide.  htm).  Also,  the  intensive  use  of  drugs  in  farm 
animals  raises  public  health  concerns,  as  about  4%  of  eggs  and  10%  of  chicken 
liver  tested  in  the  UK  in  2003  contained  residues  of  coccidiostats 
(hftp:  //research.  utu.  fi/residues/).  In  December  1998,  the  European  Union  banned 
the  use  of  four,  widely  used  growth-promoting  antibiotics  used  in  aviary 
production,  due  to  public  concern  that  antibiotic  residues  in  meat  could  lead  to 
antibiotic  resistance  in  humans.  The  ban  may  be  broadened  to  more  in-feed 
drugs  within  the  next  5  years.  Coccidiosis  is  not  limited  to  the  poultry  industry  and 
some  Eimefia  species  can  also  affect  cattle,  sheeps  and  pigs,  which  constitutes  a 
potential  threat  for  other  intensive  livestock  industries.  There  is,  therefore,  an 
increasing  economic  need  to  develop  efficient  new  methods  of  prevention  and 
treatment  of  coccidiosis.  The  interest  in  cysteine  peptidases  has  been  supported 
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by  the  fact  that  some  of  them  seem  to  be  promising  targets  for  new  selective 
inhibitors  and  anti-parasite  agents  (Selzer  et  aL,  1997;  Rosenthal,  1999). 
The  species  of  Leishmania  parasites,  belonging  to  the  family  for 
Trypanosomatidae  (together  with  the  species  of  Trypanosoma),  are  responsible 
for  leishmaniasis  diseases,  varying  in  severity  of  symptoms  depending  on  the 
species  contracted.  It  affects  a  variety  of  mammalian  hosts,  and  it  is  believed  that 
12  million  people  are  affected  in  the  world,  and  potentially  350  million  people  are 
at  risk  of  being  infected.  In  developed  countries,  leishmaniasis  has  been  on  the 
increase  as  an  opportunistic  disease  in  immuno-deficient  patients,  infected  with 
the  human  immunodeficiency  virus  (HIV).  Treatment  of  the  disease  mainly  relies 
upon  the  use  of  pentavalent  antimonials,  drugs  that  have  been  used  since  the 
1940's.  Because  of  the  length  of  time  the  drugs  have  been  used  and  sometimes 
inappropriate  dosage,  parasites  have  been  developing  resistance  to  these  drugs, 
making  them  less  and  less  effective  (Ouellette  and  Papadopoulou,  1993).  In  the 
state  of  Bihar  in-  northwestern  India,  unresponsiveness  to  pentavalent  antimonials 
has  increased  from  34  to  64%  between  1994  and  1997  (Thakur  et  al.,  1998). 
Though  other  means  of  treatment  exist,  most  of  them  are  very  expensive  and 
have  severe  side  effects.  Despite  constant  efforts  to  develop  new  drugs,  very  few 
are  getting  to  an  advanced  stage  in  chemotherapy  trials,  and  complexity  of  the 
immune  response  generated  by  Leishmania  infections  has  meant  that  no  vaccine 
has  been  developed  so  far  (Croft  and  Coombs,  2003).  Available  chemotherapy 
being  inadequate  and  expensive,  there  is  an  urgent  need  to  develop  new  and 
better  drugs.  Interest  has  been  brought  to  cysteine  peptidases  of  Leishmania  as 
potential  drug  targets,  as  some  of  them  have  been  shown  to  be  important 
virulence  factors  (Mottram  et  al.,  2004). 
1.1.  Pepticlases:  generalities 
Peptidases  (also  termed  proteases  or  proteinases)  catalyse  the  cleavage  of 
peptide  bonds  in  proteins  or  oligomeric  peptides,  either  within  the  polypeptide 
chain  (endopeptidase  activity)  or  from  amino  or  carboxyl  ends  (exopeptidase 
activity).  Proteolytic  enzymes  are  numerous  and  diverse;  they  represent  about 
2%  of  all  gene  products  (Rawlings  and  Barrett,  1999)  and  range  from  monomers 
of  10  kDa  to  multimeric  complexes  of  several  hundred  kDa.  The  location  of  the 
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scissile  bond  in  the  peptidic  chain  and  the  preferred  amino  acid  sequence  around 
it  differ  between  individual  peptidases,  but  this  could  not  be  used  to  establish  a 
comprehensive  classification  system  (Rawlings  and  Barrett,  1999).  In  1960, 
Hartley  suggested  dividing  peptidases  into  groups  depending  on  the  catalytic 
mechanism  used  (McDonald,  1995).  Five  main  catalytic  types  could  be 
recognised  based  on  the  active  site  residue  that  provides  the  nucleophilic  attack 
during  the  catalytic  reaction.  They  are  now  known  as  serine,  aspartic,  metallo-, 
cysteine,  and  threonine  peptidases.  Serine,  threonine  and  cysteine  peptidases 
effect  catalysis  after  formation  of  a  tetrahedral  transition  intermediate,  whereas 
aspartate  peptidases  and  metallopeptidases  require  the  intervention  of  a 
molecule  of  water  for  cleavage.  In  the  early  1990s,  with  the  increase  of  data  on 
primary  sequences  of  proteins  and  three-dimensional  structures  of  peptidases, 
Rawlings  and  Barrett  began  to  bring  together  sets  of  peptidases  that  were  similar 
both  in  molecular  structures  and  in  evolutionary  origin  to  create  the  MEROPS 
database  (Rawlings  et  a/.,  2002;  www.  merops.  co.  uk).  This  emphasises  the 
growing  interest  in  peptidases  and  the  wealth  of  resources  now  available. 
Serine  peptidases  have  a  catalytic  triad  involving  serine,  aspartate  and 
histidine  (Rawlings  and  Barrett,  1994).  They  are  divided  into  two  groups  in 
eukaryotes:  regulatory  peptidases  with  strict  specificity  and  digestive  enzymes 
with  broader  specificity,  such  as  trypsin  and  chymotrypsin  for  example.  in 
aspartic  peptidases,  2  aspartates  are  involved  in  the  catalytic  process  (Rawlings 
and  Barrett,  1995b).  Among  eukaryotic  aspartic  peptidases,  digestive  enzymes 
and  regulatory  peptidases  can  be  found  as  well  as  intracellular  acid  peptidases. 
Metallo-peptidases  constitute  a  vast  group  of  enzymes  involving  a  metallic  ion 
(zinc  in  most  cases)  in  the  catalytic  process  (Rawlings  and  Barrett,  1995a). 
Examples  of  metal  lo-peptidases  are  matrix  degradation  enzymes  such  as 
elastases,  and  regulatory  peptidases.  Some  enzymes  utilize  a  catalytic  threonine 
for  cleavage  (Seemueller  et  al.,  1995)  and  other  cryptic  proteases  may  also  exist 
(Sajid  and  McKerrow,  2002).  Based  on  the  fact  that  the  majority  of  peptidases 
described  so  far  in  parasitic  protozoa  are  of  the  cysteine  class,  the  main  focus  of 
this  review  will  be  put  on  this  type  of  proteolytic  enzyme  and  they  will  be  treated 
independently. 
Although  a  single  peptide  bond  is  cleaved  during  one  catalytic  reaction, 
the  flanking  amino  acids  in  the  substrate  protein  play  a  role  in  determining 
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peptidase  specificity,  as  do  the  sequences  flanking  the  catalytic  amino  acid 
residues  on  the  peptidase.  The  convention  used  to  identify  substrate  residues 
and  binding  pocket  amino  acids  on  the  peptidases  was  elaborated  by  Schlechter 
and  Berger  in  1967.  The  substrate  residues  are  designated  as  P,  and  the 
corresponding  sites  on  the  enzyme,  as  S.  Prime  residues  are  located  on  the  C- 
terminal  side  of  the  cleavage  site,  whereas  non-prime  residues  are  on  the  N- 
terminal  side.  Thus,  a  five  residue  substrate  site  cleaved  between  the  third  and 
the  fourth  amino  acid  would  be  P3-P2-Pl-P'l-P'2.  Sequences  that  directly  flank 
the  active  site  residues  are  often  very  conserved  and  play  a  role  in  the  enzymatic 
specificity  and  substrate  binding,  along  with  helping  to  determine  the  chemical 
environment.  Specificity  strictness  varies  from  one  enzyme  another;  usually 
several  peptide  bonds  are  hydrolysed  by  the  same  peptidase,  but  sometimes 
only  one  specific  bond  is  cleaved,  provided  they  fulfil  certain  sequence  or 
conformational  requirements.  The  substrate  specificity  of  an  enzyme  often  gives 
good  indication  on  the  enzyme's  biological  role  and  importance,  although  it  can 
vary  between  in  vitro  and  in  vivo  conditions. 
1.1.1.  Cystelne  peptidases 
Classification 
The  first  cysteine  peptidase  was  purified  in  1879  from  the  papaya  fruit 
Carica,  papaya  and  named  papain.  The  first  crystallographic  structure  of  a 
cysteine  peptidase  was  also  obtained  using  papain  (Drenth  et  aL,  1968).  Various 
cysteine  peptidases  have  been  identified  since  from  a  wide  variety  of  eukaryotic 
organisms  and  the  major  mammalian  peptidase  have  been  designated 
cathepsins  B,  H,  K,  L,  and  S.  All  of  the  mammalian  lysosomal  cysteine 
peptidases  are  known  as  cathepsins,  the  major  ones  being  cathepsins  B  and  L, 
but  not  all  cathepsins  are  cysteine  peptidases.  For  instance,  cathepsins  D  and  E 
are  aspartic  peptidases,  and  cathepsins  A  and  G  are  serine  peptidases  (Barrett 
and  McDonald,  1985).  Cysteine  peptidases  are  grouped  into  clans  (Barrett, 
1994),  further  divided  into  families  depending  on  sequence  similarities  and 
substrate  specificities  (Fig.  1.1).  The  main  focus  of  my  studies  will  be  on  clan  CA, 
family  C1  cysteine  peptidases. 
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Clan  CD  (H,  Q 
Clan  CE  (H,  E/D,  C)  Clan  PC  (C) 
Legumain-like  Clan  CF  (E,  C,  H) 
Clan  PB(C)  (C) 
Clan  CH  (C,  T,  H) 
Clan  PA(C)  (H,  D,  C)  Cysteine  peptidase 
[EC.  3.4.22.  XX] 
Clan  CX  (unassigned) 
Clan  CL 
Clan  CA  (C,  H,  NAD) 
Papain-like 
Papain-family 
Cathepsin  L-like 
(fam  C  1) 
Cathepsin  B-like 
subfamily  subfamily 
Bleomycin-hydrolase 
subfamily 
FIG.  1.1.  Cysteine  peptidase  superfamily.  Classification  in  subfamilies  was  based  on 
amino  acid  sequence  around  the  active  site  (see  Sajid  and  McKerrow,  2002).  Clans  are  indicated 
in  bold  and  the  amino  acids  (in  parentheses)  show  the  order  of  the  catalytic  residues  in  the  linear 
polypeptide  sequence  (Mottrarn  et  aL,  2003). 
Although  cysteine  peptidase's  main  role  is  in  protein  degradation,  the 
multiplicity  and  apparent  redundancy  of  the  clan  CA  enzymes  makes  the 
discovery  of  their  individual  functions  rather  difficult.  This  is  less  the  case  for  clan 
CD  enzymes,  whose  specificity  of  functions  seem  much  greater  (Mottram  et  aL, 
2003).  Nevertheless,  the  recent  progresses  in  genetic  knockouts  have  enabled  a 
better  insight  into  the  function  of  cysteine  peptidases  and  proved  that  they  are 
less  redundant  than  was  thought.  Cathepsin  K  in  mammals,  for  example,  has 
been  demonstrated  to  be  essential  for  bone  remodeling  (Chapman  et  aL,  1997) 
and  linked  to  the  genetic  disorder  pycnodysostosis  (Gelb  et  aL,  1996).  Some 
other  cysteine  peptidases  are  implicated  in  tumour  invasion  (Duffy,  1992)  and 
arthritis  (Trabandt  et  aL,  1990).  Therefore,  they  have  attracted  increasing  interest 
in  the  recent  years  as  targets  for  human  therapy,  in  particular  in  terms  of 
research  for  new  anti-cancer  drugs. 
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1.1.1.2.  Catalytic  mechanism  (Clan  CA,  family  CI) 
Cysteine  peptidases  have  also  been  referred  as  thiol  or  sulfhydryl 
peptidases.  The  catalytic  mechanism  of  cysteine  peptidases  is  close  to  those  of 
serine  peptidases  with  a  nucleophile  property  conferred  by  the  thiol  group.  This 
nucleophilic  behaviour  is  further  enhanced  by  the  presence  of  an  active  site 
histidine,  which  acts  as  a  proton  acceptor.  The  '-SH'  group  of  the  cysteine  side 
chain  forms  a  thiolate-imidazoliurn  -S"'HN=  group  with  the  imidazole  group  of 
the  histidine  (Polgar,  2004).  The  delocalised  electron  cloud  over  the  thiolate- 
imidazolium  group  constitutes  a  charge  relay  diad,  which  allows  an  enzymatic 
activity  within  a  pH  range  from  around  4.0  (pK.  of  cysteine)  to  8.5  (pKa  of 
histidine),  and  is  often  stabilised  by  a  highly  conserved  asparagine  and  the 
chemical  environment  of  the  catalytic  reaction  (pH,  ionic  force).  After  formation  of 
the  transient  catalytic  thiol-ester  tetrahedral  intermediate  between  the  enzyme 
and  the  substrate,  the  peptidase  returns  to  an  active  enzyme  state.  As  many  as 
one  million  peptide  bonds  per  second  can  be  degraded  with  such  a  mechanism. 
1.1.1.3.  Structure  and  specificity 
The  majority  of  family  C1  cysteine  peptidases  are  synthesised  as 
immature  precursors  or  zymogens,  with  a  pro-domain  and,  sometimes,  a 
carboxy-terminal  extension.  These  are  cleaved  in  an  endogenous  or  exogenous 
manner  to  lead  to  the  mature  catalytic  enzyme.  The  activation  is  a  regulated 
process  involving  the  proteolytic  cleavage  of  the  N-terminal  pro-peptide  in  a  pre- 
lysosomal  compartment  and  release  of  this  pro-region,  which  acts  as  self- 
inhibitor.  The  pro-regions  are  tightly  bound  to  the  catalytic  cleft  and  block  access 
to  the  active  site  (Cygler  et  aL,  1996)  to  maintain  the  peptidase  in  an  inactive 
form  during  trafficking  to  the  lysosome.  The  pro-region  can  also  contain  folding 
information  for  the  enzyme  (Pandey  et  aL,  2004).  Final  activation  can  by 
facilitated  by  decreasing  the  pH  (Turk  et  aL,  2000)  and  this  is  favoured  in  the 
acidic  pH  environment  of  the  lysosome.  Most  of  the  mature  forms  are  monomeric 
(with  the  exception  of  the  tetrameric  cathepsin  C)  with  a  molecular  mass  ranging 
from  20  to  30  kDa  (without  the  pro-region  of  approximately  60  to  100  amino 
acids).  Most  of  the  enzymes  are  endopeptidases,  although  cathepsins  B  and  H 
also  exhibit  exopeptidase  activity  (Barrett  and  Rawlings,  2001).  Although  most 
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cysteine  peptidases  are  located  in  lysosomes  or  lysosome-like  organelles,  some 
can  also  be  located  on  the  cell  surface  or  secreted  (Robertson  et  al.,  1996). 
Trafficking  of  the  mammalian  peptidases  requires  glycosylation  and  mannose-6- 
phosphate  residue  recognition  by  the  mannose-6-phosphate  receptor  (Kornfeld 
and  Mellman,  1989).  An  alternative  mechanism  involves  transmembrane 
receptors  (McIntyre  and  Erickson,  1993). 
Some  detailed  analysis  of  the  substrate  binding  sites  have  been 
performed,  in  particular  on  papain  (Turk  et  aL,  1998),  and  shown  that  some 
residues  have  a  role  of  specificity  determinants.  Preferences  for  certain  residues 
at  particular  positions  and  recognition  of  specific  motifs  can  vary  from  one 
peptidase  to  the  other,  although  similarities  are  found  among  the  same  subfamily. 
Natural  or  synthesised  low-molecular-weight  inhibitors  are  often  useful  for 
determining  binding  pockets  structures  of  cysteine  peptidases  and  elucidating  the 
relative  importance  of  different  binding  determinants  by  co-crystallisation  with  the 
enzyme  (Otto  and  Schirmeister,  1997).  This  avoids,  in  particular,  the  oxidation  of 
the  catalytic  cysteine  to  sulfinic  or  sulfonic  acid.  Among  the  natural  small 
inhibitors  of  papain-like  cysteine  peptidases,  cystatins,  stefins,  kininogens  and 
serpin  can  be  cited.  They  have  a  low  selectivity  and  are  involved  in  humans  in 
the  control  of  cysteine  peptidase  activity  and  in  the  protection  against  self 
peptidases  inappropriately  escaping  from  lysosomes,  as  well  as  for  exogenous 
organisms.  A  generic  synthetic  cysteine  inhibitor  widely  used  is  E64  (L-trans- 
epoxysuccinyl-leucyl-amido  (4-guanidino)  butane)  and  inhibits,  in  particular,  clan 
CA,  family  C1  peptidases. 
On  this  basis,  specificity  determinants  for  most  clans  of  peptidases  could 
be  determined.  The  legumain-like  family  of  cysteine  peptidases  (clan  CD),  for 
instance,  possess  a  very  strict  specificity  at  the  S1  site  (Barrett  and  Rawlings, 
2001;  Dickinson,  2002;  Mottram  et  aL,  2003),  are  insensitive  to  E64  inhibition  and 
present  specificities  at  the  P2  and  P3  positions  (Mathieu  et  aL,  2002).  Papain-like 
peptidases  are  sensitive  to  E64  and  possess  specificity  at  the  S2  position. 
Cathepsin  B  activity  can  be  discriminated  over  cathepsin  L  activity  using 
substrate  peptides  with,  respectively,  glutamate  or  alanine  (Alves  et  al.,  2001). 
The  different  amino  acid  composition  of  the  active  site,  thus  the  different 
chemical  environment,  gives  a  different  S2  specificity  to  cathepsins  B  and  L. 
Structural  differences  could  also  be  elucidated  for  these  two  subclasses  of 
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peptidases.  For  instance,  cathepsin  L  possesses  a  conserved  motif  in  the  pro- 
region  named  ERFNIN  (sequence  Glu-X-Arg-X-(IleNal)-Phe-X-Asn-X-Ile-X-Asn, 
X  being  any  amino  acid),  which  cathepsin  B  does  not  have  (Karrer  et  aL,  1993). 
Furthermore,  cathepsin  B  is  characterised  by  the  presence  of  an  insertion  loop  of 
20  amino  acids,  named  the  occluding  loop  because  of  its  positioning  in  the  active 
site,  which  seems  to  favour  dipeptidyl  carboxypeptidase  activity  (exopeptidase 
activity)  (Naegler  et  aL,  1997). 
1.1.2.  Cysteine  peptidases  in  parasitic  protozoa 
1.1.2.1.  Generalities 
A  large  number  of  the  peptidases  described  to  date  for  parasitic  protozoa 
are  cysteine  peptidases  of  clan  CA,  family  C1.  Frequently  they  are  abundant  and 
stage-regulated,  and  most  are  closely  related  to  mammalian  lysosomal  cathepsin 
L.  Many  of  the  cathepsin  L-like  cysteine  peptidases  could  be  detected  in 
lysosome-like  organelles  by  immunoelectron  microscopy.  For  example, 
Leishmania  mexicana  cathepsin  L-like  enzymes  were  localised  in  large 
organelles  known  as  megasomes  (large  lysosomes)  in  the  amastigote  form  of  the 
parasite  (Pupkis  et  aL,  1986).  In  some  cases  they  occur  on  the  surface  or  are 
secreted.  Trafficking  of  cysteine  peptidases  in  some  parasitic  protozoa  differs 
from  that  of  mammals  and  some  parasites,  including  the  trypanosomatids,  lack 
the  man  nose-6-phos  p  hate  pathway  (Huete-Perez  et  aL,  1999)  and  may  use  a 
way  involving  a  peptide  loop  in  the  pro-domain.  Furthermore,  to  achieve  proper 
targeting  to  an  intracellular  compartment  or  secretion,  the  N-terminal  extremity  of 
the  enzyme  is  essential  (Brooks  et  aL,  2000),  and  a  hydrophobic  signal  peptide  of 
about  15  to  22  amino  acids  upstream  of  the  pro-region  can  be  found.  In  some 
cases,  a  C-terminal  extension  may  also  be  present,  like  for  example  for  the  CP13 
of  L.  mexicana  (Mottram  et  al.,  1997),  but  this  sequence  is  not  required  for 
correct  trafficking  or  activation  of  the  enzyme  (Mottram  et  al.,  1997). 
The  major  cysteine  peptidase  of  Trypanosoma  cruzi,  cruzipain,  could  be 
detected  on  the  surface  of  epimastigotes  in  addition  to  its  main  lysosomal 
location  (Parussini  et  al.,  1998).  Protozoan  parasites  such  as  Entamoeba 
histolytica  are  known  to  secrete  cysteine  peptidases.  The  parasites  occur  on 
mucosal  surfaces  in  their  hosts  and  this  secretion  of  cysteine  peptidase  may 
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confer  to  them  an  advantage  for  tissue  invasion  (Que  et  aL,  2003;  Pertuz  Belloso 
et  aL,  2004).  Due  to  these  extra-lysosomal  locations,  some  parasite  cysteine 
peptidases  are  adapted  to  a  wide  range  of  pH. 
Some  structural  differences  can  be  found  between  mammalian  and 
parasite  peptidases.  The  ERFNIN  amino  acid  motif  in  the  pro-region  of 
cathepsin-L  is  highly  conserved  in  mammals,  which  is  not  the  case  in  parasitic 
protozoa  (Sajid  and  McKerrow,  2002).  Furthermore,  in  some  exceptional  cases, 
cathepsin  B-like  enzymes  lack  the  occluding  loop  or  it  is  modified  (Ward  et  al., 
1997). 
Phylogenetic  analysis  showed  that  cysteine  pepticlases  from  diverse 
parasitic  organisms  are  not  closely  related  (Hughes,  1994),  with  the  exception  of 
the  cysteine  peptidases  from  Leishmania  and  Trypanosoma.  Interestingly,  the 
diversification  of  cysteine  peptidases  of  Haemonchus  contortus  coincides  with 
the  emergence  of  mammals  in  evolution  (Hughes,  1994).  This  might  suggest  that 
parasite  cysteine  peptidase  diversification  occurred  as  an  adaptive  response  to 
mammalian  hosts.  Furthermore,  isoenzymes  encoded  by  multiple  copies  of  a 
gene,  for  example  the  CPB  genes  coding  for  isoenzymes  of  cathepsin  L-like 
enzymes  in  Leishmania  mexicana,  may  have  distinct  roles  in  the  interaction 
between  the  parasite  and  its  host  and  reflect  a  highly  adaptive  process  (Mottram 
et  al.,  1997). 
1.1.2.2.  Identified  protozoan  cysteine  pepticlases  and  their  roles 
Members  of  all  major  peptidase  classes  (mainly  cysteine  peptidases  but 
also  several  serine  pepticlases  and  fewer  meta  I lo-pe  ptid  ases  and  aspartic 
pepticlases  (McKerrow  et  aL,  1993))  have  been  reported  and  characterised  in 
parasitic  protozoa,  and  extensive  studies  have  been  performed  on  cysteine 
peptidases.  Detailed  biochemical  data  are  still  restricted  to  a  few  parasites  and  a 
few  enzymes,  and  our  understanding  of  the  physiological  roles  of  most  of  the 
enzymes  studied  is  still  limited.  However,  there  has  been  in  recent  years  an 
increasing  amount  of  data  suggesting  that  cysteine  peptidases  play  various 
indispensable  roles  in  the  biology  of  parasites.  Beside  their  catabolic  and  protein 
processing-  functions,  they  have  been  reported  to  play  key  roles  in  host-parasite 
interactions  and  virulence  in  various  parasitic  organisms.  Only  a  few  examples 
9 Chapter  1:  General  introduction 
will  be  mentioned  here,  describing  some  of  the  cysteine  peptidases  best 
characterised  so  far. 
1.1.2.2.1.  Cysteine  peptidases  of  Apicomplexa 
1.1.2.2.1.1.  Plasmodium 
Species  of  the  genus  Plasmodium  can  parasitise  a  wide  range  of  hosts.  P. 
falciparum  is  the  agent  responsible  for  the  most  virulent  form  of  human  malaria. 
Recent  estimates  suggest  that  the  number  of  infected  humans  exceeds 
500,000,000,  and  that  1-2  million  persons  die  each  year.  The  life  cycle  is  split 
between  a  vertebrate  host  and  an  insect  vector,  which  is  the  Anopheline 
mosquito.  In  the  human  host  the  parasite  is  found  primarily  inside  red  blood  cells. 
The  parasite  reproduces  asexually  until  the  red  blood  cells  breaks  open  and  a 
large  number  of  merozoites  is  released,  which  will  infect  more  red  blood  cells. 
The  characteristic  "chill  and  fever'  (paroxysm)  associated  with  malaria  occurs 
periodically.  The  different  malarias  produce  fevers  of  different  frequency, 
depending  on  how  long  it  takes  to  complete  shizogony  in  erythrocytes  (48  h  for  P. 
talciparum).  Severe  and  complicated  malaria  is  usually  caused  by  delay  in 
successfully  treating  an  uncomplicated  infection  with  P.  falciparum. 
Three  P.  talciparum  cathepsin-L  like  peptidases  have  been  identified 
(falcipains-1,  -2  and  -3)  and  the  main  cysteine  peptidase  activity  in  the  food 
vacuoles  appears  to  be  falcipain-2  (Singh  and  Rosenthal,  2001).  The  food 
vacuole  also  contains  the  aspartyl  peptidases  known  as  plasmepsins  I  and  11 
(Coombs  et  al.,  2001),  which  have  been  more  widely  characterised  than  cysteine 
peptidases.  Nevertheless,  there  is  clear  evidence  that  cysteine  peptidases  are 
involved  in  rupturing  of  red  blood  cells  after  schizogony  and  are  therefore 
involved  in  parasite  release  (Sijwali  and  Rosenthal,  2004).  Furthermore,  all  three 
peptidases  are  expressed  by  trophozoites  and  hydrolyse  haemoglobin, 
suggesting  roles  in  this  process  (Rosenthal  et  al.,  2002;  Sijwali  and  Rosenthal, 
2004).  Falcipain-2  and  falcipain-3  are  food  vacuole  hemoglobinases,  and 
falcipain-2,  the  principal  hemoglobinase  of  P.  talciparum,  also  hydrolyses  ankyrin, 
suggesting  additional  activity  against  erythrocyte  cytoskeletal  targets  (Hanspal  et 
al.,  2002).  The  definite  function  of  falcipain-1  is  still  uncertain,  as  various  roles 
have  been  attributed  to  the  enzyme.  Disruption  of  the  gene  encoding  falcipain-1 
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showed  the  enzyme  was  not  essential  in  the  erythrocyte  stage  of  the  parasite  or 
for  erythrocyte  invasion  (Sijwali  et  aL,  2004),  though  apparently  specific  inhibition 
of  falcipain-1  had  previously  been  shown  to  inhibit  erythrocytes  invasion 
(Greenbaum  et  al.,  2002).  Another  study  suggested  falcipain-1  may  have  an 
important  role  during  parasite  development  in  the  insect  vector  (Eksi  et  aL,  2004). 
There  is  an  apparent  synergy  between  plasmepsin  and  falcipain  in  the 
degradation  of  haernoglobin  (Gluzman  et  al.,  1994;  Sijwali  and  Rosenthal,  2004) 
and  these  enzymes  may  be  considered  as  potential  joint  targets  for  anti-malarial 
drugs.  Multiple  orthologs  of  the  falcipains  exist  and  have  been  identified  in  other 
plasmodial  species  and  the  predicted  mature  forms  of  the  peptidases  of  the 
different  species  are  highly  conserved  (Rosenthal,  1996).  For  example,  in  P. 
vivax,  vivapain-2  and  -3  resemble  falcipain-2  and  -3  and  are  potentially 
appropriate  therapeutic  targets  too  (Na  et  aL,  2004). 
1.1.2.2.1.2.  Toxoplasma 
Toxoplasma  gondd  is  responsible  for  toxoplasmosis  and  belongs  to  the 
subclass  Coccidia  along  with  other  parasites  including  Cry,  0  Ptosp  fidium  and 
Eimeria.  Toxoplasma  infection  is  common,  virtually  all  warm-blooded  animals, 
including  humans  can  become  infected  and  it  is  often  transmitted  to  humans  via 
domestic  and  feral  cats.  Infection  is  usually  asymptomatic,  but  acute  infection  can 
cause  lymphadenopathy  and  in  case  of  immunodepression  (for  example,  AIDS 
patients)  leads  to  severe  complications  including  encephalitis,  pneumonitis  and 
retinitis.  Infection  with  T.  gondii  of  pregnant  women  not-previously  exposed  to  the 
parasite  and  therefore  not  immune  to  it  may  increase  the  probability  of  having  a 
child  born  prematurely  or  even  stillborn,  especially  if  the  infection  occurs  during 
the  first  three  months  of  pregnancy. 
In  T.  gondfl,  a  cysteine  peptidase  gene  has  been  identified  and  encodes 
an  enzyme  closely  related  to  cathepsin  B,  named  TOxopain-1  (Que  et  aL,  2002). 
Toxopain-1  is  encoded  by  a  single  copy  gene  (TGCPI)  and  was  reported  to 
localise  to  rhoptries,  secretory  organelles  required  for  apicomplexan  parasite 
invasion.  Evidence  has  been  provided  that  it  may  be  involved  in  cell  invasion  and 
rhoptry  protein  processing  (Que  et  aL,  2002),  as  well  as  being  critical  for  cell 
invasion  in  vivo  (Que  et  aL,  2004).  Upon  release  onto  the  host  cell  surface,  a 
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number  of  microneme  proteins  have  been  shown  to  be  cleaved,  suggesting  a 
role  for  peptidases  at  that  point  (Kim,  2004),  though  most  of  the  process  may 
involve  subtilisin-like  serine  peptidases. 
1.1.2.2.1.3.  Cryptosporldium 
Cryptosporldium  is  an  intracellular  parasite  that  infects  the  small  intestine 
of  an  unusually  wide  range  of  mammals,  including  humans.  The  two  species 
responsible  for  human  cryptosporidiosis  are  C.  parvum  and  C.  hominis,  the  latter 
being  restricted  to  human,  and  the  former  being  able  to  infect  various  mammalian 
hosts  (Xu  et  aL,  2004).  Cryptosporidiosis  is  a  self-limiting  diarrhoea[  illness  in 
immunocompetent  humans,  lasting  3  to  20  days.  In  immunodeficient  patients  (for 
example,  infected  with  HIV)  the  symptoms  can  be  a  lot  more  severe,  sometimes 
leading  to  death.  Some  species  of  Cryptosporidium  have  a  major  economic 
significance,  as  cattle  can  be  infected.  The  parasites  are  transmitted  mainly  via 
contaminated  water  or  food.  Cryptosporidium  infects  the  mucosal  epithelium  of 
the  digestive  and  respiratory  tracts.  Infection  is  initiated  when  sporozoites  excyst 
from  an  ingested  sporulated  oocyst  in  the  small  intestine  of  the  host.  Sporozoites 
invade  host's  intestinal  cell  lines,  activate  caspases  and  induce  apoptosis  (Ojcius 
et  aL,  1999). 
Cysteine  peptidase  activity  has  been  detected  in  partially  excysted 
oocysts  but  its  role  still  has  to  be  evaluated  (Forney  et  aL,  1996).  Nevertheless, 
there  is  an  indication  that  cysteine  peptidase  might  be  involved  in  mucus 
penetration  by  the  parasites  and  in  sporozoite  and  merozoite  invasion  of  host 
cells  (Brown  S.  M.  A.,  PhD  thesis). 
1.1.2.2.1.4.  Eimeria 
The  diseases  caused,  transmission,  pathogenicity,  as  well  as  the 
characteristic  biochemical  and  molecular  features  of  the  parasite,  will  be 
discussed  in  1.2. 
Cysteine  peptidase  activity  has  been  detected  in  Eimeria  and  using 
specific  inhibitors  it  has  been  suggested  that  cysteine  peptidases  might  be 
involved  in  invasion  by  sporozoites  and  merozoites  of  the  host  cells  (Adams  & 
Bushell,  1988;  Coombs  et  aL,  1997),  as  well  as  in  the  penetration  of  mucus 
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layers  (Brown  S.  M.  A.,  unpublished  data).  However  very  little  is  known  about 
cysteine  peptidases  of  coccidian  parasites  and  Toxopain-1  of  Toxoplasma  gondii 
is  the  only  one  characterised  so  far  (Que  et  al.,  2002). 
Little  is  known  about  other  eimerian  peptidases  and  few  have  been 
reported  so  far.  Study  of  E.  tenella  oocysts  revealed  that  proteins  in  crude  oocyst 
homogenates  were  degraded  in  the  absence  of  peptidase  inhibitors,  and  that  the 
degradation  could  be  prevented  fully  by  using  both  typical  serine  peptidase  and 
cysteine  peptidase  inhibitors.  This  is  strongly  suggestive  of  the  presence  of  these 
two  types  of  peptidases  (Michalski  et  al.,  1994).  Furthermore,  in  vitro  incubation 
of  sporozoites  with  serine  peptidase  and  cysteine  peptidase  inhibitors 
significantly  decreased  host  cell  invasion,  suggesting  that  these  peptidases  may 
be  involved  in  invasion  by  Eimeria  sporozoites  (Adams  &  Bushell,  1988). 
Furthermore,  a  46  kDa  cysteine  peptidase  could  be  detected  on  the  surface  of 
the  sporozoites  of  E.  tenella  (Brown  S.  M.  A.,  unpublished  data).  Recent  studies 
highlighted  the  expression  of  an  aspartyl  peptidase,  named  eimepsin,  in  the 
sporulated  oocyst  of  E.  tenella  (Jean  et  al.,  2001).  Eimepsin  has  been  found  in 
the  refractile  body  organelles  (possibly  a  storage  location)  of  resting  sporozoites 
(Laurent  et  al.,  1993)  and  within  the  apical  tips  of  merozoites  and  invading 
sporozoites  (Jean  et  al.,  2000).  This  gives  support  to  the  possibility  that  eimepsin 
has  a  function  in  host  cell  invasion,  as  the  apical  tip  of  apicomplexan  parasites  is 
known  to  be  involved  in  both  attachment  to  and  penetration  of  host  cells.  But  the 
specific  function  of  eimepsin  in  the  parasite  is  still  unknown.  Metallo-peptidase 
activity  could  also  be  detected  in  sporulated  oocysts  using  specific  inhibitors 
(Kaga  et  al.,  1998),  but  still  very  little  is  known  about  these  enzymes. 
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1.1.2.2.2.  Cysteine  peptidases  of  trypanosomatids 
1.1.2.2.2.1.  Leishmania 
Leishmania  species  are  responsible  for  various  diseases  in  humans.  The 
diseases  caused,  transmission,  pathogenicity,  as  well  as  the  characteristic 
biochemical  and  molecular  features  of  the  parasite,  will  be  discussed  in  1.3. 
A  total  of  65  putative  cysteine  peptidases,  grouped  into  clans  and  13 
families,  have  been  revealed  in  the  L.  major  database  (Mottram  et  al.,  2004). 
Most  of  them  belong  to  the  same  clan  as  papain  (clan  CA).  A  review  of  cysteine 
peptidases  in  Leishmania  is  presented  in  Table  I.  I.  (from  Mottram  et  al.,  2004). 
Table  1.1.  Cysteine  pepticlases  and  cysteine  peptidase  Inhibitors  of  Leishmania 
major.  Nomenclature  for  Clans  and  Families  are  described  in  the  MEROPS  database 
(hftp:  //www.  merops.  sanger.  ac.  uk),  (from  Mottram  et  al.,  2004). 
Clan  Family  Number  Gene  Peptidase/inhibitor  Features  Reference 
CA  C1  1  CPA  CPA  Cathepsin  L-like,  lysosomal  Mottram  ef  ah,  1998 
C1  8  CPB  CPB  Cathepsin  L-like,  lysosomal  Mottram  et  aL,  1998 
C11  1  CPC  CPC  Cathepsin  B-like,  lysosomal  Mottram  et  aL,  1998 
C2  27  - 
Contain  calpain-like  Some  calcium-dependant 
domain 
C12  2-  Ubiquitin  C-terminal  Ublquitin  pathway 
hydrolase 
C19  15 
- 
Ubiquitin  hydrolase  Ubiquitin  pathway 
C48  I-  SUMO-like  Ubiquitin  pathway 
C51  2-  D-alanyl-glycyl  CHAP  domain. 
endopeptidase-like  Function  unknown 
C54  2  ATG4.1  ATG4  Autophagy  Williams,  Mottram  and 
ATG4.2  Coombs,  unpublished 
C65  1  Obutain  Ubiquitin  pathway 
CD  C13  1  GP18  GPI:  protein  GPI  protein  anchor  biosynthesis  Hilley  of  aL,  2000; 
transmamidase  Mottram  of  aL,  2003 
C14  1  MCA5  Metacaspase  Caspase-like  protein,  Amoult  et  aL,  2002 
function  unknown 
C50  I  Separase  Thought  to  control  sister  Amoult  of  aL,  2002 
chromatid  separation  during 
mitosis 
CF  C15  1  PGP  Pyroglutamyl-  Hydrolyses  N-terminal  glutamyl  Schaeffer,  Mottram  and 
peptidasel  residues  of  proteins  Coombs,  unpublished 
PC(C)  C56  1  PFP1  PfPI  Similar  to  intracellular  protease  Eschenlauer,  Coombs  and 
of  Pyrococcus,  function  unknown  Mottram,  unpublished 
1-  142  1  1CP  Inhibitor  of  cysteine  Inhibits  Clan  CA,  family  C1  Sanderson  of  aL,  2003 
peptidases;  cysteine  peptidases 
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Different  peptidase  activities  have  been  detected  in  Leishmania  and  the 
proteins  have  mainly  been  located  in  the  amastigote  form  of  the  parasites  in  the 
megasomes  (Pupkis  et  al.,  1986),  which  are  large  lysosomes.  In  the 
promastigote  form  of  the  parasite,  major  activities  are  thought  to  be  located  in  the 
multi-vesicular  tubule-lysosome  (Mullin  et  al.,  2001). 
The  family  C1  of  clan  CA  comprises  3  identified  and  characterised 
enzymes.  There  are  2  cathepsin  L-like  enzymes;  the  peptidase  CPA  (single  copy 
gene  (Souza  et  al.,  1992)),  and  the  peptidase  CPB  (multiple  copy  gene  located 
on  a  single  tandem  array  of  19  non-identical  copies  in  L.  mexicana  (Mottram  et 
al.,  1997),  and  8  in  L.  major  (Mottram  et  a/.,  2004)).  These  enzymes  possess  an 
unusual  carboxy-terminal  extension  of  unknown  function.  The  cathepsin  B-like 
enzyme  CPC  is  encoded  by  a  single  copy  gene  (Bart  et  al.,  1997).  Analysis  of  the 
peptidase  activity  showed  a  stage-specific  expression  of  these  different  enzymes 
(Robertson  and  Coombs,  1994).  Targeted  gene  disruption  of  all  CPB  genes 
resulted  in  a  decrease  in  virulence  compared  to  wild-type  parasites,  a  reduction 
of  infectivity  to  macrophages  (Mottram  et  al.,  1996)  and  a  shift  in  the  immune 
response  to  infection  in  mice  from  a  predominantly  Th-2  to  a  Th-1  response 
(Alexander  et  al.,  1998;  Buxbaum  et  al.,  2003).  Re-expression  of  multiple  CPBs 
of  the  array  in  the  null  mutant  restored  most  of  the  infectivity  in  mice,  showing 
that  the  peptidase  is  a  virulence  factor  (Mottram  et  al.,  1996;  Denise  et  aL,  2003). 
This  suggests  that  these  cysteine  peptidases  promote  the  parasite's  resistance  to 
macrophages'  microbial  activity  and  the  host's  immune  response. 
Both  L.  major  and  L.  pifanoi  possess  clan  CA  family  C1  cathepsin  L-like 
cysteine  peptidase  genes  quite  similar  to  the  ones  from  L.  mexicana  (Sakanari  et 
al.,  1997;  Rafati  et  aL,  2001),  L.  major  possessing  as  well  a  cathepsin  B-like  gene 
(Sakanari  et  aL,  1997).  Another  example  of  immuno-evasion  promoted  by 
cysteine  peptidase  activity  was  described  in  Souza  Leao  et  al.,  1995.  The 
degradation  of  host  MHC  class  11  molecules  internalised  by  amastigotes  forms  of 
L.  amazonensis  was  inhibited  by  cysteine  peptidase  inhibitors. 
There  are  other  clan  CA  cysteine  peptidases  in  Leishmania;  notably  27 
family  C2  peptidases  with  calpain-like  domains  have  been  identified  in  the  L. 
major  genome  database.  Calpains  are  involved  in  signal  transduction  pathways, 
and  remodelling  of  cystoskeleton  or  membrane  attachments.  Other  genes  for 
clan  CA  peptidases  have  also  been  identified,  and,  among  them,  there  are  19 
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genes  for  cysteine  pepticlases  of  the  families  C1  2,  C1  9,  C48,  and  C65  involved  in 
the  ubiquitin  pathway. 
Among  the  other  clans  of  cysteine  peptidases,  clan  CID  peptidases, 
including  glycosylphosphatidylinositol  (GPI):  protein  transamidase  (Hilley  et  aL, 
2000)  and  the  family  of  caspase-like  peptidases,  the  metacaspases  (Amoult  et 
aL,  2002),  have  attracted  particular  attention.  The  GPI:  protein  transamidase  is 
involved  in  the  biosynthesis  of  GPI-anchored  proteins,  and  among  the  GPI- 
anchored  proteins  in  Leishmania,  the  GP63  metal  lo-peptid  a  se,  thought  to  be 
involved  in  resistance  to  the  host's  immune  response  (Ellis  et  al.,  2002;  Yao  et 
aL,  2003),  can  be  found.  Caspase-like  peptidases  are  involved  in  apoptosis  in 
many  organisms.  Programmed  cell  death  in  Leishmania  is  believed  to  be 
caspase-independent  (Zangger  et  aL,  2002),  and  the  reason  for  the  presence  of 
metacaspase  remains  unclear,  and  its  function  remains  unknown.  A  gene 
encoding  a  pyroglutamyl  peptidase  I  has  also  been  identified  (clan  CF,  family 
C15)  and  work  on  this  enzyme  will  be  presented  in  Chapters  4  and  5  of  this 
thesis. 
1.1.2.2.2.2.  Ttypanosoma 
Trypanosoma  cruz!  causes  Chagas  disease,  also  known  as  South 
American  trypanosomiasis.  The  early  stage  of  the  disease  is  characterised  by  a 
mild  febrile  state,  followed  by  severe  heart  and  gastrointestinal  problems  some 
years  later.  The  parasite  invades  muscle  cells  and  as  cardiac  muscle  is  often 
infected,  the  illness  may  lead  to  death  through  heart  failure. 
A  major  T.  cruzi  clan  CA,  family  C1  cysteine  peptidase  is  known  as  cruzain 
(or  cruzipain,  or  gp57/51).  It  is  encoded  by  multicopy  genes  present  in  tandem 
arrays  on  more  than  one  chromosome  (Eakin  et  aL,  1992),  and  is  expressed  in 
all  life-cycle  stages,  though  the  highest  expression  rate  is  in  the  replicative  insect 
epimastigote  stage.  Cruzain  has  a  similar  carboxy-terminal  extension  to  that  of  L. 
mexicana  CPB  cysteine  peptidase  (Eakin  et  al.,  1992)  and  its  amino  acid 
sequence  shows  high  similarity  with  the  cathepsin  L-like  enzymes  of  other 
Trypanosoma  and  relatively  high  similarity  with  Leishmania  sequences  (Sakanari 
et  al.,  1997).  Cruzain,  unlike  most  cathepsin  L-like  enzymes,  also  shows  a 
carboxypeptidase  activity,  which  is  a  characteristic  of  cathepsin  B  enzymes 
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(Judice  et  aL,  2004).  The  enzyme's  specific  function  remains  uncertain  though  it 
has  been  linked  to  differentiation  from  epimastigotes  to  the  metacyclic  stage 
(Harth  et  al.,  1993;  Tomas  et  al.,  1997),  and  it  has  been  described  to  have  a 
kininogenase  activity  (Del  Nery  et  al.,  1997).  Kininogens  are  multifunctional 
glycoproteins  present  in  mammalian  plasma  and  are  potent  inhibitors  of  papain- 
like  cysteine  peptidases.  Cleavage  of  kininogens  with  cruzain  leads  to  the 
production  of  a  potent  pro-inflammatory  peptide  and  thus  cruzain  may  be  an 
important  virulence  factor  (Del  Nery  et  al.,  1997).  Furthermore,  substrate 
cleavage  analysis  of  the  different  isoenzymes  of  cruzain  showed  that  they  might 
have  different  substrate  specificities  (Del  Nery  et  aL,  1997),  as  is  the  case  for  the 
cathepsin  L-like  isoenzymes  of  L.  mexicana  (Mottram  et  al.,  1997).  A  more  recent 
study  also  linked  cruzain  to  host  cell  invasion  through  a  kinin-independent 
pathway  (Aparicio  et  al.,  2004).  There  is  some  evidence  as  well  that  T.  cruzi 
releases  cysteine  peptidase  activity  and  this  is  implicated  in  the  chronic  heart 
disease  (Morrot  et  al.,  1997). 
African  trypanosomes  (including  the  human  infective  T.  brucei 
rhodesiense  and  T.  brucei  gamblense,  and  the  non-human  infective  T.  brucei 
brucei  causing  Nagana  in  cattle)  are  responsible  for  the  usually  fatal  African 
trypanosomiasis.  The  number  of  human  cases  occurring  each  year  is  estimated 
at  more  than  40  000  (hftp:  //www.  who.  int/en/).  Less  is  known  about  the 
peptidases  of  these  African  parasites  compared  to  the  American  forms.  The 
major  cysteine  peptidase  of  Trypanosoma  bruce!  is  named  trypanopain 
(Troeberg  et  al.,  1996)  (clan  CA,  family  Cl).  Its  precise  function  is  still  unknown, 
though  it  may  be  involved  in  parasite  differentiation  during  the  life  cycle  (Pamer  et 
aL,  1989).  Cysteine  peptidases  also  seem  to  be  released  into  the  bloodstream, 
which  may  cause  platelet  aggregation  and  complication  of  the  infection  (Troeberg 
et  al.,  1996),  though  these  enzymes  may  only  be  active  for  a  short  period  of  time 
before  they  are  inhibited  by  natural  hosts  peptidase  inhibitors  in  the  serum 
(Troeberg  et  aL,  1996).  By  using  RNA  interference  to  selectively  knock  down  the 
cathepsin  B  activity  of  T.  brucei,  it  was  shown  the  cathepsin  B  activity,  and  not 
the  trypanopain  activity  as  previously  thought,  was  essential  to  the  parasite  in 
culture  and  played  a  major  role  in  host  serum  protein  degradation  by  the 
bloodstream  parasite  (Mackey  et  aL,  2004). 
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There  are  at  least  two  families  of  cysteine  peptidases  in  T.  congolese,  the 
CP1  (Fish  et  a/.,  1995)  and  CP2  families,  which  are  90%  identical  in  their  amino 
acid  sequences  and  differ  in  their  N-terminal  sequences  (Boulange  et  al.,  2001). 
Congopain  belongs  to  the  C132-type  of  enzymes.  Though  the  two  types  of 
enzymes  are  very  similar  in  sequence,  they  differ  in  substrate  specificity  and  pH 
optimum  for  activity  (Boulange  et  al.,  2001),  suggesting  distinct  roles  in  vivo,  as 
well  as  different  effects  on  the  tolerance  they  can  elicit  in  cattle.  The  exact  role  for 
these  enzymes  in  the  parasite  remains  unknown,  but  it  is  thought  they  may  have 
potential  as  anti-disease  vaccines  (Authie  et  al.,  2001). 
During  T.  congolese  infection,  it  was  observed  that  a  cysteine  peptidase  of 
the  parasite  (congopain)  elicited  an  IgG1  antibody  production  in  cattle  which 
showed  a  degree  of  resistance  to  disease  during  experimental  infections  (Authie 
et  al.,  1993).  Congopain  is  a  33-kDa  lysosomal  cysteine  peptidase,  inhibited  by 
E64  (Authie  et  al.,  1992),  which  shares  similarities  with  the  cruzain  from  T.  cruzi 
and  the  mammalian  cathepsin  L  and  may  be  an  attractive  target  for  anti- 
trypanosome  drugs  (Lalmanach  et  a/.,  2002).  It  is  a  major  antigen  in  infected 
cattle  and  antibodies  against  this  antigen  inhibit  the  enzyme's  activity  (Authie  et 
al.,  2001).  Unlike  the  related  mammalian  cathepsins  B  and  L,  congopain 
accommodates  a  prolyl  residue  at  the  P2'  site  (Chagas  et  al.,  1997). 
1.1.3.  Why  are  parasite  cysteine  peptidases  good  drug  targets? 
Cysteine  peptidase  activity  has  been  demonstrated  in  most  parasitic 
protozoa  and  some  of  the  cysteine  peptidases  well  characterised  show  common 
features,  for  example  the  similar  substrate  specificity  and  similar  genetic 
organisation  of  the  cathepsin  L-like  cysteine  peptidase  of  Leishmania  and  T 
cruzi.  Therefore,  there  is  good  indication  that  in  aiming  to  obtain  novel  anti- 
parasite  drugs,  it  would  be  useful  to  target  a  series  of  cysteine  peptidases  of 
different  organisms.  Furthermore,  some  cysteine  peptidases  involved  in  human 
diseases  are  well  characterised  and  already  targeted  by  a  library  of  compounds. 
Thirteen  papain-like  cysteine  peptidases  are  encoded  in  the  human  genome  and 
qualify  as  pharmaceutical  targets  for  the  treatment  of  osteoporosis,  arthritis 
(Taubert  et  al.,  2002),  asthma,  auto-immune  diseases,  and  potentially  for  certain 
forms  of  cancer  (Bromme  and  Kaleta,  2002).  Recent  advances  in  the  design  of 
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mammalian  cysteine  peptidase  inhibitors  were  reviewed  by  Bromme  and  Kaleta, 
2002.  To  give  an  example,  CLIK-148,  a  cathepsin-L  specific  inhibitor  designed 
from  analysis  of  the  substrate-binding  pocket,  computer  graphics  and  X-ray 
crystallographic  data,  has  been  demonstrated  to  be  an  effective  protective  drug 
in  vivo  against  tumour-induced  osteoporosis  and  bone  metastasis  of  cancer  cells 
due  to  bone  collagen  degradation  and  is  without  side  effects  (Katunuma  et  aL, 
2002).  Therefore,  a  great  methodological  knowledge  has  already  been  developed 
to  validate  cysteine  peptidases  as  drug  targets,  and  a  large  number  of  inhibitors 
are  already  available  to  direct  against  often  homologous  parasite  cysteine 
peptidases. 
Although  a  variety  of  homologous  cysteine  peptidases  are  present  in  the 
parasites'  hosts,  a  number  of  structural  and  biochemical  differences  between  the 
two  counterparts  have  been  elucidated.  This  constitutes  a  clear  advantage  in 
drug  design,  as  anti-parasite  compounds  should  not  inadvertently  target  a  host 
cysteine  peptidase.  Firstly,  many  parasitic  cathepsin-B  like  peptidases  cleave 
preferably  substrates  with  arginine  at  the  P2  position  whereas  cathepsin-L  like 
peptidases  cleave  substrates  with  a  hydrophobic  amino  acid  at  P2  (Rawlings  & 
Barrett,  1994).  It  has  been  demonstrated  that  cathepsin  L  of  Trypanosoma  cruzi 
and  Leishmania  mexicana  prefer  hydrophobic  residues  at  the  P2  position  of 
substrate,  whereas  cathepsin  B  of  the  same  organisms  can  also  accept  basic 
residues  (Del  Nery  et  al.,  1997;  St  Hilaire  et  al.,,  2000).  For  human  cathepsin-B 
and  cathepsin-L,  the  preferred  residues  are  glutamate  and  alanine,  respectively. 
Furthermore,  some  cysteine  peptidases  of  parasites  are  difficult  to  classify,  as 
some  predicted  cathepsin  B-like  enzymes  based  on  sequence  and  structure 
homology  show  cathepsin  L-like  substrate  specificity  due  to  single  amino-acid 
substitutions  in  the  catalytic  site  (i.  e.  L.  major  cathespin  B-like  enzyme;  Chan  et 
al.,  1999).  Mammalian  cathepsin-L  have  a  highly  conserved  ERFNIN  amino  acid 
motif  in  the  pro-region  which  is  not  in  the  parasite  homologues  and  cathepsins  B 
have  an  inserted  "occluding"  loop  in  the  catalytic  domain.  All  vertebrate 
cathepsins  B  have  maintained  the  loop  whereas  some  parasite  enzymes  have 
lost  it  in  the  evolution  process,  like  Giardia,  or  modified  the  loop  sequence  or  the 
glycosylation  content  of  the  loop  (Sajid  &  McKerrow,  2002).  Therefore,  parasite 
cysteine  peptidases  do  not  conform  to  the  general  properties  described  for 
vertebrate  cysteine  peptidases.  As  parasites'  cysteine  peptidases  have  both 
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lysosomal  and  extra-lysosomal  functions,  they  are  adapted  to  more  diverse 
chemical  environments  than  their  host  homologues  and  are  more  stable  over  a 
wider  pH-range  than  mammalian  cysteine  peptidases.  The  reduced  stability  of 
mammalian  cysteine  peptidases  at  pHs  higher  than  4.0  (lysosomal  pH)  may 
constitute  a  protection  mechanism  avoiding  inappropriate  proteolysis.  Parasite 
cysteine  peptidases  are  not  so  tightly  restricted  and  different  isoforms  of  the 
same  enzyme  can  be  located  in  different  cell  compartments  (Parussini  et  al., 
1998).  Furthermore,  at  least  some  parasite  cysteine  peptidases  are  trafficked  in 
the  cells  through  the  primitive  mannose-6-phosphate-independent  pathway  and 
N-glycosylation  is  not  necessarily  required.  For  example,  the  major  route  of 
trafficking  of  L.  mexicana  cysteine  peptidases  to  lysosomes  may  occur  via  the 
flagellar  pocket,  as  treatment  with  cysteine  peptidase  inhibitors  leads  to  a  build 
up  of  inactive  cathepsin  B-like  cysteine  peptidase  in  the  flagellar  pocket  (Selzer 
et  al.,  1999)  and  experiments  with  mutated  inactive  cathepsin  L-like  cysteine 
peptidase  led  to  build  up  of  unprocessed  precursor  of  the  enzyme  in  the  flagellar 
pocket  as  well  (Brooks  et  al.,  2000).  The  trafficking  of  cysteine  peptidases  in 
lower  eukaryotic  organisms  may  therefore  differ  significantly  from  that  in 
mammals,  which  is  mainly  based  on  binding  to  specific  receptors  of  mannose-6- 
phosphate  residues  on  the  surface  of  the  enzyme  (Kornfeld  and  Mellman,  1989). 
All  of  these  features  constitute  potential  advantages  in  targeting  the 
cysteine  peptidase  family  to  develop  new  anti-parasite  chemotherapy. 
1.1.4.  Cysteine  peptidase  inhibitors  as  potential  anti-protozoa  drugs 
Over  recent  years,  there  has  been  a  general  increase  of  resistance  of 
parasites  against  available  drugs,  and  therefore  there  is  an  increasing  need  to 
develop  new  therapeutics  and  identify  new  drug  targets.  For  example, 
Leishmania  strains  resistant  to  antimonials,  currently  the  frontline  drugs  of 
chemotherapy  against  leishmaniasis,  are  becoming  frequent  (Werbovetz,  2002). 
Furthermore,  antimonials  show  high  toxicity.  The  same  problem  is  encountered 
with  anti-malarial  agents  (White,  1998)  and  anti-trypanosomiasis  agents.  The 
differences  between  parasite  cysteine  peptidases  and  their  homologues  in 
mammals  have  permitted  the  development  of  inhibitors  and  the  use  of  parasite 
cysteine  peptidases  as  chemotherapeutical  targets.  It  has  now  been  clearly 
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demonstrated  that  cysteine  peptidase  inhibitors  can  be  used  as  anti-parasite 
agents  (Robertson,  1999;  Selzer  et  al.,  1997  and  1999;  Fujii  et  al.,  2005)  and  as 
tools  for  the  study  of  enzyme  function  (Greenbaum  et  al.,  2004).  As  cysteine 
peptidases  are  often  numerous  in  parasites,  key  issue  that  remain  are 
identification  of  cysteine  peptidases  that  are  not  redundant  in  function  and  play 
vital  roles  and  to  find  good  and  specific  inhibitors,  often  by  chemical  synthesis, 
screening  of  banks  of  molecules  and  rational  drug  design  based  on  structural 
information.  Through  construction  of  homology-based  enzyme  models,  structures 
of  inhibitors  can  be  predicted,  then  they  can  be  synthesised  and  tested  (Selzer  et 
al.,  1997;  Scheidt  et  aL,  1998).  Target  validation  can  be  achieved  in  different 
ways;  firstly  by  demonstrating  that  the  target  is  essential  through  genetic 
manipulation,  secondly  by  showing  that  the  parasite  lines  resistant  to  a  specific 
inhibitor  possess  a  mutated  version  of  the  target  enzyme,  and  thirdly  by  proving 
there  is  a  good  correlation  between  inhibition  of  the  target  activity  and  the 
inhibition  of  the  parasite's  growth  (Coombs  and  Mottram,  1997). 
Following  this  type  of  scheme,  both  reversible  and  irreversible  inhibitors  of 
cysteine  peptidases  have  been  identified  for  different  parasites.  In  Lelshmania, 
cathepsin  13-  and  L-like  enzymes  are  attractive  new  chemotherapy  targets  as 
they  are  required  for  parasite  growth  and  are  demonstrated  virulence  factors 
(Mottram  et  al.,  1996;  Mottram  et  al.,  1998).  Using  models  of  both  enzymes, 
inhibitors  could  be  identified  (Selzer  et  aL,  1997)  and  it  is  now  clear  that  inhibition 
of  both  types  of  activities  is  required  for  parasite  clearance  (Mottram  et  al.,  1997). 
Progression  of  L.  major  infection  in  vivo  could  be  reduced  using  these  inhibitors 
without  toxicity  (Selzer  et  aL,  1999).  This  brings  good  hope  that  new  therapeutics 
against  leishmaniasis  will  be  commercially  available  in  the  future.  Similar  studies 
have  been  undertaken  on  Trypanosoma  cruzi  and  Plasmodium  falciparum.  In  T. 
cruzi,  there  are  as  many  as  100  genes  encoding  cruzain.  This  may  be  a  problem 
in  the  attempt  of  designing  specific  inhibitor.  Nevertheless,  an  effective  inhibitor 
has  been  identified  and  named  KI  1777.  It  is  a  derivative  of  vinyl-sulfone 
compounds  and  may  be  used  in  human  clinical  trails  for  the  treatment  of  Chagas 
disease  in  the  near  future  (Jacobsen  et  aL,  2000).  In  P.  falciparum  strains, 
falcipain-2  is  highly  conserved  (Singh  and  Rosenthal,  2001)  and  a  series  of 
peptidyl  vinyl  sulfones  have  been  demonstrated  to  be  good  falcipain-2  and  -3 
inhibitors  of  potential  therapeutic  use  in  the  treatment  of  malaria  (Shenai  et  al., 
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2003).  Safety  analysis  for  these  different  potent  drugs  suggest  that  the  selectivity 
may  be  due  to  lack  of  redundancy  of  parasite  peptidases,  higher  concentration  of 
the  host  peptidases  in  intracellular  compartments,  and  differential  uptake  of 
inhibitors  by  parasites  (McKerrow  et  aL,  1999;  Selzer  et  aL,  1999).  So  it  seems 
that  the  development  of  ideal  reversible,  tight  binding  and  very  specific  inhibitors 
(or  less  specific  inhibitors  that  still  work  as  cysteine  peptidase'  role  in  the  parasite 
differs  from  those  in  the  host)  of  cysteine  peptidases  for  these  parasites  is  on  the 
way  and  there  is  hope  that  some  will  be  commercially  available  in  the  future  and 
provide  new  chemotherapies  against  major  parasitic  diseases.  Exciting  findings 
acquired  in  this  area  could  also  be  applicable  to  other  human  diseases  involving 
cysteine  peptidase  activities,  such  a  cancer. 
1.2.  Eimeria 
The  genus  Eimeria  (Apicomplexa  phylum,  subclass  Coccidia)  includes 
more  than  1700  species  of  obligate  intracellular  parasites  that  infect  all  classes  of 
vertebrates  and  some  invertebrates.  An  eimerian  species  was  most  probably  the 
first  protozoon  ever  visualised,  by  Antony  van  Leeuwenhoek  in  1674  in  the  bile  of 
a  rabbit.  As  oocysts  constitute  the  stage  that  leaves  the  host,  usually  in  faeces, 
98%  of  all  Eimeria  species  are  known  only  from  this  life-cycle  stage.  The 
diseases  caused  by  these  parasites  are  referred  to  collectively  as  coccidiosis, 
and  they  vary  tremendously  in  virulence.  Some  species  cause  diseases  that 
result  in  mild  symptoms  that  might  go  unnoticed  and  eventually  disappear,  while 
other  species  cause  highly  virulent  infections  that  are  rapidly  fatal. 
Eimeria  species  are  both  site-  and  host-specific.  Most  species  develop  in 
the  cells  of  the  host's  gastrointestinal  tract,  but  some  exceptions  can  be  found. 
Eimeria  species  seem  to  be  limited  to  specific  locations  in  specific  cells  in  a 
limited  organ.  Most  species  show  high  host  specificity  too  (E.  tenella  only  infects 
chickens),  but  some  can  cross  genetic  boundaries  and  infect  several  hosts. 
There  has  not  been  any  evidence  that  Eimerla  infects  humans,  though 
closely  related  genera,  like  Plasmodium,  Cryptospotidium  and  Toxoplasma  for 
example,  can  do  so.  Smetia  infections  in  wild  and  domesticated  animals  are 
frequent  and widespread,  but  harmless  in  most  cases.  It  is  only  when  many 
animals  are  confined  together  in  a  restricted  area,  as  it  is  the  case  for  chicken 
22 Chapter  1:  General  introduction 
flocks  infected  with  the  species  E.  tenella,  that  the  parasite  becomes  a  problem 
as  animals  are  continually  re-infected  and  eventually  develop  coccidiosis.  It  is 
particularly  a  problem  for  young  birds,  as  adults  may  become  immune. 
Coccidiosis  is  the  most  important  death-causing  agent  in  the  poultry 
industry  and  is  a  major  economical  issue.  At  least  11  species  of  Eimeria  can 
infect  chickens,  but  the  most  pathogenic  species  is  E.  tenella.  E.  necatrix 
(responsible  for  intestinal  coccidiosis),  E.  acervulina  (responsible  for  upper 
digestive  tract  coccidiosis)  and  E.  maxima  (responsible  for  middle  digestive  tract 
coccidiosis).  All  cause  chronic  intestinal  coccidiosis  and  are  responsible  for 
disease  outbreaks,  but  are  less  significant  than  E.  tenella.  E.  necatrix  produces 
fewer  oocysts,  therefore  the  development  of  a  sufficient  level  of  environmental 
contamination  requires  more  time,  whereas  E.  acervulina  and  E.  maxima  are  less 
pathogenic  and  mainly  affect  older  birds.  E.  tenella  develop  in  the  cells  of  the 
caeca  (two  blind  sacs  near  the  end  of  the  intestine).  After  three  days  of  infection, 
the  host  chicken  stops  feeding,  droops  and  by  the  fourth  day,  blood  appears  in 
the  droppings.  By  the  eight  or  ninth  day,  the  bird  is  either  dead  due  to  excessive 
blood  loss,  or  on  its  way  to  recovery.  This  type  of  coccidiosis  is  the  most  common 
in  young  chickens  and  is  therefore  a  major  problem.  Furthermore,  with  the  rising 
problem  of  resistance  of  eimerian  strains  to  most  chemicals  used  as  anti- 
coccidial  agents,  there  is  a  need  to  identify  new  drug  targets  and  develop  new 
drugs. 
1.2.1.  Life  cycle,  transmission  and  pathogenicity 
Eimeria  species  are  homoxenous;  they  have  a  direct  life  cycle  that  takes 
place  within  the  same  host.  The  infective  stage  is  the  sporulated  oocyst,  the 
environmentally-resistant  form  of  the  parasite  which  contains  4  sporocysts  (Fig. 
1.2,  b,  d)  containing  2  sporozoites  each.  Sporulated  oocysts  (Fig.  1.2,  a,  c)  can 
survive  in  a  litter  for  many  months. 
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FIG.  1.2.  Eimeria  sporulated  oocyst  structure.  Line  drawings  of  the  parts  of 
hypothetical  sporulated  oocysts/sporocysts  of  Eimeria:  a,  completely  sporulated  oocyst  showing 
major  structural  features  with  four  sporocysts  each  with  two  sporozoites;  b,  sporulated  sporocyst 
showing  major  features,  including  two  sporozoites;  c,  end  of  an  oocyst  showing  other  possible 
structures,  a  micropyle  and  micropyle  cap,  present  in  some  oocysts,  especially  those  of 
ruminants;  cl,  another  sporulated  sporocyst  showing  a  variety  of  structural  features,  some  of 
which  may  be  present  on  the  sporocysts  of  different  Eimeria  species  (a  =  anterior,  p=  posterior 
refractile  bodies  of  sporozoite)  (Duszynski,  2001). 
Unsporulated  oocysts  are  released  in  the  faeces  of  an  infected  host  (Fig. 
1.3,  u).  Under  the  appropriate  combination  of  environmental  factors  (conditions  of 
moisture,  temperature  and  direct  exposure  to  sunlight)  often  optimal  in  a  litter,  the 
oocyst  sporulates,  which  means  that  sporocysts  and  sporozoites  develop.  This  is 
an  aerobic  process  involving  high  oxygen  consumption  and  an  energy  source 
from  stored  mannitol.  Once  sporulation  is  completed  the  metabolism  is  more  lipid 
based.  The  diploid  sporoplasm  undergoes  a  meiosis  (Fig.  1.3,  v)  followed  by 
mitosis  to  form  4  sporoblasts  (Fig.  1.3,  w).  Each  sporoblast  forms  a  sporocyst 
containing  2  sporozoites  each  (Fig.  1.3,  x).  This  process  takes  about  2  days  at 
room  temperature. 
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FIG.  1.3.  Complete  life  cycle  of  Eimeria. 
(http:  //biology.  unm.  edu/biology/coccidia/eimeriabiol.  html). 
A  host  is  infected  when  it  ingests  sporulated  oocysts  from  contaminated 
food  or  water  (Fig.  1.3,  a).  The  oocyst  wall  is  mechanically  (or/and  enzymatically) 
broken  in  the  stomach/gut  of  the  host  and  the  biochemical  environment  is 
favourable  to  the  active  process  of  excystation.  Sporocysts  are  set  free  and 
exposed  to  enzymes  of  the  bile,  which  leads  to  release  of  the  sporozoites  (Fig. 
1.3,  b).  The  sporozoites  move  actively  and  enter  epithelial  cells  for  their  further 
development  (Fig.  1.3,  c).  In  E.  tenella,  the  sporozoites  penetrate  the  villus 
epithelium  of  the  caecum  at  the  tip  of  the  villi.  In  the  cell,  the  parasite  is  engulfed 
in  a  parasitophorous  vacuole  where  uninucleate  sporozoites  develop  to 
multinucleate  schizonts  (Fig.  1.3,  d)  and  schizonts  undergo  cytoplasm  division  to 
produce  merozoites  (around  900)  (Fig.  1.3,  e).  The  merozoites  break  out  of  the 
epithelium,  disrupting  the  host  cell  and  are  released  back  into  the  intestinal  lumen 
where  they  re-infect  other  epithelial  cells  (Fig.  1.3,  f).  Several  cycles  of  asexual 
multiplication  (schizogony  or  merogony)  occur  and  lead  to  the  formation  of  a 
large  number  of  merozoites  (Fig.  1.3,  g-j).  Merozoites  of  different  generations 
differ  in  size  and  quantity.  Eimeria  infections  are  self-limiting  as  asexual 
generations  are  limited  to  2  to  4  before  sexual  generation  occurs.  Then,  instead 
of  giving  a  further  generation  of  schizonts,  merozoites  re-enter  the  epithelium  and 
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begin  the  process  of  gametogony  by  which  macrogametocytes  (female  gamete) 
(Fig.  1.3,  k-o)  or  microgametocytes  (male)  (Fig.  1.3,  o-r)  are  formed.  The 
mechanism  that  triggers  this  developmental  switch  is  still  unknown.  The 
microgametocyte  buds  off  to  produce  many  flagellated  microgametes  that  leave 
the  epithelial  cells  in  which  they  were  produced  to  enter  cells  containing 
macrogametocytes  (Fig.  1.3,  s).  The  process  of  fertilisation  by  which  a 
microgamete  actively  enters  a  macrogamete,  leads  to  the  formation  of  an 
intracellular  zygote  and  the  granules  present  within  the  macrogamete  coalesce  to 
form  the  outer  cyst  wall.  The  oocyst  disrupts  the  host's  cell  membrane,  is 
released  in  the  intestinal  lumen  and  is  discharged  in  the  faeces  (Fig.  1.3,  t).  The 
entire  cycle  from  the  infection  to  the  production  of  oocyst  lasts  6  days. 
A  picture  of  a  cell-invading  merozoite  is  shown  on  Fig.  1.4.  and  a 
diagram  of  a  sporozoite  is  provided  in  Fig.  1.5.  A  typical  structural  feature  of 
apicomplexan  parasites  is  the  presence  of  a  unique  apical  complex,  composed  of 
polar  rings,  rhoptries,  micronemes,  often  a  conoid,  and  other  subcellular 
organelles  that  differ  from  species  to  species  (Tomley,  1997).  The  apical  complex 
is  involved  in  cell  invasion  (Soldati  et  a/.,  2001;  Tomley  and  Soldati,  2001).  The 
refractile  bodies,  typical  of  the  sporozoite  stage,  are  composed  of  lipid 
components  that  might  be  incorporated  into  the  parasitophorous  vacuole 
(Entzeroth  et  al.,  1998). 
FIG.  1.4.  Electron-micrograph  of  second  generation  merozoites  of  E.  tenelia. 
(Courtesy  of  Prof  D.  Ferguson,  Oxford).  C:  conoid,  D:  dense  granules,  M:  micronernes,  R: 
rhoptry. 
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FIG.  1.5.  Structure  of  a  sporozoite  of  Eimeria  species  (www.  saxonet.  de). 
The  release  of  the  merozoites  induces  rupture  of  host's  epithelial  cells, 
destroying  tissue  and  causing  haernorrhages  in  epithelial  capillaries.  This  will 
lead  to  villous  atrophy  in  the  intestine  resulting  in  malabsorption  and 
accumulation  of  cell  debris,  blood  clots,  and  necrotic  materials  in  the  caecum  of 
infected  birds  with  E.  tenella  causes  necrosis  of  the  organ,  sometimes  leading  to 
death.  Not  all  species  of  Eimeria  cause  such  dramatic  symptoms.  The 
pathogenicity  will  very  much  depend  on  the  type  of  species  ingested,  the  number 
of  sporulated  oocysts  ingested,  the  age  of  the  host  (old  chicken  for  example  may 
be  immune  against  E.  tenella),  and  the  environmental  conditions  (such  as 
crowding  effect;  Williams,  2001). 
1.2.2.  Biochemical  and  molecular  biology  features 
Studies  of  the  biochemistry  of  Eimeria  have  been  made  difficult  by  its 
intracellular  location.  It  is  therefore  difficult  to  obtain  enough  material  for  analysis 
and  parasites  cannot  be  grown  outside  of  the  host  cells.  It  is  mainly  oocysts  and 
sporozoites,  the  extracellular  stages  of  the  life  cycle  of  the  parasite,  that  have 
been  biochemically  characterised. 
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Among  the  most  peculiar  features  encountered  in  Eimeria,  there  are 
plastid-like  organelles,  the  presence  of  a  mannitol-cycle,  and  pyrophosphate- 
linked  glycolytic  enzymes  involved  in  carbohydrate  metabolism.  This  makes 
Eimeria  an  interesting  organism,  with  some  biochemical  characteristics  of 
mammals,  anaerobic  organisms,  plants  and  fungi. 
1.2.2.1.  Genomic  organisation 
The  genome  organisation  of  Eimeria  has  been  reviewed  by  Shirley  (2000) 
and  Shirley  and  Harvey  (2000).  Omeria  species  have  a  nuclear  genome  of  about 
60  Mbp  contained  on  about  14  chromosomes  of  1  to  above  7  Mbp.  The  genome 
is  currently  being  sequenced,  and  a  5-time  coverage  of  the  Houghton  strain 
genome  has  been  obtained  by  shotgun  reads 
(www.  sanger.  ac.  uk/Projects/E_tenella/).  Annotation  is  underway  and  will  be 
available  on  the  GeneDB  database.  The  GC  content  of  the  genome  has  been 
determined  for  a  few  species  and  is  around  50%  (53%  for  E.  tenella),  there  is  an 
abundance  of  the  tri-nucleotide  repeat  GCA  (Shirley,  2000),  the  codon  usage  has 
been  determined  for  nine  genes  of  E.  tenella  (Ellis  et  aL,  1994)  and  bias  was 
associated  with  the  over-representation  of  G-  or  C-rich  codons.  Additional  to  the 
nuclear  genome,  a6  kb  mitochondrial  DNA  molecule  and  a  circular  plastid  DNA 
molecule  of  about  35  kb  could  be  detected  (Williamson  et  a/.,  1994).  The  plastid 
DNA  molecule  is  contained  in  a  plastid-like  organelle,  and  it  has  been  suggested 
that  it  could  have  a  green  algae  origin  (Kohler  et  aL,  1997).  The  position  of  the 
plastid-like  organelle  in  the  cells  and  its  full  biological  function  are  unknown, 
though  it  has  been  suggested  for  other  apicomplexan  parasites  (T.  gondfl,  P. 
falciparum,  Sarcosystis  muris,  and  Babesia  ovis)  that  it  contains  some 
components  of  the  respiratory  chain  (Hackstein  et  aL,  1995),  proteins  involved  in 
haem  synthesis,  in  Type  11  fatty  acid  biosynthesis  (Vollmer  et  aL,  2001),  tRNAs 
and  transcription  factors  (Wilson  and  Williamson,  1997),  and  proteins  for 
isoprenoid  biosynthesis  (important  for  protein  prenylation  and  signal  transduction 
regulation)  (Vial,  2000).  Furthermore,  spherical  virus-like  particles  could  be 
revealed  on  electron  microscopy  and  viral-like  double-stranded  RNA  molecules 
could  be  detected  (Ellis  and  Revets,  1990),  but  the  role  of  these  RNA  viruses  in 
the  biochemistry  of  Eimeria  is  unknown  so  far. 
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Further  analysis  of  the  function  of  the  genes  requires  good  molecular 
biology  tools.  There  is  hope  that  transfection  technologies  will  provide  a  good 
method  of  study,  as  transient  transfection  in  sporozoites  of  E.  tenella  could  be 
performed  (Kelleher  and  Tomley,  1998).  But  no  gene  knock-out  or  RNA 
interference  experiments  have  been  successful  so  far,  as  studies  are  mainly 
limited  to  the  extracellular  non-replicative  forms  of  the  parasite  and  in-vitro 
propagation  of  the  life-cycle  is  very  inefficient  (Tierney  and  Mulcahy,  2003). 
1.2.2.2.  Energy  metabolism 
The  major  energy  sources  for  Smeria  through  its  life  cycle  are 
carbohydrate  compounds  (routinely  mannitol,  and  glycogen  and  amylopectin  as 
storage  forms),  though  lipids  might  be  metabolised  too  (Coombs  et  al.,  1997). 
The  presence  of  anaerobic-specific  enzymes  (like  PPi-PFK, 
phosphofructokinase,  Muller  et  al.,  2001)  in  Eimeria  suggests  that  the  parasite 
may  be  adapted  to  this  metabolic  mode  (Denton  et  aL,  1994).  Sporozoites  for 
example  may  be  facultative  anaerobes.  A  surprising  feature  is  the  presence  of 
mannitol  at  high  level  in  unsporulated  oocysts  (Schmatz  et  aL,  1989).  This  is  a 
carbohydrate  previously  detected  only  in  fungi,  with  mannitol-cycle  associated 
enzymes.  The  mannitol  cycle  occurs  in  stages  other  than  the  oocyst,  such  as 
sporozoites  (Michalski  et  al.,  1992).  The  function  though  is  still  uncertain,  though 
there  is  good  evidence  that  it  may  be  required  during  sporulation  (Allocco  et  al., 
1999).  Respiratory  chain  and  other  catabolic  pathways  are  similar  to  the  typical 
eukaroytic  pathways  and  were  reviewed  in  detail  by  Coombs  eta/.  (1997). 
Interestingly,  the  shikimate  pathway,  necessary  for  synthesis  of  aromatic 
amino  acids  and  absent  from  mammals,  is  present  in  coccidia  (Roberts  et  aL, 
1998).  This  provides  an  additional  potential  target  for  chemotherapy  and  some 
herbicide-like  compounds  have  been  found  to  have  some  efficacy  against 
enzymes  of  the  shikimate  pathway  in  apicomplexan  parasites,  like  in  Plasmodium 
falciparum  (McConkey,  1999). 
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1.2.3.  Treatment  and  control 
Avian  coccidiosis  is  considered  to  be  one  of  the  most  important 
veterinary  diseases  of  domestic  animals.  Over  the  years,  many  anti-coccidial 
compounds  have  been  shown  to  have  efficacy  and  have  been  used  as  feed 
additives  to  control  the  disease.  The  major  drugs  currently  used  against  E. 
tenella  are  polyether  ionophores  (Dutton  et  aL,  1995).  A  list  of  commercially 
available  anti-coccidial  drugs  and  their  mechanism  of  action  is  given  in  Table  1.2. 
Table  1.2.  Mechanism  of  action  of  commercially  available  avian  anticoccidial  drugs. 
(From  Coombs  et  aL,  1997). 
Compound  class  Examples  Mechanism  of  action 
Polyether  ionophore  Salinomycin  Perturb  ion  gradients 
Lasalocid 
Maduramicin 
Semduramicin 
Carban  il  ide/pyrim  Wine  Nicarbazin  Oxidative  phosphorylation  uncoupler? 
Febrifugine  Halofuginone  Not  known 
Triazine  Diclazuril  Pyrimidine  metabolism? 
Toltrazuril  Mitochondrial  respiration? 
Chlorophyll  a-D1  complex? 
Quinolone  Decoquinate  Mitochondrial  respirationlelectron  transport 
Buquinolate  Topoisomerase? 
Pyridinol  Clopidol  Mitochondrial  respiration/electron  transport 
Thiamine  analogue  Amprolium  Thiamine  uptake  and  utilisation 
Nitrobenzamide  Zoalene  Nicotinamide  antagonist? 
Nitromide 
Guanidine  Robenidine  Oxidative  phosphorylation  uncoupler? 
BenzyIpurine  Arprinocid  Purine  salvage? 
Ion  chelation  (N-oxide  active  metabolite?  ) 
Organic  arsenical 
Polyketide 
Sulphonamide 
Aminopyrimidine  and 
sulphonamide 
Roxarsone 
Oxytetracycline 
Chlortetracycline 
Sulphadimethoxine 
Sulfaquinoxiline 
Ormethoprim  and 
sulphadimethoxine 
Binds  protein  sulphydryl  groups? 
Protein  synthesis? 
Dihydropteroate  synthetase 
Dihydrofolate  reductase  and 
Dihydropteroate  synthetase 
However,  resistance  to  these  drugs  has  occurred  (Augustine  et  al.,  1996) 
and  effort  has  been  put  in  attempts  to  understand  better  the  parasite's  biology 
and  the  host  immune  response  to  the  parasite  to  find  alternative  ways  of  control, 
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like  the  development  of  vaccines.  The  basis  of  this  approach  is  the  observation 
that  it  is  possible  to  acquire  protective  immunity  to  Eimeria  species,  which  can  be 
boosted  by  increasing  the  exposure  to  the  parasite's  antigens.  Current  vaccines 
are  composed  of  oocysts  (usually  attenuated  to  avoid  averse  effect)  of  various 
species  of  Eimeria.  Commercial  live  vaccines  are  already  available,  like 
Coccivac@  (1952),  lmmunocox@)  (1987),  Paracox@  (Shirley,  1989),  Livacoxe 
(1993).  Vaccine  efficacy  has  been  reviewed  by  Chapman  et  a/.  (2002). 
Vaccination  is  the  only  alternative  to  chemotherapy  at  the  moment,  and  in 
practice  the  administration  of  drugs  remains  the  easiest,  most  cost  effective  way 
and  probably  the  most  effective  way  of  controlling  the  disease  (WaIdenstedt  et 
al.,  1999).  But  the  intensive  use  of  drugs  in  farm  animals  raises  public  health 
concerns  as  residues  of  coccidiostats  can  be  found  in  the  meat  and  this  might 
lead  to  antibiotic  resistance  in  humans.  Rotating  treatments  involving  an 
alternation  of  the  administration  of  drugs  and  vaccines,  or  of  different  vaccines,  or 
of  different  drugs  can  be  used.  Therefore,  there  are  already  methods  of  control 
available  but  none  seems  ideal  and  absolutely  efficient;  therefore  there  is  a 
constant  need  for  identifying  new  potential  drug  targets,  developing  new  drugs  or 
new  control  strategies.  Increasing  knowledge  of  the  parasite's  biology  in 
concordance  with  genome  sequencing  projects  should  bring  useful  information 
for  the  identification  and  validation  of  better  anti-coccidial  agents. 
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1.3.  Leishmania 
The  genus  Leishmania  belongs  to  the  family  of  Trypanosomatidae,  of  the 
order  Kinetoplastida.  They  are  flagellated  parasites  that  occur  as  intracellular 
amastigotes  in  vertebrate  hosts  and  promastigotes  in  invertebrate  vectors.  About 
21  species  have  been  identified  to  date,  most  of  them  having  a  specific 
mammalian  reservoir  (mainly  rodents),  and  some  of  them  being  human 
pathogens.  The  parasite  is  endemic  in  areas  of  the  tropics  and  subtropics,  in  a 
total  of  80  countries  in  South  and  Central  America,  Southern  Europe,  Asia,  the 
Middle  East,  and  Africa,  with  sporadic  cases  elsewhere  (Fig.  1.6). 
FIG.  1.6.  Leishmaniasis  distribution  in  the  world. 
(srs.  wehi.  edu.  au/media/images/handmantworld_map.  jpg) 
Leishmania  affects  2  million  people  and  causes  about  60000  deaths  a  year 
(Croft  et  al.,  2002;  Reithinger  et  al.,  2002),  and  there  has  been  an  ever  increasing 
number  of  cases  reported  every  year  over  the  last  20  years.  The  last  10  years 
have  also  seen  an  emergence  of  leishmaniasis  as  an  important  opportunistic 
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infection  in  immuno-depressed  patients;  in  particular  those  infected  with  the 
human  immunodeficiency  virus  (HIV)  (Ambroise-Thomas,  2001).  Infection  with 
Leishmania  is  also  a  frequent  cause  of  clinical  disease  in  the  dog,  especially  in 
tropical,  sub-tropical  and  temperate  areas. 
Different  Leishmania  strains  are  responsible  for  different  forms  of  the 
disease  in  humans,  with  different  severity  of  symptoms.  The  four  types  of 
diseases  are:  visceral,  cutaneous,  diffuse  cutaneous  and  mucocutaneous 
leishmaniasis.  According  to  the  human  clinical  criteria,  canine  leishmaniasis  is 
classified  as  visceral,  although  the  term  "generalized  canine  leishmaniasis"  might 
be  more  appropriate  because  it  involves  visceral  and  cutaneous  tissues  (Alvar  et 
aL,  2004). 
Visceral  leishmaniasis  is  caused  mainly  by  the  Leishmania  species  of  the 
complex  donovant,  L.  donovan!  chagasi  (in  the  Middle  East  and  Asia  mainly),  and 
L.  donovani  donovani,  L.  donovan!  infantum  and  L.  donovani  archibaldi  (in  South 
America,  mainly  eastern  Brazil)  (Desjeux,  2004).  The  parasite  infects 
macrophages  throughout  the  reticuloenend9thelial  system,  and  eventually 
reaches  spleen,  liver  and  bone-marrow  cells,  resulting  in  death  of  the  patient  if 
not  treated. 
Cutaneous  leishmaniasis  is  caused  mainly  by  L.  major,  L.  tropica,  and  L. 
aethippica  (in  Africa  and  Asia);  and  L.  guyanensis,  L.  panamensis,  and  L. 
mexicana  (in  South  and  Central  America).  In  this  case,  parasites  only  multiply  in 
the  macrophages  at  the  site  of  inoculation,  which  results  in  a  single  lesion. 
Healing  can  be  spontaneous,  resulting  in  immunity,  in  untreated  patients. 
Diffuse  cutaneous  leishmaniasis  in  caused  by  L.  aethlopica  in  Africa,  and 
by  L.  amazonensis  in  Central  and  South  America.  Symptoms  are  the  appearance 
of  widespread  nodules  in  the  skin,  which  are  difficult  to  treat  and  do  not  heal 
spontaneously. 
Mucocutaneous  leishmaniasis  is  caused  by  L.  brazifiensis  and  L. 
panamensis  in  South  America  only.  Parasites  are  inoculated  by  a  sand  fly  bite  at 
any  location  on  the  body,  which  forms  a  small  lesion  that  heals  spontaneously. 
But  the  parasites  invade  and  erode  cartilaginous  tissues  (nose  and  palate) 
causing  disfigurement  and  eventually  death  from  secondary  infections  if 
untreated. 
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Leishmaniasis  is  therefore  an  important  human  disease,  in  constant 
progression  and  emergence  of  resistance  to  available  drugs  is  an  increasing 
problem.  It  is  essential  new  drugs  are  identified  in  order  to  increase  chances  of 
controlling  the  disease. 
1.3.1.  Life  cycle  and  transmission 
The  life  cycle  of  Leishmania  alternates  between  a  vertebrate  and  an 
insect  host  (Fig.  1.7).  The  natural  reservoir  hosts,  besides  humans,  include  dogs 
and  various  wild  animals.  The  vectors  are  small  Dipteran  insects  (sandflies)  of 
the  genus  Phlebotomus  and  Lutzomyia. 
Intracellular  amastigole 
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FIG.  1.7.  Life  cycle  of  Leishmania  species.  (www.  wehi.  edu.  au/media/images/ 
leishmania_cycle.  gifl. 
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Amastigotes  (in  the  vertebrate  host)  have  virtually  no  flagellum  (Fig.  1  8). 
They  are  ingested  by  macrophages  by  phagocytosis.  The  parasites,  resistant  to 
lysosomal  enzymes  released  into  the  phagolysosome,  multiply  by  binary  fission 
within  the  macrophages  (Pearson  et  al.,  1981).  This  makes  the  macrophage  die 
eventually  and  release  the  parasites  that  can  infect  new  macrophages.  The 
sandfly  vector  (female  only)  ingests  the  infected  macrophages  from  the  blood  or 
skin,  while  having  a  blood  meal.  The  parasites  then  transform  into  procyclic 
promastigotes  in  the  midgut  of  the  insect  (Walters,  1993).  Promastigotes  are 
more  elongated,  flagellated  forms  (15-20  ltm  in  size),  with  the  kinetoplast  near 
the  anterior  end,  which  multiply  by  binary  fission  too  (Fig.  1.9).  About  10  days 
after  ingestion  of  the  parasites,  the  insect  vector  feeds  again,  and  metacyclic 
promastigotes  parasites,  which  have  migrated  from  the  midgut  to  the  proboscis, 
are  injected  into  the  vertebrate  host's  skin.  The  parasites  are  then  phagocytosed 
by  macrophages,  and  they  revert  to  the  amastigote  form  before  dividing  again 
(Sacks,  1989). 
B 
FIG.  1.8.  Ultrastructure  of  Leishmania  mexicana  amastigotes  (from  Coombs  et  al, 
1986).  The  two  electron  microscopy  images  show  that  the  lysosomes  (Lys)  occupy  a  significant 
proportion  of  the  cytoplasm,  while  organelles  of  the  secretory  pathway  are  less  conspicuous.  The 
flagellum  of  the  amastigote  stage  only  just  emerges  from  a  flagellar  pocket  (fp).  The  posterior  end 
of  the  amastigotes  is  often  intimately  connected  to  the  membrane  of  the  macrophage 
phagolysosome  compartment  (arrowheads).  N,  nucleus;  M,  mitochondrion;  k,  kinetoplast.  Scale 
bars:  500  nm. 
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FIG.  1.9.  Ultrastructure  of  Leishmania  mexicana  promastigotes  (from  Waller  and 
McConville,  2002).  Tubular  'early'  endosomes  (endo)  are  closely  associated  with  the  flagellar 
pocket  (fp).  A  single  Golgi  apparatus  is  also  proximal  to  the  flagellar  pocket  and  is  flanked  by  a 
transitional  endoplasmic  reticulum  (tER).  Multivesicular  bodies  (MVBs)  can  be  seen  arising.  The 
lysosome  compartment,  termed  the  multivesicular  tubule  (MVT)  extends  from  near  the  flagellar 
pocket,  in  close  proximity  to  IVIVBs,  to  the  posterior  end  of  the  cell.  One  or  two  microtubules  (mt) 
run  along  the  length  of  the  MVT-lysosome.  Acidocalcisomes  (ac)  cluster  principally  in  the 
posterior  of  the  cell  (note  that  glutaraldehyde  and  osmiurn  fixation  extracts  the  contents  of  some 
of  the  acidocalcisomes).  N,  nucleus.  Scale  bars:  500  nm. 
1.3.2.  Biochemical  and  molecular  biology  features 
Studies  of  the  biochemistry  of  Leishmania  have  been  possible  due  to  the 
relatively  easy  maintenance  of  the  promastigote  form  of  the  parasite  in  culture. 
The  promastigotes  multiply  by  binary  fission  and  differentiate  into  metacyclic 
promastigotes  when  reaching  the  stationary  phase  of  growth.  This  has  made 
genetic  manipulations,  and  studies  of  particular  gene's  functions  possible. 
Among  the  most  peculiar  features  present  in  Leishmania,  is  the 
kinetoplast,  a  unique  cellular  structure  located  within  the  single  mitochondrion 
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and  possessing  its  genetic  information.  The  kinetoplast  is  located  at  the  base  of 
the  flagellum  near  the  anterior  end  (Fig.  1.8).  At  the  metabolic  level,  glycolysis  is 
a  regulated  event  that  takes  place  in  the  glycosomes,  which  are  specific 
organelles  related  to  peroxisomes  (Parsons,  2004),  and  oxidative  stress  is 
regulated  using  trypanothione,  an  antioxidant  absent  from  the  mammalian  host, 
which  utilises  glutathione  instead. 
1.3.2.1.  Genomic  organisation 
Leishmania  is  a  diploid  organism.  The  haploid  genome  of  Leishmania 
major  Friedlin  (the  subject  of  this  study)  is  composed  of  36  chromosomes,  that 
vary  in  size  from  326.9  to  2821.3  kb,  with  a  total  genome  size  of  34.7  Mb  (Zhou 
et  aL,  2004).  In  terms  of  codon  usage,  the  G+C  content  at  the  third  codon 
position  represents  the  main  source  of  codon  usage  variation  (Alvarez  et  aL, 
1994).  The  genome  is  divided  into  transcription  units  (Myler  et  aL,  2000),  which 
are  transcribed  into  polycistronic  mRNAs.  The  control  of  gene  expression  is 
mainly  post-transcriptional,  using  trans-splicing  and  polyadenylation,  which 
require  the  addition  of  a  5'  cap  and  a  3'  poly  A  tail.  At  the  5'  end  of  all  mRNAs,  a 
splice  leader  sequence  (SQ  is  added  by  trans-splicing  (Graham,  1995).  The  SL 
sequence  is  composed  of  a  non-translated  39-41  nucleotide  sequence,  which  is 
well  conserved  between  trypanosomatid  species  (Gibson  et  al,  2000).  At  the  3' 
end  no  specific  signal  for  the  addition  of  the  poly  A  tail  has  yet  been  described, 
although  polypyrimidine  tracts  have  been  identified. 
Additional  to  the  nuclear  genome,  the  kinetoplast  contains  a  catenated 
network  of  DNA  (kDNA),  which  can  be  divided  into  2  groups:  maxicircles  and 
minicircles,  where  maxicircles  are  found  at  a  copy  number  of  20-50  per 
kinetoplast,  and  minicircles  are  present  at  about  10000  per  kinetoplast. 
Maxicircles  are  homogeneous  circular  DNA  molecules,  20-35  kb  in  size,  which 
have  many  of  the  characteristics  of  conventional  mitochondrial  DNA,  encoding 
proteins  involved  in  energy  production.  Minicircles  are  a  heterogeneous  group 
and  0.5-1.5  kb  in  size,  which  differ  in  sequence  number  and  types  from  species 
to  species.  They  do  not  encode  proteins,  but  encode  for  guide  RNAs  (gRNAs), 
which  have  a  role  in  the  maturation  of  the  mitochondrial  mRNAs,  a  process 
known  as  RNA  editing,  a  process  typical  of  trypanosomatids  (Schneider,  2001). 
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After  transcription,  U  nucleotides  are  inserted,  and  create  open  reading  frames 
from  non-sense  sequences  at  the  RNA  level  (Benne  et  al.,  1986).  U  deletions 
can  also  occur,  but  at  lower  frequencies.  The  small  RNA  molecules  transcribed 
from  the  minicircles  and  maxicircles  contain  the  editing  information  (Simpson  et 
al.,  2004).  RNA  editing  is  used  as  a  mechanism  of  regulation  of  mitochondrial 
gene  expression  (Worthey  et  al.,  2003). 
1.3.2.2.  Energy  metabolism  and  trypanothione 
Leishmania  species  present  a  number  of  particular  biochemical  features. 
First,  they  present  a  unique  compartmentation  of  glycolysis  within  unusual 
peroxisomes  called  glycosomes.  Like  peroxisomes,  glycosomes  are  bounded  by 
a  single-membrane.  In  Leishmania  amastigotes,  glycosomes  comprise  1%  of  the 
total  cell  volume  (Coombs  et  al.,  1986).  Some  enzymes  commonly  found  in 
peroxisomes  are  also  found  in  the  glycosomes  (Wiemer  et  al.,  1996).  So  the 
glycosomes  might  have  evolved  from  peroxisomes,  but  might  also  reflect 
recruitment  of  proteins  from  a  photosynthetic  organism  through  lateral  gene 
transfer  by  endosymbiosis  (Hannaert  et  a/.,  2003)  or  phagocytosis  (Waller  et  a/., 
2004).  This  photosynthetic  organism  is  thought  to  have  been  an  alga,  as  some 
pathways  are  related  to  those  of  algae,  plants  and  chloroplasts  (Hannaert  et  al., 
2003),  and  some  plastid-like  proteins  are  found  in  the  glycosome.  Glycolysis 
occurs  as  a  result  of  a  cooperation  between  the  cytoplasm,  the  mitochondrion 
and  the  glycosome,  and  purines,  which  the  parasite  cannot  synthesise  de  novo, 
are  also  salvaged  using  enzymes  associated  with  glycosomes.  Although  some 
enzymes  of  glycolysis  are  similar  to  those  of  the  mammalian  host,  the  glycosome 
possesses  unique  enzymes  of  algal  origin,  which  may  be  interesting  for  drug 
design  (Parsons,  2004). 
Another  interesting  characteristic  is  that  Leishmanla  parasites  regenerate 
thiols  using  trypanothione  (a  glutathione-spermidine  conjugate),  rather  than 
glutathione  (Henderson  and  Fairlamb,  1987).  This  is  the  anti-oxidant  used  to 
reduce  hydrogen  peroxide  and  other  oxidants.  Trypanothione  and  the  enzymes 
involved  in  its  synthesis  and  recycling  are  absent  from  the  mammalian  host  and 
so  have  been  proposed  as  suitable  targets  against  which  to  develop  drugs 
(Faidamb  and  Cerami,  1992;  Chibale  and  Musonda,  2003). 
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1.3.3.  Treatment  and  control 
As  a  first  strategy  of  control  of  the  disease,  the  elimination  of  natural 
reservoirs  such  as  dogs,  rodents  and  insect  vectors  has  been  used.  Sandfly 
population  control  is  an  ongoing  process  and  continued  surveillance  is  required 
to  keep  the  population  low.  However,  this  is  possible  only  under  certain 
environmental  conditions.  Therapy  against  leishmaniasis  mainly  relies  upon 
pentavalent  antimonials,  which  have  been  used  since  the  1940's,  and  include 
sodium  stibogluconate  or  meglumine  antimonite;  a  prolonged  course  being 
necessary  for  treatment.  The  mode  of  action  is  unclear,  but  the  retention  in 
macrophages  and  conversion  to  more  toxic  trivalent  derivative  are  important 
factors  (Shaked-Mishan  et  al.,  2001).  Pentamidine  is  used  as  an  alternative  to 
antimonials,  in  case  the  latter  are  not  effective  (Amato  et  al.,  1998).  But 
pentamidine  resistance  has  been  described,  relying  on  the  decrease  in 
mitochondrial  membrane  potential,  which  prevents  the  accumulation  of  the  drug 
in  the  mitochondrion  and  thus  reduces  its  toxicity  (Basselin  et  aL,  2002). 
Amphotericin  B,  an  antibiotic,  is  also  used,  where  resistance  to  other  drugs 
occurs  (Olliaro  and  Bryceson,  1993).  Many  of  these  treatments  present  severe 
side  effects,  or  are  too  expensive  for  extensive  use  in  developing  countries. 
Antimonials  have  a  cumulative  toxicity  and  parasites  are  increasingly  becoming 
resistant  to  these  drugs  (Croft  et  a/.,  2002).  Pentamidine  is  expensive  and  more 
toxic;  amphotericin  B  has  lower  toxicity  but  is  even  more  expensive.  Vaccines 
have  not  been  successful  so  far  due  to  the  complexity  of  the  immune  response 
caused  by  the  parasite  (Croft  and  Coombs,  2004).  Recently  a  new  compound 
inhibiting  various  enzymes  of  cell  signalling  pathways,  miltefosine,  has  been 
registered  for  use  against  leishmaniasis  (Seifert  et  al.,  2003),  but  there  is  a  need 
for  new  drug  discovery  and  validation  of  new  treatments. 
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1.4.  Aims  of  this  study 
The  overall  aim  of  this  project  was  to  identify  and  characterise  cysteine 
peptidases  as  possible  drug  targets  in  the  parasitic  protozoa  Eimeria  and 
Leishmania. 
This  project  was  divided  into  2  parts: 
-  Identification  of  cathepsin  B-like  peptidases  (clan  CA,  family  Cl)  in  Omeria 
tenella,  production  of  active  recombinant  enzyme  for  biochemical 
characterisation  and  drug  screening,  and  production  of  specific  antibodies  to 
study  the  localisation  of  the  enzyme  in  the  parasite. 
-  Identification  and  characterisation  of  genes  encoding  a  pyroglutamyl 
peptidase  I  (cysteine  peptidase  of  the  clan  CF,  never  described  before  in 
parasites)  in  Leishmania  major,  production  of  active  recombinant  enzyme  for 
biochemical  characterisation,  and  study  of  its  role  by  gene  replacement  and  over- 
expression  in  the  parasite. 
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Chapter  2 
Material  and  Methods 
2.1.  Parasites 
2.1.1.  Eimeria  tenella  sporozoite  preparation 
A  suspension  of  sporulated  oocysts  of  E.  tenella  (H  strain)  at  a 
concentration  of  107  cells/ml  in  5%  (w/v)  sodium  hypochlorite,  1%  (w/v) 
amphotericin  B  was  kindly  provided  by  Intervet,  Schwabenheim,  Germany.  About 
108  sporulated  oocysts  were  washed  in  phosphate-buffered  saline  (PBS)  (20  mM 
sodium  phosphate  buffer,  150  mM  sodium  chloride,  pH  7.4),  with  3  min 
centrifugation  at  13000  g  at  room  temperature  to  sediment  them  between  each 
wash.  The  oocysts  were  resuspended  in  5  ml  PBS  and  5  ml  3  mm  sterile  glass 
beads  (Sigma,  Poole)  were  added.  The  sample  was  vortexed  for  a  few  minutes, 
checking  regularly  by  phase  contrast  microscopy  for  release  of  sporocysts.  The 
sporocysts  suspended  in  the  liquid  phase  were  transferred  into  a  fresh  tube,  the 
beads  were  washed  with  PBS  and  the  liquid  phase  containing  sporocysts  was 
added  to  the  first  batch  of  sporocysts.  The  combined  sporocyst  sample  was 
centrifuged  at  800  g  for  5  min  at  room  temperature.  The  cloudy  supernatant  was 
removed  and  pelleted  sporocysts  were  resuspended  in  1%  (w/v) 
taurodeoxycholic  acid  containing  0.25%  (v/v)  trypsin  (Sigma,  Poole,  ref.  T4549) 
and  placed  in  a  shaking  water  bath  at  440C  for  1  h.  Subsequently,  the  excystation 
mixture  was  filtered  through  a  non-absorbent  cotton  wool  column  and  the  -95% 
pure  sporozoites  were  collected  in  the  flow  through  (contaminated  by  some  cell 
debris).  The  sporozoites  were  sedimented  at  3000  g  for  5  min  at  room 
temperature  and  used  immediately  or  stored  at  -200C.  The  efficiency  of 
excystation  of  6  to  12  months  old  sporulated  oocysts  was  about  50%.  The 
sporulated  oocysts  used  were  not  older  than  12  months.  The  overall  efficiency  of 
sporozoite  purification  was  30  to  35%. 
2.1.2.  Leishmania  major  culture 
Leishmania  major  (MHOM/IU80/Friedlin)  promastigotes  were  cultured  in 
HOMEM  medium  (Berens  et  al.,  1976)  (GibcoBRL,  Paisley)  with  10%  (v/v)  heat 
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inactivated  foetal  calf  serum  (HIFCS)  at  2511C  with  air  as  the  gas  phase.  Cultures 
were  inoculated  at  _105  cells/  mi  and  cells  were  sub-passaged  when  stationary 
phase  was  reached  (1-2  x  107  cells/ml)  (after  about  one  week). 
L.  major  metacyclic  promastigotes  were  purified  from  stationary  phase 
cultures  as  described  by  Da  Silva  and  Sacks,  1987.  Briefly,  promastigotes  were 
pelleted  at  1300  g  for  10  min  at  40C,  washed  in  PBS  and  resuspended  in  PBS  at 
108  cells/mi.  Peanut  agglutinin  (Vector  Laboratories,  Burlingame,  CA,  US)  was 
added  at  50  [tg/ml  (w/v)  and  the  sample  was  incubated  25  min  at  room 
temperature.  The  supernatant  contained  the  non-agglutinated  metacyclic 
promastigotes. 
L.  ma  r  amastigotes  were  purified  from  infected  BALB/c  mice  by  Susan  VO 
Baillie  (University  of  Glasgow)  as  described  (Hart  et  al.,  1981)  and  incubated  at 
250C  in  presence  of  30  ILLg/ml  gentamicin  (Sigma,  Poole). 
The  densities  of  all  cultures  were  determined  using  an  improved  Neubauer 
haernacytometer  (Weber  Scientific,  Hamilton,  NJ,  US). 
2.1.3.  L.  major  harvest  and  lysis 
Parasites  were  harvested  by  centrifugation  at  1300  g  for  10  min  at  40C, 
washed  twice  in  PBS,  and  stored  at  -800C  until  use.  Parasites  were  lysed  by 
resuspension  to  a  concentration  in  parasite  equivalents  of  2x  109  cells/ml  in  lysis 
buffer,  composed  of  50  mM  Tris/HCl  pH  8.0,0.25%  (v/v)  Triton  X-100,20%  (v/v) 
glycerol,  and,  unless  stated  otherwise,  a  cocktail  of  peptidase  inhibitors  (10  [IM 
(2S,  3S)-3-(N-{(S)-I  -[N-(4-guanidinobutyl)  carbamoyl]3-methylbutyl}carbamoyl) 
oxirane-2-carboxylic  acid  [E-64],  2  mM  1,10-phenanthroline,  4  l.  LM  pepstatin  A,  I 
mM  phenylmethylsulfonyl  fluoride  [PMSF]).  The  mixture  was  incubated  for  10  min 
on  ice  and  centrifuged  at  13000  g  for  15  min  at  411C.  The  supernatant  (designated 
as  the  soluble  fraction)  was  separated  from  the  pellet,  and  the  pellet  (designated 
as  the  membrane-bound  fraction)  was  resuspended  in  the  same  volume  as 
before  in  lysis  buffer.  Both  samples  were  either  used  immediately  or  stored  at  - 
200C  until  use. 
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2.1.4.  L.  major  cryo-preservation 
Stationary  phase  L.  major  promastigotes  were  pelleted  at  1300  g  for  10 
min  and  resuspended  at  108  cells/ml  in  HOMEM  medium  with  10%  (v/v)  HIFCS. 
One  ml  of  cell  suspension  was  mixed  with  1  ml  of  HIFCS  containing  30%  (v/v) 
glycerol  in  a  cryotube  vial  (Nunc,  Roskilde,  Denmark),  and  placed  overnight  at  - 
700C  in  an  isopropyl  alcohol  bath  (for  slow  decrease  of  temperature),  before 
transfer  to  liquid  nitrogen  (-196"C)  for  long-term  preservation  up  to  several  years. 
2.1.5.  Bloassay  for  leishmanicidal  activity 
Promastigote  viability  was  measured  using  the  3-(4,5-dimethylthiazol-2-yi)- 
2,5-diphenyl  tetrazoliurn  bromide  (MTT)  assay  as  described  in  Silva  et  aL,  2000. 
The  assay  is  based  on  the  loss  of  mitochondrial  activity  associated  with  cell 
death,  and  therefore  loss  of  the  capacity  of  reduction  of  MTT  (yellow)  into 
formazan  (blue).  L.  major  promastigotes  were  pelleted  at  1300  g  for  10  min  and 
resuspended  at  5.5  x  107  cells/ml  in  PBS.  5x  106  L.  major  cells  were  incubated  in 
a  microtiter  plate  with  gomesin  and  gomesin  analogues  at  various  concentrations 
in  a  total  volume  of  100  gl.  Gomesin  and  gomesin  analogues  were  kindly 
provided  by  Dr  Antonio  de  Miranda  (Sao  Paolo,  Brazil).  The  primary  amino  acid 
structure  of  gomesin  is  ZCRRLCYKQRCVTYCRGR*  (using  the  single  letter 
amino  acid  code,  were  Z  stands  for  pyroglutarnate  and  the  asterisk  indicates  an 
a-amide)  (Silva  et  al.,  2000).  The  gomesin  analogues  were  [Ala']-gomesin, 
where  the  N-terminal  pyroglutarnate  was  replaced  by  an  alanine,  and  Ac-[Alal]- 
gomesin,  where  the  N-terminal  pyroglutarnate  was  replaced  by  an  acetylated 
alanine.  After  an  incubation  of  1h  at  250C,  100  gl  of  2  mg/ml  MTT  dissolved  in 
PBS  was  added  (final  concentration  of  1  mg/ml),  the  mixture  was  incubated  for  1 
h  at  2511C,  and  then  the  absorbance  at  620  nm  was  read  using  a  microtiter  plate 
reader. 
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2.2.  Molecular  biology  techniques 
2.2.1.  Isolation  of  genomic  DNA  from  E.  tenella  and  L.  major 
1x  108  E.  tenella  sporozoites  or  L.  major  promastigotes  were  pelleted  by 
centrifugation  at  1300  g  for  10  min  at  4*C  and  the  cells  were  resuspended  in  150 
l.  d  of  TELT  buffer  (50  mM  Tris-HCI  pH  8.0,62.5  mM  ethylenediamine  tetraacetic 
acid  [EDTA],  2.5  M  LiCl,  4%  (v/v)  Triton  X-100)  (Medina-Acosta  and  Cross, 
1993).  The  suspension  was  incubated  for  5  min  at  room  temperature,  before 
addition  of  150  ýd  of  phenol-chloroform  (1:  1,  v/v).  The  sample  was  gently  mixed 
by  inversion  and  centrifuged  at  13000  g  for  5  min  at  411C.  The  aqueous  phase 
was  transferred  to  a  new  microfuge  tube  and  0.1  volume  of  3M  sodium  acetate 
and  2  volumes  of  100%  ethanol  were  added  to  precipitate  the  DNA.  The  mixture 
was  incubated  5  min  on  ice  before  centrifugation  at  13000  g  for  5  min  at  room 
temperature.  The  DNA  pellet  was  washed  with  70%  (v/v)  ethanol,  air  dried  briefly 
and  resuspended  in  50  pl  of  TE  buffer  (10  mM  Tris/HCl  pH  8.0,1  mM  EDTA). 
After  RNAse  H  (Sigma,  Poole)  treatment  (1  mg/ml)  for  1h  at  370C,  the  sample 
was  stored  at  40C. 
2.2.2.  Isolation  of  genomic  DNA  from  Pichia  pastoris 
A  single  colony  was  used  to  inoculated  10  ml  of  YPD  medium  (1  %  (w/v) 
yeast  extract,  2%  (w/v)  peptone,  2%  (w/v)  glucose)  and  grown  overnight  at  30*C, 
300  rpm  shaking.  Cells  were  pelleted  at  1500  g  for  10  min,  washed  with  10  ml  of 
sterile  water  and  resuspended  in  2  ml  of  SCED  solution  (1  M  sorbitol,  10  mM 
sodium  citrate,  pH  7.5,10  mM  EDTA,  10  mM  dithiothreitol  [DTT]).  To  disrupt  the 
yeast  cell  wall,  0.3  mg  of  lyticase  (227  U/mg,  Sigma,  Poole)  was  added  and 
incubated  without  shaking  at  370C  for  30  min.  Then  2  ml  of  1%  (w/v)  sodium 
dodecylsulfate  (SIDS)  were  added,  and  the  mixture  was  incubated  for  5  min  on 
ice,  before  addition  of  1.5  ml  of  5M  potassium  acetate,  pH  8.9,  and  centrifugation 
at  10000  g  for  10  min  at  40C.  Two  volumes  of  ethanol  were  added  to  the 
supernatant  and  the  mixture  was  incubated  for  15  min  at  room  temperature, 
before  centrifugation  at  10000  g  for  20  min  at  4*C.  The  pellet  was  resuspended  in 
0.7  ml  of  TE  buffer  and  1  volume  of  phenol/chloroform  (1:  1)  was  added,  before 
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centrifugation  at  10000  g  for  10  min  at  40C.  One  volume  of  chloroform  was  added 
to  the  aqueous  phase,  and  centrifuged  as  before.  Then  0.5  volume  of  7.5  M 
ammonium  acetate,  pH  7.5,  and  2  volumes  of  ethanol  were  added  to  the 
aqueous  phase,  and  the  mixture  was  incubated  for  10  min  on  dry  ice.  The 
sample  was  centrifuged  at  13000  g  for  20  min  at  40C,  the  pellet  was  washed  with 
1  ml  of  70%  (vIv)  ethanol,  air  dried  and  resuspended  in  100  ltl  of  TE  buffer.  The 
DNA  was  stored  at  411C. 
2.2.3.  Isolation  of  total  RNA 
2.2.3.1.  E.  tenella 
Total  RNA  from  E.  tenella  sporulated  oocysts;  (H  strain)  was  isolated  using 
the  method  described  in  Johnston  et  al.,  1998.  The  RNA  obtained  was  further 
DNase  treated  for  30  min  at  370C  using  1  U/ýtg  of  RNA  isolated  (DNase  1, 
RNase-free,  Sigma,  Poole)  before  storage  at  -70"C. 
2.2.3.2.  L.  major 
1x  108  L.  major  promastigotes  were  pelleted  at  1500  g  for  10  min  at  40C 
and  resuspended  in  1  ml  of  TRIzol@  reagent  (GibcoBRL,  Paisley).  The 
suspension  was  incubated  at  room  temperature  for  5  min,  0.2  ml  of  chloroform 
was  added  and  the  suspension  was  incubated  at  room  temperature  for  2  min, 
before  being  centrifuged  at  13000  g  for  15  min  at  40C.  The  upper  aqueous  phase 
was  transferred  to  a  fresh  tube  and  0.5  ml  of  isopropyl  alcohol  was  added.  The 
suspension  was  mixed  vigorously  and  incubated  at  room  temperature  for  10  min, 
before  being  centrifuged  at  12000  g  for  10  min  at  411C.  The  supernatant  was 
discarded  and  1  ml  of  70%  (v/v)  ethanol  was  added  to  the  RNA  pellet,  mixed  and 
centrifuged  at  7500  g  for  5  min  at  40C.  This  step  was  repeated,  before  air-drying 
of  the  pellet,  and  resuspension  in  100  pl  of  double  distilled  water  (ddH20).  The 
RNA  obtained  was  further  Dnase-treated  for  30  min  at  370C  using  1  U/Pg  of  RNA 
isolated  (DNase  1,  RNase-free,  Sigma,  Poole)  before  storage  at  -700C.  All 
equipment  and  reagents  were  made  RNAse-free  by  treatment  with 
diethylpyrocarbonate  (DEPC)  at  0.01  %  (v/v). 
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2.2.4.  Polymerase  chain  reaction  (PCR) 
PCR  was  used  to  amplify  fragments  of  DNA  situated  between  two  known 
regions.  All  oligonucleotides  (or  primers)  were  synthesised  by  MWG-Biotech, 
Ebersberg,  Germany.  The  two  primers  used  in  each  amplification  had  sequences 
complementary  to  those  flanking  the  region  to  amplify.  The  annealing 
temperature  and  elongation  time  for  the  PCR  cycles  where  optimised  for  each 
reaction.  A  summary  of  all  the  primers  used,  their  sequences  and  melting 
temperatures  (Tm)  is  presented  in  Table  2.1.  The  machine  used  was  the 
GeneAmp  PCR  system  2400  (Perkin  Elmer,  Beaconsfield).  If  Trn  was  high,  the 
maximum  temperature  used  for  annealing  was  650C. 
For  reactions  using  the  Taq  polymerase  system  (Promega,  Southampton), 
the  final  concentrations  of  the  PCR  reagents  were  IX  Thermophilic  DNA  buffer 
(provided  with  the  enzyme),  1.5  mM  MgC12,0.5  mM  dNTPs  mix,  100  pmol  of 
each  primer,  50-100  ng  of  cDNA  or  gDNA,  1  unit  of  Taq,  in  a  total  volume  of  50 
pl.  PCR  cycles  were:  940C  for  2  min,  1  cycle;  940C  for  1  min,  Trn-511C  for  1  min, 
720C  for  1x  (number  of  kb  of  fragment  to  amplify)  min,  30  cycles;  7211C  for  7  min. 
For  reactions  using  the  High  Fidelity  PCR  system  (Roche,  Lewes),  the 
final  concentrations  of  the  PCR  reagents  were  1X  PCR  buffer  2  (with  1.5  mM 
MgCl2  final  concentration,  provided  by  the  manufacturer),  0.5  mM  dNTPs  mix, 
100  pmol  of  each  primer,  50-100  ng  of  cDNA  or  gDNA,  2.5  units  of  High  Fidelity 
enzyme,  in  a  total  volume  of  100  til.  PCR  cycles  were:  800C  for  5  min,  1  cycle; 
940C  for  2  min,  1  cycle;  940C  for  15  s,  Trn-511C  for  30  s,  720C  for  1.5  x  (number  of 
kb  of  fragment  to  amplify)  min,  30  cycles;  720C  for  7  min. 
For  reactions  using  the  Long  Template  PCR  system  (Roche,  Lewes),  the 
final  concentrations  of  the  PCR  reagents  were  1X  PCR  buffer  2  (with  2.75  mM 
MgCl2  final  concentration),  0.5  mM  dNTPs  mix,  100  pmol  of  each  primer,  50-100 
ng  of  gDNA,  3.75  units  of  polymerase  enzyme  mix,  in  a  total  volume  of  50  ýd. 
PCR  cycles  were:  9411C  for  2  min,  1  cycle;  940C  for  10  s,  Tm-50C  for  30  s,  6811C 
for  Ix  (number  of  kb  of  fragment  to  amplify)  min,  25  cycles;  6811C  for  7  min. 
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Table  2.1.  Summary  of  the  primers  used,  their  sequences  and  Tm  (melting 
temperature  In  OC).  A,  adenine;  T,  thymine;  C,  cytosine;  G,  guanine;  1,  inosine. 
RACE  Primers  Sequence  (5'-3')  Tm 
CatBGSP  AGCAGGTACGGCAGCAACTC  61.4 
CatBGSP1  TGCCGACGGAAGTGATCCCGC  65.7 
CatBGSP2  ACAACCTCATGGCCTCCTGG  61.4 
AAP  GGCCACGCGTCGACTAGTACGGG[IGGGIIGGGIIG  >75 
AUAP  GGCCACGCGTCGACTAGTAC  54.7 
sl  TAACGCTATATAAGTATCAGTTTC  65 
PPracel  GGGTGGCGCTTCAGGCCCTCCG  71T 
PPrace2  GTGATGAACACGACGATGCCCG  64 
QCracel  GCAGGCTCGAGTGGGGTGTTG  65.7 
QCrace2  GATGAGACAGAGCAGGATGCCCATG  66.3 
PCR  Primers  Sequence  (5'-3')  Tm 
pETNdeCatBfor  GTTGTCATATGCCCTCCGATGAMGGG  66.6 
PETXhoCatBrev  GCCTCTCGAG17ATAGGTCCTGCGCTGACGGCAG  >75 
pETCatB31  or  AAGGCATATGGGTACTTACCMCTTTCTATTCAG  66 
pETCatB31rev  GCCTCTCGAGTCATAGGTCCTGCGCTGACG  73.6 
pGAPCatBfor  ATCACAGCAGCCTCGAGAAGCGGGAGGCCGAAGCTATGCCCTCCGATG  >75 
pGAPCatBrev  GGTGCCGCGGTAGGTCCTGCGCTGACGG  >75 
pGAPCatBre%19  .2  GGTGCCGCGGTTATAGGTCCTGCGCTGACGG  >75 
pPIC9CatBfor  GCGGCTACGTAATGCCCTCCGATGATTTGGG  72.1 
pPIC9CatBrev  GGTGCCTAGGTTATAGGTCCTGCGCTGACGG  73.5 
TAOM  GCAAATGGCATTCTGACATCC  57.9 
5'AOX1  GACTGGTTCCAATTGACAAGC  57.9 
a-factor  TACTATTGCCAGCATTGCTGC  57.9 
LmPPfor  CGCTTCATATGCTGCACTCCAAGGCG  68 
LmPPrev  CGATGGTCGACTCACATGGTCATCAAAG  66.6 
OEforLmPP  GGAGAGATATCATGGGCAGCCATCATCATCATC  71.9 
OErevLmPP  GCTTGGATCCTCACATGGTCATCAAAGACAGCAGG  71.7 
Hind5lor  CTGCTAAGCTTGCTGCTACTCGCCTACTTGCCTCG  74.2 
Sal5'rev  AGTGGTCGACTTrAAGCGGTGCGGAACTGCGAGG  74.3 
SmaTfor  GACCCCCGGGCGAAGACATCGTTCGCAGCGAAGG  >75 
Bgl3'rev  CTCCAGATCTTACCCGTTTCACGTTACACGGCTG  71.9 
CheckKOPPFor  CTGCGGCAGCTTGTCCTGCTACTAGTG  69.5 
CheckKOPPRev  GCACCGCTCCTTCGCTGCGAACG  69.6 
QCfor  TCTGCATATGCTCACCTGGAAGAGCAACC  68.1 
QCrev  TTGTAAAGCTTTCATTCMACGCGTCCAG  64 
QCshortfor  GCGGCATATGCTGAAGCCGAGTCTGTCCGCG  74.8 
Mutagenesis  Primers  Sequence  (51-31)  Tm 
mutCatBXa  or  GGTGMGCGGAGATCGAGGGGCGTCTGGAAACTGACAAG  >75 
mutCatBXarev  CTTGTCAGMCCAGACGCCCCTCGATCTCCGCAAACACC  >75 
mutCatBTEVfor  CTGCCTGTGAAGGAGATTGTGGACTCGCAGCGGGTTCTGGAAACTG  >75 
mutCatBTEVrev  CAGTTTCCAGAACCCGCTGCGAGTCCACAATCTCCTTCACAGGCAG  >75 
mutCPPfor  CAGGGCGCTACCTGGCCAACTGCGCCCTC  >75 
mutCPPrev  GAGGGCGCAGTTGGCCAGGTAGCGCCCTG  >75 
mutHPPfor  GGCATCTTCGTTAGCGTTGTCGATCCG  68 
mutHPPrev  CGGATCGACAACGCTAACGAAGATGCC  68 
mutEl  PPfor  GGCTCATCTGCGTTCAGGTGCAGGGCTGC  73.7 
mutEl  PPrev  GCAGCCCTGCACCTGAACGCAGATGAGCC  73.7 
mutE2PPfor  CAGGGCTGCAACCAGCTCTTTTCTAGCG  695 
mutE2PPrev  CGCTAGAAAAGAGCTGGTTGCAGCCCTG  69.5 
47 Chapter  2:  Material  and  Methods 
2.2.5.  Reverse  transcription  (RT)-PCR 
2.2.5.1.  cDNA  synthesis 
Five  gg  of  total  RNA  from  E.  tenella  sporozoites  or  L.  major  promastigotes 
were  added  to  10  pmol  of  oligo-dT  primer  in  a  total  volume  of  11  ýd.  The  mix  was 
incubated  for  10  min  at  700C  and  placed  on  ice  for  1  min.  Four  ýd  of  5X  First 
Strand  buffer  (provided  with  the  enzyme),  2  [ti  of  0.1  M  DTT,  1  ýd  of  10  mM  dNTP 
mix  and  40  units  RNase  OUT  (GibcoBRL,  Paisley)  were  added  and  the  mix  was 
equilibrated  at  420C  for  5  min  before  addition  of  200  units  of  SUPERScript  11 
(GibcoBRL,  Paisley).  The  sample  was  incubated  for  50  min  at  420C,  then  15  min 
at  7011C  to  terminate  the  reaction.  After  incubation  on  ice  for  a  few  minutes,  2 
units  of  RNase  H  (Sigma,  Poole)  were  added  and  the  mix  was  incubated  for  20 
min  at  370C  to  eliminate  the  template  RNA,  before  storage  at  -200C.  As  a 
negative  control  and  to  rule  out  that  any  subsequent  PCR  may  produce 
fragments  from  amplification  on  remaining  gDNA,  a  sample  of  RNA  was  treated 
as  described  above,  except  that  the  addition  of  SUPERScript  11  enzyme  was 
omitted.  This  sample  was  used  as  template  for  negative  control  PCRs  on  cDNA. 
2.2.5.2.  Rapid  amplification  of  cDNA  ends  (RACE) 
2.2.5.2.1.  Gene  encoding  a  cathepsin  B-like  enzyme  In  E.  tenelia 
To  confirm  the  chosen  start  methionine,  an  experiment  of  rapid 
amplification  of  cDNA  ends  was  performed  at  the  5'  end  (5'  RACE  system  kit, 
GibcoBRL,  Paisley).  Total  mRNA  from  sporozoites  was  transcribed  into  single- 
stranded  cDNA  using  SUPERScript  11  reverse  transcriptase  and  the  specific 
primer  CatBGSP.  Excess  dNTPs  and  primer  were  removed  from  cDNA  and  a 
homopolymeric  tail  of  dCs  was  added  to  the  end  of  the  single-stranded  cDNA 
using  terminal  deoxynucleotidyl  transferase,  following  the  manufacturer's 
instructions.  The  5'  end  was  then  amplified  from  dC-tailed  cDNA  using  the 
abridged  anchor  primer  (AAP)  and  the  specific  nested  primer  CatBGSP1  with  the 
Taq  polymerase,  followed  by  a  secondary  amplification  using  the  abridged 
universal  anchor  primer  (AUAP)  and  the  catBGSP2  primer  with  the  Taq 
polymerase. 
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2.2.5.2.2.  Gene  encoding  a  pyroglutamyl  peptidase  I-like  enzyme  in  L.  major 
PCR  on  total  clDNA  was  performed  using  a  primer  with  a  sequence 
complementary  to  the  splice  leader  (SL  primer)  and  the  PPracel  primer,  with  the 
Taq  polymerase.  PCR  product  was  diluted  1:  50  (v/v)  in  ddH20  and  2  PI  were 
used  as  a  template  for  a  semi-nested  PCR  using  the  SL  and  the  PPrace2 
primers,  with  the  Taq  polymerase. 
2.2.5.2.3.  Gene  encoding  a  glutaminyl  cyclase-like  enzyme  in  L.  major 
The  same  method  as  in  2.2.5.2.2.  was  used,  with  the  SL  and  QCracel 
primers  for  the  first  PCR,  and  the  SL  and  QCrace2  primers  for  the  second  PCR. 
2.2.6.  Site-directed  mutagenesis 
Site-directed  mutagenesis  was  used  to  introduce  site-specific  mutation  in 
the  gene  encoding  the  cathepsin  B-like  enzyme  of  E.  tenella  in  order  to  introduce 
Factor  Xa  (with  the  primers  mutCatBXafor  and  mutCatBXarev,  7  point-mutations 
required)  or  Tabacco  etch  virus  (TEV)  protease  Nla  (with  the  primers 
mutCatBTEVfor  and  mutCatBTEVrev,  12  point-mutations  required)  cutting  sites 
into  the  translated  protein.  The  pET28a(+)  construct  with  the  sequence  for  the  N- 
terminal  His-tagged  E.  tenella  cathepsin  B  was  used  as  a  template. 
The  method  was  also  used  for  generating  active  site  mutants  of  the 
pyroglutamyl  peptidase  I  (PPI)  of  L.  major.  Based  on  the  work  of  Le  Saux  and  co- 
workers  (Le  Saux  et  aL,  1996),  the  choice  was  made  to  mutate  cysteine-210  to 
alanine  (using  the  primers  mutCPPfor  and  mutCPPrev),  histidine-234  to  serine 
(using  the  primers  mutHPPfor  and  mutHPPrev),  glutamic  acid-101  to  glutamine 
(using  the  primers  mutElPPfor  and  mutEIPPrev)  and  glutamic  acid-107  to 
glutamine  (using  the  primers  mutE2PPfor  and  mutE2PPrev)  (L.  major  PPI 
numbering).  The  most  likely  glutamic  acid  residue  to  be  part  of  the  catalytic  triad 
was  Glu-101,  but  the  very  close  Glu-107  was  mutated  too.  One  or  2  point- 
mutations  were  required,  and  the  pET28a(+)  construct  with  the  sequence  for  the 
N-terminal  His-tagged  L.  major  PPI  was  used  as  a  template. 
The  QuickChange  Site-Directed  Mutagenesis  Kit  (Stratagene,  La  Jolla, 
CA,  US)  was  used.  The  reactions  contained  1X  reaction  buffer  (provided  with  the 
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kit),  100  ng  of  plasmid  DNA  (expression  vector  carrying  the  gene  to  mutate),  2 
liM  of  each  forward  and  reverse  primer,  I  ýtl  of  dNTP  mix,  2.5  units  of  Pfu  Turbo 
DNA  polymerase.  Cycles  were:  951C  for  30  s,  I  cycle;  9511C  for  30  s,  5511C  for  1 
min,  680C  for  7  min,  18  cycles.  Then  10  units  of  Dpnl  enzyme  (provided  with  the 
kit)  were  added  and  incubated  at  37*C  for  2  h,  to  remove  any  residual  methylated 
template.  Fifty  ýtl  of  E.  coli  XL-1  Blue  Supercompetent  cells  (provided  with  the  kit) 
were  transformed  with  1  ltl  of  PCR  using  the  heat  shock  method  (see  2.2.7.5.1.  ) 
and  250  ltl  were  plated  on  Luria-Bertani  (LB)  agar  (1  %  tryptone  (w/v),  0.5%  yeast 
extract  (w/v),  1%  NaCl (w/v),  20%  (w/v)  agar)  plates.  The  plates  were  incubated 
overnight  at  370C.  Plasmid  was  extracted  from  colonies,  sequenced  and  re- 
transformed  in  E.  coli  BL21  (DE3)  for  expression. 
2.2.7.  DNA  fragment  cloning 
Cloning  of  DNA  fragments  was  done  using  2  different  strategies.  The  first 
one  involved  digestion  by  restriction  enzymes  of  both  DNA  insert  and  vector 
recipient  prior  to  ligation  of  the  2  fragments  together.  The  second  involved 
cloning  of  PCR  products  by  amplification  with  the  Taq  polymerase.  Taq 
polymerase  adds  a  single  A-nucleotide  to  the  3'  ends  of  the  PCR  product,  which 
can  then  be  inserted  in  the  pGEM-T  Easy  vector  (Promega,  Southampton), 
containing  a  3'  single  T-nucleotide  overhang. 
2.2.7.1.  Digestion  of  DNA  with  restriction  enzymes 
Typically,  restriction  digests  used  3  units  of  restriction  enzyme  in  a  total 
volume  of  20  pl  per  500  ng  of  DNA  to  digest,  and  reactions  contained  1X  buffer 
(final  concentration).  The  buffer  used  in  each  case  was  provided  with  the  enzyme 
by  the  manufacturer  (Promega,  Southampton).  For  multiple  digests,  compatible 
buffer  systems  were  chosen.  The  reactions  were  incubated  1-4  h  at  370C  or  2511C 
(depending  on  the  enzyme). 
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2.2.7.2.  Isolation  of  DNA  fragments 
PCR  products  or  DNA  fragments  obtained  by  restriction  digests  were 
separated  on  1%  (w/v)  agarose  gels  containing  0.5  ýtg/ml  of  ethidiurn  bromide,  in 
0.5X  TBE  (45  mM  Tris-borate,  I  mM  EDTA).  The  DNA  ladder  1  kb  Plus 
(Promega,  Southampton)  was  used.  DNA  was  visualized  using  a  transilluminator 
(UVP  Laboratory  Products,  Cambridge)  at  312  nm.  Fragments  of  DNA  were 
purified  from  the  gel  using  the  QlAquick  gel  extraction  kit  (Qiagen,  Crawley). 
2.2.7.3.  Ligations, 
Ligations  of  fragments  into  the  pGEM-T  Easy  vector  (Promega, 
Southampton)  used  50  ng  of  vector,  150  ng  of  insert,  1X  buffer  and  3  units  of  T4 
DNA  ligase.  The  reactions  were  incubated  16  h  at  41C.  A  positive  control  (using 
the  control  insert  DNA)  and  a  background  control  (vector  without  insert  DNA) 
were  used. 
Ligations  of  gel-purified  digested  DNA  fragments  and  expression  vector, 
or  L.  major  transfection  vectors,  used  500  ng  of  insert,  250  ng  of  vector,  1X  buffer 
and  3U  of  T4  DNA  ligase  (Promega,  Southampton).  Reactions  were  incubated 
for  16  h  at  160C.  The  only  E.  coli  expression  vector  used  was  the  pET28a(+) 
vector  (Novagen,  Nottingham)  and  L.  major  transfection  vectors  were  derivatives 
of  the  pXG  vector,  developed  by  Beverley  and  co-workers  (Ha  et  al.,  1996). 
2.2.7.4.  Competent  cells 
2.2.7.4.1.  E.  coli 
E.  coli  DH5cc  competent  cells  were  from  Promega,  Southampton. 
BL21(DE3),  JM109(DE3)  and  HMS174(DE3)  cells  were  made  competent  the  day 
of  use  using  the  calcium  chloride  method  described  in  Sambrook  et  al.,  1989.  A 
single  colony  was  picked  from  LB  agar  plate  and  grown  overnight  at  370C  in  5  ml 
of  LB  broth.  This  culture  was  used  to  inoculate  100  ml  of  LB,  and  the  cells  were 
grown  at  370C  until  the  cell  density  reached  an  optical  density  (OD)  at  600  nm  of 
0.4-0.6.  Cells  were  then  pelleted  at  2500  g  for  10  min  at  411C,  resuspended  in  10 
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ml  of  ice-cold  sterile  0.1  M  CaC12,  pelleted  again  as  before  and  resuspended  in  2 
ml  ice-cold  0.1  M  CaC12.  Cells  were  stored  on  ice  until  use. 
2.2.7.4.2.  Pichia  pastoris 
P.  pastoris  X-33  and  KM71  cells  were  made  electro-competent  the  day  of 
use  using  the  sorbitol  method  described  in  the  Invitrogen  (Paisley)  "Pichia 
Expression  Kit"  manual  (Version  F,  catalog  no.  K1710-01),  with  some 
modifications.  A  single  colony  was  used  to  inoculate  5  ml  of  YPD  medium  and 
grown  overnight  at  3011C.  One  ml  of  this  culture  was  used  to  inoculate  500  ml  of 
YPD  and  grown  to  OD600  Of  1.3-1.5.  Cells  were  centrifuged  at  1500  g  for  5  min  at 
40C,  resuspended  in  100  ml  YPD  medium,  20  mM  N-2-hydroxyethylpiperazine- 
N'-2-ethanesulphonic  acid  (HEPES)  pH  8,  and  2.5  ml  of  1M  DTT  was  added. 
The  mixture  was  incubated  at  300C  for  15  min  without  shaking.  The  suspension 
was  brought  to  500  ml  with  ice-cold  sterile  water.  The  cells  were  sedimented  as 
before,  resuspended  in  250  ml  ice-cold  sterile  water,  sedimented  again  as 
before,  resuspended  in  20  ml  ice-cold  1M  sorbitol,  sedimented  as  before  and 
resuspended  in  1  ml  of  ice-cold  IM  sorbitol.  The  cells  were  stored  at  4"C  until 
use. 
2.2.7.5.  Transformation  of  competent  cells 
2.2.7.5.1.  E.  coff 
E  coli  cells  were  transformed  with  the  ligation  products  using  a  heat 
shock  method  (Sambrook  et  aL,  1989).  Ten  ng  of  DNA  was  incubated  with  200  gl 
of  competent  cell  suspension  on  ice  for  20  min,  heat  shocked  for  50  s  at  4211C, 
and  incubated  on  ice  again  for  2  min.  One  ml  of  LB  was  added  and  the  mixture 
was  incubated  at  370C  for  1h  before  plating  of  100  gl  on  a.  LB  agar  plate 
containing  the  appropriate  antibiotic  for  selection.  In  the  case  of  pGEM-T  Easy 
ligation  product  transformation  in  DH5a,  a  white/blue  selection  was  used,  by 
adding  isopropylthio-P-D-galactoside  (IPTG)  (40  gg/ml)  and  5-bromo-4-chloro-3- 
indolyl-P-D-galactoside  (X-gal)  (40  ;.  tg/ml).  White  colonies  correspond  to  positive 
clones  containing  a  DNA  insert  in  the  P-galactosidase  gene,  which  leads  to  the 
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expression  of  an  inactive  P-galactosidase  not  able  to  act  on  the  chromogenic 
substrate  X-gal. 
2.2.7.5.2.  Pichia  pastoris 
pPIC9  and  plasmid  derivatives  were  linearized  with  Sacl,  and  pGAPZaA 
and  plasmid  derivatives  were  linearized  with  Awil.  Linearized  DNA  was 
transformed  by  electroporation  as  described  in  the  Invitrogen  (Paisley)  "Pichia 
Expression  Kit"  manual  (Version  F,  catalog  no.  K1710-01)  using  the  Bio-Rad 
(Hemel  Hempstead)  GenePulser  at  a  charging  voltage  of  1500  V,  capacitance  of 
25  ýF  and  resistance  of  200  Q.  Eighty  gl  of  competent  cell  suspension  were 
incubated  with  10  jig  of  linearized  DNA  in  an  ice-cold  0.2  cm  electroporation 
cuvette  (BioRad,  Hemel  Hempstead)  for  5  min  on  ice.  Reactions  were  pulsed 
once  and  1  ml  of  ice-cold  1M  sorbitol  was  immediately  added  to  the  reaction. 
The  reaction  was  transferred  to  a  new  tube  and  either  300  gi  were  directly  plated 
on  RBD  plates  (1  M  sorbitol,  2%  (w/v)  glucose,  1.34%  (w/v)  Yeast  Nitrogen  Base 
with  Ammonium  Sulfate  without  amino  acids  [GibcoBRL,  Paisley],  4x  10-5%  (W/V) 
biotin,  0.005%  (w/v)  amino  acids  (L-glutamic  acid,  L-methionine,  L-lysine,  L- 
leucine,  L-isoleucine  [Sigma,  Poole]),  20%  (w/v)  agar),  in  the  case  of 
transformation  of  the  KM71  cells  with  the  pPIC9  and  plasmid  derivatives,  or  the 
reaction  was  incubated  for  2h  at  3011C  before  plating  of  300  ýtl  on  YPB  plates 
containing  100  [ig/ml  of  Zeocin,  in  case  of  transformation  of  the  X-33  cells  with 
the  pGAPZaA  and  plasmid  derivatives.  Plates  were  incubated  at  30*C  for  3-4 
days. 
2.2.7.6.  Plasmid  DNA  purification 
The  isolation  of  plasmid  DNA  from  E.  coli  was  performed  using  the 
QlAprep  Miniprep  kit  (Qiagen,  Crawley).  The  presence  of  the  correct  insert  was 
checked  by  restriction  digests,  which  were  separated  by  agarose  gel 
electrophoresis. 
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2.2.7.7.  DNA  sequencing 
Plasmid  DNA  was  sent  to  GRI  Genomics  (Braintree,  UK)  for  sequencing. 
Sequences  were  analysed  using  the  Vector  NTI  program  (Informax,  Bethesda, 
MA,  US). 
2.2.8.  L.  major  prornastigotes  transfection 
2.2.8.1.  Strategy  for  L.  major  pyroglutarnyl  peptidase  I  (PPI)  gene  cloning 
for  over-expression  and  knockout 
For  over-expression  of  the  native  and  cysteine-210-mutated  PPIs  in  L. 
major,  the  vector  pGL102  was  chosen  (derivative  of  pXG  vector  [Cruz  et  al., 
1991a]).  The  restriction  sites  Smal  (5'  end)  and  BamHI  (3'  end)  were  chosen  on 
the  vector.  As  another  Smal  site  exists  in  the  gene,  the  engineered  site  was  the 
one  for  EcoRV,  cohesive  end,  which  will  religate  into  the  Smal  site  on  the  vector 
after  digestion.  The  restriction  sites  were  added  to  the  ends  of  the  fragment  by 
PCR  on  -100  ng  of  either  the  pETLmPP  plasmid,  or  the  pET28a(+)  construct 
with  the  sequence  for  the  cysteine-210-mutated  N-terminal  His-tagged  L.  major 
PPI,  using  the  primers  OEforLmPP  and  OErevLmPP. 
The  834  bp  excised  bands  were  gel-purified,  digested  with  EcoRV  and 
BamHl,  re-gel  purified  and  cloned  into  pGL102  previously  digested  with  Smal 
and  BamHl  to  give  the  final  plasmids  pGL102LmPPI  and  pGL102LmPPI*.  The 
sequence  was  confirmed  using  the  PCR  primers  for  sequencing. 
For  gene  knockout,  the  vector  pGL345  was  chosen  (derivative  of  pXG 
vector,  hygromycin  selection).  Flanks  at  the  5'  (-  500  bp)  and  3'  (-  1  kb)  ends  of 
the  PPI  gene  were  selected  in  the  L.  major  database.  Restriction  sites  for  Hind  I  11 
(5'  end)  and  San  (3'  end),  or  Smal  (5'  end)  and  Bg1l  1  (3'  end)  were,  respectively, 
introduced  by  PCR  at  the  ends  of  the  5'  flank  and  the  3'  flank.  PCR  used  the 
primers  Hind6for  and  Sal5'rev  for  the  5'  flank,  and  the  primers  SmaVor  and 
Bgl3'rev  for  the  3'  flank. 
The  excised  5'  flank  band  was  gel-purified,  digested  with  HindIll  and  San, 
re-purified  and  cloned  into  pGL345  previously  digested  with  the  same  enzymes. 
The  excised  3'flank  band  was  gel-purified,  digested  with  Smal  and  Bglll,  re-gel 
purified  and  sub-cloned  in  the  pGL345  plasmid  containing  the  5'flank  previously 
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digested  with  the  same  enzymes  to  give  the  pGLLmPPKO.  The  hygromycin 
selection  marker  was  replaced  by  the  blasticidin  resistance  marker  (cut  from  the 
pGL842  vector)  on  the  plasmid  by  digestion  with  Spel  and  BamHl. 
2.2.8.2.  DNA  preparation 
In  the  case  of  episomal  constructs  for  over-expression,  20  gg  of  circular 
plasmid  was  ethanol-precipitated  (Sambrook  et  al.,  1989),  resuspended  in  20  pl 
of  sterile  water,  and  stored  at  -200C. 
In  the  case  of  integrative  constructs  for  gene  replacement,  40  pg  of 
plasmid  was  linearised  by  digestion  with  Hindill  and  BgIll.  The  digested  DNA 
fragments  were  separated  on  ethidiurn  bromide-free  agarose  gel,  fragments  were 
revealed  by  gel  immersion  in  a  6.5  x  10-4%  (w/v)  methylene  blue  solution,  gel 
extracted  with  the  QlAquick  gel  extraction  kit  (Qiagen,  Crawley),  ethanol 
precipitated  (Sambrook  et  aL,  1989),  resuspended  in  20  [d  of  sterile  water,  and 
stored  at  -2011C. 
2.2.8.3.  Transfection 
L.  major  promastigotes  from  log-phase  cultures  at  a  density  of  about  0.5- 
1X  107  cells/ml  were  preferentially  used.  About  108  cells  were  used  per 
transfection.  The  cells  were  pelleted  at  1300  g  for  10  min  at  40C,  washed  twice  in 
sterile  ice-cold  electroporation  buffer  (120  mM  KCI,  0.15  mM  CaC12,10  MM 
K2HP04,25  MM  HEPES,  2  mM  EDTA,  and  5  mM  MgC12,  pH  7.6),  and 
resuspended  in  electroporation  buffer  to  a  concentration  of  about  2x  108  cells/mi. 
Cells  (0.5  ml  per  transfection)  were  put  in  contact  with  the  DNA  to  transfect  (20 
lag)  and  incubated  on  ice  for  15  min.  A  no  DNA  control,  to  check  efficiency  of 
drug  selection,  and  empty  vector  control  to  compare  phenotypes  (for  episomal 
expression  only),  were  always  included.  The  mixture  was  placed  into  an  ice-cold 
4  mm  Gene  Pulse  cuvette  (BioRad,  Hemel  Hempstead)  and  pulsed  twice  at  25 
gF,  1500  V,  (3.75  kV/cm)  on  the  BioRad  Gene  Pulser  II  apparatus.  At  least  10  s 
separated  the  2  pulses.  The  cells  were  then  incubated  on  ice  for  20  min  before 
being  transferred  to  5  ml  HOMEM  medium  with  10%  HIFCS  and  incubated  at 
250C  overnight.  The  next  day,  the  cells  were  placed  in  medium  containing  the 
55 Chapter  2:  Material  and  Methods 
appropriate  selection  drug  (depending  on  the  construct  transfected).  All  selection 
drugs  were  from  Calbiochem,  Nottingham.  Hygromycin  B  was  used  at  a  final 
concentration  of  50  gg/ml;  blasticidin  S  hydrochloride  at  15  gg/ml;  neomycin 
(G418)  at  50  gg/ml;  and  puromycin  at  40  gg/ml.  Clonal  dilution  (from  1:  2  (vIv)  to 
1:  64  (v/v),  serial  dilution)  was  performed  on  transfected  cells  in  96-well  plates,  in 
order  to  isolate  clonal  populations.  Genomic  DNA  was  extracted  from  drug- 
resistant  clones  and  correct  integration  was  confirmed  using  the  CheckKOPPFor 
and  CheckKOPPRev  primers. 
2.2.9.  Southern-blot  analysis 
2.2.9.1.  Southern  blotting  of  DNA  fragments 
Southern  blotting  allows  detection  of  specific  sequences  within  the 
genomic  DNA.  Between  2  and  10  ýtg  of  gDNA  were  digested  to  completion  using 
specific  restriction  enzymes,  and  the  DNA  fragments  were  separated  on  a  1% 
(w/v)  agarose  gel  in  1x  TBE  buffer.  The  DNA  was  blotted  according  to  the 
Southern  method  (Sambrook  et  aL,  1989).  After  electrophoresis  for  8h  at  50  V, 
the  gel  was  incubated  in  125  mM  HCI  for  30  min  under  gentle  agitation  to  allow 
the  depurination  of  the  DNA.  The  gel  was  then  incubated  for  30  min  in  1.5  M 
NaCl,  0.5  M  NaOH  (for  DNA  denaturation),  and  30  min  in  1M  Tris  pH  7.5,1.5  M 
NaCl  (for  neutralisation).  Each  wash  was  interspersed  by  a  10  min  wash  in 
ddH20.  The  DNA  was  transferred  by  capillarity  onto  a  Hybond-N+  nylon 
membrane  (Amersham)  in  20X  SSC  (300  mM  tri-sodium  citrate,  3M  NaCl,  pH  7) 
using  standard  methods  (Sambrook  et  aL,  1989).  The  DNA  was  then  fixed  onto 
the  membrane  by  ultraviolet  (UV)  cross-linking  (Spectrolinker  XL-1000  UV  linker, 
Spectronics  Corporation,  Westbury,  NY,  US). 
2.2.9.2.  Southern  hybridisation  with  nucleic  acid  probes 
Nylon  membrane  was  pre-incubated  at  6511C  for  4h  in  20  ml  of  Church- 
Gilbert  hybridisation  solution  (340  mM  Na2HP04,158  mM  NaH2PO4,240  mM 
SDS,  1  mM  EDTA),  supplemented  with  0.2  mg/ml  of  denatured  salmon  sperm 
DNA  (GibcoBRL,  Paisley).  Thirty  ng  of  nucleic  acid  probe  was  prepared  from 
agarose  gel-purified  restriction  endonuclease  fragments  using  the  Prime-It  11 
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Random  Primer  kit  (Stratagene,  La  Jolla,  CA,  US)  according  to  the 
manufacturer's  instruction.  Labeled  A  nucleotides  were  introduced  using  50  ýLCi 
of  a  32  dATP  (Perkin  Elmer,  Beaconsfield)  per  probe,  and  the  dATP  buffer  from  the 
kit.  Probe  was  purified  on  a  Microspin  S-200  HR  column  (Amersham,  Chalfont 
St.  Giles)  and  boiled  for  5  min  before  incubation  on  ice  for  2  min.  The  membrane 
was  hybridised  by  incubation  with  the  labeled  probe  in  20  ml  of  Church-Gilbert 
solution  at  650C  overnight.  Membranes  were  then  washed  under  high  stringency 
2  times  for  5  min  in  2X  SSC,  0.1%  (w/v)  SDS,  followed  by  15  min  in  1X  SSC, 
0.1%  SIDS,  and  2  times  for  10  min  in  O.  1X  SSC,  0.1%  SIDS.  All  wash  solutions 
were  pre-warmed  at  6511C.  Membranes  were  sealed  in  polythene  and  exposed  to 
X-ray  film  (Konica  Medical  Film)  for  I  to  10  days.  Hybridisation  signals  were 
detected  with  a  film  processor  (X-Ograph  imaging  system  Compact  X4). 
2.3.  Biochemical  methods 
2.3.1.  Recombinant  protein  expression 
2.3.1.1.  In  E.  coli 
For  all  expression  experiments  in  E.  coli  the  pET28a(+)  vector  (Invitrogen, 
Pailsey)  was  used. 
For  expression  in  Ecoli  of  the  pro-mature  cathepsin  B  of  E  tenella  with  a 
N-terminal  His-tag,  the  cloning  was  performed  between  the  Ndel  site  and  the 
Xhol  site.  The  recognition  sequences  for  these  restriction  enzymes  were  firstly 
added  to  the  sequence  by  PCR,  with  the  primers  pETNdeCatBfor  and 
pETXhoCatBrev.  The  full-length  product  was  cloned  into  pGEMT-easy  and  the 
resulting  plasmid  was  cut  with  Ndel  and  EcoRl,  and  HindIll  and  Xhol.  The 
NdellEcoRl  band  was  gel  purified  and  subcloned  into  pET28a(+).  The  resulting 
plasmid  was  cut  with  HindIll  and  Xhol  and  the  HindlillXhol  band  was  inserted. 
This  construct  was  transformed  in  E.  coli  strains  BL21(DE3),  JM109(DE3),  or 
HMS174(DE3)  competent  cells  for  expression.  Cells  were  grown  to  an  OD60onm  Of 
0.4  to  0.6  in  LB  containing  50  pg/ml  kanamycin  (Sigma,  Poole)  before  being 
induced  for  4h  with  0.5-1.5  mM  I  PTG  at  25  or  37*C. 
For  expression  in  E.  coli  of  the  truncated  pro-mature  cathepsin  B  of  E. 
tenella  with  a  N-terminal  His-tag,  the  cloning  was  performed  between  the  Ndel 
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and  the  Xhol  sites.  The  procedure  was  the  same  as  above.  The  primers  used 
were  pETCatB31for  and  pETCatB31rev.  The  protein  was  expressed  in  the 
BL21  (DE3)  cells,  by  induction  4h  with  1  mM  IPTG  at  37"C. 
For  expression  in  Ecoli  of  the  pro-mature  cathepsin  B  of  E  tenella  with  a 
N-terminal  His-tag  and  carrying  the  mutation  for  the  Factor  Xa  and  the  TEV 
protease  cleavage  sites  in  the  protein,  proteins  were  expressed  in  the  BL21  (DE3) 
cells,  by  induction  4h  with  1  mM  IPTG  at  370C. 
For  expression  in  E.  coli  of  the  native  pyroglutamyl  peptidase  I  of  L.  major 
with  a  N-terminal  His-tag,  the  cloning  was  performed  between  the  Ndel  and  the 
SO  sites.  The  procedure  was  the  same  as  before.  The  primers  used  were 
LmPPfor  and  LmPPrev.  The  protein  was  expressed  in  the  BL21(DE3)  cells,  by 
induction  5h  with  1  mM  IPTG  at  20*C. 
For  expression  in  E.  coli  of  the  active  site  mutated  pyroglutamyl  peptidase 
I  of  L.  major  with  a  N-terminal  His-tag,  proteins  were  expressed  in  the  BL21  (DE3) 
cells,  by  induction  5h  with  1  mM  IPTG  at  20"C. 
For  expression  in  E.  coli  of  the  native  and  truncated  glutarninyl  cyclase 
(QC)  of  L.  major  with  a  N-terminal  His-tag,  the  cloning  was  performed  between 
the  Ndel  and  the  HindIll  sites.  The  procedure  was  the  same  as  before.  The 
primers  used  for  cloning  of  the  full  length  QC  were  QCfor  and  QCrev.  The 
primers  used  for  cloning  of  the  truncated  QC  were  QCshortfor  and  QCrev  The 
protein  was  expressed  in  the  BL21(DE3)  cells,  by  induction  4h  with  1  mM  IPTG 
at  15,25,  or  37"C. 
2.3.1.2.  In  Pichia  pastods 
2.3.1.2.1.  Constitutive  system 
The  pGAPZaA  vector  (Invitrogen,  Paisley)  was  chosen  for  constitutive 
expression.  Constructs  were  designed  for  constitutive  expression  of  the  pro- 
mature  cathepsin  B  with  a  C-terminal  His-tag  (using  the  primers  pGAPCatBfor 
and  pGAPCatBrev),  and  the  pro-mature  cathepsin  B  without  a  His-tag  (using  the 
primers  pGAPCatBfor  and  pGAPCatBrev2),  with  subsequent  release  into  the 
medium  of  the  culture.  The  DNA  fragments  were  cloned  between  the  Xhol  and 
Sacil  sites.  The  final  constructs  and  control  empty  vector  were  linearised  with 
Avrll  prior  to  transfection  into  the  host  Pichia  pastoris  cells  X-33.  Cells  were 
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spread  on  plates  selective  for  Zeocin  resistance  (100  jig/ml)  and  incubated  3  to  4 
days  at  300C  until  colonies  developed,  as  described  in  the  Pichia  expression  kit 
manual  (Invitrogen,  Paisley).  Insertions  of  the  fragments  were  verified  by  PCR  on 
genomic  DNA  extracted  from  positive  clones  as  described  in  the  Pichia 
expression  kit  manual,  using  the  couples  of  PCR  primers  a-factor  and  TAOX1. 
One  positive  colony  for  each  of  the  constructs  was  selected  and  tested  for 
expression  of  the  target  protein  as  described  in  the  manufacturer's  manual  (final 
volume  of  50  ml  of  YPD  medium).  One  ml  aliquots  were  taken  a  regular  time 
intervals,  cells  were  separated  from  the  supernatant  of  culture  by  centrifugation 
and  samples  of  supernatant  were  used  for  analysis  using  gelatin  SDS-PAGE,  the 
azocasein  assay,  and  either  directly  on  Coomassie  blue-stained  SDS-PAGE  gels 
and  westem-blots,  or  after  tricholoacetic  acid  (TCA)  precipitation  on  Coomassie 
blue-stained  SDS-PAGE  gels  and  western-blots.  The  cells  were  resuspended  in 
1  ml  of  50  mM  Tris  pH  8.0  and  analysed  on  Commassie  blue-stained  SDS-PAGE 
gels.  Once  the  optimum  time  of  growth  had  been  determined,  the  cells  were 
directly  grown  to  that  time  point  and  harvested  by  centrifugation  at  3000  g  for  5 
min,  and  the  supernatant  and  cells  were  stored  at  -2011C  until  further  treatment 
and  analysis. 
2.3.1.2.2.  Inducible  system 
A  construct  was  designed  for  inducible  expression  of  the  pro-mature 
enzyme  cathepsin  B-like  enzyme  of  E.  tenella,  with  subsequent  release  into  the 
culture  medium.  The  pPIC9  vector  (Invitrogen,  Paisley)  was  used,  and  the  DNA 
fragment  was  cloned  between  the  SnaBl  and  Awil  sites.  The  primers  used  for 
PCR  were  pPlC9CatBfor  and  pPlC9CatBrev.  The  final  construct  pPlC9catB  and 
control  empty  vector  were  linearised  with  Sacl  prior  to  transfection  in  the  host 
Pichia  pastoris  cells  KM71.  As  the  KM71  strain  contains  a  mutation  in  the 
endogenous  AOXI  gene  (encoding  the  alcohol  oxidase  enzyme),  only  His'  Muts 
phenotypes  will  be  generated  by  successful  recombination  (His+  refers  to 
histidine  prototrophy,  and  Muts  refers  to  "Methanol  utilization  slow"  caused  by  the 
loss  of  the  alcohol  oxidase  activity  encoded  by  the  AOX1  gene).  Cells  were 
spread  on  plates  selective  for  histidine  prototrophy  (His+)  and  incubated  3  to  4 
days  at  30"C  until  colonies  developed,  as  described  in  the  Pichla  expression  kit 
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manual  (Invitrogen,  Paisley).  Insertions  of  the  fragments  were  verified  by  PCR  on 
genomic  DNA  extracted  from  positive  clones  as  described  in  the  Pichia 
expression  kit  manual,  using  the  couples  of  PCR  primers  a-factor  and  TAOX1,  or 
5'AOX1  and  TAOX1. 
Positive  colonies  for  each  of  the  transfection  were  selected  and  tested  for 
expression  of  the  cathepsin  B  as  described  in  the  manufacturers  manual.  One 
positive  colony  for  each  of  the  transfection  was  selected,  and  used  to  inoculate 
100  ml  of  BMGY  medium  (1%  (w/v)  yeast  extract,  2%  (w/v)  peptone,  100  mM 
potassium  phosphate  pH  6.0,1.34%  (w/v)  YNB,  4x  10-5%  biotin  (w/v),  I%  (v/v) 
glycerol).  The  culture  was  grown  at  3011C  shaking  at  300  rpm,  in  a11  flask,  until 
the  culture  reached  an  OD600  of  5-10  (24-48  h).  The  cells  were  then  harvested  by 
centrifugation  at  3000  g  for  5  min  and  resuspended  in  20  ml  of  BMMY  medium 
(1%  (w/v)  yeast  extract,  2%  (w/v)  peptone,  100  mM  potassium  phosphate  pH  6, 
1.34%  (w/v)  YNB,  4x  10-5  %  biotin  (w/v),  0.5%  (v/v)  methanol),  placed  in  a  250  ml 
flask  and  the  culture  was  grown  again  at  3011C  shaking  at  300  rpm.  The  cells 
were  induced  by  addition  of  methanol  to  0.5%  (v/v,  final  concentration)  every  24 
h,  0.5  ml  aliquots  were  taken  a  regular  time  intervals  and  cells  were  separated 
from  the  supernatant  of  culture  by  centrifugation  and  samples  of  supernatant 
were  analysed  using  gelatin  SDS-PAGE,  the  azocasein  assay,  and  either  directly 
on  Coomassie  blue-stained  SDS-PAGE  gels,  or  after  TCA  precipitation  on 
Coomassie  blue-stained  SDS-PAGE  gels  and  western-blots.  Once  the  optimum 
time  of  growth  had  been  determined,  cells  were  directly  grown  to  that  time  point 
and  harvested  by  centrifugation  at  3000  g  for  5  min,  and  the  supernatant  and 
cells  were  stored  at  -200C  until  further  treatment  and  analysis. 
2.3.2.  Protein  defolding,  refolding  and  activation  procedures 
A  summary  of  the  conditions  tested  for  unfolding,  refolding,  purification 
and  activation  of  various  preparations  of  recombinant  cathepsin  B  of  E.  tenella  is 
presented  in  Table  2.2. 
The  N  i-aga  rose-pu  rifled  soluble  pro-mature  cathepsin  B  expressed  in  E. 
coli  BL21  (DE3)  or  in  HMS1  74(DE3)  was  treated  as  described  in  Sanderson  et  a/., 
2000,  for  unfolding  and  re-folding  attempts  of  the  enzyme. 
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The  Ni-agarose-pu  rifled  soluble  pro-mature  cathepsin  B  expressed  in  E. 
coli  BL21(DE3)  was  treated  as  described  in  Hellberg  et  a/.,  2002,  with  a  few 
modifications.  The  sample  was  diluted  1:  10  (v/v)  in  8M  urea  or  6M  guanidium, 
100  mM  NaH2PO4,10  mM  Tris/HCl  pH  6.3  to  unfold  the  protein.  A  fraction  of  this 
sample  was  then  diluted  dropwise  1:  100  (v/v)  in  a  refolding  buffer  composed  of 
50  mM  Tris/HCl  pH  6.8,300  mM  NaCl,  5%  glycerol  (v/v),  0.1  mM  EDTA,  0.5  mM 
oxidised  glutathione,  3  mM  reduced  glutathione  and  the  mixture  was  incubated 
overnight  at  40C.  Another  fraction  of  the  sample  was  directly  dialysed  against  100 
times  its  volume  of  50  mM  Tris  pH  6.8  overnight  at  40C.  The  diluted  sample  in 
refolding  buffer  was  concentrated  with  a  Centricon  device  through  YM-10 
membrane  (Amicon,  Watford)  from  11  to  3  ml  to  a  final  concentration  of  100 
[tg/ml  and  dialysed  over  night  against  500  ml  of  50  mM  Tris/HCI,  pH  6.8  at  40C. 
The  2  samples  treated  separately  with  or  without  refolding  by  dilution  were 
diluted  1:  1  (v/v)  in  100  mM  Tris/HCI,  pH  8.8,0.08%  SDS,  20  mM  DTT  at  37,16. 
Aliquots  were  taken  at  various  time  from  0  min  to  1h  and  subsequently  analysed. 
The  inclusion  bodies  of  pro-mature  cathepsin  B  expressed  in  E.  coli 
HMS174(DE3)  were  treated  as  described  in  Sanderson  et  al.,  2000,  and  Sijwali 
et  a/.,  2001. 
Samples  of  Nickel-agarose  purified  truncated  cathepsin  B  were  diluted 
1:  1  (v/v)  in  0.1  M  sodium  acetate  buffer,  pH  5.0  or  0.1  M  Tris/HCl  buffer,  pH  8.0 
supplemented  with  20  mM  DTT  and  incubated  at  37*C  for  20  min,  with  or  without 
the  inhibitor  E64  (final  concentration  of  300  ýtM). 
A  sample  of  purified  truncated  cathepsin  B  was  diluted  1:  4  (v/v)  to  a  final 
concentration  of  about  100  pg/ml  in  0.1  M  Tris/HCl  pH  8.0,8  M  urea  (total  volume 
of  500  pl)  and  incubated  1h  at  370C,  to  unfold  the  protein  without  rupturing  the 
disulfide  bonds.  The  sample  was  then  dialysed  for  2h  at  40C  against  500  ml  of 
50  mM  Tris/HCl,  pH  8.0  and  stored  at  -2011C  for  later  analysis. 
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Table  2.2.  Summary  of  the  conditions  tested  for  unfolding,  refolding,  purification  and 
activation  of  various  preparations  of  recombinant  cathepsin  B  of  E.  tenella.  BL21  and 
HMS  174  are  E.  coli  strains  used  for  expression. 
Sample  Expressed  in  Expressed  in  HMS174 
Step  Expressed  in  HMS174  at 
at  37"C/  Solubillsation 
o of  f  protei  BL21/soluble  25"C/  Soluble 
of  Inclusion  bodies 
preparation  fraction 
Unfolding/  6M  guanidium 
Sanderson  et  al.,  2000 
solubilisation  of  8M  urea 
X  Sijwali  et  al.,  2001 
inclusion  bodies  10  rnM  DTT 
Dilution,  pH  8.0, 
Refolding  EDTA,  DTT,  X  pH  8.0  GSSG/GSH,  40C 
12  h 
Purification  of 
refolded  protein 
Nickel-agarose  X  Anion-exchange 
370C 
3711C  371C  pH  4.0  to  7.0 
Activation  pH  4.0  to  7.0  pH  4.0  to  7.0  protein  concentration 
(combinations  5  mM  EDTA  5  mM  EDTA  from  50  to  500  pg/ml 
of  the  listed  10  mM  DTT  10  mM  DTT  5  mM  EDTA 
components)  0.9  M  NaCl  0.9  M  NaCl  10  rnM  DTT 
During  1  to  24  h  During  1  to  6h  0.9  M  NaCl 
During  1  to  7h 
2.3.3.  Protein  processing 
2.3.3.1.  Non-specific 
The  idea  behind  using  non-specific  peptidases  in  an  attempt  to  cleave 
the  pro-domain  from  the  mature  domain  of  the  cathepsin  B  of  E.  tenella  was  that 
domains  within  a  protein  are  tightly  folded  units  (Richardson,  1981)  and  a 
correctly  folded  protein  will  have  its  loops  and  hinges  most  accessible  to 
proteolytic  cleavage.  Using  mild  conditions,  i.  e.  low  enzyme/substrate  (protein 
that  requires  cleavage)  ratios  and  short  incubation  times  might  make  it  possible 
to  separate  domains  by  limiting  the  number  of  bonds  cleaved  and  hopefully 
limiting  processing  to  accessible  bonds  located  in  these  loops  between  domains. 
Three  commercially  available  peptidases  were  chosen:  trypsin-TPCK  from 
bovine  pancreas  (ref.  T1426,12700  U/mg),  cc-chymotrypsin-TLCK  from  bovine 
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pancreas  (ref.  C3142,57  U/mg)  and  subtilisin  A  from  Bacillus  ficheniformis  (ref. 
P5380,10.6  U/mg)  (all  Sigma,  Poole)  for  their  broad  substrate  specificity  and 
ease  of  use.  A  stock  solution  of  each  peptidase  at  a  concentration  of  1  mg1ml 
was  prepared  in  50  mM  Tds/HCI,  pH  8.0.  The  N  i-agarose-pu  rifled  soluble  pro- 
mature  cathepsin  B  expressed  in  E.  -  coli  BL21(DE3)  was  used  as  the  substrate. 
To  start  with,  enzyme/substrate  ratios  were  fixed  at  1:  50  and  1:  500  (w/w). 
Reactions  were  in  50  mM  Tris/HCI,  pH  8.0  and  samples  were  incubated  at  3711C 
for  2  min  to  1  h.  The  reactions  were  terminated  by  dilution  in  an  equal  volume  of 
2x  SDS-PAGE  loading  buffer  (0.1  M  Tris/HCl  pH  6.8,15%  (v/v)  glycerol,  3%  (w/v) 
SIDS,  0.8%  (v/v)  P-mercaptoethanol,  0.0001%  (w/v)  Pyronin  Y).  Then  ratios  were 
adjusted  if  necessary  (where  there  was  too  extensive  cleavage)  down  to  1:  5000 
(W/W). 
2.3.3.2.  Specific 
I 
A  method  to  achieve  specific  cleavage  at  a  particular  location  is  to  use  a 
specific  peptidase  that  will  only  cut  bonds  in  this  location.  As  no  obvious  specific 
cutting  site  could  be  detected  within  the  region  thought  to  make  the  link  between 
pro-  and  mature  domains  of  the  cathepsin  B  of  E.  tenella,  it  was  decided  to 
engineer  the  specific  cleavage  sites  for  the  Factor  Xa  and  the  TEV  protease  at 
that  junction. 
Biotinylated  Factor  Xa  from  the  Factor  Xa  Cleavage  Capture  Kit 
(Novagen,  Nottingham),  and  recombinant  TEV  protease  (Invitrogen,  Paisley) 
were  used. 
Digestions  with  Factor  Xa  used  10  to  50  [ig  of  nickel-agarose  purified 
cathepsin  B  of  E.  tenella  produced  in  E.  coli  and  carrying  the  Factor  Xa  cleavage 
site,  5  ýtl  of  1OX  cleavage  buffer,  1,0.2,  or  0.01  U  of  Factor  Xa  in  a  final  volume 
of  50  jd  at  20  *C  for  various  lengths  of  incubation.  Non-specific  cleavage  on  the 
purified  pro-mature  cathepsin  B  of  E.  tenella  produced  in  E.  coli  not  carrying  the 
mutations  for  the  Factor  Xa  cleavage  site  was  also  tested. 
Twenty  jig  of  nickel-agarose  purified  cathepsin  B  of  E.  tenella  produced 
in  E  coli  and  carrying  the  TEV  cleavage  site  was  incubated  with  7.5  jil  20X 
cleavage  buffer,  1.5  gi  0.1  M  DTT,  10  U  TEV  in  a  final  volume  of  150  gl  at  2011C 
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for  various  lengths  of  incubation.  Non-specific  cleavage  on  the  purified  pro- 
mature  cathepsin  B  of  E.  tenella  produced  in  E.  coli  not  carrying  the  mutations  for 
the  TEV  cleavage  site  was  also  tested. 
2.3.4.  Determination  of  protein  concentrations 
Protein  concentrations  were  either  determined  spectrophotometrically  at 
280  nm  (provided  the  extinction  coefficient  P,  of  the  protein  was  known),  or  using 
the  BioRad  protein  assay,  based  on  the  Bradford  method  (Bradford,  1976)  and 
using  bovine  serum  albumin  (BSA)  as  the  protein  standard. 
2.3.5.  Protein  precipitation 
To  reduce  quickly  the  volume  of  protein  solution  to  analyse,  one  of  the 
methods  used  was  trichloroacetic  acid  (TCA)  precipitation.  This  was  used  in 
particular  prior  to  SDS-PAGE  analysis.  The  disadvantage  is  that  the  protein  will 
be  irreversibly  denatured.  TCA  was  added  to  the  protein  sample  at  10%  (v/v)  final 
concentration,  and  the  mixture  was  incubated  overnight  at  -200C.  The  sample 
was  then  centrifuged  at  13000  g  for  20  min  at  40C,  the  pellet  was  washed  in  1  ml 
100%  ice-cold  acetone,  and  resuspended  usually  in  10-30  pl  2x  SDS-PAGE 
loading  buffer  (0.1  M  Tris/HCl  pH  6.8,15%  (v/v)  glycerol,  3%  (w/v)  SDS,  0.8% 
(v/v)  P-mercaptoethanol,  0.0001  %  (w/v)  Pyronin  Y). 
2.3.6.  Protein  concentration 
Devices  used  for  protein  concentration  were  YM-1  0  Centricon  Centrifugal 
devices  (Amicon,  Watford),  following  the  manufacturers  instructions. 
2.3.7.  Protein  purification 
2.3.7.1.  Nickel-agarose  chromatography 
Soluble,  or  solubilised,  recombinant  N-terminal  His-tagged  cathepsin  13- 
like  proteins  of  E  tenella  produced  in  E  coli,  as  well  as  soluble  recombinant  N- 
terminal  His-tagged  PPI  and  PPI  active  site  mutants  of  L.  major  produced  in  E. 
coli,  were  purified  by  gravity  on  a3  ml  nickel-agarose  column  (Qiagen,  Crawley) 
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following  the  manufacturer's  instructions.  The  column  was  pre-equilibrated  with  5 
volumes  of  10  mM  Tris/HCl,  pH  8.0,  the  sample  was  applied,  and  the  column  was 
washed  with  5  volumes  of  the  same  buffer,  followed  by  a  washing  with  5  volumes 
of  10  mM  Tris/HCl,  pH  8.0,  with  30  mM  imidazole.  Protein  was  eluted  in  3  times  1 
ml  of  10  mM  Tris/HCI,  pH  8.0,  with  500  mM  imidazole.  Eluted  fractions  were 
dialysed  against  various  buffers  (see  2.3.2.  for  the  cathepsin  B-like  proteins  of  E. 
tenella),  or  against  100  volumes  of  50  mM  HEPES  pH  8.0,1  mM  EDTA,  2  mM 
Tris(2-carboxyethyl)phosphorine  hydrochloride  (TCEP,  Sigma,  Poole)  (for  the 
PPI,  and  PPI  active  site  mutants  of  L.  major)  overnight  at  411C. 
2.3.7.2.  Use  of  BioCAD 
The  same  proteins  were  also  purified  using  the  BioCAD  700  E 
workstation  (PE  Biosystems,  Foster  City,  CA,  US),  with  a  1.7  ml  POROS  MC  4.6 
mm  column.  The  POROS  beads  were  charged  with  nickel  ions.  The  purification 
work  was  partially  done  by  myself,  and  by  Alan  Scott  (University  of  Glasgow). 
The  column  was  equilibrated  with  50  mM  Tris/HCl,  pH  8.0,  and  flow  rate  of  5-10 
ml/min.  Sample  was  applied,  flow-through  was  re-loaded,  and  the  column  was 
washed  with  20  ml  of  50  mM  Tris/HCl,  pH  8.0,  and  15  ml  of  50  mM  Tris/HCI,  pH 
8.0,30  mM  imidazole.  The  protein  was  eluted  with  a  gradient  of  50-500  mM 
imidazole  in  the  same  Tris  buffer,  over  15  ml.  Protein  was  detected  by 
absorbance  at  280  nm.  Fractions  containing  the  protein  were  pooled  and  treated 
as  described  2.3.7.1. 
2.3.7.3.  Ammonium  sulfate  saturation 
This  method  was  used  for  the  purification  of  the  recombinant  cathepsin  B 
of  E.  tenella  produced  in  P.  pastoris.  Different  aliquots  of  supernatant  of  culture 
containing  the  released  recombinant  cathepsin  B  were  incubated  with  various 
percentages  of  a  saturating  solution  of  ammonium  sulphate  for  2h  at  40C  with 
mild  agitation  to  fractionate  the  proteins  present  in  the  culture  supernatant 
according  to  their  solubility  at  various  concentrations  of  ammonium  sulphate.  The 
samples  were  then  centrifuged  for  15  min  at  13000  9  at  40C  and  the  pellet  was 
resuspended  in  the  same  volume  of  50  mM  sodium  acetate,  pH  5.0.  The  samples 
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of  resuspended  pellets  and  supernatant  were  tested  for  enzyme  activity  and  the 
protein  profile  was  assessed  by  SDS-PAGE. 
2.3.8.  Protein  native  molecular  mass  determination 
To  determine  the  molecular  mass  of  the  recombinant  pyroglutamyl 
peptidase  I  of  L.  major  with  a  N-terminal  His-tag,  expressed  in  E.  coli,  and 
purified  using  a  nickel-agarose  column,  gel-filtration  analysis  was  performed.  The 
column  used  was  a  high-resolution  Sepharose  12  (1  cm  diameter,  30  cm  long), 
which  was  equilibrated  in  50  mM  Tris  and  150  mM  NaCl,  pH  7.4,  and  run  at  0.5 
ml/min.  Calibration  was  with  the  following  proteins:  ribonuclease  A  (13.7  kDa), 
chymotrypsinogen  (25  kDa),  ovalbumin  (43  kDa),  BSA  (67  kDa),  alcohol 
dehydrogenase  (1150  kDa)  and  P-amylase  (200  kDa)  (all  Sigma,  Poole).  The  pure 
soluble  protein  was  provided  to  Dr.  Helen  Denton  (University  of  Glasgow),  who 
carried  out  the  experiment. 
2.3.9.  Protein  deglycosylation 
Supernatant  of  P.  pastoris  culture  containing  the  released  recombinant 
cathepsin  B  of  E.  tenella  was  treated  with  40%  followed  by  70%  saturation  of 
ammonium  sulphate  and  aliquots  (equivalent  to  about  20  pg  of  enzyme)  were 
deglycosylated  using  100  U  of  PGNase  F  (500000  U/ml,  New  England  Biolabs, 
Hitchin)  for  2.5  h  at  370C.  The  reactions  were  terminated  by  freezing  at  -2011C. 
Deglycosylation  was  assessed  by  SDS-PAGE  and  western-blot  analysis. 
2.3.10.  SDS-PAGE 
Proteins  analysed  by  SDS-PAGE  included  recombinant  proteins,  and 
Ecofi,  P.  pastotis  and  L.  major  lysates.  The  samples  were  mixed  with  equal 
volumes  of  2X  loading  buffer  and  boiled  for  5  min.  Proteins  were  separated  by 
SDS-PAGE  according  their  molecular  masses.  The  method  was  as  described  by 
Laemmli  (1970).  Gels  used  12%  (w/v)  polyacrylamide  (BioRad,  Hemel 
Hempstead)  and  were  run  using  a  Mini-Protean  11  slab  system  (BioRad,  Hemel 
Hempstead)  according  the  manufacturers  instructions.  Gels  were  stained  with 
0.25%  (w/v)  Coomassle  Brilliant  Blue  R250  and  destained  with  10%  (vIv)  acetic 
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acid,  12.5%  (v/v)  methanol,  or  used  for  electro-blotting  for  specific  protein 
analysis. 
2.3.11.  Antibody  production 
Full  length,  N-terminal  His-tagged,  n  ickel-ag  a  rose-pu  rifled  recombinant 
cathepsin  B-like  enzyme  of  E  tenella  produced  in  E.  coli  was  used  to  raise 
antiserum  in  a  rabbit  (done  by  Diagnostic  Scotland,  using  standard  methods). 
Full  length,  N-terminal  His-tagged  nickel-agarose  purified  recombinant 
pyroglutamyl  peptidase  I  (PPI)  of  L.  major  produced  in  E.  coli,  and  full  length,  N- 
terminal  His-tagged  nickel-agarose  purified  recombinant  glutaminyl  cyclase  (QC) 
of  L.  major  produced  in  E.  coli  were  used  to  raise  antiserum  in  a  rat  (done  by 
Biological  Services,  University  of  Glasgow),  by  inoculation  of  50  ýLg  of  protein 
diluted  to  a  ratio  of  1:  1  (v/v)  in  complete  Freund's  adjuvant  (Sigma,  Poole)  in  a 
total  volume  of  100  VI,  followed  by  two  other  inoculations  of  50  pg  of  protein 
diluted  to  a  ratio  of  1:  1  (v/v)  in  incomplete  Freund's  adjuvant  (Sigma,  Poole),  with 
one  month  time  separating  each  inoculation. 
2.3.12.  Western-blot  analysis 
Samples  were  in  1X  loading  buffer  and  proteins  were  separated  on  12% 
(v/v)  SDS-PAGE  gels.  Separated  proteins  were  transferred  to  Hybond-C 
nitrocellulose  membrane  (Amersham,  Chalfont  St.  Giles)  by  electroblotting  in 
transfer  buffer  (20  mM  Tris/HCI,  15  mM  glycine,  20%  (v/v)  methanol)  using  a 
BioRad  (Hemel  Hempstead)  mini  transblot  cell,  at  411C  for  1h  at  100  V.  Ponceau 
S  staining  allowed  protein  ladder  visualization  and  labeling  on  the  membrane. 
The  membrane  was  then  blocked  for  1h  at  room  temperature  in  20  mM  Tris/HCI 
pH  7.6,13.7  mM  NaCl,  0.2%  (v/v)  Tween-20,  and  5%  (w/v)  low  fat  dried  milk.  It 
was  then  incubated  overnight  with  primary  antibodies  at  40C  in  20  mM  Tris/HCI 
pH  7.6,13.7  mM  NaCl,  0.1%  (v/v)  Tween-20.  Anti-cathepsin  B  of  E.  tenella 
antisera  were  used  at  a  dilution  1:  8000  (v/v),  anti-PPI  of  L.  major  antiserum  was 
used  at  1:  500  (v/v),  and  anti-His-tag  antibody  was  used  at  1:  2000  (v/v).  Blots 
were  washed  4  times  for  30  min  with  20  mM  Tris/HCI  pH  7.6,13.7  mM  NaCl,  1% 
(w/v)  low  fat  dried  milk,  and  then  incubated  with  secondary  antibody  for  2h  at 
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room  temperature  in  200  mM  Tris/HCl  pH  7.6,137  mM  NaCl,  1%  (w/v)  low  fat 
dried  milk.  Secondary  antibodies  were  anti-rabbit  IgG-conjugated  horseradish 
peroxidase  (HRP)  (Promega,  Southampton)  at  1:  5000  (v/v),  anti-rat  IgG- 
conjugated  HRP  (Pierce,  Cramlington)  at  1:  1500  (v/v),  or  anti-mouse  IgG- 
conjugated  HRP  (Pierce,  Cramlington)  at  1:  2000  (v/v),  depending  on  the  primary 
antibody  used.  The  membrane  was  washed  3  times  for  30  min  with  20  mM 
Tris/HCl  pH  7.6,13.7  mM  NaCl,  1%  (w/v)  low  fat  dried  milk.  Bound  antibodies 
were  detected  by  using  the  Supersignal  Enhanced  Chemiluminescence  (ECL) 
reagents  (Pierce,  Cramlington)  according  the  manufacturers  instructions. 
Fluorescence  was  detected  by  autoradiography  with  reflexion  autoradiography 
film  (NEN  Life  Sciences,  Boston,  MA,  US). 
2.3.13.  Indirect  immunofluorescence 
2.3.13.1.  Analysis  of  the  subcellular  localisation  of  the  cathepsin  B-like 
enzyme  in  E.  tenella 
The  anti-cathepsin  B  of  E.  tenella  antiserum  raised  in  rabbit  was  sent  to 
Professor  David  J.  P.  Ferguson  (Oxford  University,  John  Radcliffe  Hospital, 
Oxford),  who  performed  all  of  the  cathepsin  B  localisation  studies  on  various  E. 
tenella  stages  of  the  life  cycle. 
2.3.13.2.  Analysis  of  the  subcellular  localisation  of  the  pyroglutarnyl 
pepticlase  I  enzyme  in  L.  major 
All  steps  were  at  room  temperature.  Stationary  phase  parasites  were 
collected  by  centrifugation  for  10  min  at  1300  9,  washed  in  PBS,  and 
resuspended  at  2x  107  cells/ml  in  PBS.  An  equal  volume  of  6%  (w/v) 
paraformaldehyde  in  PBS  was  added  and  the  mixture  was  incubated  on  ice  for  1 
h.  Five  volumes  of  PBS  were  added  and  the  cells  were  washed  and  harvested  as 
above.  Cells  were  resuspended  at  2x  107  cells/ml  in  PBS.  Slides  were  pre- 
treated  with  200  jal  of  0.01%  (w/v)  poly-L-lysine  solution  (Sigma,  Poole), 
incubated  for  5  min  and  then  allowed  to  dry  for  2  h.  Then  200  pl  of  parasite 
suspension  was  applied  to  the  slide  and  incubated  15  min.  The  cells  were 
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permeabilised  in  0.1%  (v/v)  Triton  X-100  in  PBS  for  10  min  (in  a  glass  chamber), 
slides  were  washed  3  times  in  PBS  for  5  min,  and  blocked  for  1h  with  20%  (v/v) 
HIFCS  in  PBS.  The  primary  antibody  at  a  dilution  1:  25,1:  100  or  1:  500  (v/v)  (anti- 
pyroglutamyl  peptidase  of  L.  major  raised  in  rat)  in  PBS,  with  20%  (v/v)  HIFCS 
was  incubated  on  the  slides  for  1  h.  The  slides  were  washed  3  times  for  5  min 
with  PBS,  and  the  secondary  antibody  at  a  dilution  of  1:  500  (v/v)  (Alexa  Fluor@ 
568  goat  anti-rat  IgG  [Molecular  Probes,  Paisley])  in  PBS  with  20%  HIFCS  was 
incubated  for  1h  at  room  temperature.  The  secondary  antibody  solution  also 
contained  the  4',  6-diamidino-2-phenylindole  DAR  staining  (5  Pg/ml,  final 
concentration).  The  slides  were  washed  3  times  for  5  min  with  PBS  and  mounted 
with  anti-quenching  agent  (MOWIOL-DABCO  in  50%  (v/v)  PBS).  The  edges  of 
the  coverslips  were  sealed  with  varnish  and  the  slides  were  stored  at  40C  in  the 
dark  until  analysis.  Fluorescence  signals  were  visualized  by  UV  fluorescence 
microscopy  on  a  Zeiss  Axioplan  fluorescence  microscope  with  a  Hamamstsu 
Digital  Camera  using  the  OpenLab  software  (Improvision,  University  of  Warwick). 
2.3.14.  Enzyme  activity  measurements 
2.3.14.1.  Substrate-gel  electrophoresis 
Reducing  gelatin  SDS-PAGE  was  as  described  in  Robertson  et  aL,  1990. 
Native  gelatin  SDS-PAGE  was  as  described  in  Pandey  et  aL,  2003.  All  gelatin 
gels  contained  gelatin  at  0.2%  (w/v)  final  concentration.  After  electrophoresis,  the 
gels  were  incubated  for  1h  in  2.5%  (v/v)  Triton  X-100,  and  then  in  0.1  M  sodium 
acetate,  pH  5.0,  supplemented  with  10  mM  DTT  at  3711C  for  6-16  h  before 
staining  with  Coomassie  blue. 
2.3.14.2.  Azocasein  assay 
The  proteolytic  activity  of  various  enzyme  fractions  towards  azocasein 
(Sigma,  Poole)  was  tested.  Fifty  ýtl  of  a  1%  (w/v)  azocasein  solution  in  1X  PBS 
was  mixed  with  400  ltl  of  0.1  M  Tris/HCl  pH  8.0  or  0.1  M  sodium  acetate  pH  5.0 
with  or  without  10  mM  DTT  and/or  1  mM  (2S,  3S)-3-(N-{(S)-1-[N-(4- 
guanidinobutyl)carbamoyl]3-methylbutyllcarbamoyl)oxirane-2-carboxylic  acid 
(E64),  and  50  gl  of  sample  to  test  (about  5-10  pg  of  recombinant  protein)  and 
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incubated  at  3711C  overnight.  Controls  without  sample  or  with  25  jtg  of  a- 
chymotrypsin  (Sigma,  Poole,  57  U/mg)  were  also  included.  After  incubation,  500 
ýtl  of  ice  cold  1%  TCA  were  added  to  the  samples,  incubated  for  10  min  on  ice 
and  centrifuged  at  13000  g  for  5  min  at  room  temperature.  The  absorbance  of  the 
supernatant  was  measured  at  400  nm. 
2.3.14.3.  Spectrophotometric  assays 
In  all  experiments,  1  unit  of  activity  represents  1  Itmol  of  substrate 
hydrolysed  per  min.  All  measurements  were  in  triplicate. 
The  extinction  coefficient  at  410  nm  for  the  substrate  was  measured  using 
a  standard  curve  of  free  chromogenic  substituent  in  the  buffer  used  for  the 
assays.  The  extinction  coefficient  used  for  the  paranitroanilide  (pNA)  substrates 
(all  Bachem,  St.  Helens)  was  9.5  x  103  1  /mol/cm  in  all  buffer  systems.  The  light 
path  was  1  cm. 
2.3.14.3.1.  Recombinant  cathepsin  B  of  E.  tenella 
The  assays  using  the  chromogenic  substrates  benzyloxycarbonyl-Phe- 
Arg-pNA  (Z-Phe-Arg-pNA)  and  Z-Arg-Arg-pNA  consisted  of  50  mM  sodium 
acetate  pH  5.0,2  mM  EDTA,  10  mM  DTT,  with  333  ltM  of  chromogenic  substrate 
in  a  total  volume  of  600  ld.  The  buffer  was  incubated  at  3711C  with  the  enzyme 
sample  for  10  min  and  the  reaction  was  started  by  addition  of  the  substrate.  The 
reaction  was  followed  continuously  for  10  min  at  410  nm. 
2.3.14.3.2.  Recombinant  pyroglutamyl  peptidase  I  of  L.  major 
The  assays  using  the  chromogenic  substrates  pGlu-pNA  (Bachem,  St. 
Helens)  consisted  of  different  buffers,  with  2  mM  of  chromogenic  substrate  in  a 
total  volume  of  1  mi.  The  buffer  was  incubated  at  320C  with  the  enzyme  sample 
for  5  min  and  the  reaction  was  started  by  addition  of  the  substrate.  The  reaction 
was  followed  continuously  for  10  min  at  410  nm. 
The  dependence  on  DTT  was  measured  in  25  mM  potassium  phosphate 
buffer  pH  8.0.  The  reaction  was  started  by  addition  of  2  mM  of  substrate  and 
measured  continuously  for  10  min. 
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The  pH  dependence  was  determined  using  2  different  methods.  The  first 
comprised  assaying  the  activity  in  a  mix  of  4  buffers  (25  mM  acetic  acid,  25  mM 
2-(N-morpholino)  ethanesulphonic  acid  (MES),  75  mM  Tris,  25  mM  glycine) 
adjusted  to  the  appropriate  pH,  with  10  mm  DTT.  The  reaction  was  started  by 
addition  of  2  mM  pGlu-pNA.  The  second  method  used  a  set  of  buffers,  which  was 
composed  of  "Good"  buffers  (Good  et  aL,  1966),  as  they  are  biologically  and 
chemically  non-reactive  and  their  pK.  show  a  minimum  dependence  on  the 
temperature  and  the  ionic  strength.  These  were  MES/NaOH  (25  mM,  pH  5.4  and 
6.5),  piperazine-NN'-bis-2-ethanesulphonic  acid  (PIPES)/NaOH  (25  mM,  pH  6.3 
and  7),  3-(N-morpholino)  propanesulphonic  acid  (MOPS)/  NaOH  (25  mM,  pH  6.5 
and  7.5),  HEPES/NaOH  (25  mM,  pH  7.0  and  8.0),  NN-bis  (2-hydroxyethyl) 
glycine  (BICINE)/NaOH  (25  mM,  pH  7.8  and  8.8),  2-(cyclohexylamino) 
ethanesulphonic  acid  (CHES)/NaOH  (25  mM,  pH  8.5,9.0,10.0  and  10.5),  3- 
(cyclohexylamino)-l-propanesulphonic  acid  (CAPSO)/NaOH  (25  mM,  pH  9.0,9.5 
and  10.0).  Assays  also  included  10  mM  DTT.  The  reaction  was  started  by 
addition  of  2  mM  of  pGlu-pNA. 
The  effect  of  EDTA,  and  magnesium  ions  was  measured  in  50  mM 
HEPES  pH  8.0,10  mM  DTT  using  the  substrate  pGlu-pNA.  The  reaction  was 
started  by  addition  of  2  mM  of  substrate  and  measured  continuously  for  10  min. 
Enzyme  stability  was  tested  in  50  mM  HEPES  pH  8.0,2  mM  Tris(2- 
carboxyethyl)phosphorine  hydrochloride  (TCEP),  1  mM  EDTA  with  the  substrate 
pGlu-pNA,  at  various  time  points.  Enzyme  stability  was  tested  at  -20,4,  and 
370C. 
The  measurement  of  the  Km  for  hydrolysis  of  pGlu-pNA  was  performed 
using  10  ýN  to  2  mM  of  substrate,  in  50  mM  HEPES  pH  8.0,1  mM  EDTA,  2  mM 
TCEP,  at  32*C. 
For  testing  of  inhibitors'  effects,  the  inhibitor  (or  ion  to  test)  was  added  to 
the  buffer-enzyme  mix  and  incubated  for  10  min  at  320C.  Assays  were  in  50  mM 
HEPES  pH  8.0,2  mM  TCEP.  The  reaction  was  started  with  200  liM  of  pGlu-pNA, 
and  was  then  as  described  for  the  peptidase  assay. 
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2.3.14.4.  Fluorometric  assays 
In  all  experiments,  I  unit  of  activity  represents  1  Itmol  of  substrate 
hydrolysed  per  min.  All  measurements  were  in  triplicate. 
The  extinction  coefficients  for  the  different  products  of  cleavage  were 
measured  using  a  standard  curve  of  free  fluorescent  substituent.  All  substrates 
were  from  Bachem,  St.  Helens.  The  extinction  coefficient  for  P-naphtylamine  (P- 
NA)  was  found  to  be  2.6  x  109  I/mol/cm  in  all  buffer  systems  (excitation  320/ 
emission  410  nm).  The  extinction  coefficient  for  7-amino-4-methylcoumarin 
(AMC)  was  found  to  be  5.8  x  109  I/mollcm  in  all  buffer  systems.  The  light  path 
was  1  cm  (excitation  380/  emission  465  nm). 
2.3.14.4.1.  Recombinant  cathepsin  B  of  E  tenella 
Peptidase  activity  was  assessed  using  the  fluorogenic  substrates  Z-Phe- 
Arg-AMC  and  Z-Arg-Arg-AMC  at  a  concentration  of  200  pM  unless  otherwise 
stated  in  50  mM  sodium  acetate,  pH  5.0,5  mM  EDTA,  and  10  mM  DTT. 
Reactions  were  in  a  total  volume  of  1  ml,  at  370C  and  started  by  addition  of  the 
substrate  after  a  pre-incubation  of  the  buffer-enzyme  mix  for  10  min  at  3711C.  The 
appearance  of  AMC  was  measured  using  excitation  at  380  nm  and  emission  at 
465  nm.  Activities  were  calculated  from  the  rate  over  the  first  10  min. 
The  dependence  on  DTT  and  on  salt  was  measured  using  10  gl  of  crude 
Pichia  supernatant  in  50  mM  sodium  acetate,  pH  5.0,  using  the  substrate  Z-Phe- 
Arg-AMC.  The  reaction  was  started  by  addition  of  50  gM  of  substrate  and 
measured  continuously  for  5  min. 
The  effect  of  EDTA  was  measured  using  10  ýJ  of  crude  Pichia  supernatant  in 
50  mM  sodium  acetate  pH  5.0,10  mM  DTT  with  the  substrate  Z-Phe-Arg-AMC. 
The  reaction  was  started  by  addition  of  30  ýM  of  substrate  and  measured 
continuously  for  5  min  (excitation  380  nm/emission  465  nm). 
The  pH  dependence  was  determined  using  2  different  methods.  The  first 
comprised  assaying  the  activity  in  a  mix  of  4  buffers  (25  mM  acetic  acid,  25  mM 
MES,  75  mM  Tris,  25  mM  glycine)  adjusted  to  the  appropriate  pH,  with  10  PI  of 
crude  Pichla  supernatant  and  10  mM  DTT.  The  reaction  was  started  by  addition 
of  30  gM  of  Z-Phe-Arg-AMC.  The  second  method  involved  using  3  different 
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buffers  separately,  depending  on  their  pH  range.  These  buffers  were  0.1  M  acetic 
acid,  0.1  M  sodium  acetate  and  0.1  M  potassium  phosphate.  Each  assay  used  2 
l.  d  of  crude  Pichia  supernatant.  All  buffers  were  supplemented  with  10  mM  DTT. 
The  reaction  was  started  by  addition  of  30  gM  of  Z-Phe-Arg-AMC. 
Km  measurements  towards  Z-Phe-Arg-AMC  and  Z-Arg-Arg-AMC  used  0.5 
ýtg  of  enzyme  per  assay  and  were  in  50  mM  sodium  acetate  pH  5.0, 
supplemented  with  10  mM  DTT  and  5  mM  EDTA.  The  enzyme  sample  was 
incubated  for  10  min  at  370C  in  the  assay  buffer  before  start  of  the  reaction  by 
addition  of  the  substrate  (10  gM  to  1.5  mM).  The  assays  were  continuous  for  10 
min  at  370C. 
For  testing  of  inhibitors'  effects,  the  inhibitor  was  added  to  the  buffer-enzyme 
mix  and  incubated  for  10  min  at  370C.  The  reaction  was  then  as  described  for  Km 
measurements. 
2.3.14.4.2.  Recombinant  pyroglutamyl  peptidase  I  of  L.  major 
All  assays  were  at  320C  in  a  total  volume  of  1  ml.  The  buffer  was 
incubated  at  320C  with  the  enzyme  sample  for  5  min  and  the  reaction  was  started 
by  addition  of  the  substrate.  Excitation  and  emission  wavelengths  were, 
respectively,  320  and  410  nm  for  the  P-NA  fluorogenic  substrates. 
The  measurement  of  the  Km  for  hydrolysis  of  pGlu-PNA  and  H-Glu-PNA 
was  performed  using  0.1  jiM  to  1  mM  of  substrate,  in  50  mM  HEPES  pH  8.0,1 
mM  EDTA,  2  mM  TCEP.  All  other  assays  against  pGlu-PNA  used  200  gM  of  this 
substrate. 
Assays  against  the  H-Gln-PNA  substrate  were  in  50  mM  HEPES  pH  8.0, 
I  mM  EDTA,  2  mM  TCEP,  with  200  gM  of  this  substrate. 
2.3.14.4.3.  Native  pyroglutamyl  peptidase  I  of  L.  major 
L.  major  promastigote  cell  lysis  is  described  in  2.1.3.  Typically  5-10  x  107 
L.  major  stationary  phase  promastigotes  equivalent  were  tested  per  assay.  The 
buffer  consisted  of  1  ml  of  50  mM  HEPES  pH  8.0,1  mM  EDTA,  2  mM  TCEP,  or  1 
ml  of  50  mM  Tris,  pH  8.0.  The  buffer  was  pre-incubated  at  320C  for  5  min  with 
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200  ýM  of  pGlu-PNA  and  the  assay  was  started  by  addition  of  the  cell  extract  to 
analyse.  The  measurements  were  continuous  for  10  min.  Excitation  and  emission 
wavelengths  were,  respectively,  320  and  410  nm. 
2.4.  L.  major  infectivity 
2.4.1.  In  vitro  infectivity  in  macrophages 
Peritoneal  macrophages  were  extracted  from  peritoneal  lavage  of  CD-1 
mice  (work  done  by  Susan  Baillie,  University  of  Glasgow).  Macrophages  were 
resuspended  in  RPMI  medium  (GibcoBRL,  Paisley)  with  10%  (v/v)  HIFCS  at  a 
concentration  of  5x  105  cells/ml,  200  ýtl  of  this  suspension  was  placed  in  each 
well  of  cavity  slides  (VWR,  Lutterworth),  incubated  at  370C  for  24  h  in  5%CO2, 
95%  air.  Stationary  phase  L.  major  promastigotes  or  purified  metacyclics  of  L. 
majorwere  diluted  in  RPMl  with  10%  (v/v)  HIFCS,  and  200  ýLl  were  added  to  the 
macrophage  suspension  at  a  ratio  of  2:  1  or  0.51  respectively,  following  the 
method  described  in  Frame  et  a/.,  2000.  After  24  h  in  5%  C02v  95%  air  at  3711C, 
the  L.  major  promastigotes  were  washed  off  and  400  ld  of  RPMI  with  10%  (v/v) 
HIFCS  was  added.  After  3  days  of  further  incubation  at  370C  the  medium  was 
removed  and  replaced  by  fresh  medium  and  slides  were  further  incubated  for  3 
days  at  370C.  The  cells  were  then  fixed  with  methanol  and  stained  with  Giemsa 
stain,  and  the  parasite  loads  were  determined  microscopically  by  counting  200 
macrophages.  Each  cell  line  of  L.  major  being  analysed  was  infected  into  3  wells 
of  the  cavity  slide. 
2.4.2.  Infectivity  in  BALB/c  mice 
Groups  of  6  mice  were  inoculated  in  the  footpad  with  5x  105  stationary- 
phase  L.  major  promastigotes,  or  105  purified  metacyclic  promastigotes  of  L. 
major  resuspended  in  20  ýtl  of  PBS,  pH  7.4.  The  thickness  of  the  infected 
footpads  was  measured  regularly  over  a  5-12  weeks  period. 
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2.5.  Bioinformatic  analyses 
Vector  NTI  (v.  6.0)  was  used  to  analyse  DNA  and  protein  sequences 
(searching  for  open  reading  frames,  restriction  sites,  design  of  oligonucleotides 
for  PCR,  construction  of  cloning  and  expression  plasmids).  Sequence  alignments 
were  studied  with  Align  X  (Clustal  X)  and  ContigExpress  was  used  to  align 
overlapping  sequences.  For  phylogenetic  analyses,  sequences  were  aligned 
using  Align  X  (Vector  NTI  program),  cut  to  the  same  amino  acid  length  (166),  and 
insertions  were  removed  manually.  The  edited  sequences  were  realigned  using 
Align  X.  The  unrooted  phylogenetic  tree  was  generated  using  the  neighbour- 
joining  method  in  the  Molecular  Evolutionary  Genetics  Analysis  (MEGA)  program, 
version  2.1  (Kumar  et  aL,  2001),  with  1000  bootstrap  replicates. 
The  following  web  sources  were  used  for  database  mining  and  analysis  of 
DNA  and  protein  sequences: 
TIGR  databases:  www.  tigr.  org 
The  Sanger  Institute:  www.  sanger.  ac.  uk 
GeneDB:  www.  genedb.  org 
NCBI:  www.  ncbi.  nim.  nih.  gov 
MEROPS:  www.  merops.  sanger.  ac.  uk 
Protein  domain  predictions  were  with: 
SignalP  (Nielsen  et  al.,  1996):  www.  cbs.  dtu.  dk/services/SignalP 
Target  Pv1.0:  www.  cbs.  dtu.  dk/services/TargetP 
TMpred:  www.  ch.  embnet.  org 
2.6.  Statistical  analyses 
Values  were  expressed  either  as  mean  ±  standard  deviation  (SD)  when 
the  number  of  repetitions  was  more  than  2,  or  mean  ±  standard  error  (SE)  when 
the  number  of  repetitions  was  2.  Levels  of  significance  were  calculated  by 
unpaired  t  tests  using  the  GraphPad  Prism  program  (San  Diego,  CA,  US). 
Differences  were  considered  significant  at  P<0.05. 
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Chapter  3 
Expression'and  characterisation  of 
the  recombinant  cathepsin  B  of  E.  tenella 
3.1.  Introduction 
Invasion  of  host  cells  by  Eimeria,  and  other  apicomplexan  parasites, 
involves  the  regulated  release  of  specialised  secretory  organelles;  namely 
micronemes,  rhoptries  and  dense  granules,  located  at  the  anterior  end  of  the 
parasite  (Dubremetz,  1998)  and  forming  the  apical  complex.  Maturation, 
trafficking  and  secretion  of  many  of  the  secretory  organelles'  proteins  rely  upon 
proteolytic  processing  (Soldati  et  a/.,  1998;  Carruthers  et  al.,  2000;  Reiss  et  a/., 
2001).  After  several  cycles  of  asexual  multiplication  (schizogony  or  merogony), 
gametogony  begins;  macrogametocytes  (female  gamete)  and  microgametocytes 
(male)  are  formed,  and  fuse  to  form  oocysts,  that  are  released.  The  oocyst  wall 
ensures  the  parasite  survival  in  the  external  environment  before  finding  the  next 
host.  The  oocyst  wall  formation  therefore  constitutes  an  essential  process  for 
disease  transmission.  The  wall  is  sequentially  formed  by  the  release  of  three 
macrogamete  organelles  structurally  similar  to  the  dense  granules  of  the 
infectious  stages  (Ferguson  et  al.,  2000);  the  veil  forming  bodies,  the  wall  forming 
bodies  type  1  (associated  to  the  Golgi  apparatus  and  located  in  the  cytoplasm), 
and  the  wall  forming  bodies  type  2  (associated  to  the  endoplasmic  reticulurn  and 
found  in  vacuolar  spaces)  (Ferguson  et  al.,  2003).  Peptidases  have  been  shown 
to  be  involved  in  the  oocyst  wall  formation  in  Eimetia  (Belli  et  a/.,  2003a;  Belli  et 
al.,  2003b),  by  maturation  of  precursor  proteins  found  in  the  wall  forming  bodies. 
Some  cysteine  peptidases  from  apicomplexan  parasites  have  been 
identified  as  important  factors  for  invasion  of  host  cells  (Kim,  2004).  These 
enzymes  include  the  cathepsin  B-like  toxopain-1  in  Toxoplasma  gondii  (Que  et 
aL,  2002),  and  falcipain-1  in  Plasmodium  falciparum  (Greenbaum  et  a/.,  2002). 
Furthermore,  parasite  cysteine  peptidases  have  attracted  particular  attention  over 
the  recent  years  because  of  their  importance  in  parasite  survival,  interaction  with 
the  host  cells  and  pathogenicity.  Some  of  them  seem  to  be  promising  targets  for 
new  selective  inhibitors  and  anti-parasite  agents  (Selzer  et  al.,  1997;  Rosenthal, 
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1999).  The  well  studied  cathepsin  L-like  enzyme,  CPB2.8,  of  Leishmania 
mexicana  provides  a  good  example  (Mottram  et  a/.,  1996;  Coombs  and  Mottram, 
1997). 
Cathepsin  B  enzymes,  which  belong  to  the  clan  CA,  family  C1  of  cysteine 
peptidases  comprise  a  signal  peptide,  a  pro-domain  and  a  mature  domain.  The 
pro-domain,  which  might  possess  in  some  cases  folding  information  (Pandey  et 
al.,  2004),  has  been  shown  to  be  a  strong  inhibitor  of  the  catalytic  domain  (Sijwali 
et  al.,  2002),  and  so  maintains  the  peptidase  in  an  inactive  form  during  trafficking 
to  the  lysosome.  Activation  of  the  enzyme  is  a  regulated  process  involving  the 
proteolytic  cleavage  (endogenous  or  exogenous)  of  the  pro-peptide,  facilitated  by 
decreasing  the  pH  (Turk  et  aL,  2000),  which  is  favoured  in  the  acidic  pH 
environment  of  the  lysosome. 
The  ever-increasing  number  of  gene  sequences  and  EST  data  published 
in  the  public  domain  provides  a  great  resource  for  analyses  and  potential 
identification  of  targets  for  therapeutics.  Up  to  now,  the  anticoccidial  drugs 
dominating  the  market  for  the  treatment  of  avian  Eimeria  have  been  polyether 
ionophores,  which  perturb  ion  gradients  in  the  parasite  (Dutton  et  al.,  1995).  But 
because  of  problems  of  drug  resistance  and  occurrence  of  mutant  populations, 
toxicity  and  limited  efficacy  of  current  drugs,  identification  and  evaluation  of  new 
drugs  and  new  targets  is  constantly  and  urgently  needed. 
The  aim  of  this  part  of  my  work  was  to  obtain  active  recombinant 
cathepsin  B  of  E.  tenella  for  biochemical  characterisation,  and  drug  screening. 
The  difficulty  of  maintaining  Eimeria  species  in-vitro  somewhat  limited  the  extent 
of  the  possible  functional  investigation  in  the  parasite.  Nonetheless,  cysteine 
peptidase  inhibitors  have  been  shown  to  block  sporozoite  invasion  (Samantha 
Brown,  unpublished  data),  and  to  get  an  insight  on  what  might  be  the  role  of  the 
enzyme,  immunolocalisation  studies  on  invasive  and  sexual  stages  of  Eimeria 
tenella  were  performed  in  collaboration  with  Prof  David  J.  Ferguson,  Oxford. 
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3.2.  Results 
3.2.1.  Cloning  of  the  cathepsin  B  gene 
Database  searches  on  the  genomic  database  of  E.  tenella  using  the 
cathepsin  B  of  Toxoplasma  gondii  (accession  number  AAL60053)  as  a  query 
allowed  detection  of  a  1535  bp  open  reading  frame  (Contig5436, 
www.  geneDB.  org).  Amplification  by  PCR  of  the  complete  putative  sequence 
coding  for  the  cathepsin-B  like  protein  (MEROPS  clan  CA,  family  C11)  on  both 
gDNA  and  cDNA  gave  a  single  product  of  the  same  size,  about  1.6  kb,  which 
corresponds  to  the  predicted  size  for  the  amplification  product  using  the  specific 
primers  designed  (Fig.  3.1).  The  amplified  fragments  were  sequenced  and  both 
fragments  presented  the  same  nucleotide  sequences,  confirming  the  absence  of 
introns  in  the  gene.  The  results  of  5'  RACE  permitted  detection  of  the  presence  of 
a  mRNA  comprising  a  40  bp  5'  untranslated  region  (5'  UTR),  confirming  the  start 
methionine  (Fig.  3.2).  Furthermore,  the  start  methionine  conforms  to  a  Kozak 
eukaryotic  consensus  (Kozak,  1999)  and  the  consensus  assigned  to  protozoan 
parasites  (Yamauchi,  1991)  favouring  the  presence  of  a  purine  at  position  -3  and 
+4  of  the  start  ATG.  The  complete  ORF  encodes  a  pre-pro-enzyme  of  512  amino 
acids  W,  =  55,937). 
1.65 
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FIG.  3.1.  PCR  amplification  of  the  cathepsin  B-like  gene  of  E.  tenefia.  Electrophoresis 
on  1%  agarose  gel  of  10  lal  of  PCR  products  from  the  amplification  on  genomic  DNA  (lane  1)  and 
cDNA  (lanes  2  and  3)  of  the  putative  full  sequence  coding  for  the  cathepsin  B-like  enzyme  of  E. 
tenella.  Negative  control  PCR,  representative  of  the  amplification  on  genomic  DNA  present  in  the 
cDNA  preparation  after  reverse  transcription,  is  shown  on  lane  4.  The  marker  used  is  the  1kb 
Plus.  The  size  of  fragments  is  indicated  on  the  left  of  the  figure  in  kb. 
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mRIGKLW 
1  TATTCGATTT  CCACTTAGCT  ACTACGCTTT  GCATTCTGAG  TTTGTGAAAA  TGAGGATAGG  GAAGCTGTGG 
ATAAGCTAAA  GGTGAATCGA  TGATGCGAAA  CGTAAGACTC  AAACACTTTT  ACTCCTATCC  CTTCGACACC 
ATLA  Iss  PLI  FSCA  mPS  DDLGGAK 
71  GCCACCTTGG  CCATTTCCAG  CCCCCTGATC  TTCAGTTGTG  CGATGCCCTC  CGATGATTTG  GGCGGCGCTA 
CGGTGGAACC  GGTAAAGGTC  GGGGGACTAG  AAGTCAACAC  GCTACGGGAG  GCTACTAAAC  CCGCCGCGAT 
-EDL  Qsv  GNAI  DAI  FDR  ILRDVEK 
141  AGGAAGATCT  GCAGTCTGTG  GGCAATGCCA  TCGATGCCAT  ATTCGACCGG  ATTCTGCGAG  ATGTAGAGAA 
TCCTTCTAGA  CGTCAGACAC  CCGTTACGGT  AGCTACGGTA  TAAGCTGGCC  TAAGACGCTC  TACATCTCTT 
-DIG  HGKA  LQA  CGP  SGSHT0GVEN 
211  GGATATTGGA  CATGGCAAAG  CCCTCCAAGC  TTGCGGTCCC  AGCGGTTCCC  ACACGCAAGG  TGTGGAGAAC 
CCTATAACCT  GTACCGTTTC  GGGAGGTTCG  AACGCCAGGG  TCGCCAAGGG  TGTGCGTTCC  ACACCTCTTG 
CRRVLKG  EPD  ESHE  LLP  YLLKDQE 
281  TGCAGGCGTG  TGCTGAAAGG  AGAGCCTGAC  GAATCTCATG  AGTTGCTGCC  GTACCTGCTT  AAGGACCAGG 
ACGTCCGCAC  ACGACTTTCC  TCTCGGACTG  CTTAGAGTAC  TCAACGACGG  CATGGACGAA  TTCCTGGTCC 
-AMR  LWR  DHFRRHV  GEL  VSSASEH 
351  AGGCCATGAG  GTTGTGGCGG  GATCACTTCC  GTCGGCACGT  GGGCGAGCTG  GTATCCAGTG  CATCGGAACA 
TCCGGTACTC  CAACACCGCC  CTAGTGAAGG  CAGCCGTGCA  CCCGCTCGAC  CATAGGTCAC  GTAGCCTTGT 
-SGA  DTPLQGP  VLK  SLAESEFWGS 
421  TAGCGGGGCA  GATACCCCCC  TTCAGGGGCC  GGTATTGAAA  AGCCTCGCGG  AAAGCGAATT  CTGGGGAAGC 
ATCGCCCCGT  CTATGGGGGG  AAGTCCCCGG  CCATAACTTT  TCGGAGCGCC  TTTCGCTTAA  GACCCCTTCG 
RPAV  SNG  ALQ  HLRV  KMQ  RLKLQAA 
491  CGGCCAGCTG  TTAGCAACGG  AGCTTTGCAG  CACTTGAGGG  TGAAGATGCA  GCGGCTGAAG  CTGCAAGCAG 
GCCGGTCGAC  AATCGTTGCC  TCGAAACGTC  GTGAACTCCC  ACTTCTACGT  CGCCGACTTC  GACGTTCGTC 
-EQG  LDP  EQAVTWE  AEV  SPRFKYH 
561  CTGAGCAGGG  TCTAGACCCT  GAACAGGCGG  TGACGTGGGA  AGCAGAAGTG  TCTCCTCGTT  TCAAATACCA 
GACTCGTCCC  AGATCTGGGA  CTTGTCCGCC  ACTGCACCCT  TCGTCTTCAC  AGAGGAGCAA  AGTTTATGGT 
.SIK  DAKRHMG  TYL  SFYSDPDKPE 
631  CACCATCAAA  GACGCGAAAA  GGCATATGGG  TACTTACCTT  TCTTTCTATT  CAGATCCAGA  CAAGCCAGAG 
GTCGTAGTTT  CTGCGCTTTT  CCGTATACCC  ATGAATGGAA  AGAAAGATAA  GTCTAGGTCT  GTTCGGTCTC 
VPLGEPL  PVK  VFAETQQ  VLETDKF 
701  GTGCCGCTTG  GGGAGCCACT  GCCTGTGAAG  GTGTTTGCGG  AGACGCAGCA  GGTTCTGGAA  ACTGACAACT 
CACGGCGAAC  CCCTCGGTGA  CGGACACTTC  CACAAACGCC  TCTGCGTCGT  CCAAGACCTT  TGACTGTTCA 
-DAR  EAF  PQCAEVI  GHV  RDQGDCG 
771  TTGACGCGAG  GGAGGCCTTT  CCTCAATGCG  CAGAGGTGAT  TGGCCATGTC  CGAGACCAAG  GCGACTGCGG 
AACTGCGCTC  CCTCCGGAA.  A  GGAGTTACGC  GTCTCCACTA  ACCGGTACAG  GCTCTGGTTC  CGCTGACGCC 
.scw  AFASTEA  LND  RFCIKSGGRH 
841  CTCGTGCTGG  GCCTTTGCTA  GCACAGAGGC  CCTGAACGAC  CGTTTCTGCA  TCAAGTCAGG  CGGCCGCCAT 
GAGCACGACC  CGGAAACGAT  CGTGTCTCCG  GGACTTGCTG  GCAAAGACGT  AGTTCAGTCC  GCCGGCGGTA 
REALsPQ  HTT  SCCDLLH  CLSFGCS 
911  CGGGAGGCTC  TGTCGCCGCA  GCATACGACT  TCATGCTGCG  ACCTACTGCA  CTGTTTGTCT  TTTGGCTGCT 
GCCCTCCGAG  ACAGCGGCGT  CGTATGCTGA  AGTACGACGC  TGGATGACGT  GACAAACAGA  AAACCGACGA 
-GGQ  PRM  AWRWFSN  DGV  VTGGDYN 
981  CCGGGGGCCA  GCCGAGGATG  GCTTGGCGGT  GGTTTTCGAA  CGATGGGGTG  GTAACCGGTG  GTGACTACAA 
GGCCCCCGGT  CGGCTCCTAC  CGAACCGCCA  CCAAAAGCTT  GCTACCCCAC  CATTGGCCAC  CACTGATGTT 
-ELH  TGKScwP  yEI  PFCRHHSEGP 
1051  CGAGCTGCAC  ACGGGTAAAA  GCTGCTGGCC  TTACGAGATT  CCCTTCTGCC  GGCACCACTC  GGAAGGGCCC 
GCTCGACGTG  TGCCCATTTT  CGACGACCGG  AATGCTCTAA  GGGAAGACGG  CCGTGGTGAG  CCTTCCCGGG 
YPKCEGP  LPK  APKCRKD  CEEAEYT 
1121  TACCCAAAGT  GTGAGGGGCC  CTTGCCCAAG  GCTCCGAAGT  GCCGCAAGGA  TTGTGAGGAA  GCAGAGTACA 
ATGGGTTTCA  CACTCCCCGG  GAACGGGTTC  CGAGGCTTCA  CGGCGTTCCT  AACACTCCTT  CGTCTCATGT 
-SKV  KPF  KDD  LHFA  TSA  YSVE0RD 
1191  CCAGCAAAGT  GAAGCCATTC  AAGGATGATC  TACATTTCGC  CACGAGTGCA  TACAGTGTGG  AAGGCCGGGA 
GGTCGTTTCA  CTTCGGTAAG  TTCCTACTAG  ATGTAAAGCG  GTGCTCACGT  ATGTCACACC  TTCCGGCCCT 
-QIK  RELMENG  TLT  GAF  LVYEDFL 
1261  CCAAATTAAA  CGGGAACTTA  TGGAAAATGG  CACTCTCACT  GGCGCTTTCC  TCGTGTATGA  GGACTTCCTG 
GGTTTAATTT  GCCCTTGAAT  ACCTTTTACC  GTGAGAGTGA  CCGCGAAAGG  ACCACATACT  CCTGAAGGAC 
LYKE  GvY  HHV  TGMP  MGG  HAVKVIG 
1331  CTGTACAAGG  AGGGGGTGTA  TCACCACGTG  ACAGGCATGC  CCATGGGTGG  TCACGCAGTG  AAGGTGATTG 
GACATGTTCC  TCCCCCACAT  AGTGGTGCAC  TGTCCGTACG  GGTACCCACC  AGTGCGTCAC  TTCCACTAAC 
-FGN  EDG  RDYWLAV  NSW  NEYWGDK 
1401  GCTTCGGGAA  CGAAGACGGG  AGGGACTACT  GGCTAGCTGT  GAACAGCTGG  AACGAATACT  GGGGAGATAA 
CGAAGCCCTT  GCTTCTGCCC  TCCCTGATGA  CCGATCGACA  CTTGTCGACC  TTGCTTATGA  CCCCTCTATT 
-GTF  KIEMGEA  GID  XEF  CGGEPKV 
1471  AGGCACTTTC  AAAATTGAAA  TGGGAGAGGC  AGGAATAGAT  AAAGAATTCT  GTGGAGGGGA  GCCGAAAGTG 
TCCGTGAAAG  TTTTAACTTT  ACCCTCTCCG  TCCTTATCTA  TTTCTTAAGA  CACCTCCCCT  CGGCTTTCAC 
PND  KNAS  LLP  SAQDL 
1541  CCCAATGACA  AAAACGCCTC  ATTGCTGCCG  TCAGCGCAGG  ACCTATGAAA  CTAAAGGCGA  TTCAAGGGC 
GGGTTACTGT  TTTTGCGGAG  TAACGACGGC  AGTCGCGTCC  TGGATACTTT  GATTTCCGCT  AAGTTCCCG 
FIG.  3.2.  Complete  sequence  of  the  contig  containing  an  open  reading  frame 
encoding  a  cathepsin  B-like  enzyme  of  E.  tenella.  The  sequence  of  the  5'  UTR  obtained  from 
5'  RACE  experiment  is  on  grey  background.  The  translation  of  the  putative  ORF  is  shown  in  bold. 
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The  amino  acid  sequence  was  analysed  with  the  SignalP  algorithm  (Nielsen 
et  al.,  1997)  and  a  pre-peptide  of  21  hydrophobic  amino  acids  could  be  predicted. 
By  comparison  with  cathepsins  B  from  other  organisms  (Fig.  3.3),  a  pro-domain 
of  213  amino  acids  could  be  predicted  as  well.  As  a  comparison,  the  cathepsin  B- 
like  enzyme  of  T.  gondii  (Que  et  al.,  2002)  has  a  pre-peptide  of  34  amino  acids,  a 
pro-domain  of  239  amino  acids  and  the  mature  enzyme  is  composed  of  296 
residues  (Fig.  3.4).  The  cathepsin  B-like  enzyme  of  E.  tenella  has  a  long  pro- 
domain  very  similar  to  the  one  from  T.  gondii.  But  both  enzymes  lack  the  ERFNIN 
motif,  usually  found  in  the  pro-domain  of  cathepsins  L-  and  H-like  enzymes.  The 
C-terminal  end  of  the  enzyme  contains  a  potential  site  for  asparagine-linked 
glycosylation  (N-X-S/T)  at  position  502.  The  complete  pre-pro-enzyme  showed 
42%  similarity  with  the  T.  gondii  cathepsin  B  and  the  mature  enzyme  of  491 
amino  acids  showed  good  similarity  to  the  human  cathepsin  B  (45%),  the 
cathepsin  B  of  L.  major  (39%),  T.  gondii  (57%),  and  S.  mansoni  (44%).  The 
position  of  the  catalytic  cysteine,  histidine  and  asparagine  in  the  cathepsin  B-like 
enzyme  of  E.  tenella  are  respectively  263,445,  and  465  (E.  tenella  cathepsin  B 
numbering).  The  pro-enzyme  contains  16  cysteine  residues,  which  can  possibly 
be  involved  in  the  formation  of  8  disulfide  bridges.  The  positions  for  10  of  the 
cysteine  residues  in  the  different  enzymes  of  the  different  organisms  compared 
were  conserved.  The  occluding  loop  diagnostic  of  cathepsin  B  enzymes  can  also 
be  identified  at  H  iS352  and  H  iS353 
. 
This  loop  might  confer  to  the  enzyme  an 
exopeptidase  activity  in  addition  to  the  endopeptidase  activity.  By  comparison  to 
the  human  cathepsin  B,  a  C-terminal  extension  of  8  amino  acids  can  be  detected. 
This  short  extension  is  similar  to  the  one  found  for  T.  gondii  (26  amino  acids)  but 
differs  from  the  very  long  extensions  found  for  some  cathepsin  L-like  enzymes. 
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1  70 
Et  (1)  -------------  MRIGKLWATLAISSPLIFSCAMPSDDLGGAKEDLQSVGN  ---  AIDAIFDRILR--DV 
Tg  (1)  ME  GRKSFRVLGTPLPFAALAAILLLGCMYTRAAGTPDDSLFPLSEDTSVDPRESFSAEDVLNAFVSPESV 
Sm  (1)  -  -------------------------------------------------------------------- 
Lm  (1)  ---------------------------------------------------------------------- 
Hum  (1)  ---------------------------------------------------------------------- 
71  140 
Et  (53)  EKDIGHGKALQACGPSGSHTQGVENCRRVLK  ----------  GEPDESHELLPYLLKDQEAMRLWRDHFRR 
Tg  (71)  ESLFDSIVAEQVVATSGNLTESAPRDRDSAPERRSDGGTLRGHPEDAGELLRLLLADSEDMELWKANFFR 
Sm  (1)  ---------------------------------------------------------------------- 
Lm  (1)  ---------------------------------------------------------------------- 
Hum  (1)  ---------------------------------------------------------------------- 
141  210 
Et  (113)  HVG  ----------------  ELVSSASEHSGADTPLQGPVLKSLAESEFWGSRPAVSNGALQHLRVKMQRL 
Tg  (141)  HLTHSMRHIVRDSVLVSEKAFPSEQAGEAGRDPGDLKKALEETGEDVFWESRPASSNAAVALIKKKMEKQ 
Sm  (1)  ---------------------------------  MNQYSCYLLQLYIIILLSYGTLNEIDARRHKRMYQPL 
Lm  (1)  ---------------------------------  MALRAKSALCLVAVFALLLATTVSGLYAKPSDFPLLG 
Hum  (1)  --------------------------------------------  MWQLWASLCCLLVLANARSRPSFHPL 
211  280 
Et  (167)  KLQAAEQGLDPEQAVTWEAEVSPRFKYHSIKDAKRHMGTYLSFYSDPDKPEVPLGEPLPVKVFAETQQVL 
Tg  (211)  AGKTGEG  ----  AG-HTWEPEVSLRFRYLSLKDAKKLMGTFLVN-TKVEGFPTPKGMPLPAKEFENATEPV 
Sm  (38)  SMELINFINY  ---  EANTTWKAAPTTRFRTVSDIRRMLGALPDP  ----------  NGEQLETLCTGYISDEL 
Lm  (38)  KSFVAEVNSKAKGQWTASANNGYLVTGKSLGEVRKLMGVTDMS  ---------  TEAVPPRNFSVEELQQDL 
Hum  (27)  SDELVNYVN  ----  KRNTTWQAGHNFYNVDMSYLKRLCGTFLG------------GPKPPQRVMFTEDLKL 
281  350 
Et  (237)  ETDKFDAREAFPQCAEVIGHVRDQGDCGSCWAFASTEALNDRFCIKSGGRHREALSPQHTTSCCDLLHCL 
Tg  (275)  P-AHFDARTAFPACKDVVGHVRDQGDCGSCWAFASTEAFNDRLCIRSQGKRLMPLSAQHTTSCCNAIHCA 
Sm  (95)  P-KSFDARVEWPHCPSIS-EIRDQSSCGSCWAFGAVEAMSDRICIKSKGKHKPFLSAENLVSCC  ---  SSC 
Lm  (99)  P-EFFDAAEHWPMCLTIS-EIRDQSNCGSCWAIAAVEAISDRYCTFG-GVPDRRMSTSNLLSCC  ---  FIC 
Hum  (81)  P-ASFDAREQWPQCPTIK-EIRDQGSCGSCWAFGAVEAISDRICIHTNAEVSVEVSAEDLLTCCG--SMC 
351  420 
Et  (307)  SFGCSGGQPRMAWRWFSNDGVVTGGDYNELHTGKSCWPYEIPFCRHHSEGP-YPKCEGPLP--KAPKCRK 
Tg  (344)  SFGCNGGQPGMAWRWFERKGVVTGGDFDALCKGTTCWPYEVPFCAHHAKAP-FPDCDATLVPRKTPKCRK 
Sm  (160)  GMGCNGGFPHSAWLYWKNQGIVTGDLYNTTNG  ---  CQPYEFPPCEHHVIGP-LPSCDGDVE---TPSCKT 
Lm  (163)  GLGCHGGIPTVAWLWWVWVGIAT  -------  ED  ---  CQPYPFDPCSHHGNSEKYPPCPSTIYD--TPKCNT 
Hum  (147)  GDGCNGGYPAEAWNFWTRKGLVSGGLYESHVG  ---  CRPYSIPPCEHHVNGS-RPPCI'GEGD  -q,  PKCSK 
421  490 
Et  (374)  DCEEAEYTSKVKPFKDDLHFATSAYSVEG-RDQIKRELMENGTLTGAFLVYEDFLLYKEGVYIiHVTGMPM 
Tg  (413)  DCEEQAYADNVHPFDQDTHKATSAYSLRS-RDDVKRDMMTHGPVSGAFMVYEDFLSYKSGVYKHVSGLPV 
Sm  (223)  NCQPGYN  ----  IPYEKDKWYGEKVYRIHSNPEAIMLELMRNGPVEVDFEVYADFPNYK.  (,  GVYQHVSGALL 
Lm  (221)  TCERNEM  -------  DLVKYKGSTSYSVKG-EKELMIELMTNGPLELTMQVYSDFVGYKSGVYKHVLGDFL 
Hum  (210)  ICEPGYS  ----  PTYKQDKHYGYNSYSVSNSEKDIMAEIYKNGPVEGAF'SVYSDFL,  I,  YKSGVYQHVTGEMM 
491*  560 
Et  (443)  GGHAVKVIGFGNEDGRDYWlýA%NSWNEYWGDKGTFKIEMG--EAGIDKEFCGGEPKVPNDKNASLLPSAQ 
Tg  (482)  GGRAIKIIGWGTENGEEYWHAVNSWNTYWGDGGQFKIAMG--QCGIDGEMVAGEAAWQETEGVVNGEEEL 
Sm  (289)  GGHAVRLLGWGEENNVPYWLIANSWNSDWGDKGYFKIVRGKNECGIESDVNAGIPKIKN  ------------ 
Lm  (283)  GGHAVKLVGWGTQDGVPYWKVANSWNTDWGDKGYFLIQRGNNECKIESGGVAGIPAQE  ------------ 
Hum  (276)  GGHAIRILGWGVENGTPYWLVANSWNTDWGDNGFFKILRGQDHCGIESEVVAGIPRTDQYWEKI  ------ 
561  580 
Et  (Sll)  DL  ------------------ 
Tg  (550)  PGQRAAGARAGAHAEEEREM 
Sm  (348)  -------------------- 
Lm  (341)  -------------------- 
Hum  (340)  -------------------- 
FIG.  3.3.  Alignment  of  the  cathepsin  B  of  Eimeria  tenelia  with  cathepsin  B  enzymes 
from  different  organisms.  Numbering  is  based  on  the  cathepsin  B  of  Toxoplasma  gondii. 
Dashes  indicate  gaps  in  the  alignment.  The  predicted  signal  peptides  are  underlined.  Active  site 
residues  are  starred.  Conserved  residues  are  on  grey  background.  The  starts  for  the  mature 
enzymes  are  in  bold.  Et,  Eimeria  tenella  ;  Tg,  Toxoplasma  gondii  (accession  number  AAL60053, 
Que  et  al.,  2002);  Sm,  Schistosoma  mansoni  (CAC8521  1,  Klinkert  et  al.,  1994);  Lm,  Leishmania 
major  (AAB48119,  Sakanari  et  al.,  1997);  Hum,  human  cathepsin  B  (NP  680093,  Chan  et  al., 
1986). 
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Pre-0  Pro-O  Mature  0  C-terminal 
21  213  270  8 
E.  tenella  [:::::  11 
34  239  2170  26 
.. 
1  AM  T.  gondii  1:  -:  ":  ýI 
S.  mansoni 
22  71  255 
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17  62  252 
Human 
FIG.  3.4.  Schematic  comparative  representation  of  the  different  cathepsin  B 
sequences.  The  sequences  used  are  from  the  alignment  in  figure  3.3.  The  pre-,  pro-,  mature 
and  C-terminal  domains  are  represented  as  blocks  and  the  size  in  amino  acids  for  each  domain  is 
indicated  on  top  of  each  block. 
3.2.2.  The  cathepsin  B  gene  may  be  single  copy  in  the  E.  tenella  genome 
By  Southern  blotting  of  gDNA  and  hybridization  with  a  probe  specific  to 
the  cathepsin  B  gene,  a  single  DNA  fragment  at  about  1  kb  was  detected  (Fig. 
3.5).  Another  DNA  fragment  at  about  1.4  kb  should  be  detected  too,  but  the 
amount  of  DNA  run  on  the  gel  was  low,  and  as  the  intensity  of  the  band  depends 
on  the  length  of  hybridization,  this  band  may  not  have  been  labeled  enough  for 
detection.  The  result  obtained  is  indicative  that  the  gene  encoding  a  cathepsin  B- 
like  enzyme  in  E.  tenella  occurs  in  one  copy  in  the  genome.  This  result  is 
supported  by  the  sequence  data  from  the  Sanger  database. 
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FIG.  3.5.  Southern  blot  analysis  of  E.  tenella  genornic  DNA  using  the  cathepsin  B 
sequence  as  a  probe.  (A)  Schematic  representation  of  the  cathepsin  B  gene  on  Contig5413 
(Eimeria  assembly,  Wellcome  Trust  Sanger  Institute).  The  ORF  is  shown  as  an  arrow.  EcoRl 
sites  are  represented  as  well  as  the  predicted  sizes  of  the  resulting  digestion  fragments.  (B) 
Southern  blot  analysis.  Two  ýtg  of  genomic  DNA  were  digested  with  EcoRl,  separated  on  1% 
agarose  gel,  blotted  on  nylon  membrane  and  hybriclised  with  32  P-labelled  cathepsin  B  full  gene. 
The  blot  was  exposed  for  6  days.  The  positions  of  the  molecular  size  markers  (bp)  are  shown  on 
the  left  of  the  figure.  The  arrow  indicates  the  band  at  about  1  kb. 
3.2.3.  Expression  of  recombinant  full-length  cathepsin  B  in  E.  coli 
3.2.3.1.  Expression  in  E.  coli  BL21(DE3) 
The  sequence  encoding  the  pro-mature  cathepsin  B  was  amplified  from 
cDNA  and  cloned  in  the  pET28a(+)  vector  for  expression  in  E.  coli  with  a  N- 
terminal  His-tag.  The  plasmid  obtained  and  predicted  protein  are  schernatised  in 
Fig.  3.6.  Expression  in  E.  coli  BL21(DE3)  resulted  in  detection  of  an  abundant 
protein  at  56  kDa  corresponding  to  the  expected  size  for  the  pro-mature  enzyme, 
and  no  protein  corresponding  to  the  size  of  the  mature  enzyme  (around  30  kDa) 
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could  be  detected  (Fig.  3.7).  The  vast  majority  of  the  protein  was  found  to  be  in 
the  soluble  fraction  of  cell  lysates,  and  about  20  mg  of  pure  pro-mature  cathepsin 
B  could  be  obtained  from  1  liter  of  E.  coli  culture.  Western  blot  analysis  using 
anti-His-tag  antibody  on  the  purified  enzyme  detected  a  single  protein  at  57  kDa 
(F  i g.  3.8). 
The  pure  soluble  enzyme  did  not  present  any  activity  against  the  substrates 
benzoyl-Phe-Arg-7-amino-4-methylcoumarin  (Z-Phe-Arg-AMC)  and  Z-Arg-Arg- 
AMC. 
A 
Kar 
B 
His-tag  (22) 
in  B 
)96) 
(1272) 
11(1511) 
(1639) 
FIG.  3.6.  Construct  for  expression  of  recombinant  pro-cathepsin  B  of  E.  tenefla  in 
E.  coli.  (A)  Schematic  representation  of  the  plasmid  resulting  from  the  cloning  of  the  pro-mature 
sequence  of  the  cathepsin  B  of  E.  tenella  in  the  pET28a(+)  vector  (Novagen)  for  expression  of 
pro-mature  cathepsin  B  with  a  N-terminal  His-tag.  Kan,  kanamycin  resistance  gene;  f1  origin, 
origin  of  replication  of  the  phage  fl;  lacl,  gene  encoding  the  lac  repressor  protein.  (B)  Schematic 
representation  of  the  protein  expressed  from  the  pETcatB  plasmid.  The  size  in  amino  acids  of  the 
different  fragments  is  indicated  between  brackets. 
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FIG.  3.7.  Analysis  of  expression  and  purification  of  N-terminal  His-tagged  pro- 
mature  cathepsin  B  of  E.  tenella  expressed  in  E.  coli  BL21(DE3).  Ten  lLl  samples  were 
loaded  on  SDS-PAGE  gel  (12%  acrylamide)  and  post-electrophoresis  stained  with  Coomassie 
blue.  Lane  M,  protein  standards;  lane  1,  E.  coli  cell  lysate  prior  to  isopropyl  [ý-D-thiogalactoside 
induction;  lane  2,  cell  lysate  after  4h  induction  at  37C;  lane  3,  E.  coli  whole  cell  lysate;  lane  4, 
soluble  fraction;  lane  5,  Nickel-agarose  column  load;  lane  6,  flow  through;  lane  7,  elution  fraction 
with  500  mM  imidazole.  10-3  XMr  is  indicated  on  the  left  of  the  figure. 
Mr  1 
ý11' 
50- 
44MMW 
20 
FIG.  3.8.  Detection  of  N-terminal  His-tagged  pro-mature  cathepsin  B  of  E.  tenella 
expressed  in  E.  coli  BL21(DE3)  using  anti  His-tag  antibody.  Membrane  exposure  of  2  min, 
anti-His-tag  antibody  dilution  of  1:  2000  (v/v).  Lane  M,  protein  standards;  lane  1,10  pI  of 
recombinant  protein  expressed  in  BL21(DE3)  and  purified  on  nickel-agarose  column.  10-3  X  M,  is 
indicated  on  the  left  of  the  figure.  Arrow  indicates  the  His-tagged  pro-mature  enzyme. 
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3.2.3.2.  Expression  in  E.  co/iJM109(DE3)  and  HMS174(DE3) 
Different  E.  coli  strains  were  tested  as  the  levels  of  soluble  expression 
may  vary  from  one  strain  to  the  other.  Expression  in  JM109(DE3)  and 
HIVIS1  74(DE3)  strains  of  E.  coli  was  evaluated  at  150C,  2511C  and  3711C,  using 
0.5,1,  or  1.5  mM  IPTG  for  induction  (Fig.  3.9).  It  revealed  that  at  370C  the  over- 
expressed  protein  was  mainly  found  associated  with  the  inclusion  bodies  and  that 
the  concentration  in  IPTG  did  not  have  any  effect.  At  1511C,  the  expression  was 
considerably  reduced  and  hardly  detectable.  As  it  seemed  that  the  concentration 
in  IPTG  did  not  have  an  effect,  it  was  fixed  at  1  mM.  Expression  in  both  strains  at 
250C  with  1  mM  IPTG  resulted  in  over-expression  of  a  protein  of  57  kDa, 
occurring  approximately  equally  in  the  soluble  fraction  of  whole  E.  coli  cell  lysates 
and  inclusion  bodies  (Fig.  3.10).  As  the  expression  pattern  in  the  two  strains  was 
very  similar,  further  analysis  were  performed  on  the  HMS174(DE3)  strain  only 
(arbitrary  choice). 
Inclusion  bodies  produced  in  E.  coli  HMS174(DE3)  were  solubilised  (see 
Table  2.2,  Chapter  2),  and  the  purity  of  the  enzyme  could  be  increased  using 
nickel-agarose  column,  though  the  purification  was  not  complete  (Fig.  3.11). 
Western  blot  analysis  was  performed  using  antibodies  raised  in  rabbit  against  the 
purified  recombinant  enzyme  produced  in  a  soluble  manner  in  E.  coli  BL21  (DE3). 
Analysis  on  the  solubilised  inclusion  bodies  generated  via  expression  in 
HMS174(DE3)  detected  a  major  protein  of  57  kDa  corresponding  to  the  pro- 
mature  enzyme,  plus  other  proteins,  which  could  correspond  to  E.  coli  cross 
reacting  proteins  or,  for  the  proteins  with  a  molecular  mass  less  than  57  kDa,  to 
products  of  processing  of  the  pro-enzyme  (Fig.  3.11).  Nevertheless,  no  protein  at 
30  kDa  that  would  correspond  to  the  mature  enzyme  was  detected. 
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FIG.  3.9.  Analysis  of  expression  of  the  N-terminal  His-tagged  pro-mature  cathepsin 
B  of  E.  tenelia  in  E.  coli  JM109(DE3)  and  HMS174(DE3)  at  371C  and  15'C.  Ten  pl  samples 
were  loaded  on  SDS-PAGE  gel  (12%  acrylamide)and  post-electrophoresis  stained  with 
Coomassie  blue.  Lanes  M,  protein  standards;  lanes  1  to  12,  JM109(DE3);  lanes  13  to  24, 
HMS174(DE3).  Above  the  lane  numbers  are  indicated  the  concentrations  in  mM  of  IPTG  used  for 
induction,  as  well  as  the  temperature  of  induction.  Inductions  were  for  4  h.  S:  soluble  fraction,  1: 
insoluble  fraction.  10-3  X  M,  is  indicated  on  the  left  of  the  figure. 
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FIG.  3.10.  Analysis  of  expression  of  the  N-terminal  His-tagged  pro-mature 
cathepsin  B  of  E.  tenella  in  E.  co/iJM109(DE3)  and  HMS174(DE3)  at  25'C.  Induction  was  with 
1  mM  IPTG  for  4  h.  Ten  ýd  samples  were  loaded  on  SDS-PAGE  gel  (12%  acrylamide)  and  post- 
electrophoresis  stained  with  Coomassie  blue.  Lane  M,  protein  standards;  lane  1,  JM109(DE3) 
soluble  fraction;  lane  2,  JM109(DE3)  inclusion  bodies;  lane  3,  HMS174(DE3)  soluble  fraction; 
lane  4,  HMS174(DE3)  inclusion  bodies.  10-3  XMr  is  indicated  on  the  left  of  the  figure. 
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FIG.  3.11.  Solubilisation  of  N-terminal  His-tagged  pro-mature  cathepsin  B  of  E. 
tenella  produced  in  E.  coli  HMS174(DE3)  at  37'C  and  purification.  Analysis  on  SDS-PAGE 
gel  (12%  acrylamide)  stained  with  Coomassie  blue.  Lane  M,  protein  standards;  lane  1,  soluble 
fraction  of  E.  coli  HMS174(DE3)  lysate;  lane  2,  insoluble  fraction;  lane  3  and  4,  inclusion  bodies 
washes;  lane  5,  solubilised  inclusion  bodies  before  loading  on  anion-exchange  column-,  lane  6, 
eluted  fraction.  10-3  XMr  is  indicated  on  the  left  of  the  figure.  10  pl  samples  were  loaded.  Arrow 
indicates  the  pro-mature  enzyme. 
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FIG.  3.12.  Detection  of  N-terminal  His-tagged  pro-mature  cathepsin  B  of  E.  tenella 
produced  in  E.  coli  HMS174(DE3)  at  37'C  using  anti  cathepsin  B  of  E.  tenella  antibody 
raised  in  rabbit.  Antibody  was  used  at  a  dilution  1:  5000  (v/v).  Membrane  was  exposed  15 
seconds.  Lane  1,10  pl  of  solubilised  inclusion  bodies  from  expression  in  HMS  1  74(DE3).  10-3  X  M, 
is  indicated  on  the  left  of  the  figure.  Arrow  indicates  pro-mature  enzyme. 
3.2.4.  Attempts  to  activate  the  pro-mature  cathepsin  B  produced  in  E.  coli 
Various  sample  of  enzyme  produced  in  a  soluble  manner  in  E.  coli 
BL21(DE3)  or  HMS174(DE3),  or  as  inclusion  bodies  in  HMS174(DE3)  were 
treated  using  methods  and  combinations  of  methods  described  in  the  literature 
for  activation  of  cysteine  peptidases.  The  summary  of  which  samples  were 
treated  is  presented  in  Table  2.2,  chapter  2.  The  aim  in  all  cases  was  to  try  to 
improve  folding  and  disulfide  bridge  formation  and  so  induce  activation  (removal 
of  the  pro-domain)  and  obtain  mature  active  enzyme.  The  samples  treated  were 
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analysed  on  Coomassie  blue-stained  SDS-PAGE,  western-blots,  gelatin  gels  and 
assayed  for  activity  using  the  azocasein  assay  and  against  the  "typical"  cathepsin 
B  substrates  Z-Phe-Arg-AMC  and  Z-Arg-Arg-AMC.  Non-induced  E.  coli  cell 
lysates  treated  in  the  same  manner  and  no  enzyme  controls  were  included  in  the 
measurements  of  activity. 
In  all  cases,  no  maturation  to  the  mature  size  enzyme  (about  30  kDa) 
could  be  detected,  and  no  activity  against  azocasein  or  gelatin  could  be  detected 
(results  not  shown).  The  maximum  activity  observed  among  all  the  samples 
tested  against  the  substrate  Z-Phe-Arg-AMC  was  30  mU/mg,  but  this  may  have 
been  due  to  the  pro-mature  enzyme  itself. 
3.2.5.  Expression  of  recombinant  truncated  cathepsin  B  in  E.  coH 
The  idea  was  to  test  if  the  removal  of  most  of  the  pro-domain  would 
facilitate  the  folding,  processing  and/or  activation  process  of  the  enzyme  in  order 
to  get  a  significant  increase  in  activity  (as  has  been  the  case  for  some  other 
cysteine  peptidases  of  Apicomplexa  [Shenai  et  al.,  2000;  Sijwali  et  aL,  2001  ]). 
The  sequence  encoding  the  total  mature  domain  of  the  cathepsin  B  and 
31  amino  acids  of  the  pro-domain  was  amplified  from  cDNA  and  cloned  in  the 
pET28a(+)  vector  for  expression  in  E.  coli  BL21  (DE3)  with  a  N-terminal  His-tag. 
The  plasmid  obtained  and  predicted  protein  are  schernatised  in  Fig.  3.13.  Cells 
transformed  with  the  construct  were  induced  for  either  4h  at  370C  with  1  or  0.5 
mM  IPTG,  or  4h  at  20*C  with  1  or  0.5  mM  IPTG.  An  over-expressed  protein  of 
36  kDa,  corresponding  to  the  expected  size  for  the  truncated  cathepsin  B,  could 
be  detected  in  all  cases,  but  it  was  found  in  the  insoluble  fraction  of  E.  coli  lysates 
if  expressed  at  37"C  (results  not  shown).  The  highest  rate  of  expression  in  a 
soluble  manner  was  obtained  by  induction  at  200C  with  0.5  mM  IPTG,  and  the 
soluble  protein  produced  was  purified  using  Ni-agarose  affinity  chromatography 
(Fig.  3.14). 
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FIG.  3.13.  Construct  for  expression  in  E.  coli  BL21(DE3)  of  recombinant  cathepsin 
B  of  E.  tenella  with  31  amino  acids  of  pro-domain.  (A)  Schematic  representation  of  the 
plasmid  resulting  from  the  cloning  of  the  sequence  of  the  cathepsin  B  of  E.  tenella  with  31  amino 
acids  of  the  pro-domain  in  the  pET28a(+)  vector  (Novagen)  for  expression  of  mature  cathepsin  B 
with  a  N-terminal  His-tag  and  31  amino  acids  of  pro-domain.  Kan,  kanamycin  resistance  gene;  f1 
origin,  origin  of  replication  of  the  phage  fl;  lacl,  gene  encoding  the  lac  repressor  protein.  (B) 
Schematic  representation  of  the  protein  expressed  from  the  pETcatB  plasmid.  The  size  in  amino 
acids  of  the  different  fragments  is  indicated  between  brackets. 
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FIG.  3.14.  Expression  in  E.  coli  BL21(DE3)  at  201C  of  recombinant  cathepsin  B  of  E. 
tenella  with  a  truncated  pro-domain.  Lane  M,  protein  standards;  lane  1,  E.  coli  cell  lysate  after 
isopropyl  P-D-thiogalactoside  induction,  soluble  fraction;  lane  2,  elution  fraction  1  from  Nickel- 
agarose  column  with  500  mM  imiclazole;  lane  3,  elution  fraction  2;  lane  4,  elution  fraction  3.10-3  X 
M,  is  indicated  on  the  left  of  the  figure.  10  ýtl  samples  were  loaded. 
3.2.6.  Attempts  to  activate  the  truncated  cathepsin  B  produced  in  E.  coli 
Unfolding  and  folding  attempts  of  the  truncated  cathepsin  B  were  as 
described  in  Table  2.2.  Samples  of  Nickel-agarose  purified  truncated  cathepsin  B 
diluted  1:  1  (v/v)  in  0.1  M  sodium  acetate  buffer  pH  5.0  or  0.1  M  Tris/HCl  buffer  pH 
8.0  supplemented  with  20  mM  DTT  and  incubated  at  370C  for  20  min  showed  a 
shift  in  size  of  about  2  kDa  (Fig.  3.15).  Precipitation  was  observed  in  the  samples 
incubated  at  pH  5.0,  which  resulted  in  lower  amount  of  protein  being  visible  on 
the  gel.  The  shift  was  not  inhibited  when  the  samples  were  incubated  in  the 
presence  of  300  ýM  of  E64  (Fig.  3.15). 
Analysis  on  western  blot  using  anti-cathepsin  B  antibodies  detected  a 
single  protein  of  34  kDa,  2  kDa  short  compared  to  the  truncated  cathepsin  B 
sample  not  incubated  in  the  described  conditions  (Fig.  3.16).  Using  anti-His-tag 
antibodies,  the  protein  at  34  kDa  could  still  be  detected  (Fig.  3.17),  suggesting 
some  processing  of  the  protein,  but  not  at  the  N-terminus.  The  samples 
incubated  at  pH  5.0  or  pH  8.0  were  loaded  onto  gelatin  gels  and  post- 
electrophoresis  and  washing  the  gels  were  incubated  at  pH  5.0  and  pH  8.0  with 
DTT,  but  no  activity  could  be  detected.  The  same  samples  were  assayed  at  pH 
5.0  or  8.0  with  10  mM  DTT  against  Z-Phe-Arg-pNA,  but  no  activity  was  detected. 
91 Chapter  3:  Expression  and  characterisation 
of  the  recombinant  cathepsin  B  of  E.  tenella 
1234 
40- 
30- 
FIG.  3.15.  Analysis  of  the  processing  of  the  truncated  cathepsin  B  of  E.  tenelia 
expressed  in  E.  coli.  SDS-PAGE  gel  (12%  acrylamide)  stained  with  Coomassie  blue.  Lane  M', 
protein  standards;  lane  1,10  pg  of  purified  protein;  lane  2,3  pg  of  the  purified  protein;  lane  3,10 
ýig  of  purified  protein  left  18  In  at  40C  after  purification;  lane  4,10  pg  of  purified  truncated 
cathepsin  B  incubated  in  0.1  M  Tris/HCl  pH  8.0,10  mM  DTT  at  37C  for  20  min;  lane  5,10  pg  of 
purified  truncated  cathepsin  B  incubated  in  0.1  M  Tris/HCI  pH  8.0,10  mM  DTT  at  37"C  for  20  min 
with  300  pM  E64 
. 
10-3  X  M,  is  indicated  on  the  left  of  the  figure. 
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FIG.  3.16.  Detection  of  the  truncated  cathepsin  B  of  E.  tenella  expressed  in  E.  coli 
with  anti-cathepsin  B  antibodies.  Antibody  dilution  of  1:  5000  (v/v).  Membrane  was  exposed  30 
seconds.  Lane  1,10  pg  of  purified  protein;  lane  2,10  pg  of  purified  truncated  cathepsin  B 
incubated  in  0.1  M  Tris/HCI  pH  8.0,10  mM  DTT  at  370C  for  20  min,  10-3  XMr  is  indicated  on  the 
left  of  the  figure. 
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FIG.  3.17.  Detection  of  the  truncated  cathepsin  B  of  E.  tenella  expressed  in  E.  coli 
with  anti-His-tag  antibodies.  Antibody  was  used  at  a  dilution  of  1:  2000  (v/v).  Membrane  was 
exposed  30  seconds.  Lane  1,10  pg  of  purified  protein;  lane  2,10  Vg  of  purified  truncated 
cathepsin  B  incubated  in  0.1  M  Tris/HCI  pH  8.0,10  mM  DTT  at  371)C  for  20  min.  10-3  X  Mr  is 
indicated  on  the  left  of  the  figure. 
Truncated  cathepsin  B  purified  on  Ni-agarose  was  directly  assayed  at  pH 
4.0,5.0,6.0  or  7.0  in  the  presence  of  5  mM  EDTA,  10  mM  DTT  and  0.9  M  NaCl 
against  Z-Phe-Arg-AMC,  but  no  activity  could  be  detected.  The  protein  fell  out  of 
solution  rapidly  at  pH  4.0,5.0  and  6.0.  The  same  sample  was  then  assayed  at  pH 
5  or  7  with  or  without  5  mM  EDTA  and  with  or  without  10  mM  DTT,  to  test  the 
influence  of  these  components,  against  Z-Phe-Arg-AMC  or  Z-Arg-Arg-AMC.  The 
protein  fell  out  of  solution  and  no  activity  could  be  detected. 
The  soluble  truncated  cathepsin  B  obtained  was  also  treated  to  unfold  and 
slowly  refold  the  protein,  to  try  to  improve  the  folding  and  disulfide  bridge 
formation.  The  unfolded  and  dialysed  truncated  cathepsin  B  (Sanderson  et  al., 
2000)  was  assayed  at  pH  5.0  or  8.0  with  10  mM  DTT  against  Z-Phe-Arg-AMC, 
but  no  activity  could  be  detected. 
3.2.7.  Non-specific  processing  of  the  soluble  recombinant  pro-mature 
cathepsin  B  expressed  in  E.  coli  BL21  (DE3) 
The  idea  of  this  approach  was  that  a  correctly  folded  protein  will  have 
primarily  its  loops  and  hinges  accessible  to  proteolytic  cleavage  in  mild 
conditions.  Using  low  enzyme/substrate  ratio  and  short  incubation  time- 
digestions  with  enzymes  of  wide  substrate  specificity  might  allow  the  separation 
of  different  domains;  i.  e.  the  separation  of  the  pro-domain  from  the  mature 
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domain  of  the  enzyme.  Based  on  the  structure  of  the  human  cathepsin  B  (Fig. 
3.18),  the  domain  at  the  junction  between  the  pro-  and  the  mature  domains 
seems  accessible  to  the  solvent.  Provided  the  folding  might  be  similar  in  the 
cathepsin  B  of  E.  tenella,  cleavage  might  be  possible  at  that  junction. 
FIG.  3.18.  Crystal  structure  of  human  procathepsin  B  at  3.3  Angstrom  resolution 
(Turk  et  al.,  1996).  a-helixes  are  in  orange,  P-sheets  are  in  pink  and  strands  are  in  grey. 
Residues  at  the  N-,  and  C-termini  and  at  the  start  of  the  mature  domain  are  in  yellow  and  marked 
by  arrows. 
An  analysis  using  SDS-PAGE  of  a  trypsin  digest  of  the  partially  purified 
(on  Ni-agarose)  pro-mature  cathepsin  B  using  enzyme/substrate  ratios  of  1-500 
or  1:  5000  is  shown  on  Fig.  3.19A.  The  pro-mature  cathepsin  B  seems  to  be 
reasonably  quickly  degraded  into  fragments.  In  particular  fragments  at  31,29,20 
and  16  kDa  seemed  to  increase  in  amount  over  time.  The  sample  corresponding 
to  30  min  incubation  with  a  1:  5000  ratio  of  trypsin  seemed  to  yield  a  good 
representation  of  these  fragments  and  was  therefore  chosen  for  further  analyses. 
A  chymotrypsin  digest  analysis  at  ratios  of  1:  500  and  1:  5000  is  shown  on 
Fig.  3.19B.  The  ratio  of  1:  5000  seemed  to  be  again  adequate  for  analysis  as 
several  fragments  (at  34,28,18,16  kDa,  for  example)  seemed  to  increase  in 
amount  over  time  in  a  sensible  time  for  analysis. 
In  the  case  of  the  use  of  subtilisin,  the  ratio  had  to  be  adjusted  to  1-50000, 
as  at  a  ratio  of  1:  5000,  practically  all  cathepsin  B  was  degraded  within  2  min  of 
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incubation  (Fig.  3.19C).  Analysis  of  a  digest  at  ratio  1:  50000  is  presented  on  Fig. 
3.19D.  Within  30  to  60  min  of  incubation,  2  major  fragments  at  42  and  28  kDa 
seemed  to  clearly  increase  in  amount. 
Samples  of  cathepsin  B  incubated  either  with  trypsin  1:  5000  for  30  min, 
chymotrypsin  1:  5000  for  60  min,  or  subtilisin  1:  50000  for  45  min  were  analysed 
using  gelatin  SDS-PAGE,  but  no  activity  could  be  detected  when  gels  were 
incubated  at  pH  5.0  or  8.0  with  20  mM  DTT.  The  same  samples  were  tested  for 
activity  against  Z-Phe-Arg-pNA  at  pH  5.0,7.0  or  8.0  +/-  5  mM  EDTA,  +/-  10  mM 
DTT.  No  activity  could  be  detected  except  in  the  samples  with  trypsin  at  pH  7.0  or 
8.0.  This  activity  was  not  E64  inhibited  (11  mM)  but  could  be  inhibited  with  TLCK 
(0.1  mg/ml),  an  inhibitor  of  serine  peptidases,  at  pH  7.0  but  not  8.0.  Knowing 
TLCK  is  not  stable  at  pH  above  7.5,  it  can  be  concluded  that  the  activity  detected 
was  due  to  trypsin. 
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FIG.  3.19.  Analysis  of  the  non-specific  cleavage  of  the  recombinant  N-terminal  His- 
tagged  cathepsin  B  of  E.  tenella  produced  in  E.  coli.  40  pg  of  cathepsin  B  were  used  per  test. 
Cleavages  were  at  room  temperature  and  analysed  using  SIDS-PAGE  (12%  acrylamide)  and 
staining  with  Coomassie  blue.  Lane  M,  protein  standards.  Arrows  mark  bands  appearing  with 
time.  10-3  X  M,  is  indicated  on  the  left  of  the  figure.  (A)  Cleavage  with  trypsin.  Trypsin  ratio  was  of 
1:  500  (w/w)  (lanes  I  to  5)  or  1:  5000  (w/w)  (lanes  6  to  9).  Lane  1,  incubation  0  min;  lanes  2  and  6, 
2  min;  lanes  3  and  7,15  min;  lanes  4  and  8,30  min;  lanes  6  and  9,11  h.  (B)  Cleavage  with 
chymotrypsin.  Same  labelling  as  in  (A).  (C)  Cleavage  with  subtilisin.  Same  labelling  as  in  (A).  (D) 
Cleavage  with  subtilisin,  ratio  1:  50000.  Lane  1,  incubation  of  0  min;  lane  2,2  min;  lane  3,15  min; 
lane  4,30  min;  lane  5,1  h.  Samples  marked  with  a  star  were  further  analysed  by  gelatin  SDS- 
PAGE  and  tested  for  activity. 
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3.2.8.  Specific  processing  of  the  recombinant  pro-mature  cathepsin  B 
The  idea  of  this  approach  was  to  introduce  various  very  specific  cleavage 
sites  for  commercially  available  enzymes  at  the  limit  between  the  predicted  pro- 
and  mature  domains,  predictions  based  on  the  domains  of  the  T.  gondii 
cathepsin  B  (Que  et  A,  2002).  This  would  be  done  by  site-directed  mutagenesis 
on  the  existing  complete  cathepsin  B  expression  construct  in  pET28a(+).  The 
hypothesis  was  that  it  might  allow  for  easy  removal  of  the  pro-domain  and 
activation  of  the  enzyme,  provided  the  soluble  enzyme  was  properly  folded. 
Thrombin  and  enterokinase  did  cleave  the  non-mutated  cathepsin  B, 
whereas  the  Factor  Xa  and  the  TEV  protease  did  not,  and  mutagenesis  to 
introduce  the  specific  cleavages  sites  for  these  2  peptidases  was  performed.  The 
resulting  proteins  were  expressed  in  a  soluble  manner  in  E.  coli  BL21(DE3)  at 
250C  and  purified  on  nickel-agarose  column.  A  scheme  of  the  method  used  and 
the  results  of  cleavage  of  the  mutated  proteins  by  the  Factor  Xa  or  the  TEV  are 
shown  on  Fig.  3.20  and  Fig.  3.21,  respectively.  In  case  of  cutting  with  the  TEV, 
two  protein  fragments  could  be  detected,  at  the  predicted  sizes  for  the  pro- 
domain  (-26  kDa)  and  the  mature  domain  (31  kDa).  In  case  of  cleavage  with  the 
Factor  Xa,  an  additional  protein  was  detected  2  kDa  smaller  than  the  pro-domain, 
which  could  correspond  to  the  size  of  the  pro-domain  without  the  His-tag,  or  a 
product  of  unspecific  cleavage.  This  was  tested  by  western-blotting,  using  anti 
His4ag  antibodies  (Fig.  3.20D).  A  single  protein  at  the  expected  size  for  the  pro- 
domain  (-26  kDa)  was  detected  in  both  cleaved  samples.  The  additional  protein 
fragment  resulting  from  the  Factor  Xa  cleavage  does  not  correspond  to  a  His- 
tagged  protein. 
The  cleaved  samples  were  analysed  using  gelatin  SIDS-PAGE  with 
incubation  at  pH  5.0  or  8.0,  but  no  activity  could  be  detected.  Based  on  the 
possibility  that  the  enzyme  might  get  inactivated  irreversibly  during  the 
electrophoresis,  the  azocasein  assay  was  used.  The  activity  was  tested  at  pH  5.0 
or  8.0  with  24  h  incubation  at  3711C.  From  the  measurements  taken,  no  real 
positive  cleavage  of  the  azocasein  occurred  compared  to  the  negative  control 
(unprocessed  recombinant  cathepsin  B  of  E.  tenella)  (results  not  shown).  The 
same  samples  were  also  tested  for  activity  continuously  for  30  min  against  Z- 
Phe-Arg-AMC  but  no  cleavage  of  the  substrate  could  be  detected. 
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FIG.  3.20.  Mutagenesis  for  specific  cleavage  by  the  Factor  Xa  at  the  predicted 
junction  between  the  pro-  and  the  mature  domains  of  the  recombinant  cathepsin  B  of  E. 
tenella  expressed  in  E.  coli.  (A)  Schematic  representation  of  the  method  used.  Amino  acids  are 
represented  by  the  single  letter  code.  Sizes  of  fragments  are  not  to  scale.  (B)  Expression  of 
recombinant  N-terminal  His-tagged  protein  carrying  the  mutation  for  the  Factor  Xa  cleavage  site. 
Lane  M,  protein  standards;  lane  1,  E.  coli  cell  lysate  after  IPTG  induction  4h  at  250C,  insoluble 
fraction;  lane  2,  E  coli  cell  lysate,  soluble  fraction;  lane  3,  elution  fraction  1  from  Nickel-agarose 
column;  lane  4,  elution  fraction  2;  lane  5,  elution  fraction  3.10-3  X  Mr  is  indicated  on  the  left  of  the 
figure.  10  ýd  samples  were  loaded.  (C)  Analysis  of  cleavage  (overnight)  of  recombinant  cathepsin 
B  (40  Vg)  with  Factor  Xa  (1  Unit)  at  room  temperature  using  SDS-PAGE  (12%  acrylamide)  and 
staining  with  Coomassie  blue.  Lane  1,  non-mutated  cathepsin;  lane  2,  mutated  cathepsin  B.  (D) 
Detection  of  His-tagged  proteins  on  gel  on  figure  C.  Anti  His-tag  antibody  dilution  of  1:  2000  (v/v). 
Membrane  exposure  of  1  min.  Lane  1,  non-mutated  cathepsin;  lane  2,  mutated  cathepsin  B. 
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FIG.  3.21.  Mutagenesis  for  specific  cleavage  by  the  TEV  (Tabacco  etch  virus)  Nla 
protease  at  the  predicted  junction  between  the  pro-  and  the  mature  domains  of  the 
recombinant  cathepsin  B  of  E.  tenella  expressed  in  E.  coli.  (A)  Schematic  representation  of 
the  method  used.  Amino  acids  are  represented  by  the  single  letter  code.  Sizes  of  fragments  are 
not  to  scale.  (B)  Expression  of  recombinant  N-terminal  His-tagged  protein  carrying  the  mutation 
for  the  TEV  protease  cleavage  site.  Lane  M,  protein  standards;  lane  1,  E.  coli  cell  lysate  after 
IPTG  induction  4h  at  250C,  insoluble  fraction;  lane  2,  E.  coli  cell  lysate,  soluble  fraction;  lane  3, 
elution  fraction  1  from  Nickel-agarose  column;  lane  4,  elution  fraction  2;  lane  5,  elution  fraction  3. 
10-3  x  M,  is  indicated  on  the  left  of  the  figure.  10  pl  samples  were  loaded.  (C)  Analysis  of  cleavage 
(overnight)  of  recombinant  cathepsin  B  (40  pg)  with  TEV  protease  (10  Units)  at  room  temperature 
using  SDS-PAGE  (12%  acrylamide)  and  staining  with  Coomassie  blue.  Lane  1,  non-mutated 
cathepsin  B;  lane  2,  mutated  cathepsin  B.  (D)  Detection  of  His-tagged  proteins  on  gel  on  figure  C. 
Anti  His-tag  antibody  dilution  of  1:  2000  (v/v).  Membrane  was  exposed  1  min.  Lane  1,  non- 
mutated  cathepsin  B;  lane  2,  mutated  cathepsin  B. 
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3.2.9.  Expression  of  recombinant  full-length  cathepsin  B  in  Pichia  pastoris 
The  idea  behind  trying  to  express  the  enzyme  in  the  Pichia  system  was 
that,  by  expressing  in  a  eukaryotic  system,  the  protein  may  be  glycosylated, 
which  might  be  necessary  for  the  enzyme  activity.  Moreover,  the  release  into  the 
supernatant  of  culture  may  provide  potentially  easy  purification.  Both  constitutive 
and  inducible  expressions  were  tested.  The  constitutive  system  is  easier  to  use, 
but  in  some  cases  inducible  expression  may  be  more  successful,  as  it  involves 
reaching  a  high  cell  density  before  starting  of  the  induction. 
3.2.9.1.  Constitutive  system 
The  sequence  encoding  the  pro-mature  cathepsin  B  was  amplified  from 
cDNA  and  cloned  in  the  pGAPZaA  vector  for  expression  in  a  constitutive  manner 
and  release  of  the  recombinant  enzyme  without  or  with  a  C-terminal  His-tag  into 
the  supernatant  of  culture  of  P.  pastoris  X-33  cells.  The  plasmids  obtained  and 
predicted  proteins  are  schematised  in  Fig.  3.22  and  Fig.  3.23,  respectively. 
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FIG.  3.22.  Construct  for  expression  of  recombinant  pro-cathepsin  B  of  E.  tenelia  in 
Pichia  pastoris,  constitutive  system.  (A)  Schematic  representation  of  the  plasmid  resulting 
from  the  cloning  of  the  pro-mature  sequence  of  the  cathepsin  B  of  E.  tenella  in  the  pGAPZCt 
vector  for  constitutive  expression  of  pro-mature  cathepsin  B  in  the  supernatant  of  culture.  (B) 
Schematic  representation  of  the  protein  expressed  from  the  pGAPcatB  plasmid.  The  size  in 
amino  acids  of  the  different  fragments  is  indicated  between  brackets. 
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FIG.  3.23.  Construct  for  expression  of  recombinant  pro-cathepsin  B  of  E.  tenefla 
with  a  C-terminal  His-tag  in  Pichia  pastoris,  constitutive  system.  (A)  Schematic 
representation  of  the  plasmid  resulting  from  the  cloning  of  the  pro-mature  sequence  of  the 
cathepsin  B  of  E.  tenella  in  the  pGAPZct  vector  for  constitutive  expression  of  pro-mature 
cathepsin  B  in  the  supernatant  of  culture.  (B)  Schematic  representation  of  the  protein  expressed 
from  the  pGAPcatB  plasmid.  The  size  in  amino  acids  of  the  different  fragments  is  indicated 
between  brackets. 
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3.2.9.1.1.  Confirmation  of  transformants 
Transformants  were  selected  on  Zeocin  plates  (100  pglml),  and 
insertions  of  the  fragments  were  verified  by  PCR  on  genomic  DNA  extracted  from 
positive  clones,  using  the  PCR  primers  a-factor  and  TAOX1.  Results  are  shown 
in  Fig  3.24.  Analysis  of  transformants  by  PCR  showed  integration  for  all  three 
plasmids  transfected.  A  DNA  fragment  between  200  and  300  bp  was  amplified  on 
the  genomic  DNA  extracted  from  cells  transfected  with  the  empty  vector,  which 
corresponds  to  the  predicted  size  of  295  bp.  On  the  genomic  DNA  extracted  from 
the  cells  transfected  with  the  pGAPHisCatB  plasmid  and  the  pGAPCatB  plasmid, 
the  size  of  the  predicted  amplified  fragments  was  about  1800  bp.  Two  positive 
clones  were  therefore  detected  for  the  former  plasmid  (Fig.  3.24A)  and  all  the 
clones  tested  for  the  latter  plasmid  seemed  to  be  positive  (Fig.  3.24B),  as  a  DNA 
fragment  between 1650  and  2000  bp  was  amplified. 
3.2.9.1.2.  Analysis  of  expression 
One  positive  colony  for  each  of  the  constructs  was  selected  and  tested  for 
expression  of  the  target  protein  as  described  in  the  manufacturers  manual  (final 
volume  of  50  ml  of  YPD  media).  One  ml  aliquots  were  taken  a  regular  time 
intervals,  cells  were  separated  from  the  supernatant  of  culture  by  centrifugation 
and  samples  of  supernatant  and  cell  lysates  were  used  for  analysis  using  gelatin 
SDS-PAGE,  the  azocasein  assay,  and  either  with  Coomassie  blue-stained  SDS- 
PAGE  or  western  blot  analysis. 
Analysis  of  the  supernatant  of  culture  of  the  Pichia  cells  having  integrated 
the  empty  vector  or  the  pGAPHisCatB  or  pGAPCatB  plasmids  showed  in  all 
cases  the  presence  of  a  faint  single  protein  between  40  and  50  kDa  after  24  to  48 
h  of  culture  (results  not  shown).  This  protein  is  unlikely  to  be  related  to  the  protein 
of  interest,  as  it  is  expressed  in  the  negative  control  cells  that  had  integrated  the 
empty  vector.  No  protein  at  the  expected  size  for  the  pro-mature  cathepsin  B 
(55.4  kDa)  could  be  detected  in  crude  supernatant  or  in  the  cell  extracts  by  SDS- 
PAGE  (results  not  shown).  By  western-blot  analysis,  a  protein  corresponding  to 
the  expected  size  for  the  pro-mature  cathepsin  B  at  about  55  kDa  could  be 
detected  in  the  crude  supernatant  of  culture  and  the  cell  extracts  of  the  Pichia 
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cells  transfected  with  the  pGAPCatB  and  pGAPHisCatB  plasmids  but  not  in  the 
control  cells  transfected  with  the  empty  vector  (Fig.  3.25).  Signs  of  processing 
could  also  be  detected  as  smaller  bands  could  be  visualised,  especially  in  the 
supernatant  of  culture  of  the  cells  transfected  with  the  pGAPCatB  plasmid.  The 
proteins  trapped  inside  the  cells  were  of  less  interest,  as  purification  would  be 
more  difficult. 
By  TCA  precipitation  of  a  small  volume  of  supernatant  of  culture  of  Pichia 
cells  transfected  with  the  pGAPHisCatB  and  the  pGAPCatB  plasmids,  the  protein 
between  40  and  50  kDa  was  more  easily  detected  by  SDS-PAGE  (Fig.  3.26). 
However,  it  does  not  seem  to  be  related  to  the  cathepsin  B,  as  it  was  not 
recognised  with  anti-cathepsin  B  antibodies  (Fig.  3.25).  An  additional  protein  at 
about  55  kDa,  corresponding  to  the  expected  size  for  the  pro-mature  cathepsin  B 
could  also  faintly  be  detected  after  48  to  72  h  of  culture  (Fig.  3.26),  and  the 
expression  seemed  stable  for  at  least  8  days  (results  not  shown).  By  western-blot 
analysis  of  the  TCA-precipitated  supernatant  of  culture  of  Pichia  cells  transfected 
with  the  pGAPHisCatB  plasmid  and  the  pGAPCatB  plasmid,  the  results  obtained 
by  SDS-PAGE  were  confirmed.  That  is,  a  55  kDa  band  corresponding  to  the 
predicted  size  for  the  pro-mature  cathepsin  B  could  be  detected  after  48  h  of 
culture  (Fig.  3.27).  Moreover,  signs  of  processing  of  the  protein  could  be 
observed  in  the  supernatant  of  cells  transfected  with  the  pGAPCatB  plasmid  (Fig. 
3.27). 
Aliquots  of  supernatant  of  the  cultures  described  above  were  analysed 
using  gelatin  SDS-PAGE  with  incubation  at  pH  5.0  and  pH  8.0  for  24  h  at  37*C, 
but  no  difference  in  activity  could  be  detected  between  the  cathespin  13- 
expressing  cells  and  the  negative  control  cells.  The  same  pattern  of  proteins  was 
detected  in  all  cases  (proteins  were  in  high  molecular  weight  range,  above  50 
kDa).  50  ýLl  of  supernatant  of  culture  were  tested  as  well  for  activity  using  the 
azocasein  assay,  but  no  activity  could  specifically  be  detected  compared  to  the 
control  cells  supernatant.  The  activity  detected  on  azocasein  was  in  all  cases 
DTT  inhibited  and  not  E64  inhibited  (the  activity  was  probably  due  to  the  release 
of  a  peptidase  into  the  supernatant  of  culture  not  related  to  the  cathepsin  B) 
(Table  3.1).  This  peptidase  activity  did  degrade  the  cathepsin  B. 
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FIG.  3.24.  Verification  of  insertion  of  the  pGAPHiscatB  and  pGAPcatB  constructs  in 
the  Pichia  X-33  genome.  PCR  analysis  of  Pichia  transformants,  using1%  agarose  gel  and 
ethidium  bromide  staining.  (A)  Cells  transfected  with  the  pGAPZ(IA  empty  vector  (lanes  1  to  4),  or 
with  the  pGAPHiscatB  plasmid  (lanes  5  to  8).  (B)  Cells  transfected  with  the  pGAPcatB  plasmid. 
Size  in  bp  is  indicated  on  the  left  of  the  figure.  M,  corresponds  to  molecular  mass  in  kDa. 
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FIG.  3.25.  Analysis  of  expression  of  the  cathepsin  B  of  Eimeria  tenelia  in  Pichia 
pastoris  X-33,  constitutive  system.  Analysis  by  western  blot  (1:  8000  dilution  of  last  bleed  anti 
cathepsin  B  antiserum;  1:  5000  dilution  of  anti-rabbit  antibody;  2  min  exposure)  of  the  supernatant 
of  culture  (lanes  1,3  and  5)  and  the  Pichia  cell  extracts  (lanes  2,4  and  6)  transfected  with  the 
pGAPZccA  vector  (lanes  1  and  2),  the  pGAPcatB  plasmid  (lanes  3  and  4)  and  the  pGAPHiscatB 
plasmid  (lanes  5  and  6)  at  t=  72  h.  10  pl  of  suspension  were  loaded.  M,  corresponds  to  molecular 
mass  in  kDa. 
104 
12345678  123456 Chapter  3:  Expression  and  characterisation 
of  the  recombinant  cathepsin  B  of  E.  tenella 
123456789 
50- 
20 
FIG.  3.26.  Analysis  of  expression  of  the  cathepsin  B  of  Eimeria  tenefia  in  Pichia 
pastoris  X-33,  constitutive  system,  by  TCA  precipitation  of  the  supernatant  of  cultures. 
Analysis  on  post-el  ectroph  ores  is  Coomassie  blue-stained  12%  (w/v)  SDS-PAGE  gel  of  the 
equivalent  of  0.2  ml  of  TCA-precipitated  supernatant  of  culture  of  Pichia  cells  transfected  with  the 
pGAPHisCatB  plasmid  (lanes  1  to  5)  and  the  pGAPCatB  plasmid  (lanes  6  to  9).  Lane  1,24  h; 
lane  2,48  h;  lane  3,72  h;  lane  4,96  h;  lane  5,168  h;  lane  6,24  h;  lane  7,48  h;  lane  8,72  h;  lane 
9,96  h.  The  arrow  indicates  the  55  kDa  protein.  M,  corresponds  to  molecular  mass  in  kDa. 
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FIG.  3.27.  Detection  of  the  cathepsin  B  of  Eirneria  tenella  expressed  and  released  by 
Pichia  pastoris  X-33,  constitutive  system,  in  TCA-precipitated  supernatant  of  cultures. 
Analysis  by  western  blot  (1:  8000  dilution  of  last  bleed  anti  cathepsin  B  antiserum;  1:  5000  dilution 
of  anti-rabbit  antibody;  2.5  min  exposure)  of  the  equivalent  of  0.2  ml  of  TCA-precipitated 
supernatant  of  culture  of  Pichia  cells  transfected  with  the  pGAPHisCatB  plasmid  (lanes  1  to  5) 
and  the  pGAPCatB  plasmid  (lanes  6  to  9).  Lane  1,24  h;  lane  2,48  h;  lane  3,72  h;  lane  4,96  h; 
lane  5,168  h;  lane  6,24  h;  lane  7,48  h;  lane  8,72  h;  lane  9,96  h.  M,  corresponds  to  molecular 
mass  in  kDa. 
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Table  3.1.  Azocaseln  assay  on  Pichia  culture  supernatant  after  192  h  of  culture.  Fifty 
l.  d  of  a  1%  (w/v)  azocasein  was  mixed  with  400  pl  50  mM  sodium  acetate  pH  5.0  and  50  l.  Ll  of 
sample  to  test  (about  10  pg  of  recombinant  protein)  and  incubated  at  37"C  overnight.  The 
absorbance  of  the  supernatant  was  measured  at  400  nm. 
Sample  Absorbance  (400  nm) 
Control  without  protein  0.09 
pPlC9catB  supernatant  0.948 
pPlC9catB  supernatant  0  464  10  mM  DTT,  1  mM  E64  . 
pPIC9catB  supernatant  0.975 
1  mM  E64 
pPIC9catB  supernatant  0.471 
10  mM  DTT 
pPIC9  supernatant  0.861 
pPIC9  supernatant  0.921 
1  mM  E64 
pPIC9  supernatant  0.459 
10  mM  DTT 
3.2.9.2.  Inducible  system 
The  sequence  encoding  the  pro-mature  cathepsin  B  was  amplified  from 
cDNA  and  cloned  in  the  pPIC9  vector  for  expression  in  an  inducible  manner  and 
secretion  into  the  supernatant  of  culture  of  P.  pastoris  KM71  cells  of  the 
recombinant  enzyme  without  a  His-tag.  The  plasmid  obtained  and  predicted 
protein  are  schernatised  in  Fig.  3.28. 
3.2.9.2.1.  Confirmation  of  transformants 
Insertions  of  the  fragments  were  verified  by  PCR  on  genomic  DNA 
extracted  from  positive  clones,  using  the  pairs  of  PCR  primers  a-factor  and 
XAOX1,  or  5'AOX1  and  3'AOX1  (see  Table  2.1,  chapter  2).  Results  of  PCRs  on 
genomic  DNA  extracted  from  KM71  His'  Muts  are  shown  on  Fig.  3.29.  By  PCR 
using  the  (x-factor/3'AOX1  primers,  a  DNA  fragment  of  1661  bp  is  predicted  to  be 
amplified  on  the  genomic  DNA  from  KM71  cells  transfected  with  the  pPlC9catB 
plasmid,  and  a  DNA  fragment  of  195  bp  is  predicted  to  be  amplified  on  the 
genomic  DNA  from  KM71  cells  transfected  with  the  pPIC9  empty  vector.  Using 
the  5'AOX1/3'AOX1  primers,  a  DNA  fragment  at  3.6  kb  corresponding  to  the 
amplification  from  the  endogenous  mutated  AOXII  gene  should  be  detected  in  all 
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His"'  Muts  cells.  The  amplification  of  the  inserted  fragment  from  the  pPIC9catB 
construct  would  yield  a  product  at  1968  bp  and  the  amplification  of  the  inserted 
fragment  from  the  pPIC9  empty  vector  would  yield  a  product  at  492  bp. 
Therefore,  from  the  results  on  Fig.  3.29,  the  clone  selected  for  each  transfection 
seems  to  correspond  to  a  positive  clone. 
3.2.9.2.2.  Analysis  of  expression 
One  positive  colony  for  each  of  the  transfections  was  selected  and  tested 
for  expression  of  the  target  protein.  Cells  were  induced  with  0.5  %  methanol  (v/v, 
final  concentration)  every  24  h  and  0.5  ml  aliquots  were  taken  a  regular  time 
intervals.  Cells  were  separated  from  the  supernatant  of  culture  by  centrifugation 
and  samples  of  supernatant  were  used  for  analysis  using  gelatin  SDS-PAGE,  the 
azocasein  assay,  and,  either  directly  or  after  TCA-precipitation,  Coomassie  blue- 
stained  SDS-PAGE  and  western  blot  analysis.  The  control  strain  transfected  with 
the  empty  vector  was  induced  and  its  supernatant  of  culture  was  also  analysed 
after  TCA-precipitation. 
Time  course  analysis  of  expression  showed  that  the  recombinant  protein 
was  already  present  about  24  h  after  the  start  of  induction,  that  the  amount  of 
protein  increased  slightly  until  96  h  after  induction  and  then  remained  stable  until 
at  least  192  h  after  induction  (data  not  shown).  The  cells  were  routinely  harvested 
192  h  after  the  start  of  induction.  Analysis  of  expression  showed  a  major  protein 
at  about  30  kDa  on  Coomassie  blue-stained  SIDS-PAGE  gels  in  the  supernatant 
of  cells  transfected  with  the  pPIC9catI3  plasmid,  but  not  in  the  supernatant  of  the 
cells  transfected  with  the  empty  pPIC9  vector  (Fig.  3.30).  This  corresponds  to  the 
size  expected  for  the  mature  cathepsin  B-like  enzyme.  Using  specific  anti-pro- 
cathepsin  B  antiserum,  a  major  protein  at  about  30  kDa  (Fig.  3.30,  lane  6),  the 
size  expected  for  the  mature  enzyme,  was  found  in  the  supernatant  of  culture  of 
the  KM71  Pichia  cells  transfected  with  the  pPIC9CatB  plasmid  for  inducible 
expression.  Based  on  Coomassie  blue-stained  SIDS-PAGE  analysis,  the 
expression  was  estimated  to  be  about  100  mg  of  protein  per  litre  of  culture.  In  the 
TCA-precipitated  supernatant  of  culture  at  the  time  of  harvest,  2  major  proteins 
were  detected  using  specific  anti-pro-cathepsin  B  antiserum  (Fig.  3.30,  lane  7). 
One  band  was  the  protein  at  30  kDa,  the  other  was  slightly  larger  (about  32  kDa). 
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Fainter  proteins  at  about  54  kDa  and  22  kDa  could  also  be  detected,  which  could 
correspond,  respectively,  to  the  pro-mature  enzyme  and  the  pro-domain. 
By  western  blot  analysis  of  the  cell  extracts  of  Pichia  cells  transfected  with 
the  pPlC9catB  plasmid  and  the  empty  vector,  only  traces  of  the  54  kDa  protein 
could  be  detected  in  the  cell  extracts  of  the  cells  transfected  with  the  pPIC9catB 
plasmid  but  not  the  empty  vector,  suggesting  that  most  of  the  protein  expressed 
was  released  into  the  medium  (results  not  shown). 
Supernatants  of  cultures  of  both  the  cathepsin  B-expressing  and  control 
cells  were  tested  for  activity  against  the  Z-Phe-Arg-AMC  substrate  and  there  was 
significantly  greater  activity  (3000-fold)  in  the  supernatant  of  culture  of  cells 
expressing  a  processed  protein  recognised  by  anti-cathepsin  B  antiserum, 
compared  to  the  same  volume  of  supernatant  of  culture  of  cells  transfected  with 
the  empty  vector.  The  culture  supernatant  containing  the  active  enzyme  was 
analysed  immediately  or  stored  at  -200C  for  later  analysis. 
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FIG.  3.28.  Construct  for  expression  of  recombinant  pro-cathepsin  B  of  E.  tenefla  in 
Pichia  pastoris,  inducible  system.  (A)  Schematic  representation  of  the  plasmid  resulting  from 
the  cloning  of  the  pro-mature  sequence  of  the  cathepsin  B  of  E  tenella  in  the  pPIC9  vector  for 
inducible  expression  of  pro-mature  cathepsin  B  in  the  supernatant  of  culture.  Amp,  ampicillin 
resistance  gene;  CoIE1,  origin  of  replication;  AOX1,  alcohol  dehydrogenase  gene;  HIS4;  histidine 
prototrophy  gene.  (B)  Schematic  representation  of  the  protein  expressed  from  the  pPIC9catB 
plasmid.  The  size  in  amino  acids  of  the  different  fragments  is  indicated  between  brackets. 
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FIG.  3.29.  Verification  of  insertion  of  the  pPlC9catB  construct  in  the  Pichia  KM71 
genome.  (A)  Schematic  representation  of  the  position  of  the  different  primers  used  for  PCR  and 
their  position.  (x,  cc-factor  sequence;  AOX1,  alcohol  dehydrogenase  gene;  ARG4,  gene  for 
arginine  prototrophy.  (B)  PCR  analysis  of  Pichia  transformants  using  1%  agarose  gel  and 
ethidium  bromide  staining.  Ten  jal  of  reactions  were  loaded.  PCRs  used  the  primers  C(- 
factor/3'AOX1  (lanes  1  and  2),  and  5'AOX1/3'AOX1  (lanes  3  and  4).  Genomic  DNA  from  KM71 
cells  transfected  with  the  pPIC9catB  plasmid  was  analysed  on  lanes  1  and  3.  Genomic  DNA  from 
KM71  cells  transfected  with  the  pPIC9  empty  vector  was  analysed  on  lanes  2  and  4.  Size  in  bp  is 
indicated  on  the  left  of  the  figure. 
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FIG.  3.30.  Analysis  of  expression  of  the  cathepsin  B  of  Eimeria  tenelia  in  Pichia 
pastoris  KM71,  inducible  system.  Fifteen  pl  of  supernatant  of  culture  of  Pichia  cells  transfected 
with  the  pPIC9catB  plasmid  (lanes  2  and  6)  and  the  empty  pPIC9  vector  (lanes  1  and  5)  were 
analysed  using  Coomassie  blue-stained  12%  (w/v)  SIDS/PAGE  (lanes  1  and  2)  and  by  western 
blot  analysis  (lanes  3  and  4;  1:  8000  dilution  of  last  bleed  anti-cathepsin  B  antiserum;  1:  5000 
dilution  of  anti-rabbit  antibody;  5  min  exposure).  The  equivalent  to  0.5  ml  of  supernatant  of  culture 
of  Pichia  cells  transfected  with  the  pPIC9catB  plasmid  (lanes  3  and  7)  and  the  empty  pPIC9 
vector  (lanes  4  and  8)  after  TCA-precipitation  were  analysed  using  Coomassie  blue-stained  12% 
(w/v)  SDS/PAGE  (lanes  3  and  4)  and  by  western  blot  analysis  (lanes  7  and  8;  1:  8000  dilution  of 
last  bleed  anti-cathepsin  B  antibody;  1:  5000  dilution  of  anti-rabbit  antibody;  2  min  exposure). 
3.2.10.  Purification  of  recombinant  full-length  cathepsin  B  expressed  and 
secreted  by  Pichia  pastoris 
The  enzyme  was  purified  from  the  supernatant  of  culture  by  ammonium 
sulfate  precipitation.  The  enzyme  was  found  to  precipitate  mainly  between  40 
and  70  %  ammonium  sulfate  saturation  (Fig.  3.31).  The  protein  appeared  to  be 
slightly  purer  using  70%  rather  than  80%  saturation  precipitation  and  the  smear 
apparent  in  the  low  molecular  mass  range  of  the  gels  with  crude  extract 
disappeared  (Fig.  3.32,  lane  1).  In  addition,  the  yellow-brown  colour  of  the  culture 
supernatant  (due  to  the  abundant  polysaccharides  present)  also  was  less  in  the 
pellet  resuspensions  compared  with  the  crude  extract.  Thus,  ammonium  sulfate 
precipitation  improved  the  purity  of  the  enzyme  significantly.  A  40  %  saturation 
precipitation  followed  by  a  70  %  saturation  precipitation  on  the  supernatant  of 
precipitation  resulted  in  the  presence  of  2  proteins  at  about  30  and  32  kDa  on 
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Coomassie  blue-stained  gels  (Fig.  3.32,  lane  2),  specifically  recognised  by  anti- 
pro-cathepsin  B  antiserum  (Fig.  3.32,  lane  4). 
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FIG.  3.31.  Ammonium  sulfate  precipitation  of  the  cathepsin  B  of  Eimeria  tenella 
produced  by  Pichia  pastoris  KIVI71,  Inducible  system.  Aliquots  of  supernatant  of  culture  of 
Pichia  cells  expressing  the  cathepsin  B  were  incubated  for  2h  at  4"C  with  gentle  agitation  In  the 
presence  of  increasing  ammonium  sulfate  saturation  concentrations.  The  precipitated  proteins 
were  pelleted  for  15  min  at  13000  g,  4"C  and  resuspended  in  the  Initial  volume  of  50  mM  sodium 
acetate,  pH  5.0.  The  activity  was  measured  and  compared  to  the  non-treated  sample.  The  activity 
present  in  the  pellet  was  expressed  as  a  percentage  of  the  initial  activity. 
3.2.11.  Deglycosylation  of  recombinant  full-length  cathepsin  B  expressed  In 
Pichia  pastoris 
After  treatment  with  the  PGNase  F  for  deglycosylation,  a  single  protein  at 
30  kDa  corresponding  to  the  mature  cathepsin  B  could  be  detected  on 
Coomassie  blue-stained  SDS-PAGE  gel  (Fig.  3.32,  lane  3),  specifically 
recognised  by  anti-pro-cathepsin  B  antibodies  (Fig.  3.32,  lane  5). 
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FIG.  3.32.  Deglycosylation  of  the  cathepsin  B  of  Eimeria  tenefla  produced  and 
released  by  Pichia  pastoris  KM71,  inducible  systern.  The  supernatant  of  culture  of  cathepsin 
B-expressing  Pichia  cells  (lane  1)  was  treated  with  40%  ammonium  sulfate  for  2h  at  4'C  with 
gentle  agitation;  the  supernatant  of  this  treatment  was  then  incubated  in  the  presence  of  70% 
ammonium  sulfate  for  2h  at  40C  with  gentle  agitation,  and  the  precipitated  fraction  after  this  step 
was  resuspended  and  analysed  on  a  Coomassie  blue-stained  12%  (w/v)  SDS-PAGE  gel  (lane  2) 
and  by  western  blot  analysis  (lane  4,1:  8000  dilution  of  last  bleed  anti-cathepsin  B  antiserum; 
1:  5000  dilution  of  anti-rabbit  antibody;  3  min  exposure).  The  purified  enzyme  was  treated  with 
PGNAse  F  (0.5  U,  1h  at  37'C)  and  analysed  on  a  SDS-PAGE  gel  (lane  3)  and  by  western-blot 
(lane  5)  as  described  for  the  non-deglycosylated  sample.  Fifteen  pl  of  each  sample  were  loaded 
on  the  gels. 
3.2.12.  Characterisation  of  the  active  recombinant  cathepsin  B  expressed  in 
Pichia  pastoris 
An  activity  of  about  0.6  U/ml  towards  the  substrate  Z-Phe-Arg-pNA  (333 
pM)  in  50  mM  sodium  acetate  pH  5.0,2  mM  EDTA,  10  mM  DTT,  could  be 
detected  in  the  sample  of  crude  culture  supernatant  (concentration  of  100  pg 
protein/ml),  whereas  the  crude  supernatant  of  culture  of  Pichia  cells  transfected 
with  the  empty  pPIC9  vector  showed  a  maximum  of  activity  of  0.2  mU/ml  against 
the  same  substrate.  The  Km  for  Z-Phe-Arg-pNA  could  not  be  measured  as  the 
substrate  was  falling  out  of  solution  at  higher  concentrations.  No  activity  towards 
100  [,  M  of  Z-Arg-Arg-pNA  could  be  detected  under  the  conditions  used.  Higher 
concentrations  of  substrate  provoked  its  precipitation  in  the  assay  buffer.  From 
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the  alignment  on  Fig.  3.3,  it  can  be  predicted  that  the  Eimeria  cathepsin  B  should 
be  able  to  cleave  Arg  at  the  P2  position,  as  it  possesses  Glu-325  (human 
cathepsin  B  numbering),  allowing  the  enzyme  to  accommodate  Arg  at  the  P2  site 
like  the  human  cathepsin  B  (Hasnain  et  al.,  1993;  Chan  et  al.,  1999).  But  it  is  also 
known  that  the  human  cathepsin  B  has  a  7-fold  preference  for  Phe  over  Arg  at 
the  P2  position  (Hasnain  et  al.,  1993),  so  the  concentration  of  Z-Arg-Arg-pNA 
may  not  be  sufficient  for  detection  of  activity. 
3.2.12.1.  Dependence  on  DTT  and  EDTA 
The  enzyme  activity  was  strictly  dependent  on  the  presence  of  DTT,  10 
mM  being  the  minimum  required  for  maximum  activity.  EDTA  seemed  to  have  a 
beneficial  effect  on  the  activity,  with  5  mM  being  the  minimum  required  for 
observation  of  maximum  activity  (Fig.  3.33). 
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FIG.  3.33.  Dependence  of  the  activity  of  the  recombinant  cathepsIn  B  of  Eimeria 
tenefla  on  DTT  and  EDTA-  Enzyme  activity  was  tested  for  dependence  on  DTT  and  EDTA,  and 
measured  in  50  mM  sodium  acetate  pH  5.0,  using  the  substrate  Z-Phe-Arg-AMC,  In  a  total 
volume  of  0.6  mi.  30  til  of  crude  Pichia  supernatant  were  used  for  each  assay.  The  reaction  was 
started  by  addition  of  50  pM  of  substrate  and  measured  continuously  for  5  min  at  37"C 
(Excitation:  380  nm/Emission:  465  nm).  Dependence  of  the  activity  on  DTT  was  measured  in  the 
absence  of  EDTA,  and  dependence  of  the  activity  on  EDTA  was  measured  in  the  presence  of  10 
mM  DTT.  Activity  towards  Z-Phe-Arg-AMC  in  the  control  supernatants  (from  Pichia  transfected 
with  the  empty  plasmid)  was  negligible  under  these  conditions. 
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3.2.12.2.  Dependence  on  salt 
Sodium  chloride,  which  may  in  some  cases  stabilise  enzyme  activity,  did 
not  seem  to  have  any  beneficial  effect  at  concentrations  up  to  200  mM;  on  the 
contrary,  above  200  mM  it  seemed  to  be  slightly  detrimental,  reducing  the  activity 
by  20%  (Fig.  3.34).  Sodium  chloride  was  omitted  from  all  subsequent  assays. 
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FIG.  3.34.  Dependence  of  the  activity  of  the  recombinant  cathepsin  B  of  Eirneria 
tenella  on  salt.  Enzyme  activity  was  tested  for  dependence  on  NaCl,  and  measured  in  50  mM 
sodium  acetate  pH  5.0,  using  the  substrate  Z-Phe-Arg-AMC,  in  a  total  volume  of  0.6  ml.  30  I.  Ll  of 
crude  Pichia  supernatant  were  used  for  each  assay.  The  reaction  was  started  by  addition  of  50 
I.  tM  of  substrate  and  measured  continuously  for  5  min  at  3711C  (Excitation:  380  nm/Emission:  465 
nm). 
3.2.12.3.  pH  optimum 
In  terms  of  pH  dependence,  the  activity  was  close  to  zero  when  the  pH 
was  under  4.0  or  above  9.0  and  seemed  to  present  2  maxima,  at  pH  5.0  and  pH 
8.0,  in  the  mix  of  buffers  (Fig.  3.35A).  The  reason  why  the  activity  seems  to  drop 
at  pH  5.5  and  6.0  is  unclear  at  present,  but  might  be  due  to  changes  in  ionic 
strength  in  the  buffer.  Using  individual  buffers,  the  activity  dropped  drastically 
when  the  pH  was  under  4.0  or  above  9.0.  The  activity  seemed  to  present  2  peaks 
in  these  conditions,  one  between  pH  4.0  and  5.5,  one  at  pH  7.5.  The  activity 
decreased  rapidly  or  slightly  (depending  on  the  buffer)  between  pH  5.5  and  6.5 
(Fig.  3.35B). 
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FIG.  3.35.  Dependence  of  the  activity  of  the  recombinant  cathepsin  B  of  Elmeria 
tenella  on  pH.  (A)  The  pH  dependence  was  determined  using  a  mix  of  4  buffers  (25  mM  acetic 
acid,  25  mM  MES,  75  mM  Tris,  25  mM  glycine)  adjusted  to  the  appropriate  pH,  with  2  ý11  of  crude 
Pichia  supernatant  and  10  mM  DTT.  The  reaction  was  started  by  addition  of  30  IaM  of  Z-Phe-Arg- 
AMC.  (B)  Three  different  buffers  were  used  separately,  depending  on  their  pH  range.  These 
buffers  were  0.1  M  acetic  acid,  0.1  M  sodium  acetate  and  0.1  M  potassium  phosphate.  All  buffers 
were  supplemented  with  10  mM  DTT.  The  reaction  was  started  by  addition  of  30  ýLM  of  Z-Phe- 
Arg-AMC.  Reactions  used  10  ýd  of  crude  Pichla  supernatant  and  were  measured  continuously  for 
5  min  at  370C  (Excitation:  380  nm/Emission:  465  nm).  Results  are  the  means  ±  SID  from  3 
independent  measurements. 
3.2.12.4.  K  ..  s  against  Z-Phe-Arg-AMC  and  Z-Arg-Arg-AMC 
Purified  enzyme  was  active  against  the  substrates  Z-Phe-Arg-AMC  and  Z- 
Arg-Arg-AMC;  activity  was  20-fold  higher  against  Z-Phe-Arg-AMC  than  against  Z- 
Arg-Arg-AMC  (Fig.  3.36A).  The  strong  preference  for  a  phenylalanine  residue  at 
the  P2  site  compared  to  arginine  is  a  characteristic  for  this  class  of  enzymes.  The 
Km  and  specific  activities  were  respectively  168  ±  33  ýN  and  6  U/mg  protein 
against  Z-Phe-Arg-AMC;  and  1.40  ±  0.25  mM  and  0.3  U/mg  protein  against  Z- 
Arg-Arg-AMC  (Fig.  3.36B).  The  purified  enzyme  had  very  comparable 
characteristics  to  the  purified  and  deglycosylated  enzyme,  with  a  variation  of  Kms 
lower  than  8%  and  variation  of  activity  lower  than  10%.  The  use  of  culture 
supernatant  from  control  cultures  (Pichia  with  the  empty  vector)  showed  that  it 
contained  no  detectable  activity  towards  Z-Phe-Arg-AMC  (<  0.2  mU/ml). 
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FIG.  3.36.  Analysis  of  the  activity  of  the  non-deglycosylated  and  deglycosylated 
cathepsin  B  of  Eimeria  tenella  produced  in  Pichia  pastoris  against  the  synthetic 
fluorogenic  substrates  Z-Phe-Arg-AMC  and  Z-Arg-Arg-AMC.  Bars  indicate  the  standard 
deviation  around  the  mean,  based  on  3  repetitions  of  each  measurement.  0.5  ýIg  of  enzyme  was 
used  per  assay.  (A)  Representation  of  the  activity  (U/mg  protein)  of  the  different  enzyme  fractions 
against  the  2  substrates  Z-Phe-Arg-AMC  and  Z-Arg-Arg-AMC.  Enzyme  samples  were  tested  for 
activity  in  a  final  volume  of  1  mi.  The  enzyme  sample  was  incubated  for  10  min  at  370C  in  the 
assay  buffer  before  start  of  the  reaction  by  addition  of  the  substrate  (200  plM,  unless  for  K, 
determination  were  10  pM  to  1.5  mM  were  used).  Excitation  and  emission  wavelengths  were 
respectively  380  and  465  nm.  The  assays  were  continuous  for  10  min  at  370C.  (B) 
Representation  of  the  Km  (pM)  of  the  different  enzyme  fractions  against  the  2  substrates  Z-Phe- 
Arg-AMC  and  Z-Arg-Arg-AMC.  Results  are  the  means  ±  SID  from  3  independent  measurements. 
3.2.12.5.  Inhibitors 
Various  peptidase  inhibitors  were  tested  on  both  the  non-deglycosylated 
and  deglycosylated  enzymes  (Tables  3.1A  and  B).  As  expected,  the  cysteine 
peptidases  inhibitors  (2S,  3S)-3-(N-{(S)-l-[N-(4-guanidinobutyl)carbamoyl]3- 
m  ethyl  butyllca  rba  moyl)oxi  ra  ne-2-ca  rboxyl  ic  acid  (E64),  N-methyl-piperazine- 
Phe-homoPhe-vinylsulfone-phenyl  (K1  1777),  Z-Phe-Arg-d  iazomethyl  ketone 
(ZFRDMK),  leupeptin  and  N-tosyl-L-lysine-chloromethyl  ketone  (TLCK)  strongly 
inhibited  the  enzymes.  The  sulfhydryl-blocking  agent,  iodoacetamide,  showed 
strong  inhibition  too,  while  N-ethyl  maleimide  (NEM)  did  not.  The 
metal  lopeptidase  inhibitor  1,10-phenanthroline,  the  serine  peptidase  inhibitors 
phenylmethylsulphonyl  fluoride  (PMSF)  and  benzamidine,  and  the  aspartyl 
peptidase  inhibitor  pepstatin  A  did  not  show  any  affect  unless  used  at  very  high 
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concentrations.  This  might  be  due  to  interfering  interactions  with  other  amino 
acids  involved  in  the  catalytic  reaction. 
Table  3.2.  Testing  of  various  inhibitors  on  the  purified  recombinant  cathepsin  B  of 
Eimeria  tenella.  For  testing  the  effect  of  inhibitors,  the  inhibitor  was  added  to  the  buffer-enzyme 
mix  and  incubated  for  10  min  at  370C.  The  reaction  was  started  by  addition  of  200  i.  LM  of  the 
substrate  Z-Phe-Arg-AMC  and  monitored  continously  for  5  min  (excitation:  380  nm/Emission: 
465  nm).  The  activity  remaining,  relative  to  the  maximum  activity  measured  without  inhibitor,  is 
indicated  in  percentage,  as  well  as  the  standard  deviation  based  on  3  repeats  of  each 
measurement.  E64:  (2S,  3S)-3-(N-{(S)-1  -[N-(4-guanidinobutyl)carbamoyl]3- 
methýbutyl)carbamoyl)oxirane-2-carboxylic  acid;  K1  1777:  N-methyl-piperazine-Phe-homoPhe- 
vinylsulfone-phenyl;  ZFRDMK:  Z-Phe-kg-diazomethylketone;  TLCK:  N-tosyl-L-lysine- 
chloromethyl  ketone;  PMSF:  phenylmethylsulphonyl  fluoride;  NEM:  N-ethyl  maleimide.  (A)The 
purified  enzyme  was  used  (0.5  jig  per  assay).  (B)  The  purified  deglycosylated  enzyme  was  used 
(0.5  pg  per  assay). 
A 
Inhibitor  Concentration  (gM)  Activity 
E64  100  0 
10  2±0.2 
1  7±2.4 
Kl  1777  10  0 
1  1.3  ±  0.3 
ZFRDMK  100  0 
10  1.8  ±  0.3 
Leupeptin  100  0.4  ±  0.1 
10  3.3  ±  0.2 
TLCK  100  1.3  0.2 
10  4.3  0.6 
lodoacetamide  100  0.7  0.1 
10  14  2.5 
Bestatin  100  3  0.2 
10  59  ±5 
1,10-phenanthroline  1000  50  ±8 
100  97  ±5 
PMSF  1000  66.8  ±4 
100  99  7 
Benzamidine  1000  72.1  ±6 
100  98  6 
Pepstatin  A  10  99  ±  1.5 
1  100  5 
NEM  100  86  3 
10  91  2 
2-pyrrolidinone  100  95  3 
10  100  0.5 
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B 
Inhibitor  Concentration  (ýM)  Activity 
E64  100  0 
10  0 
1  4±1.5 
Kl  1777  10  0.2  ±  0.1 
1  1.6  ±  0.3 
ZFRDMK  100  0 
10  2.1  ±  0.1 
Leupeptin  100  0 
10  2.1  ±  0.8 
TLCK  100  0.6  ±  0.4 
10  5.6  ±  0.9 
3.2.10.6.  Gelatin  and  azocasein  are  not  substrates  for  the  enzyme 
Samples  of  purified  and  deglycosylated,  or  not,  cathepsin  B  produced  and 
released  by  P.  pastoris  were  analysed  on  gelatin  SDS/PAGE.  No  activity  could 
be  detected  in  the  conditions  tested  on  either  reducing  or  native  gels. 
Samples  of  purified  and  deglycosylated,  or  not,  cathepsin  B  produced  and 
released  by  P.  pastoris  were  analysed  using  the  azocasein  assay.  The  activity 
detected  on  azocasein  was  in  all  cases  close  to  the  control  without  enzyme 
(absorbance  of  -0.1,  see  Table  3.1). 
3.2.13.  The  cathepsin  B  enzyme  Is  expressed  in  E.  tenella  oocysts  and 
sporozoites 
The  analysis  by  western-blot  of  total  protein  content  of  sporulated  oocysts 
and  sporozoites  with  specific  anti-cathepsin  B  antibodies  detected  a  protein  at 
-30  kDa,  which  may  correspond  to  the  mature  cathepsin  B.  Faint  proteins  at  just 
above  50  kDa  and  about  20  kDa  may  correspond  to  the  pro-mature  protein  and 
the  pro-domain,  respectively  (Fig.  3.37). 
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FIG.  3.37.  Immuno-detection  of  the  cathepsin  B  of  Eimeria  tenella  on  sporozoite 
and  oocyst  extracts.  Detection  using  the  anti-cathepsin  B  of  E.  tenella  antibodies  raised  in  rabbit 
(1:  1000),  followed  by  HRP-conjugated  anti-rabbit  antibodies  (1:  2000).  Membrane  exposure  of  2.5 
min.  Lane  1,  total  protein  from  -105  oocysts  equivalent;  lane  2,  total  protein  from  _106 
sporozoites.  Molecular  mass  standards  are  indicated  on  the  left  of  the  figure.  The  full  arrow 
indicates  the  expected  size  for  the  mature  cathepsin  B  enzyme  (31  kDa),  and  the  hollow  arrow 
indicates  the  size  expected  for  the  pro-cathepsin  B  (57  kDa). 
3.2.14.  Localisation  of  the  cathepsin  B  in  the  asexual  stages  of  the  life  cycle 
In  sporozoites,  it  was  shown  that  the  anti-cathepsin  B  antibodies  were 
detecting  proteins  at  the  sizes  of  the  pro-mature  and  mature  enzymes  (Fig.  3.37). 
The  antibody  was  also  tested  against  purified  organelles  from  E.  tenella 
sporozoites,  on  fractions  thought  to  correspond  to  micronernes  and  rhoptries 
(samples  extracted  and  purified  on  sucrose  gradient  by  Dr  Fiona  Tomley's  group, 
Institute  of  Animal  Health,  Compton).  In  the  lane  corresponding  to  sporozoites,  2 
proteins  were  detected  at  respectively  about  55  kDa  and  30  kDa,  which 
correspond  to  the  expected  sizes  for  the  pro-mature  and  mature  cathepsin  B, 
respectively  57  and  31  kDa  (Fig.  3.38).  The  same  2  proteins  were  also  detected 
in  the  fraction  thought  to  correspond  to  micronemes,  as  well  as  an  additional 
protein  at  about  100  kDa  of  unknown  origin.  The  same  bands  could  not  be 
detected  in  the  fraction  thought  to  correspond  to  rhoptries  (Fig.  3.38B,  lane  3). 
Two  proteins  at  respectively  45  and  70  kDa  were  detected  though  it  is  unknown 
what  these  proteins  may  be  (Fig.  3.38,  lane  3). 
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FIG.  3.38.  SDS-PAGE  and  western-blot  analysis  of  Eimeria  tenella  sporozoite, 
micronerne  and  rhoptry  preparations.  Lane  1,  total  protein  from  -10  6  sporozoites  equivalent; 
lane  2,  total  microneme  proteins  from  -4  x  106  sporozoites  equivalent;  lane  3,  total  rhoptry 
proteins  from  -4  x  10  6  sporozoites  equivalent.  Molecular  weight  standards  are  indicated  on  the 
left  of  the  figure.  (A)  Coomassie  blue-stained  gel.  (B)  Detection  using  the  anti-cathepsin  B  of  E. 
tenella  antiserum  raised  in  rabbit  (1:  750),  followed  by  HRP-conjugated  anti-rabbit  antibodies 
(1:  5000).  Membrane  exposure  of  30  sec.  The  full  arrow  indicates  the  expected  size  for  the  mature 
cathepsin  B  enzyme  (31  kDa),  and  the  hollow  arrow  indicates  the  size  expected  for  the  pro- 
cathepsin  B  (57  kDa). 
The  immunolocalisation  study  of  the  cathepsin  B  in  the  asexual  stages  of 
E.  tenella  was  done  by  Prof  David  Ferguson  (Oxford).  The  antibody  against  the 
cathepsin  B  was  used  to  stain  sections  of  the  caecum  of  chickens  infected  with  E. 
tenella,  or  on  purified  sporozoites.  In  purified  sporozoites,  the  staining  was 
localised  to  the  anterior  end  of  the  parasite  using  the  anti-cathepsin  B  antibodies, 
and  the  staining  pattern  was  very  similar  to  the  one  obtained  with  the  anti-MIC2 
antibodies  (Fig.  3.39A).  MIC2  is  an  adhesive  E.  tenella  microneme  protein 
(Bromley  et  al.,  2003).  The  apparent  microneme  staining  using  anti-cathepsin  B 
antibodies  is  consistent  with  the  results  obtained  by  western  blot  analysis  on 
sporozoites  organelle  preparations  (Fig.  3.38).  During  schizogony,  a  discrete 
zone  at  the  periphery  of  the  schizont  was  strongly  stained  (Fig.  3.40).  The  nature 
of  the  structure  stained  was  unclear.  Very  little  signal  was  detected  from  the 
merozoites.  However,  it  was  possible  to  identify  a  single  small  spherical  structure 
positively  stained  within  the  merozoite  cytoplasm  (Fig.  3.40).  But  the  signal  was 
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very  faint,  and  it  is  unclear  if  the  signal  detected  was  real  and  what  these 
structures  might  be.  No  specific  apical  staining  could  be  detected  compared  to 
the  anti-MIC2  staining  in  the  mature  schizonts  (Fig.  3.39B),  and  the  cathepsin  B 
might  therefore  be  cytoplasmic  in  fully  formed  merozoites. 
FIG.  3.39.  Immunollocallisation  of  the  cathepsin  B  in  sporozoites  (A)  and  merozoites 
(B)  of  E.  teneila.  Blue  colour  corresponds  to  DAPI  staining  of  DNA.  Red  colour  corresponds  to 
auto-fluorescence  of  the  posterior  refractile  body  in  A,  and  staining  of  a  perinuclear  structure  in  B. 
CatB:  anti-cathepsin  B  antibodies.  MIC2:  anti-MIC2  antibodies.  Sections  of  the  caecum  of 
chickens  infected  for  112  h  were  used  in  B. 
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FIG.  3.40.  Immunolocalisation  of  the  cathepsin  B  in  mature  schizonts  of  E.  tenella. 
Sections  of  the  caecum  of  chickens  infected  for  96  h  were  used.  (A)  and  (B)  are  the  same 
photographs,  the  signal  being  increased  in  photograph  (B).  Long  arrows  indicate  staining  on  the 
periphery  of  the  early  schizont,  short  arrows  indicate  staining  at  the  tip  of  mature  merozoites. 
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3.2.15.  Localisation  of  the  cathopsin  B  In  the  sexual  stages  of  the  life  cycle 
of  E.  tenella 
This  work  was  done  by  Prof  David  Ferguson  (Oxford).  In  the  sexual 
stages,  no  staining  could  be  found  in  the  microgametes  (male),  and  there  was  a 
light  staining  of  the  cytoplasm  of  early  macrogametocytes  (Fig.  3.41).  However, 
in  the  mature  macrogametocyte,  granules  at  the  periphery  of  the  cells  were 
stained,  and  more  specifically,  the  periphery  of  these  granules  was  stained  (Fig 
3.41  and  3.42).  The  size  and  location  of  the  granules  would  be  consistent  with 
being  wall-forming  bodies  (Fig.  3.43),  probably  of  type  1,  due  to  their  location  and 
appearance  in  the  mature  macrogametes  (Vieira  et  al.,  1997;  Mouafo  et  al., 
2002).  In  early  oocysts  within  epithelial  cells  and  in  the  gut's  lumen,  there  was  a 
strong  staining  of  the  cytoplasm,  as  well  as  some  staining  of  cytoplasmic 
structures  probably  related  to  wall  forming  bodies  (Fig.  3.44). 
FIG.  3.41.  Immunolocalleation  of  the  cathopsin  B  In  the  sexual  stages  of  E.  tenella. 
Sections  of  the  caecurn  of  chickens  infected  for  96  h  were  used.  Mi:  microgamete;  eMa:  early 
macrogamete;  Ma:  macrogamete;  WFB:  wall  forming  bodies. 
124 Chapter  3:  Expression  and  characterisation 
of  the  recombinant  cathepsin  B  of  E.  tenella 
FIG.  3.42.  Immunolocallsation  of  the  cathepsin  B  In  the  sexual  stages  of  E.  tensile. 
Sections  of  the  caecum  of  chickens  infected  for  96  h  were  used.  M:  merozoites;  MI:  microgamete; 
Ma:  macrogamete;  WFB:  wall  forming  bodies.  Arrows  indicate  the  staining  at  the  tip  of  the 
merozoites. 
Jim 
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FIG.  3,43.  Phase  microscopy  of  sexual  stages  of  E.  tenella.  Sections  of  the  caecurn  of 
chickens  infected  for  96  h  stained  with  azure  A  were  used.  Mi:  microgamete;  Ma:  macrogamete; 
WFB:  wall  forming  bodies. 
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FIG.  3.44.  Immunolocallsation  of  the  cathepsin  B  In  oocysts  of  E.  tenefla.  Sections 
of  the  caecum  of  chickens  infected  for  136  h  were  used.  Blue  staining  corresponds  to  DAPI 
staining  of  DNA.  Red  staining  corresponds  to  staining  of  a  perinuclear  structure.  Ma: 
macrogamete;  0:  oocyst.  Arrows  indicate  structures  that  may  be  wall  forming  bodies. 
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3.3.  Discussion 
Peptidases  have  been  shown  to  take  part  in  essential  events  of  the  life 
cycle  in  Eimeria,  such  as  the  formation  of  the  oocyst  wall  (Belli  et.  a/,  2003a;  Belli 
et.  al,  2003b)  and  host  cell  invasion  (Fullet  and  McDougald,  1990).  By  database 
mining  using  the  cathepsin  B  sequence  of  T.  gondii  (Que  et  aL,  2002),  a  single 
complete  sequence  coding  for  a  cathepsin  B-like  enzyme  was  identified  in  the 
Eimeria  tenella  EST  database.  The  sequence  was  amplified  on  gDNA  and  cDNA 
and  this  showed  that  no  introns  are  present.  The  gene  was  shown  to  be  single 
copy.  The  predicted  enzyme  contained  the  cysteine,  asparagine,  histidine 
catalytic  triad  and  showed  good  similarity  with  the  cathepsin  B  of  T.  gondii  (42%) 
and  other  cathepsin  Bs  from  different  organisms  (Fig.  3.3). 
Soluble  recombinant  pro-cathepsin  B  could  be  successfully  expressed  in 
various  E.  coli  cell  lines,  but  no  maturation  to  a  mature  size  protein  with 
significant  activity  against  the  substrate  Z-Phe-Arg-AMC,  which  has  been  shown 
to  be  a  substrate  for  cathepsin  B  enzymes  (Caffrey  et  aL,  2002),  could  be 
observed,  despite  the  numerous  conditions  tested  for  unfolding,  refolding  and 
activation.  This  may  suggest  that  the  enzyme  did  not  self-activate,  or  that  the 
enzyme  did  not  properly  fold,  and  conditions  for  proper  folding  and  self-activation 
were  not  obtained. 
Expression  of  the  cathepsin  B-like  enzyme  without  the  full  pro-domain  may 
have  been  favourable  for  folding  and/or  activation.  In  this  case,  however  it  does 
not  seem  to  have  had  a  beneficial  effect.  No  activity  towards  gelatin  or  Z-Phe- 
Arg-AIVIC  could  be  detected  in  any  of  the  conditions  tested.  Incubation  at  370C 
with  10  mM  DTT  seemed  to  yield  some  processing  but  the  western  blot  analysis 
suggested  that  it  did  not  happen  at  the  N-terminal  end,  which  would  be  where  a 
cleavage  would  be  expected  in  case  of  removal  of  the  pro-region  and  activation. 
This  may  suggest  again  that  the  protein  does  not  self-activate.  The  fact  that  the 
protein  fell  out  of  solution  in  the  assays  at  pH  below  6  tends  to  indicate  a  sub- 
optimal  folding.  As  cathepsins  usually  fold  around  the  pro-domain  (Wiederanders, 
2000;  Cappetta  et  aL,  2002),  this  would  not  be  unexpected.  There  has  been  proof 
though,  that  some  cathepsins  can  fold  and  be  active  when  expressed  without 
their  pro-domain  (Sijwali  et  aL,  2001,  Pandey  et  aL,  2004),  hence  the  reason  for 
testing  this  possibility. 
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It  has  recently  been  shown  that  the  cathepsin  B  of  Schistosoma  mansoni 
that  the  activation  process  is  not  autocatalytic,  rather  it  can  be  processed  and 
activated  using  the  endogenous  asparaginyl  endopeptidase  (Sajid  et  a/.,  2003). 
This  is  consistent  with  the  conclusions  we  drew  from  our  attempts  to  activate  the 
E.  tenella  cathepsin  B-like  enzymes  expressed  in  Ecoli.  Whether  or  not  there  is 
an  asparaginyl  endopeptidase  in  E.  tenella  that  activates  the  cathepsin  B-like 
enzyme  is  not  known  as  yet  (although  no  asparaginyl  endopeptidase  gene  in  the 
genome  database  of  Eimetia  could  be  identified).  A  variety  of  commercially 
available  peptidases  were  tested  for  their  ability  to  activate  the  soluble  cathepsin 
B  from  E.  tenella  produced  in  E.  coli.  Although  processing  could  be  detected, 
there  was  no  indication  that  any  of  the  cleaved  fragments  corresponded  to  the 
mature  cathepsin  B,  and  no  activity  could  be  detected  in  any  of  the  methods 
tested.  Non-specific  peptidases  would  in  theory  preferentially  cut  in  the  most 
accessible  domains  of  a  protein,  that  is  to  say,  in  accessible  hinges  and  loops.  By 
looking  at  the  three  dimensional  structure  of  the  human  cathepsin  B,  one  could 
expect  that  the  Smeria  peptidase,  provided  it  folds  into  a  comparable  structure, 
would  not  be  cut  in  multiple  places,  as  it  looks  like  a  rather  compact  globular 
protein.  Nevertheless  this  method  did  not  generate  any  active  protein. 
As  no  active  peptidase  could  be  generated  by  non-specific  cleavage  of 
the  pro-mature  protein,  the  idea  came  to  introduce  a  cleavage  site  for  specific 
peptidases  commercially  available,  by  mutagenesis  at  the  predicted  junction 
between  mature  and  pro-domains.  Specific  cleavage  using  Factor  Xa  and  TEV 
protease  generated  a  protein  the  size  of  the  mature  cathepsin  B.  The  mature 
fragment  produced  did  not  show  activity  in  the  conditions  tested,  even  when 
assayed  at  a  pH  that  would  promote  the  dissociation  of  the  pro-domain  that  might 
stay  bound  and  act  as  an  inhibitor  (Carmona  et  aL,  1996).  The  fact  that  still  no 
active  enzyme  could  be  produced  might  be  due  to  the  fact  that  some  proteins 
expressed  in  E.  coli  do  not  get  fully  their  native  conformation  even  if  expressed  in 
a  soluble  manner  (Jean  et  aL,  2000).  It  also  might  be  due  to  the  fact  that  the 
expression  in  E.  coli  lacks  the  typical  eukaryotic  phenomenon  of  glycosylation 
and  the  peptidase  might  need  them  to  be  active,  as  it  is  the  case  for  the  human 
glutamate  carboxypeptidase  11  (Barinka  et  a/.,  2004).  This  is  why  three  Pichia 
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systems  were  tested,  in  order  to  get  soluble,  released  and  active  Eimeria 
cathepsin  B. 
Pro-mature  cathepsin  B  could  successfully  be  produced  in  the  constitutive 
Pichia  expression  system,  and  the  protein  seemed  to  be  successfully  released 
into  the  culture  medium.  Furthermore,  the  suppression  of  the  C-terminal  His-tag 
seemed  to  favour  processing  of  the  pro-mature  protein.  No  signs  of  processing 
could  be  detected  in  the  supernatant  of  culture  of  the  cells  transfected  with  the 
plasmid  encoding  for  the  pro-mature  cathepsin  B  C-terminal  His-tagged,  though 
some  apparent  processing  was  observed  in  the  cell  extracts.  It  is  unknown  why 
no  complete  processing  and  no  significant  activity  against  Z-Phe-Arg-AMC 
compared  to  the  control  cells  could  be  detected  in  these  cases. 
Active  mature  recombinant  cathepsin  B  of  Eimeria  tenella  was 
successfully  produced  in  the  Pichia  pastoris  inducible  system  (Fig.  3.30).  The 
enzyme  was  released  in  the  supernatant  of  culture  at  a  concentration  of  about 
100  gg/ml,  and  was  readily  purified  by  sequential  ammonium  sulfate  precipitation 
(Fig.  3.31).  The  characteristics  of  the  enzyme  conform  to  what  is  expected  for  a 
cathepsin  B;  it  is  strictly  dependant  on  reducing  agents  (Fig.  3.33),  it  cleaves 
Phe-Arg  and  Arg-Arg  substrates  with  a  preference  for  Phe-Arg  (Fig.  3.36),  it  is 
inhibited  strongly  by  general  cysteine  peptidase  inhibitors  like  E64  and 
iodoacetamide,  as  well  as  by  the  specific  inhibitor  K11777  (Table  3.1). 
Interestingly,  it  is  active  over  a  wide  spectrum  of  pHs  (Fig.  3.35),  whereas  most 
cathepsin  Bs  are  mostly  active  at  acidic  pH.  This  might  reflect  a  broad  distribution 
of  the  enzyme  in  various  locations  in  the  cell. 
The  reason  why  the  soluble  enzyme  produced  in  E.  coli  was  not  active 
remains  unclear.  Glycosylations,  which  do  not  occur  in  bacterial  expression 
systems,  did  not  seem  to  play  an  important  role  in  the  enzyme  activity.  It  is  still 
unknown  if  the  cathepsin  B  of  Eimeria  tenefia  is  capable  of  cis-maturation  by 
autocatalytically  removing  its  pro-domain,  as  it  seems  to  be  the  case  for  the 
cathepsin  B  of  T  gondii  (Que  et  aL,  2002)  and  has  been  reported  for  other 
cysteine  peptidases  of  the  same  family  (Turk  et  aL,  2001),  or  if  it  requires  an 
heterologous  enzyme  for  processing,  which  may  be  provided  in  this  case  by  the 
expressing  host.  If,  indeed,  a  host  enzyme  is  required  for  maturation,  this  may 
explain  why  different  sorts  of  maturation  patterns  were  observed  in  different 
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Pichia  host  cell  lines.  Recombinant  expression  in  the  Pichia  inducible  system  of  a 
version  of  the  cathepsin  B  carrying  mutations  at  the  active  site  residues  would 
allow  determining  if  there  is indeed  cis-  or  trans-activation. 
Immuno-blotting  using  anti-cathepsin  B  of  Eirneria  tenella  polyclonal 
antibodies  allowed  detection  of  the  enzyme  in  sporozoite  and  oocyst  extracts 
(Fig.  3.37).  The  enzyme  seems  therefore  to  be  expressed  at  these  stages  of  the 
life  cycle.  The  pro-  and  mature  enzyme  could  also  be  detected  in  the  fraction 
thought  to  correspond  to  microneme  proteins,  but  not  rhoptry  proteins  (Fig.  3.38). 
The  absence  of  specific  anti-microneme  protein  or  anti-rhoptry  protein  antibodies 
of  E.  tenella  does  not  allow  to  give  a  definite  proof  of  the  specificity  of  the  anti- 
cathepsin  B  antibody  binding,  and  other  contaminating  proteins  could  be 
detected  in  these  fractions.  Also,  the  organelle  fractions  are  not  completely  pure, 
although  preparations  appear  clean  by  observation  by  electron  microscopy 
(Bromley  et  al.,  2003). 
Immunolocalisation  studies  of  the  cathepsin  B,  on  various  E.  tenella  stages 
of  the  life  cycle,  were  done  by  Prof  David  Ferguson  (Oxford).  The  enzyme 
showed  an  anterior  end  localisation  in  sporozoites,  similar  to  the  pattern  found  for 
MIC2,  a  microneme  protein  of  E.  tenella.  In  merozoites,  the  enzyme  seemed  to 
localise  to  a  single  dot  at  one  tip,  but  the  signal  was  very  faint  and  might  be  not 
real.  The  signal  was  diffuse  in  the  cytoplasm  and  no  apical  localisation  could  be 
detected  like  with  the  anti-MIC2  antibodies.  So  the  cathepsin  B  may  localise  to 
micronernes  in  sporozoites,  but  may  not  in  merozoites.  This  might  reflect  a  stage 
specific  expression  of  the  cathepsin  B.  But  a  cytoplasmic  localisation  in 
sporozoites  might  still  be  possible,  as  it  cannot  be  excluded  that  microneme 
preparations  might  be  contaminated  by  cytoplasmic  material.  Nevertheless,  there 
was  reasonable  evidence  that  the  cathepsin  B  of  E.  tenella  did  not  localise  to 
rhoptries.  This  is  in  contrast  to  the  results  obtained  for  toxopain  of  T.  gondd  (Que 
et  aL,  2000),  which  was  reported  to,  localise  to  rhoptries,  but  could  reflect  a 
different  role  for  the  enzyme.  Cysteine  peptidases  from  E.  tenella  appear  to  have 
a  role  in  host  cell  invasion,  as  invasion  can  be  inhibited  by  cysteine  peptidase 
inhibitors  (Samantha  Brown,  PhD  thesis);  the  sequencing  of  the  genome  of  E. 
tenella  will  provide  a  good  tool  for  investigation  of  the  parasite's  cysteine 
peptidase  repertoire,  though  the  presence  of  introns  in  most  genes  and  lack  of 
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definite  intron  prediction  system  makes  protein  prediction  still  problematic.  In 
sporozoites,  the  cathepsin  B  seemed  to  be  found  in  microneme  preparations.  In 
the  sexual  stages  of  the  parasite,  the  enzyme  is  located  in  mature  macrogametes 
and  early  oocysts  to  granules,  the  size  and  location  of  which  would  be  consistent 
with  being  wall-forming  bodies.  With  formation  of  the  oocyst  wall,  the  localisation 
in  the  oocysts  spread  to  the  entire  cytoplasm.  Peptidases  had  previously  been 
reported  to  be  involved  in  the  oocyst  wall  formation  in  Eimeria  (Belli  et  a/., 
2003a),  by  maturation  of  precursor  proteins  found  in  the  wall  forming  bodies,  but 
this  is  the  first  a  time  a  cysteine  peptidase  has  actually  been  shown  to  localise  to 
such  formations.  Similar  roles  for  cysteine  peptidases  have  been  suggested  in 
Giardia.  Three  cathepsin  B-like  cysteine  proteases,  CP1,  CP2  and  CP3,  were 
purified  from  G.  lamblia  (Ward  et  a/.,  1997).  CP2  might  be  involved  in  excystation 
of  trophozoites  as  excystation  is  inhibited  in  the  presence  of  C132  specific  inhibitor 
(Ward  et  al.,  1997),  though  this  has  not  been  definitely  established.  Another 
stage  regulated  cathepsin  B-like  cysteine  protease  known  as  ESCP  has  been 
reported  to  process  a  cyst  wall  protein  and  may  therefore  be  involved  in  the 
parasite's  encystation  (Touz  et  aL,  2002).  The  oocyst  wall  formation  being  an 
essential  process  for  parasite's  survival  in  the  external  environment  and 
propagation  of  the  disease,  these  may  be  exciting  findings.  The  enzyme  is  now 
available  for  drug  screening,  and  provided  specific  inhibitors  can  be  obtained,  the 
cathepsin  B  of  E.  tenella  might  present  a  good  new  drug  target. 
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4.1.  Introduction 
Pyroglutamyl  peptidase  (also  referred  to  as  pyrrolidonecarboxylate 
peptidase,  pyroglutamate  aminopeptidase,  pyrrolidonecarboxylyl  peptidase,  5- 
oxoprolyl  peptidase,  pyroglutamyl  aminopeptidase  and  pyroglutamyl  peptide 
hydrolyse)  belongs  to  the  class  of  omega  peptidases  (EC  3.4.19.  -)  and 
hydrolyses  N-terminal  L-pyroglutamate  residues  (L-pGlu)  from  peptides  and 
proteins  containing  this  modification  (Browne  and  O'Cuinn,  1983;  Cummins  and 
O'Connor,  1996).  Pyroglutamyl  peptidase  activity  was  first  detected  in 
Pseudomonas  fluorescens  (Doolittle  and  Armentrout,  1968)  and  has  been  since 
described  in  tissues  from  mammals  (Dando  et  aL,  2003;  Cummins  and  O'Connor, 
1996),  bacteria  (Ito  et  aL,  2001;  Ogasahara  et  a/.,  2001),  birds  (Tsuru  et  a/., 
1982),  fish,  reptiles  (Prasad  et  aL,  1982)  and  plants  (Kembhavi  et  aL,  1993). 
They  are  divided  into  two  classes,  the  cysteine  peptidase  pyroglutamyl  peptidase 
I  (EC  3.4.19.3.,  MEROPS  C15  [180]),  and  the  metallopeptidase  pyroglutamyl 
peptidase  11  (EC  3.4.19.6.,  MEROPS  M1  [181]).  Pyroglutamyl  peptidase  I  is  a 
soluble,  intracellular  enzyme  (Cummins  and  O'Connor,  1998),  whereas 
pyroglutamyl  peptidase  11  is  membrane-bound  (O'Connor  and  O'Cuinn,  1984). 
4.1.1.  Pyroglutarnyl  metabolism  in  human 
4.1.1.1.  Pyroglutamyl  peptidase  I 
Pyroglutamyl  peptidase  I  (PPI)  occurs  as  a  monomeric  enzyme  of 
relatively  low  molecular  mass  (-  25  kDa)  and  with  a  pH  optimum  from  6.5  to  8.5, 
that  is  located  in  the  cytosol  in  mammals  (Mantle  et  aL,  1991;  Cummins  and 
O'Connor,  1996;  Dando  et  aL,  2003).  PPI  activity  exhibits  a  strict  requirement  for 
reducing  environment  (Dando  et  aL,  2003).  It  has  broad  substrate  specificity  in 
that  it  can  hydrolyse  a  variety  of  natural  or  synthetic  peptides  containing  L-pGlu 
at  the  N-terminal  position  (Cummins  and  O'Connor,  1996;  Dando  et  a/.,  2003). 
The  rate  of  hydrolysis  of  the  various  peptides  depends  on  the  amino  acid  residue 
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following  the  pGlu  in  the  sequence  and  it  has  been  shown  that  mammalian  PPI 
does  not  cleave  pGlu-Pro  bonds  (Browne  and  O'Cuinn,  1983).  Although  PPI  has 
been  shown  to  have  broad  substrate  specificity,  it  also  has  a  strong  specificity  for 
pGlu  residues  and  will  not  cleave  modified  pGlu  residues  (Capecchl  and  Loudon, 
1985).  A  schematic  representation  of  the  catalytic  reaction  is  shown  on  Fig.  4.1. 
0/H 
N0 
11-: 
--NH-CH-CO- 
H20  0/H 
N0 
11-OH 
pGlu 
H2N-CH-CO---- 
I 
K 
FIG.  4.1.  Schematic  representation  of  the  reaction  catalysed  by  PPI.  The  dotted 
arrow  represents  the  cleavage  site  by  PPI.  The  dashes  at  the  C-terminus  represent  the 
continuation  of  the  amino  acid  chain.  The  reaction  releases  free  pyroglutarnate  (pGlu)  and  the 
amino  acid  chain.  R:  variable  side  group  of  the  amino  acid. 
The  catalytic  triad  of  the  PPI  was  found  to  be  composed  of  Glu-81,  Cys- 
144  and  His-I  68  (Bacillus  amylotumetaciens  numbering,  Yoshimoto  et  al.,  1993). 
These  residues  are  conserved  in  the  human  and  the  mouse  enzymes  (Dando  et 
aL,  2003). 
Due  to  the  nature  of  the  active  site  and  the  requirement  of  the  catalytic 
cysteine,  sulfhydryl-blocking  agents  (iodoacetate,  iodocetamide)  are  potent 
inhibitors  (Dando  et  aL,  2003).  Metallic  ions  such  as 
CU2+,  Zn 
2+ 
and 
Ni2+  were 
also  shown  to  be  strong  inhibitors,  reversible  by  addition  of  a  chelating  agent  in 
excess  or  by  dialysis  (Dando  et  aL,  2003).  PPI  was  not  inhibited  by  serine 
peptidase  inhibitors,  such  as  phenyimethylsulphonyl  fluoride  (PMSF)  or  cysteine 
peptidase  (family  Cl)  inhibitors,  such  as  (2S,  3S)-3-(N-{(S)-l  -[N-(4- 
guanidinobutyl)carbamoyl]3-methylbutyl}carbamoyl)oxirane-2-carboxylic  acid 
(E64).  Among  active  site  specific  inhibitors,  chloromethyl  ketone  derivatives  of 
pGlu  are  irreversible,  potent  inhibitors  (Fujiwara  et  aL,  1982).  Other  specific 
inhibitors  include  aldehyde  analogues  of  pGlu,  natural  compounds  isolated  from 
Streptomyces,  and  the  pyroglutamyl  analogue  2-pyrrolidone,  also  used  to 
stabilise  PPI  activity  during  storage  (Cummins  and  O'Connor,  1998). 
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The  biological  activity  of  some  peptides  is  regulated  via  modifications  such 
as  cyclisation  of  N4erminal  glutamine  to  L-pGlu,  acetylation  of  the  Werminal 
residue  or  amidation  of  the  carboxy  terminal  residue.  The  pyroglutamyl  group 
confers  a  relative  stability  towards  aminopeptidase  degradation  to  these 
peptides.  In  fact,  12.3%  of  proteins  with  signal  peptides  are  initiated  with  Gln 
once  the  signal  peptide  is  removed  (Liao  et  al.,  2003).  Also,  removal  of  the  N- 
terminal  translation  initiator  methionine  is  often  crucial  for  the  function  and 
stability  of  proteins  (Hirel  et  al.,  1989;  Liao  et  al.,  2003),  and  pGlu-modified 
peptides  can  then  occur  if  the  second  amino  acid  is  a  Gln,  though  this  is  not 
systematic  (Predel  et  al.,  1999).  Many  of  the  naturally  occurring  peptides 
containing  the  pGlu  modification  are  substrates  for  PPI  (see  Table  4.1).  Among 
them  are  neuropeptides.  Neuropeptides  are  up  to  40  amino  acid-long  peptides 
released  to  allow  inter-cellular  communication,  and  regulate  processes  such  as 
differentiation,  growth  and  metabolism  in  mammals  (Cummins  and  O'Connor, 
1998).  In  addition  to  giving  resistance  to  aminopeptidase  cleavage,  the  pGlu 
modification  has  also  been  shown  to  be  essential  to  the  bioactivity  of  some 
peptides.  For  instance,  the  chernotactic  protein-2  activity  in  human  is  dependent 
on  its  pGlu  modification,  as  receptor  recognition  involves  the  N-terminal  part  of 
the  molecule  (Van  Coillie  et  a/.,  1998).  In  human,  free  pGlu  has  been  shown  to 
improve  learning  and  to  help  prevent  age-associated  memory  loss  (Grioli  et  al., 
1990). 
As  the  L-pGlu  N-terminal  modification  can  be  determinant  in  biological 
activity  of  peptides  (Perlman  et  a/.,  1994),  PPI  has  been  attributed  a  role  of 
neuropeptide  regulation  and  metabolism  in  mammalian  systems,  though  the  lack 
of  its  release  from  the  cells  still  causes  doubts  regarding  its  function  (Salers  et 
a/.,  1991).  PPI  may  participate  in  the  protein  metabolism  (Lauffart  and  Mantle, 
1988)  and  increased  levels  of  PPI  have  been  observed  in  the  spinal  cord  of 
patients  with  motor  neurone  disease  (Mantle  et  al.,  1995).  However,  only  very 
few  mammalian  PPIs  have  been  fully  characterised  so  far  and  a  definite 
physiological  role  still  has  to  be  attributed. 
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Table  4.1.  Some  natural  bloactive  compounds  cleaved  by  mammalian  PPI.  TRH, 
thyrotropin-releasing  hormone;  LHRH,  luteinizing  hormone-releasing  hormone;  ACE,  angiotensin 
converting  enzyme.  [1],  Fujiwara  et  al.,  1979;  [2],  Cummin  and  O'Connor,  1996;  [3],  Dando  et  al., 
2003. 
Protein/peptide  N-terminal  cleavage  site  Organism  Reference 
TRH  pGlu-His  Human  [1,2] 
LHRH  pGlu-His  Human  [1,2,3] 
Bombesin  pGlu-Gln  Frog  [2,3] 
Bradykinin  pGlu-Gly  Human  [1,3] 
potentiator  B 
ACE  inhibitor  pGlu-Trp  Human  [3] 
Leukopyrokinin  pGlu-Thr  Human  [3] 
Neurotensin  pGlu-Leu  Human  [1,2,3] 
Litorin  pG[u-Gln  Frog  [11 
4.1.1.2.  Pyroglutamyl  peptidase  11 
A  distinct  PP  activity  membrane-bound  and  inhibited  by  reducing  and 
chelating  agents  was  demonstrated  in  several  mammals  (Friedman  et  al.,  1986; 
Gallagher  et  al.,  1997).  Compared  to  PPI,  PPII  has  a  relatively  high  molecular 
mass  (-  230  kDa)  and  is  not  inhibited  by  PPI  inhibitors  (Friedman  et  aL,  1985). 
PPII  purified  from  rat  and  porcine  brain  showed  a  dimeric  architecture 
characteristic  of  membrane-bound  peptidases  (Bauer,  1994).  The  activity  of  this 
metal  lo  peptida  se  is  mainly  located  in  the  central  nervous  system  (CNS)  in 
mammals,  where  it  is found  mainly  associated with  neurons  (Bauer  et  al.,  1990; 
Cruz  et  aI.,  1991b).  A  characteristic  of  PPII  is  that  it  is  highly  specific  for 
thyrotropin-releasing  hormone  (TRH)  and  TRH-like  peptides  (Elmore  et  aL, 
1990),  which  stimulate  the  release  of  thyroid-stimulating  hormones.  The 
increased  release  of  thyroid  hormones  increases  the  metabolic  rate,  glucose 
absorption,  blood  pressure  and  heart  rate,  decreases  the  cholesterol  level  in 
plasma,  stimulates  growth  hormone  production,  and  regulates  the  CNS 
development  (Cummins  and  O'Connor,  1998).  PPII  is  therefore  thought  to  be  an 
important  regulatory  element  that  influences  the  activity  of  TRH  at  target  sites 
(Schomburg  and  Bauer,  1995).  PPII  expression  and  activity  is  indeed  regulated 
by  TRH  (Joseph-Bravo  et  aI.,  1998).  The  only  site-specific  inhibitor  of  PPIl  known 
to  date  is  CPHNA  (N-[l(RS)-carboxy-2-phenylethyl]-N-imidazole  benzyl-histidyl 
p-naphthylamide)  (Chadi  et  al.,  1989). 
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A  third  PP  activity  was  isolated  from  serum  and  its  narrow  specificity  for 
TRH-like  peptides  lead  to  the  name  "serum  thyroliberinase"  (Bauer  and  Nowak, 
1979).  However,  given  its  high  resemblance  to  the  PPII  activity,  it  is  possible,  but 
not  yet  known,  that  it  is  a  product  of  the  same  gene.  There  has  been  recent 
evidence  that  the  thyroliberinase  activity  results  from  the  cleavage  of  the  PPII 
liver  enzyme  (Schmitmeier  et  aL,  2002). 
4.1.1.3.  Glutaminyl  cyclase 
Glutaminyl  cyclase  (QC),  or  glutaminyl-peptide  cyclotransferase  (EC 
2.3.2.5.,  MEROPS  clan  MH,  family  M28),  is  the  enzyme  involved  in  cyclisation  of 
N-terminal  glutamine,  which  is  unmasked  by  proteolytic  processing  of  precursor 
proteins  by,  for  example,  prohormone  convertases  (Seidah  et  al.,  1998).  Peptides 
modified  by  a  QC  are  constitutively  secreted  in  humans,  and  tissue-specific  forms 
of  the  enzyme  may  exist  (Sykes  et  al.,  1999).  The  enzyme  localises  to  the 
secretory  pathway  (Pohl  et  al.,  1991).  The  cyclisation  of  glutamine  can  occur 
spontaneously,  especially  under  the  catalytic  influence  of  phosphate  ions 
(Chikuma  et  al.,  2004),  but  previous  studies  have  demonstrated  that  the 
formation  of  pGlu  residues  in  cells  must  be  enzymatically  catalysed  because  the 
non-enzymatic  conversion  is  slow  under  physiological  conditions  (Consalvo  et  al., 
1988).  QCs  have  also  been  identified  in  various  mammals  (Busby  et  aL,  1987) 
and  plants  (Oberg  et  aL,  1998).  It  was  previously  proposed  the  mammalian  QC 
has  some  features  in  common  with  zinc  aminopeptidases,  and  human  pituitary 
glutaminyl  cyclase  and  bacterial  zinc  aminopeptidase  share  a  common  fold  and 
active  site  residues.  In  contrast  to  the  aminopeptidase,  however,  QC  does  not 
appear  to  require  zinc  for  enzymatic  activity  (Booth  et  aL,  2004).  The  human  QC 
possesses  6  key  active  site  residues:  histidines  140  and  330,  glutamates  201 
and  202,  and  aspartates  159  and  248  (Bateman  et  al.,  2001),  although  the  2 
aspartates  have  no  catalytic  role.  Little  is  known  about  the  biological  role  of  QC  at 
present.  Researchers  have  suggested  that  QC  is  responsible  for  modification  of 
storage  proteins  during  seed  germination  in  plants  (Gololobov  et  al.,  1996),  as 
well  as  in  vivo  modification  of  bioactive  peptides  in  mammals  (Hinke  et  al.,  2000). 
These  findings  support  the  view  that  pGlu  modification  might  be  important  for 
protection  of  the  N-terminus  of  bioactive  peptides  against  exopeptidases. 
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Moreover,  this  enzymatically  catalysed  N-terminal  formation  of  the  pyroglutamic 
acid  residue  could  be  important  in  developing  the  proper  receptor-binding 
conformation  of  such  peptides  (Ziegler  et  aL,  1998). 
4.1.2.  Pyroglutamyl  peptidase  activity  in  bacteria 
Most  bacterial  PPs  examined  so  far  are  soluble,  have  broad  substrate 
specificity,  require  a  reducing  environment  and  occur  as  multimers  (Fujiwara  et 
al.,  1979;  Awade  et  aL,  1992a;  Awade  et  aL,  1992b).  In  terms  of  substrate 
specificity,  catalytic  residues  and  inhibitors,  they  resemble  the  mammalian  PPI 
enzymes.  Structures  for  the  PPs  of  Thennococcus  litoralis  and  Bacillus 
amylotumefaciens  are  known  (Protein  Data  Bank  [PDB]  identification  numbers 
1A2Z  and  1AUG,  respectively).  The  known  PPs  bacterial  genes  are  single  copy, 
and  are  characterised  by  inverted  repeats  of  the  gene  found  upstream  and 
downstream  of  the  ORFs,  suggesting  transcriptional  control  (Cummins  and 
O'Connor,  1998).  The  expression  of  the  PP  gene  of  Pseudomonas  fluorescens  is 
regulated  by  the  intracellular  levels  of  pyroglutamic  acid  and  iron  (Le  Saux  and 
Robert-Baudouy,  1997).  Like  for  the  mammalian  PPIs,  a  definite  function  still  has 
to  be  attributed.  It  has  been  suggested  they  may  play  a  role  in  intracellular 
protein  metabolism  (Lazdunski,  1989),  though  the  presence  of  PP  activity  is  not 
ubiquitous  among  the  bacterial  kingdom. 
The  only  indication  of  the  presence  of  a  QC  in  bacteria  was  presented  by 
Cook  and  Russell  in  1991.  They  suggested  the  glutamine  cyclase  reaction  of 
Streptococcus  bovis  was  a  mechanism  of  deriving  energy  from  non-oxidative  and 
non-reductive  deamination. 
4.1.3.  Bioactive  peptides  containing  pGlu 
Aside  from  neuropeptides,  various  bioactive  peptides  possess  a  N- 
terminal  L-pGlu  modification  and  can  be  synthesised  by  various  organisms.  As 
examples,  a  variety  of  anti-microbial  peptides  have  been  isolated  from  mammals 
(Tang  et  al.,  2002;  Boman,  2003),  insects  (Rabel  et  al.,  2004),  shrimp 
(Destournieux  et  al.,  1997),  spider  (Silva  et  al.,  2000),  and  scorpions  (Cociancich 
et  al.,  1993).  The  widespread  occurrence  of  these  compounds  suggests  they 
may  play  a  role  in  innate  immunity  against  microorganisms  and  other  pathogens 
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(Selsted  and  Ouellette,  1995;  Ganz  and  Lehrer,  1999).  Gomesin,  an  18  amino 
acid  N-terminal  pGlu-modified  peptide  isolated  from  a  spider  (Silva  et  a/.,  2000) 
showed  strong  bacterial  growth  inhibition,  affected  development  of  filamentous 
fungi  and  yeast,  as  well  as  the  viability  of  the  parasite  Leishmania  amazonensis. 
The  mechanism  of  inhibition  of  growth  is  unknown.  However,  this  observation 
might  support  a  need  for  bacteria  and  other  pathogens,  such  as  parasites,  to 
possess  a  PIP  activity,  for  degradation  of  such  bioactive  compounds.  There  is 
some  evidence  that  the  innate  immune  response  of  humans  involves  various  lytic 
factors,  including  antibacterial  peptides.  These  peptides  are  classified  in  different 
families,  depending  on  their  structure.  Humans  possess  2  classes  of  defensins, 
a-  and  P-defensins,  which  are  cationic  15-45  amino  acid  long  peptides  with  a 
pattern  of  disulfide  bridges  essential  to  the  activity  (Torres  and  Kuchel,  2004). 
Defensins  are  produced  in  the  phagolysosomes  of  neutrophils  and  macrophages 
as  well  as  in  epithelial  cells  (Selsted  and  Ouellette,  1995)  and  play  a  role  in 
innate  immunity  acting  as  anti-microbial  agents  and  chemokines  (Hoover  et  al, 
2001;  Schibli  et  aL,  2002).  Some  of  the  P-defensins  have  a  pGlu  modification  at 
the  N-terminus  (Selsted  et  aL,  1993).  Another  family  of  anti-microbial  peptides  in 
humans,  the  cathelicidins,  are  produced  in  epithelial  cells  as  pre-pro-proteins. 
The  pro-protein  possesses  a  N-terminal  pGlu  (Andersson  et  aL,  2002),  and  upon 
maturation,  the  mature  C-terminal  domain  acts  as  a  potent  anti-microbial  agent 
(Isogai  et  aL,  2003).  In  insects,  various  homologues  of  the  defensins  exist, 
namely  the  cecropins  (Cornet  et  aL,  1995).  The  only  reported  proofs  of  action  of 
human  anti-microbial  peptides  on  parasitic  protozoa  are  that  resistance  in 
humans  against  Trypanosoma  bruce!  brucei  can  occur  as  the  parasite  is  killed  by 
lytic  factors  (anti-microbial  peptides)  found  in  the  serum  (Lugli  et  a/.,  2004),  and 
that  the  enteric  parasite  Giardia  lamblia  can  be  killed  by  cationic  neutrophil 
peptides  produced  by  the  intestine  epithelium  (Aley  et  aL,  1994).  In  Drosophila, 
an  anti-microbial  peptide  with  a  N-terminal  pGlu  has  been  identified  (Rabel  et  a/., 
2004).  So  there  is  some  evidence  that  pGlu-modified  peptides  with  anti-microbial 
activity  exist  in  human  and  insects,  the  two  hosts  of  Leishmania. 
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4.1.4.  Pyroglutamyl  peptidase  in  parasites 
The  sequence  for  a  PP  with  resemblance  to  mammalian  PPI  was 
identified  in  the  genomes  of  L.  major,  L.  intantum,  T.  brucei  and  T.  cruzi. 
Interestingly,  no  sequence  with  identity  to  the  human  PPI  could  be  identified  in 
the  genomes  of  P.  falciparum,  P.  yoeffl,  T.  gondii,  E.  tenella,  E.  histolytica,  S. 
mansoni,  or  T.  vaginalis.  It  is  still  unclear  if  the  presence  of  a  PPI  may  be  specific 
to  kinetoplastids,  as  the  sequencing  and  annotation  of  most  of  the  genomes  cited 
are  uncompleted.  The  sequence  for  a  possible  glutaminyl  cyclase,  the  enzyme 
responsible  for  the  cyclisation  of  Gin  residues  to  pGlu,  and  sequences 
homologous  to  the  mammalian  PPII  enzyme  were  also  identified  in  the  genomes 
of  L.  major,  L.  intantum,  T.  brucei  and  T.  cruzi.  No  studies  have  previously  been 
reported  on  PP  activity  in  parasites  and  it  is  unknown  what  role  it  may  play.  But 
one  hypothesis  we  considered  is  that  it  might  be  involved  in  bioactive  peptide 
inactivation  in  the  mammalian  host  or  in  the  insect  vector.  As  these  parasite  PPs 
seem  to  resemble  mammalian  PPIs,  it  may  be  predicted  that  they  may  have  a 
broad  substrate  specificity  and  be  able  to  cleave  various  regulatory  and  anti- 
microbial  factors. 
This  study  focused  on  the  PPI  of  L.  major.  The  aim  was  to  express 
recombinant  active  PPI  for  biochemical  characterisation  in  order  to  get  an  insight 
on  which  of  the  eukaryotic  or  prokaryotic  enzymes  it  is  the  most  closely  related 
to,  in  terms  of  oligomerisation,  substrate  specificity,  kinetic  features  and 
inhibitors.  A  second  aim  was  to  try  to  obtain  recombinant  glutaminyl  cyclase,  for 
characterisation  and  antibody  production,  in  order  to  investigate  the  occurrence 
and  possible  role  of  the  enzyme  in  the  parasite. 
4.2.  Results 
4.2.1.  Cloning  of  the  pyroglutamyl  peptidase  I  gene  of  L.  major 
Database  searches  on  the  genomic  database  of  L.  major  using  the 
human  PPI  as  a  query  (accession  number  NP  060182, 
www.  ncbi.  nim.  nih.  org/entrez/)  detected  a  834  bp  open  reading  frame  (Fig.  4.1) 
translating  into  a  277  amino  acid  protein  (LmjF34.2000,  www.  genedb.  org)  with 
the  PPI  features,  although  it  was  annotated  as  a  hypothetical  protein  of  unknown 
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function.  No  other  sequence  with  PPI  features  could  be  detected  in  the  L.  major 
database  (now  totally  sequenced),  which  indicates  the  PPI  is  a  single  copy  gene 
in  L.  major.  The  amino  acid  sequence  was  analysed  with  the  SignalP  algorithm 
(Nielsen  et  al.,  1997),  and  TMpred  (Hofmann  and  Stoffel,  1992),  and  no  signal 
peptide  or  trans-membrane  domain  were  predicted. 
5'  RACE  on  total  cDNA  was  performed  using  a  5'  primer  with  a  sequence 
complementary  to  the  splice  leader  (SL  primer)  and  a  3'  primer  with  a  sequence 
complementary  to  a  sequence  downstream  of  the  predicted  start  ATG.  The  PCR 
product  obtained  was  used  as  a  template  for  a  semi-nested  PCR  using  the  SL 
and  the  PPrace2  primers  (see  Table  2.1).  The  results  of  the  5'  RACE  showed  the 
presence  of  a  mRNA  comprising  a  49  bp  5'  untranslated  region  (UTR),  and 
confirming  the  start  methionine  attributed  in  LmjF34.2000  (Fig.  4.2). 
1  GTCCTCAGCA  CTGAAAGGGA  ATCATCCTCC  ACCTTCCCTC  CCCAACCA(('  A('r(,  ('A('A('(, 
CAGGAGTCGT  GACTTTCCCT  TAITAGGA3G  TO(ýAACCGA(l, 
71  GATCAATGTC  TCACTATTGC  AA--CGGCCTT  CTACGAGCAC  ACAGGGCTCC  TCGCAGTTCC  GCJkCCGCTTA 
CTAGTTACAG  AGTGATAACG  TTCGCCGGAA  GATGCTCGTG  TGTCCCGAGG  AGCGTCAAGG  CGTGGCGAAT 
MLHSXAGIVVFITGYGPFATVKV 
141  AAATGCTGCA  CTCCAAGGCG  GGCATCGTCG  TGTTCATCAC  GGGCTACGGG  CCCT'I'CGC('A  C'PGI'GAA(;  (!  'I' 
TTTACGACGT  GAGGTTCCGC  CCGTAGCAGC  ACAAGTAGTG  CCCGATGCCC  GGGAAGCGGT  GACAC711CCA 
-NPSSDIALRVAEGLKRHPDVAEV 
211  GAACCCCAGC  TCCGACATTG  CCCTTCGTGT  CGCGGAGGGC  CTGAAGCGCC  ACCCCGACGT  CGCGGAGGTG 
CTTGGGGTCG  AGGCTGTAAC  GGGAAGCACA  GCGCCTCCCG  GA=CGCGG  TGGGGCTGCA  GCGCCTCCAC 
RYTELDVSVTSVAAYFEKVERDTA 
281  CGCTACACGG  AGCTGGATGT  CAGCGTGACC  AGCGTCGCAG  CGTACTTTGA  GAAGGTGGAA  AGGGACACTG 
GCGATGTGCC  TCGACC7rACA  GTCGCACTGG  TCGCAGCGTC  GCATGAAACT  CrTCCACCTT  TCCCTGTGAC 
-DIIAEHGAGVKILLCHLGVHND 
351  CCGACATCAT  CGCCGAACAC  GGCGCCGGCC  AGGTGAAGAT  CCTTCTCTGC  CACCTAGGTG  TTCACAATGA 
GGCTGTAGTA  GCGGCTTGTG  CCGCGGCCGG  TCCACTTCTA  GGAAGAGACG  GTGGATCCAC  AAGTGTTAC-l' 
-TTGLICVEvQGCN9LFSsvPDVD 
421  CACAACGGGG  CTCAT(:  7rGCG  TTGAGGTGCA  GGGCTGCAAC  GAGCTCTTTT  CTAGCGTCCC  TGACGTGGAC 
GTGTTGCCCC  GAGTAGACGC  AACTCCACGT  CCCGACGTTG  CrCGAGAAAA  GATCGCAGGG  ACTGCACCTG 
GKVLNHEPIvPEDGAIEVFHESWF 
491  GGTAAGGTGC  TCAACCACGA  GCCCATTGTA  CCGGAGGACG  GCGCCATTGA  AGTATTTCAC  GAGAGCTGGT 
CCATTCCACG  AGTTGGTGCT  CGGGTAACAT  GGCCTCCTGC  CGCGGTAACT  TCATAAAGTG  CTCTCGAC'CA 
-GKEGSPQLEKLERLIQQVNDTVA 
561  TCGGCAAGGA  GGGCTCGCCG  CAGCTCGAGA  AGCTGGAGCG  CTTGATTCAA  CAGGTAAACG  ACACCGTTGC 
AGCCGTTCCT  CCCGAGCGGC  GTCGAGCTCT  TCGACCTCGC  GAACTAAGTT  GTCCATTTGC  TGTGGCAAC(, 
-ESWHHWVTGAVTNN9VTSADTDR 
631  CGAGTCATGG  CATCACTGGG  TGACGGGTGC  CGTGACCAAC  AATGAGGTGA  CATCGGCGGA  CACAGACAGA 
GCTCAGTACC  GTAGTGACCC  ACTGCCCACG  GCACTGGTTG  TTACTCCACT  GTAGCCGCCT  GTGTCTGTCT 
KDMAMPTFQAPSSAISRNAGRYLC 
701  AAGGACATGG  CGATGCCAAC  GTTTCAGGCG  CCGAGCTCrG  CAATTTCGCG  CAACGCAGGG  CGCTACCTG'r 
TTCCTGTACC  GCTACGGTTG  CAAAGTCCGC  GGCTCGAGAC  GTTAAAGCGC  GTTGCGTCCC  GCGATGGACA 
-NCALYHALRLQEKNPGVVYGIFv 
771  GCAACrGCGC  CCTCTACCAC  GCACTTCGAC  TTCAGGAAAA  GAACCCGGGT  GTCGTCTATG  GCATCTTCGT 
CGTrGACGCG  GGAGATGGTG  CGTGAAGCTG  AAGTCCTTTT  CTTGGGCCCA  CAGCAGATAC  CCTAGAAGCA 
-HVVDPIRGKTEIEGGPIVAYNpp 
841  TCACGTTGTC  GATCCGATTC  GCGGCAAGAC  GGAGATCGAG  GGCGGTCCCA  TTGTGGCTTA  CAACCCACCG 
AGTGCAACAG  CTAGGCTAAG  CGCCGTTCTG  CCTCTAGCTC  CCGCCAGGGT  AACACCGAAT  GTTGGGTGGC 
TIVsvQv0cLMHGLLSLXTm 
911  ACGATCGTAC  AGTCGGTGCA  AGTGCAGTGT  CTCATGCACG  GCCTGCTGTC  TTTGATGACC  ATGTGACGAA 
TGCTAGCATG  TCAGCCACGT  TCACGTCACA  GAGTACGTGC  CGGACGACAG  AAACTACTGG  TACACTGCTT 
981  GACATCGTTC  GCAGCGA 
CTGTAGCAAG  CGTCGCT 
FIG.  4.2.  Complete  sequence  encoding  a  PPI  enzyme  in  L.  major.  The  sequence  of 
the  5'  UTR  obtained  from  the  5'  RACE  experiment  is  shown  with  a  grey  background.  The 
translation  of  the  putative  ORF  is  shown  in  bold  (single  letter  amino  acid  code).  Dots  indicate 
codons  that  are  split  over  the  line  break. 
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The  834  bp  ORF  translating  into  a  277  amino  acid  protein  with  PPI 
features  was  located  on  chromosome  34  of  L.  ma  r.  The  protein  was  aligned  jo 
with  known  PPIs  from  mammals,  plant  and  bacteria  (Fig.  4.3)  and  the 
corresponding  identity  table  is  presented  in  Table  4.2.  The  L.  major  protein 
showed  little  similarity  with  the  various  PPIs,  but  the  catalytic  residues  Glu-81, 
Cys-144  and  His-168  were  conserved  in  all  the  sequences  (Thermococcus 
litoralis  numbering),  placing  the  L.  major  enzyme  in  the  C15  family  of  cysteine 
peptidase  (Barrett  and  Rawlings,  2001).  Only  13  residues  were  fully  conserved  in 
the  5  sequences.  The  L.  major  enzyme  also  has  a  large  insertion  (position  145- 
199)  of  unknown  function. 
1  50 
AthPPI  (1)  MGSEGPTGVT--  o  !  &Fý  ý  rl]HGVAEMPTEKMANNLKEYLAKNCVSKDVNLG 
BamPPI  (1)  ------  MEKKVý  i  jEF'PUGGETVMPSWEAVKRLNGAAEGP  --------- 
TlitPPI  (1)  -------  MKKV:,  IjjZF;  ý  POGGDSKIPTEQIAKYFDRKQIGN  --------- 
HsPPI  (1)  ---  MEQPRKAV,  ",  JEF, 
-3P[IGEHTVMASWIAVQELEKLGLGDS  -------- 
LmPPI  (1)  -MLHSKAGIVVFI[BYGPIIATVK-IPSSDIALRVAEGLKRHPDVAEVR-- 
51  100 
AthPPI  (51)  SCTVLETAGQGALASLYQLLQSAVNTKESESLTGKTIWVHFIIVNSGAT-K 
BamPPI  (36)  -------  ASIVSEQVPTVFYKSLAVLREAIKKHQPDIIICVIQAGGRM-Q 
TlitPPI  (3s)  -------  AMVYGRVLPVSVKRATIELKRYLEEIKPEIVINIII,  AIITYS-N 
HsPPI  (40)  -------  VDLHVYEIPVEYQTVQRLIPALWEKHSPQLVVHVIVSCMAT-T 
LmPPI  (48)  YTELDVSVTSVAAYFEKVERDTADIIAEHGAGQVKILLCHIIVIiNDTTGL 
101-  150 
AthPPI  (100)  FAIOQQAVMEATFRCPDELGWKPQNLPIVPSDGPISTVRK'I'NLPVEE  --- 
BamPPI  (78)  ITPlRVAIMLNEARIPDNEGNQPVGEDIS-QGGPAA--YWTGLPIKIZ  --- 
TlitPPI  (77)  ITV§RIAVMIIDARIPDNDGYQPIDEKIE-EDAPLA--YMATLPVRA  --- 
HsPPI  (82)  VTLOKCC3HMKGYKGLDNCR-FCPGSQCCV-EDGPES--IDSIIDMDA  --- 
LmPPI  (98)  ICVIIVQGC71ELFSSVPDVDGKVLNHEPIVPEDGAIEVFHESWFGKEGSPQ 
151  200 
AthPPI  (147)  ----------------------  ITKALEKN  ------------------  GF 
BamPPI  (122)  ----------------------  IVEEIKKE  ------------------  Gl 
TlitPPI  (121)  ----------------------  ITKTLRDN  ------------------  GI 
HsPPI  (125)  ----------------------  VCKRVTTLGL  ----------------  DV 
LmPPI  (148)  LEKLERLIQQVNDTVAESWHHWVTGAVTNNEVTSADTDRKDMAMPTFQAP 
201  250 
AthPPI  (157)  EVITrDýFýINYVYYHSLRFAEQNKT--RSIOVMVPLFVAVDEET-- 
BamPPI  (132)  PAAVM':  ":  ZTFýJINHLFYGLMDEISRHHPHIRC,  (II  I  MI  PYI  PEQTL  ---  Q 
TlitPPI  (131)  PATIM':  '.  -Ze:  --YLSIYVMFKTLHFSKIEGYPLKA(, 
g  i  IBVPYTPDQVVNKFF 
HsPPI  (137)  SVTIM-: 
-'MRYLJDFTYYTSLYQS  -----  HGR-lýAGMPPI,  (3KPYNADQL 
LmPPI  (198)  SSAIMRNýYLIINCALYHALRLQEKNPGVVYGISMIWDPIRGKTEIEG 
251  292 
AthPPI  (203)  ----------------  QMRFTVSLLEVLASICK  --------- 
BamPPI  (179)  KS  ---  APSLSLDHITKALKIAAVTAAVHEDDIETGGGELH-- 
TlitPPI  (181)  LLGKNTPSMCLEAEIKAIELAVKVSLDYLEKDRDDIKIPL-- 
HsPPI  (182)  G  --------------  RALRAIIEEMLDLLEQSEGKINYCHKH 
LmPPI  (248)  GP  ------------  IVAYNPPTIVQSVQVQCLMHGLLSLMTM 
FIG.  4.3.  Alignment  of  the  pyroglutamyl  peptidase  I  (PPI)  of  L.  major  with  various 
known  PPIs  from  different  organisms.  Dashes  indicate  gaps  in  the  alignment.  The  catalytic 
triad  residues  are  starred.  Identical  residues  are  on  black  background.  Conservative  residues  are 
on  grey  background  Ath,  Arabidopsis  thaliana;  (GenBank  Accession  No.:  NP  173758);  Barn, 
Bacillus  amyloliquefaciens  (JX0244);  Tlit,  Thermococcus  litoralis  (CAA74299);  Hs,  Homo  sapiens 
(NP  060182),  Lm,  L.  major,  PPI,  pyroglutamyl  peptidase  1. 
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Table  4.2.  Similarity  table  of  the  L.  major  PPI  with  various  PPls.  Numbers  represent 
percentage  of  identity.  ArabTh  :  Arabldopsis  thaliana;  Bamyl  :  Bacillus  amyloliquefaciens;  Tlit 
Thermococcus  fitoralis;  Hum:  Homo  sapiens;  Lm  :  L.  major. 
AthPPI  BamPPI  TlitPPI  HsPPI  LmPPI 
AthPPI  100  32  33  33  23 
BarnPPI  100  49  38  15 
TlitPPI  100  37  15 
HsPPI  100  20 
LmPPI  100 
Using  the  human  PPI  as  a  query  (accession  number  NP  060182, 
www.  ncbi.  nlm.  nih.  org/entrez/)  also  allowed  detection  of  PPIs  in  the  genomic 
databases  of  other  parasites.  For  instance,  a  PPI-like  sequence  was  detected  in 
the  genome  of  L.  infantum,  Trypanosoma  brucei  and  T.  cruzi.  These  sequences 
were  aligned  as  before  (Fig.  4.4)  and  a  somewhat  higher  similarity  was  detected 
among  them  (Table  4.3).  T.  brucei  and  T.  cruzi  PPs  are  quite similar  to  each 
other,  as  are  the  L.  infantum  and  L.  major  PPs.  Interestingly,  the  L.  major  PP  was 
only  just  under  30%  homologous  to  the  PPs  of  the  2  Trypanosoma  species, 
which  is  the  percentage  of  similarity  between  the  human  and  the  bacterial 
enzymes  (Dando  et  al.,  2003). 
To  study  the  structure  that  the  L.  major  PP  might  have,  it  was  sent  to 
SwissModel  for  structure  prediction,  using  the  PPs  from  T.  fitorafis  and  B. 
amylotumefaciens  (PDB  1A2Z  and  1AUG,  respectively)  as  templates.  Only  the 
residues  5  to  41  and  193  to  240  could  be  assigned  a  structural  prediction  by 
superposition  to  residues  1  to  36  of  the  B.  amylotumefaciens  PP  or  residues  128 
to  171  of  T.  fitoralis,  respectively.  The  rest  of  the  sequence  did  not  show  sufficient 
similarity  for  three-dimensional  structure  prediction. 
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i  50 
LiPPI  (1)  MLHSKAGIVV  FIEt:  'M  -'-'VK-'JMSE)BALRkIVENLKRHPDVAEMRYTE 
LmPPI  (1)  MLHSKAGIV-VFIEI'  M'  ",  ';.  -VMýý,  DBALPkIAECLKRHPDVAEVRYTE 
TbPPI  (1)  --MKPTKPLLYIEe- 
M  '-'ýý3M-,:  'UAQ,  'ýBAE(:  )VRQS-GEADVIIHET 
TcPPI  (1)  --MRRSNLQLYM&C: 
M  KPMMED  -  SELQVHYEK 
51  99 
LiPPI  (51)  MVTTU&:,  AMEK7.  ERE  IADI  IAEHGAGKVKIECHIJMBN  -  DTTGLIR 
LmPPI  (51)  "TS',  'TSjA.  AMEK,  ERDTADI  IAEHGAGQVKIECHLEVMN  -  DTTGLIC 
TbPPI  (48)  jWLEATUSýýRLNESVTAELEATHPEN-  RVEVN-VJI,  MSRFKEKVLR 
TcPPI  (48)  l--'&--,  LEAUTSAJZID'-LEGALAQHMEDNPDG-  -  CVMLHIMI  jSRE1-:  EGKMR 
1-19 
LiPPI  (100) 
ýIVJQGYMFASVPDVDGKVL14HEPIVPEDGTIEVI-'HEMWF(, 
KAGSPQLE 
LmPPI  (100)  '.  ZQG-'MMFSSVPDVDGKVLNHEPIVPEDGAIEVIý'H  F(;  KEGSPQLE 
TbPPI  (97)  LMRAF-13MEGNP  -------------  IDDELPLSTCKfFVK(,  CKLE 
TcPPI  (96)  LMCGYMEGSP  -------------  IDESI  PMDVCLEjMLVRDGCI)I-:  ý;  K 
iso  I  ()() 
LiPPI  (150)  KLERMIQQVMDTIAESWHHSVTGAVTKNEVTPSDADRKDMAMPAFQASSW 
LmPPI  (150)  KLERMQQ',  IZDTVAESWHHWVTGAVTNNEVTSADTDRKDMAMP'I'FQAOS.  13 
TbPPI  (132)  TTTANIEE:,  IAIERN  -------------------------  GSDIHIPFIliý1W 
TcPPI  (133)  ATAENEELJZAAISK  ---------  RGR  -------------  RE("DPQQjHW 
249 
LiPPI  (200' 
. -ýIER',  =: 
ýECAMIHALRISEKNPGIJYGVlTMVVDPIRGKTEIEGGP 
LmPPI  (200)  ýý,  "=LECAýALPIgEKNPGVIYGIUMEVVDPIRGKTEIEGGP 
TbPPI  (157)  IMYDMYEYqllRGVKMEEALNSIZUTIý'AVIIM  I  VASTVVC 
TcPPI  (161)  IJORDMYEYTERSLKI.  C*  KKWRGRJIFAVIMANPFTCN  ------- 
ýýc  283 
LiPPI  (250)  IVAYNPTTMVSSIIWRFMH(41LSLMT  ------ 
LmPPI  (250)  IVAYNPPTIVESVEIQCLMHGMLSLMTM  ----- 
TbPPI  (200)  -------  MEERVAUJRMLVSHlLKHMEAVE  --- 
TcPPI  (204)  ----  NPSLEERTAELSLVSClVRIVRNKHIV- 
FIG.  4.4.  Alignment  of  the  pyroglutamyl  peptidase  I  (PPI)  of  L.  major  with  various 
predicted  PPIs  in  different  trypanosomatids.  Dashes  indicate  gaps  in  the  alignment.  The 
catalytic  triad  residues  are  starred.  Identical  residues  are  on  black  background;  conservative 
residues  are  on  grey  background.  Li,  Leishmania  infantum  (GeneDB  CDS:  LinJ34.1440);  Tb, 
Tfypanosoma  brucei  (GeneDB  CDS:  Tb04.11-119.1350);  Tc,  Trypanosoma  cruzi  (GeneDB  CDS: 
TcOO.  1047053506635.60);  Lm,  L.  major  (GeneDB  CDS:  LmjF34.2000);  PPI,  pyroglutamyl 
peptidase  1. 
Table  4.3.  Similarity  table  of  the  L.  major  PPI  with  various  parasites'  PIRls. 
Numbers  represent  percentage  of  identity.  Li  :  L.  infantum;  Lm  :  L.  major,  Tb  :  T.  brucei;  Tc  :  T. 
cruzi. 
UPPI  LmPPI  TbPPI  TcPPI 
UPPI  100  78  26  27 
LmPPI  100  27  28 
TbPPI  100  56 
TcPPI  100 
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4.2.2.  Expression  of  recombinant  L.  major  PPI  in  E.  coli 
The  full  open  reading  frame  (ORF)  for  the  PPI  of  L.  major  was  cloned  in 
the  pET28a(+)  vector  (Novagen)  for  expression  of  PPI  with  a  N-terminal  His-tag. 
The  resulting  pETLmPP  plasmid  is  represented  on  Fig.  4.5.  Cells  transformed 
with  the  pETLmPP  plasmid  were  induced  either  for  4h  at  370C  with  1  mM  IPTG, 
or  for  4h  at  200C  with  1  mM  IPTG.  An  over-expressed  protein  of  about  32  kDa, 
corresponding  to  the  expected  size  for  N-terminal  His-tagged  protein,  could  be 
detected  in  all  cases,  but  it  was  found  in  the  insoluble  fraction  of  E.  coli  lysates  if 
expressed  at  370C.  The  highest  rate  of  expression  in  a  soluble  manner  was 
obtained  by  induction  at  200C  with  1  mM  IPTG,  and  the  soluble  protein  produced 
was  purified  on  Ni-agarose  column  (Fig.  4.6).  The  BioCAD  purification  on  Ni- 
agarose  column  resulted  in  a  protein  above  95%  pure,  although  a  few 
contaminating  E.  coli  proteins  remained.  From  a1  liter  induced  culture,  about  4 
mg  of  enzyme  were  routinely  purified.  As  a  control,  non-transformed  BL21  (DE3) 
E.  coli  cells  were  treated  in  the  same  manner  and  both  the  insoluble  and  soluble 
fractions  were  analysed  using  Coomassie-blue  stained  SDS-PAGE.  No  over- 
expressed  protein  could  be  observed  in  any  of  the  fractions  (results  not  shown). 
The  soluble  fraction  was  kept  as  a  control  for  the  analysis  of  the  enzyme  activity. 
Xho  1  (159) 
fl  origin  HindIII  (174) 
Sal  1  (180) 
Sma  1  (345) 
Ka(n  Xhol  (573) 
Sma  1  (5080  LmPAPI 
Clal (4897)  Ndel  (1018) 
p 
Ncol  (1076) 
pE  LmPP 
p  6  IL48  b,  p 
FIG.  4.5.  Construct  for  expression  of  recombinant  pyroglutamyl  pepticlase  I  (PPI)  of 
L.  major  in  E.  coli.  Schematic  representation  of  the  plasmid  resulting  from  the  cloning  of  the 
sequence  of  the  PPI  of  L.  major  in  the  pET28a(+)  vector  (Novagen)  for  expression  of  PPI  with  a 
N-terminal  His-tag.  Kan,  kanamycin  resistance  gene;  fl  origin,  origin  of  replication  of  the  phage 
fl;  lacl,  gene  encoding  the  lac  repressor  protein. 
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FIG.  4.6.  Analysis  of  expression  and  purification  of  the  L.  major  PPI  expressed  in  E. 
coli  BL21(DE3).  A  SIDS-PAGE  gel  (12%  acrylamide)  stained  with  Coomassie  blue.  Lane  M, 
protein  standards;  lane  1,  E.  coli  cell  lysate  after  IPTG  induction,  crude  lysate;  lane  2,  load  for  Ni- 
agarose  column;  lane  3,  flow-through;  lane  4,30  mM  imidazole  wash;  lanes  5  to  9,  elution 
fractions  from  Ni-agarose  column  with  500  mM  imidazole.  10-3  XMr  is  indicated  on  the  left  of  the 
figure.  10  lal  samples  were  loaded. 
Active  site  mutants  of  the  PPI  of  L.  majorwere  generated  by  site-directed 
mutagenesis.  Based  on  the  work  of  Le  Saux  and  co-workers  (Le  Saux  et  al., 
1996),  cysteine-210  was  mutated  to  alanine,  histidine-234  to  serine,  glutamic 
acid-101  to  glutamine  and  glutamic  acid-107  to  glutamine  (L.  major  PPI 
numbering).  The  mutated  L.  major  PPIs  were  all  partially  soluble  when  induced  at 
200C,  and  were  purified  as  the  native  recombinant  PPI  with  similar  yields  (results 
not  shown). 
4.2.3.  Biochemical  characteristics  of  the  recombinant  PPI  of  L.  major 
For  all  investigations,  controls  without  enzyme  were  carried  out,  and  it 
was  confirmed  that  there  was  no  spontaneous  hydrolysis  of  the  substrates  used. 
Control  assays  using  crude  soluble  fraction  from  non-transformed  E.  coli  did  not 
show  any  activity  towards  pGlu-pNA  (less  than  0.1  mU/ml),  whereas  the  same 
extract  of  cells  expressing  the  L.  major  PPI  showed  a  significant  activity  (-1 
U/ml). 
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4.2.3.1.  Dependence  on  reducing  conditions,  EDTA  and  magnesium  Ion 
The  recombinant  PPI  from  L.  major  showed  a  strong  dependence  on 
reducing  agents,  as  expected  for  a  cysteine  peptidase  and  as  reported  for  other 
PPIs  (Cummins  and  O'Connor,  1998;  Dando  et  aL,  2003).  The  presence  in  the 
assay  buffer  of  at  least  10  mM  DTT  or  0.5  mM  TCEP  was  required  to  observe  full 
activity  (Fig.  4.7). 
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FIG.  4.7.  Dependence  of  L.  major  PPI  activity  on  DTT.  Assays  used  10.6  pg  enzyme, 
2  mM  pGlu-pNA  and  were  in  25  mM  potassium  phosphate  buffer,  pH  8.0.  Results  are  the  means 
±  SID  from  3  independent  measurements. 
As  for  the  human  PPI,  no  stabilising  effect  was  observed  in  the  presence 
of  EDTA  (Dando  et  aL,  2003)  for  the  L.  major  recombinant  enzyme  (Fig.  4.8),  but 
I  mM  EDTA  was  routinely  included  in  the  assay  buffer  to  chelate  ions  like  Ni2+, 
which  may  be  present  in  traces  due  to  Nickel-agarose  purification  and  have  been 
shown  to  be  inhibitory  on  PPI  enzymes  (Dando  et  aL,  2003,  section  4.2.3.6.  ). 
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FIG.  4.8.  Effect  of  EDTA  on  L.  major  PPI  activity.  Experiments  used  11.4  Vg  enzyme, 
2  mM  pGlu-pNA  and  were  in  50  mM  HEPES  buffer,  pH  8.0,  with  10  mM  DTT-  Results  are  the 
means  ±  SD  from  3  independent  measurements. 
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The  effect  of  Mg2+  ions,  which  would  be  chelated  by  the  EDTA  included 
in  the  buffer  and  might  be  beneficial  to  enzyme  activity,  was  investigated.  No 
beneficial  effect  was  observed  (Fig.  4.9),  and  therefore  Mg2+  was  not  added  to 
the  assays.  ' 
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FIG.  4.9.  Effect  of  Mg2+  on  L.  major  PPI  activity.  Experiments  used  11.4  pg  enzyme, 
2  mM  pGlu-pNA  and  were  in  50  mM  HEPES  buffer,  pH  8.0,  with  10  mM  DTT.  Results  are  the 
means  ±  SD  from  3  independent  measurements. 
4.2.3.2.  pH  optimum 
Activity  towards  the  synthetic  substrate  pGlu-pNA  was  observed  over  a 
wide  spectrum  of  pHs,  with  maximum  activity  being  between  pH  8.8  and  10.5 
(Fig.  4.10).  This  is  slightly  higher  than  has  been  reported  for  other  PPIs  (Awade 
et  aL,  1992a,  Dando  et  aL,  2003),  but  confirms  an  alkali  optimum  for  the  enzyme. 
The  activity  decreased  rapidly  below  pH  8.0.  Though  the  observed  pH  optimum 
was  above  8,  assays  were  performed  at  pH  8.0,  for  biological  significance. 
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FIG.  4.10.  Effect  of  pH  on  L.  major  PPI  activity.  (A)  Experiments  used  11.4  pg  enzyme 
and  were  in  the  mix  of  buffers  (25  mM  acetic  acid,  25  mM  MES,  75  mM  Tris-base,  25  mM 
Glycine),  supplemented  with  I  mM  EDTA,  10  mM  DTT,  2  mM  pGlu-pNA.  (B)  Experiments  used 
11.4  pg  enzyme  and  were  in  the  buffers  indicated  in  the  legend,  supplemented  with  I  mM  EDTA, 
10  mM  DTT,  2  mM  pGlu-pNA.  Results  are  the  means  ±  SD  from  3  Independent  measurements. 
4.2.3.3.  Storage  and  stability 
The  recombinant  L.  major  PPI  was  found  to  be  stable  for  at  least  3 
months  at  -200C  in  50  mM  HEPES  pH  8.0,1  mM  EDTA,  2  mM  TCEP,  and  3h  at 
370C  but  lost  almost  all  activity  in  6  days  storage  at  40C  in  the  same  suspension 
buffer  (Fig.  4.11).  The  enzyme  was  thus  routinely  stored  at  -20,  DC,  and  fresh 
aliquots  were  defrosted  immediately  prior  to  analysis. 
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FIG.  4.11.  Stability  of  L.  major  PPI,  stored  In  50  mM  HEIRES  pH  8.0,2  rnM  TCEP,  I 
rnM  EDTA.  Experiments  used  10.5  pg  enzyme,  2  mM  pGlu-pNA  and  were  In  50  mM  HEPES  pH 
8.0,  supplemented  with  2  mM  TCEP  and  I  mM  EDTA. 
4.2.3.4.  L.  major  PPI  is  a  monomer 
Gel  filtration  analysis  showed  that  the  active  recombinant  enzyme  has  a 
molecular  mass  of  about  36  kDa  (Fig.  4.12).  The  predicted  molecular  mass  for  a 
monomer  of  the  enzyme  is  32.5  kDa.  The  fraction  containing  the  protein  showed 
significant  activity  towards  pGlu-PNA  (1  U/mg  protein).  Mammalian  PPIs  are  also 
monomers  (Dando  et  aL,  2003). 
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FIG.  4.12.  Determination  of  the  molecular  mass  of  the  recombinant  L.  major  PPI  by 
gel-filtration  analysis.  The  enzyme  was  produced  in  E.  coli  with  a  N-terminal  His-tag.  The 
purified  PPI  was  applied  to  a  Sepharose  12  10  x  300mm  gel-filtration  column,  which  had  been 
calibrated  with  the  following  proteins:  1,  ribonuclease  A;  2,  chymotrypsinogen;  3,  ovalbumin;  4, 
BSA;  5,  alcohol  dehydrogenase;  6,0-amyiase.  The  broken  line  indicates  the  ratio  V.  (elution 
volume)  to  V.  (void  volume)  of  recombinant,  active  L.  major  PPI  and  the  arrow  head  Indicates  the 
inferred  molecular  mass  (36  kDa). 
4.2.3.5.  Activity  towards  pGlu-,  H-Glu-  and  H-Gln-  substrates 
Purified  enzyme  was  active  towards  the  substrates  pGlu-pNA,  pGlu-PNA, 
H-Glu-PNA,  with  a  strong  preference  for  the  pGlu  substrates  (20-fold  greater 
activity)  (Fig.  4.13).  The  enzyme  did  not  present  any  activity  towards  H-Gly-PNA. 
Other  PPIs  have  been  reported  not  to  cleave  Glu  at  the  N-terminus  (Dando  et  a/., 
2003).  The  activity  towards  H-Glu-PNA  being  low,  it  cannot  be  excluded  that  this 
activity  might  be  due  to  cleavage  of  pGlu-PNA  present  at  a  low  concentration  in 
the  H-Glu-PNA  substrate,  and  resulting  from  spontaneous  cyclisation  of  the  H- 
Glu-PNA  substrate.  The  Kms  and  specific  activities  were,  respectively,  4.5  ±  0.5 
jiM  and  1.02  ±  200  mU/mg  protein  towards  pGlu-PNA;  33.5  ±  2.5  l.  N  and  904  ± 
310  mU/mg  against  pGlu-pNA;  85  ±  18  ýt!  Vl  and  50  ±  12  mU/mg  protein  towards 
H-Glu-PNA.  This  falls  within  the  range  of  expected  Km  values  reported  for 
mammalian  PPIs  towards  pGlu-pNA  (20  to  80  ýLM)  (Mantle  et  al.,  1995;  Cummins 
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and  O'Connor,  1998;  Dando  et  al.,  2003),  and  not  the  range  for  the  bacterial 
enzymes  (180  to  250  VM)  (Le  Saux  et  al.,  1996;  Ito  et  al.,  2001). 
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FIG.  4.13.  Analysis  of  the  activity  of  the  PPI  of  L.  major  produced  in  E.  coli  against 
the  synthetic  substrates  pGlu-PNA,  pGlu-pNA,  and  H-Glu-PNA.  (A)  K,  s  (JIM)  of  the  3 
substrates.  (B)  Activities  (U/mg  protein)  of  the  enzyme  against  the  3  substrates.  Enzyme  samples 
were  tested  for  activity  in  a  final  volume  of  1  ml.  The  enzyme  sample  was  incubated  for  5  min  at 
320C  in  50  mM  HEPES  pH  8.0  buffer,  supplemented  with  2  mM  TCEP  and  1  mM  EDTA,  before 
start  of  the  reaction  by  addition  of  the  substrate  (200  pM,  unless  for  K,  determination  0.1  plM  to  1 
mM  were  used).  Excitation  and  emission  wavelengths  were  respectively  320  and  410  nm  for  the 
DNA  fluorogenic  substrates.  Reading  wavelength  was  410  nm  for  the  pNA  chromogenic 
substrate.  The  assays  were  continuous  for  10  min  at  320C.  Results  are  the  means  1  SID  from  3 
independent  measurements. 
Activity  towards  H-Gln-PNA  was  also  investigated,  but  the  results  were 
more  difficult  to  analyse.  There  was  an  initial  low  rate  for  about  5  min,  which 
quickly  accelerated  to  reach  the  rate  that  occurred  towards  the  pGIu-pNA 
substrate  (Fig.  4.14).  The  initial  rate  only  was  observed  when  there  was  no  pre- 
incubation  of  the  substrate  in  the  assay  buffer  at  320C.  If  pre-incubation  was 
used,  the  rate  detected  was  immediately  the  same  as  maximum  rate  towards 
pGlu-PNA.  It  was  concluded  that  a  small  proportion  of  the  H-GIn-IMA  substrate 
was  quickly  converting  to  pGlu-PNA.  The  Km  towards  pGlu-1-INA  is  about  4  pM, 
thus  a  spontaneous  cyclisation  of  only  about  5%  of  the  200  pM  of  H-GIn-IMA 
used  in  the  assay  would  result  in  the  maximum  rate  towards  the  pGlu-[MA 
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substrate.  It  had  previously  been  shown  that  up  to  6%  of  H-Gln-PNA  could 
convert  spontaneously  to  pGlu-PNA  when  incubated  at  3711C  for  2h  (Chikuma  et 
aL,  2004).  Lower  concentrations  of  H-Gln-PNA  were  also  investigated  but  the 
initial  rate  then  was  at  the  limit  of  detection  and  precise  measurements  were  not 
possible.  It  is  therefore  not  certain  if  PPI  presents  some  activity  towards  H-GIn- 
PNA,  as  the  very  low  activity  detected  could  be  due  to  a  very  small  fraction  of 
pGlu-PNA  already  present  in  the  H-Gln-PNA  substrate.  The  PPI  has  an  apparent 
activity  of  10  mU/mg  protein  towards  200  ltM  of  H-Gln-PNA  and  it  seems  likely 
that  PPI  may  not  have  any  activity  at  all  against  this  substrate. 
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FIG.  4.14.  Typical  traces  obtained  with  0.2  mU  of  recombinant  PPI  of  L.  major 
produced  In  E.  coil,  and  the  substrates  200  liM  pGlu-PNA  (A),  and  200  plVI  H-Gln-ONA  (B). 
Assays  were  in  50  mM  HEPES  pH  8.0,2  mM  TCEP,  1  mM  EDTA,  at  32"C.  In  both  A  and  B,  the 
buffer  was  pre-incubated  for  5  min  at  320C,  and  the  reaction  was  started  by  simultaneous  addition 
of  PPI  and  substrate.  Measurements  were  continuous  (excitation  320  nm,  emission  410  nm).  AU. 
arbitrary  fluorescence  units;  s,  seconds. 
4.2.3.6.  Inhibitors 
The  human  PPI  had  been  reported  to  be  inhibited  by  transition  metal  ions 
(Dando  et  aL,  2003).  Various  ions  were  tested  on  the  recombinant  PPI  of  L. 
major  (Table  4.4).  Nickel,  copper  and  zinc  ions  showed  strong  inhibition  of  the 
enzyme;  nickel  almost  completely  inhibited  the  enzyme  when  at  1  mM.  As 
expected,  calcium,  magnesium,  sodium  and  lithium  ions  did  not  have  any  effect. 
152 
0  10  20  30  40  50  60 
Time  (s) Chapter  4:  Expression  and  characterisation  of  recombinant 
pyroglutamyl  peptidase  I  of  L.  major 
Table  4.4.  The  effects  of  various  Ions  on  the  activity  of  the  purified  recombinant  PPI  of 
L.  major.  Assays  were  in  50  mM  HEPES  pH  8.0,2  mM  TCEP.  The  ions  were  added  to  the 
buffer-enzyme  mix  and  incubated  for  10  min  at  3211C.  The  reaction  was  then  started  by  addition  of 
200  pM  pGlu-pNA  and  monitored  continuously  for  5  min  at  410  nm.  The  activity  remaining  Is 
indicated  as  a  percentage  of  the  activity  of  the  non-treated  enzyme  In  the  same  conditions. 
Values  correspond  to  mean  ±  SID  from  3  measurements. 
Ion  Concentration  (mM)  Activitv  M 
Ni`  1  1.0  0.3 
Ni>  0.1  52  1.0 
Mg 
:  94  2.1 
Na+  100  2.5 
Ca 
2+  1  88  ±I.  6 
CU:  1  8.7  0.3 
Li+  1  92  0.7 
Zn 
2+  1  19.8  ±  0.4 
Other  inhibitors  were  tested,  but  only  sulfhydryl  blocking  agents  such  as 
iodoacetamide,  iodoacetic  acid  and  N-ethyl  maleimide  (NEM)  showed  strong 
inhibition  of  the  enzyme  (Table  4.5).  Though  the  PPI  is  a  cysteine  peptidase,  the 
common  cysteine  peptidase  inhibitor  (2S,  3S)-3-(N-((S)-1  -[N-(4- 
guanidinobutyl)carbamoyl]3-methylbutyl)carbamoyl)oxirane-2-carboxylic  acid  (E64) 
did  not  inhibit  the  enzyme's  activity.  This  reflects  the  very  different  catalytic 
mechanism  of  PPI  compared  with  clan  CA,  family  C1  peptidases,  such  as  papain. 
This  is  consistent  to  what  was  found  for  the  human  enzyme  (Dando  et  a/.,  2003). 
Surprisingly,  the  serine  peptidase  inhibitor  phenylmethylsulphonyl  fluoride  (PMSF) 
showed  some  inhibition,  but  only  at  the  mM  range,  and  the  pGlu  analogue  2- 
pyrrolidinone,  reported  to  be  an  inhibitor  for  the  bacterial  enzymes  (Cummins  and 
O'Connor,  1998),  inhibited  only  when  at  I  mM. 
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Table  4.5.  The  effects  of  various  Inhibitors  on  the  activity  of  the  purified  recombinant 
PPI  of  L.  major.  Assays  were  in  50  mM  HEPES  pH  8.0,2  mM  TCEP.  Inhibitors  were  added  to 
the  buffer-enzyme  mix  and  incubated  for  10  min  at  3211C.  The  reaction  was  then  started  by 
addition  of  200  pM  pGlu-pNA  and  monitored  continuously  for  5  min  at  410  nm.  The  activity 
remaining  is  indicated  as  a  percentage  of  the  activity  of  the  non-treated  enzyme  In  the  same 
conditions,  with  the  standard  deviation  based  on  3  repeats  of  each  measurement.  PMSF: 
phenylmethylsulphonyl  fluoride;  NEM:  Wethyl  maleimide. 
Inhibitor  Concentration  (pM)  Activity  (%) 
E64  100  79  ±  1.2 
10  91.8  ±  2.1 
Pepstatin  A  10  93  ±  1.6 
1  A4  A+IA 
PMSF 
lodoacetamide 
lodoacetic  acid 
1,10-phenanthroline 
1000  46.6  0.8 
100  101  1.0 
100  1.7  0.3 
10  7.4  0.8 
100  0 
10  1.2  0.4 
1000  98.2  0.7 
100  98.8  1.9 
Benzamidine  1000  96  2.2 
100  100  1.2 
Bestatin  10  101  1.7 
NEM  100  1.9  0.4 
10  3.1  0.3 
2-pyrrolidinone  1000  66  2.5 
100  86.7  3.0 
10  99  ±  2.8 
4.2.4.  Biochemical  analysis  of  active  site  mutants  of  the  recombinant  PPI  of 
L.  major 
As  expected  for  a  pyroglutamyl  peptidase  I  (Dando  et  a/.,  2003),  the 
active  site  cysteine  and  histidine  predicted  for  the  PPI  of  L.  ma  r,  at  respectively  Vo 
positions  210  and  234  (PPI  of  L.  major  numbering),  from  the  alignment  with  PPI 
from  different  organisms  (Fig.  4.3  and  4.4)  were  found  to  be  essential  for  the 
enzyme's  activity.  Mutants  lacking  the  active  site  cysteine  (C210A)  or  histidine 
(H234S)  had  practically  no  activity  (Table  4.6).  The  E101Q  mutated  enzyme  had 
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about  2%  of  activity  compared  with  the  unmutated  recombinant  enzyme,  with  a 
Km  for  pGlu-pNA  about  30  times  higher  than  that  of  the  unmutated  enzyme.  In 
contrast,  the  E107Q  mutated  enzyme  still  had  50%  of  the  activity  of  the  native 
enzyme  and  the  Km  was  only  2.5  fold  higher.  These  results  confirmed  that 
glutamic  acid  101  is  part  of  the  active  site,  whereas  glutamic  acid  107  probably 
plays  a  minor  role  in  the  catalytic  reaction. 
Table.  4.6.  Biochemical  analysis  of  the  recombinant  PPI  active  site  mutants  of  L. 
major  expressed  In  E.  coH  and  purified  on  Nickel-agarose  column.  The  amino  acids  are 
represented  using  the  single  letter  code.  Numbering  refers  to  the  native  PPI  of  L.  major.  Activity  is 
expressed  as  a  percentage  of  the  activity  of  the  recombinant  non-mutated  PPI  of  L.  major  In  the 
same  conditions.  Assays  were  in  50  mM  HEPES  pH  8.0.1  mM  EDTA,  2  mM  TCEP,  200  PM 
pGlu-pNA,  at  3211C  and  measured  continuously  for  10  min  at  410  nm.  The  K,,  of  the  different 
enzymes  was  measured  for  the  substrate  pGlu-PNA.  N/A:  non  applicable. 
Mutant  Activity  remaining  Km  (pGlu-pNA) 
C21  OA  <0.5%  N/A 
H234S  <0.3%  N/A 
E101Q  2%  936  ±5  gM 
E107Q  50%  88  ±  26  pM 
4.2.5.  Cloning  of  the  glutaminyl  cyclase  gene  of  L.  major 
Database  searches  on  the  genomic  database  of  L.  major  using  the 
human  glutaminyl  cyclase  (QC)  as  a  query  (GenBank  accession  number  NP 
036545)  detected  a  2724  bp  open  reading  frame  translating  into  a  907  amino 
acid  protein  (GeneDB;  LmjF05.0950)  with  QC  features,  and  which  was  annotated 
as  a  putative  glutaminyl  cyclase.  No  other  sequence  with  QC  features  could  be 
detected  in  the  L.  major  database  (now  totally  sequenced),  which  suggested  that 
the  putative  QC  is  a  single  copy  gene  in  L.  major,  localised  on  chromosome  5. 
The  amino  acid  sequence  was  analysed  with  the  SignalP  algorithm  (Nielsen  et 
al.,  1997),  and  TMpred  (Hofmann  and  Stoffel,  1992),  and  a  trans-membrane 
domain  was  predicted  near  the  N-terminus  (position  120-144  on  the  predicted 
protein). 
0 
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The  results  of  the  5'  RACE  showed  a  mRNA  comprising  a  108  bp  5' 
untranslated  region  (UTR),  confirming  the  start  methionine  attributed  (Fig.  4.15). 
101  CTGCCTTTTC  TTTTCTGATG  CAACATCAAT 
GACGGAAAAG  AAAAGACTAC  GTTGTAGTTA 
FIG.  4.15.  L.  major  QC  5'  untranslated  region  (UTR)  determined  by  5'  RACE.  5'  UTR 
is  on  grey  background.  The  predicted  start  ATG  is  underlined. 
The  protein  was  aligned  with  the  human  QC  (Fig.  4.16).  A  schematic 
representation  of  the  alignment  is  shown  in  Fig.  4.17.  The  complete  L.  major 
protein  and  the  L.  major  QC  protein  fragment  from  position  408  to  907  showed 
little  overall  sequence  identity  with  to  the  human  QC  (11%  and  16%  identity, 
respectively).  However,  blocks  of  sequence  identity  were  observed  around  the 
active  site  residues  of  the  human  QC.  It  has  a  very  long  N-terminal  extension  of 
407  amino  acids,  which  contains  a  trans-membrane  domain,  whereas  the  human 
enzyme  possesses  a  signal  peptidase  for  localisation  in  the  secretory  system. 
This  suggests  a  different  location  for  the  L.  major  QC.  From  the  6  key  catalytic 
residues  in  the  human  QC,  5  were  conserved  in  L.  major  QC:  His-140,  Glu-201, 
Glu-202,  Asp-248  and  His-330  (human  enzyme  numbering).  The  Asp-159  was 
not  conserved,  but  in  the  human  QC  the  Asp  residues  are  not  thought  to  be 
involved  in  the  catalytic  reaction  (Bateman  et  al.,  2001).  The  L.  major  QC  has  a 
long  insertion  from  positions  733-757  (L.  major  QC  numbering)  of  unknown 
function.  By  computational  analysis,  it  is  unclear  if  the  L.  major  QC  may  be 
functional,  but  it  possesses  the  necessary  residues  for  activity. 
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1  80 
HsQC  (1)  ---------------------------------------------------------------------  --------  -- 
LmQC  (1)  MQHQSLAARRRGRRLARRGESAFWCSLLKRCLPCLPLRWKSVHATSRTRRILMGILLCLITTLIFLIGLLVCLTWKSNRS 
81  160 
HsQC  (1)  ------------------------------------------------------------------------------- 
LmQC  (81)  NTPLEPAAVQSTRAPRVPPEVGVEDPWAEDPVDVAVIRQREEAVVRKWKENGFRPTYWEVERRTLPRLTKRALESWFEHG 
161  240 
HsQC  (1)  -------------------------------------------------------------------------------- 
LmQC  (161)  RRAAASATAVDVAEDVLTAHAWDAVDGGDADADLFDSLAFLYPPAQQRQHYRAAMDAILRHGPRVGGTKRDALLHHLVDE 
241  320 
HsQC  (1)  -----------------------------------------------------------------------------  -- 
LmQC  (241)  GLGRRRYDAARRAYHPAPPHLSPRGKELLEKAAASWPDAPHLAAAPQDDVAGREPGWRWSLSWDNFTADI  PIRIDGSSRV 
321  400 
HsQC  (1)  ---------------------------------------------------------------------------  -- 
LmQC  (321)  EMQNLVFQFPGGLQFRRKQAAAASAAATGAKDALDEFVGGVPNRRRTRADDRKDVLEAEYHPADMTGETVYTQENFLQWA 
401  480 
HsQC  (1)  -------  MAGGRHMREVBILHLIVLLVIALPWASRGVMPE-  SIIWP  -  EEKNYHQPJIMNSSALRQIAEGTS  I  SEMWQNDLQP 
LMQC  (401)  QDGVPFNPRPALV"PHIRV',  JISPE§KGARVPLKPILIMPIAEPATQQPVKH"IAAliWDSKYFADI  PFI  AACDý;  AMPV 
481  560 
HsQC  (73)  LLIIIYPGS  PGSYAARQH  I  MQRIQRLQADWJLEI[ITFLSQTPYGYRSFSNI  I  STLNPTAKRHIVLACIYL).,;  Kil-'ý;  IIWNNR 
LmQC  (481)  VFLLMT  I  KNIAVLTDVAEALTESYKAERSCMVGG3ASAAVPGLTSTFRNATTEAEVRERIArllýý;  1114111AI'  I  JJQY  FFARP 
561  640 
HSQC  (153  VFVBATDSAVPCF&NMLELARALDKKLLSLKTVSDS  KJDLSLQLj]FflýFL=PQjP  1,8H!  EHMlA  F  MAMI  IP  PGA 
LMQC  (561ý  YSIIGEQQNFVALW,  -IRNHPTKVEVDVRTWLDWVQHLJI--IISVILSIM-yKý,  DMN,  Iiliý,  )PWj,,  w!;  VMRS 
641  720 
HsQC  (233)  O"s  --  -QLHGMS!  L'ýl!  LZ!  IIAPNPMPIFFINSARWMER-IQAIDIEHELGLLKDIIýý,  lýE(-,  PYFQ)NIý;  Y(;  GV 
LMQC  (639)  -'AjjFA4jYM"PAGTMRMMYjjTQSG  IMYAGISQR2WMRHRAMQHSSAI  SAE  I,  I,  Wl,  '51)1-:  A'I'A  1,  PPAE 
721  800 
HsQC  (303)  IQDLý  --------------------------------------------- 
LMQC  (719)  AREY.  11M,  GSPHEAVASLNAAYTRRLLANNASRPSVASLPRSWLMYGSPHEMLTI,  Ilý;  VAIýl"I'll[)VRl-'Vl-:  NFDQLR 
801  -  880 
HBQC  (317)  ----  ----------------------------------------------- 
LmQC  (799)  VYDRLDREIAAESSFDAERYLNTINHNIFFSPSQQEDLRRNRDVFVADDDHKIiWLDTQPlUMIMK!;  MMi\NlM;  ý; 
881  907 
HsQC  (338)  MLDE  IDNjNKILkVF'a]rLHL  ----- 
LMQC  (879)  IVHDISTDMAGIIWSTMLGDYWTRKE 
FIG.  4.16.  Alignment  of  the  glutaminyl  cyclase  (QC)  of  L.  major  with  the  human  QC. 
Dashes  indicate  gaps  in  the  alignment.  Active  site  residues  are  starred.  Conserved  residues  are 
on  black  background.  The  predicted  signal  peptide  is  underlined.  Lm,  Leishmania  major  (GeneDB 
CDS:  LmjFO5.0950);  Hs,  Homo  sapiens  (Song  et  al.,  1994). 
L.  major 
1  120  144  548  183  607/8  658  872  907 
361 
FIG.  4.17.  Schematic  comparison  of  the  QC  of  L.  major  and  the  human  QC.  TIVI,  trans- 
membrane  domain;  SP,  signal  peptide.  Amino  acids  are  represented  using  the  single  letter  code. 
Numbers  indicate  the  positions  for  the  various  domains/amino  acids. 
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4.2.6.  Recombinant  expression  of  the  glutaminyl  cyclase  gene  of  L.  major  in 
E.  coli 
The  sequence  encoding  the  L.  major  QC  without  the  trans-membrane 
domain  from  amino  acid  position  145  to  907  (L.  major  QC  numbering),  and  the 
sequence  encoding  for  a  fragment  of  the  L.  major  QC  from  amino  acid  position 
408  to  907  (L.  major  QC  numbering),  aligning  with  human  QC  from  position  29 
(the  start  of  the  human  QC  without  the  signal  peptide)  were  amplified  and  cloned 
into  the  pET28a(+)  vector  for  recombinant  expression  in  Ecoli.  The 
corresponding  plasmids  are  represented  in  Fig.  4.18  and  Fig.  4.19. 
Smal 
rial  (1340) 
LmQC 
Ncol(2239) 
(2902) 
2960) 
lacl 
FIG.  4.18.  Construct  for  expression  of  recombinant  QC  of  L.  major  in  E.  coli. 
Schematic  representation  of  the  plasmid  resulting  from  the  cloning  of  the  sequence  of  the  QC  of 
L.  major  from  position  145  to  907  in  the  pET28a(+)  vector  (Novagen)  for  expression  of  the  QC 
with  a  N-terminal  His-tag.  Kan,  kanamycin  resistance  gene;  f1  origin,  origin  of  replication  of  the 
phage  fl;  lacl,  gene  encoding  the  lac  repressor  protein. 
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Sm 
Clal 
Xshort 
mal  (1340) 
Ndel  (1606) 
Ncol  (1664) 
FIG.  4.19.  Construct  for  expression  of  recombinant  truncated  OC  of  L.  major  in  E. 
coli.  Schematic  representation  of  the  plasmid  resulting  from  the  cloning  of  the  sequence  of  the 
QC  of  L.  major  from  position  408  to  907  in  the  pET28a(+)  vector  (Novagen)  for  expression  of  the 
truncated  QC  with  a  N-terminal  His-tag.  Kan,  kanamycin  resistance  gene;  f1l  origin,  origin  of 
replication  of  the  phage  fl;  lacl,  gene  encoding  the  /ac  repressor  protein. 
E.  coli  BL21  (DE3)  cells  transformed  with  the  plasmids  were  induced 
either  for  4h  at  370C  with  1  mM  IPTG  (Fig.  4.20),  or  for  4h  at  200C  or  150C  with 
1  mM  IPTG  (results  not  shown).  With  the  pETLmQC  plasmid,  an  over-expressed 
protein  of  about  98  kDa,  corresponding  to  the  expected  size  for  N-terminal  His- 
tagged  protein  could  be  detected,  and  with  the  pETLmQCshort  plasmid,  an  over- 
expressed  protein  of  56  kDa,  corresponding  to  the  expected  size  for  N-terminal 
His-tagged  protein  (55.7  kDa)  could  be  detected,  but  it  was  found  in  the  insoluble 
fraction  of  E.  coli  lysates  in  all  cases  (results  shown  for  induction  at  370C  only, 
Fig.  4.20).  The  expression  in  E.  coli  did  not  result  in  production  of  soluble  protein 
for  enzyme  characterisation. 
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A  Mr 
50- 
20- 
- 
--ý  4 
B 
50 
20 
FIG.  4.20.  Analysis  of  expression  of  N-terminal  His-tagged  QC  of  L.  major  in  E.  coli 
BL21(DE3).  Ten  pl  samples  were  separated  on  a  SDS-PAGE  gel  (12%  acrylamide)  and  then 
stained  with  Coomassie  blue.  Lane  Mr,  protein  standards.  10-3  XMr  is  indicated  on  the  left  of  the 
figure.  (A)  Analysis  of  expression  of  the  full  length  QC  of  L.  major.  Lane  1,  E.  coli  total  cell  lysate 
after  4h  induction  at  370C  with  1  mM  IPTG.  (B)  Analysis  of  expression  of  the  truncated  QC  of  L, 
major.  Lane  1,  E.  coli  total  cell  lysate  after  4  In  induction  at  370C  with  1  mM  IPTG.  Arrows  indicate 
the  over-expressed  QC. 
4.2.7.  Analysis  of  potential  genes  for  pyroglutarnyl  pepticlases  11  of  L.  major 
Database  searches  on  the  genornic  sequence  database  of  L.  major 
using  the  human  PPIl  as  a  query  (accession  number  NP  037513)  detected  3 
potential  genes  for  metal  lopeptidase  (clan  MA(E),  family  M1)  PPIls  in  L.  major, 
LmjF29.2240,  LmjF26.0300,  LmjF12.1250,  all  annotated  as  aminopeptidase-like 
proteins,  and  respectively  located  on  chromosomes  29,26  and  12. 
The  proteins  were  aligned  with  the  human  PPII  (Fig.  4.21).  The  similarity 
table  is  presented  in  Table  4.7.  Two  of  the  L.  major  proteins  showed  good 
similarity  (42-44%)  to  the  human  enzyme,  whereas  the  last  one  was  not  very 
similar  (11  %  similarity).  However,  the  predicted  active  site  residues  (Schomburg 
et  al.,  1999)  were  all  conserved  between  the  different  proteins.  The  3  L.  major 
putative  enzymes  had  the  typical  metal-binding  motif  HEXXH  (Schomburg  et  al., 
1999)  at  position  440-444  (human  numbering).  Studies  for  the  presence  of  PPll- 
like  activities  in  L.  major  are  described  in  chapter  5. 
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FIG.  421.  AlIgnm*nt  of  th*  pot*ntlal  pyroglutamyl  peptidases  11  (PPIQ  of  L  major 
with  Ow  human  PplL  Dash"  indca-.  0  gaps  in  Via  aligninent.  Active  site  residues  are  starred. 
Qwmerls*ed  nmidues  we  an  bLack  background.  Conservative  residues  are  on  grey  background 
Lm.  Lsahfnania  mabr(Ger*08  CDS:  (1)  LrniF292240.  (2)  LmjF26.0300,  (3)  LrrýF12.1250);  Hs, 
"Orno  Sapieru  (S&Omburg  of  a,,  I  Mý 
Tatie.  4.7.  Similarity  table  of  the  L  mglor  predicted  pyroglutamyl  peptidases  11 
(PRO  *rIth  the  human  PPIL  Ntxnbers  represent  percentage  of  identity.  Hs.  Homo  sapiens;  Lrn, 
L  major. 
HSPPII  Lmppll  (1)  LMPPII  (2)  LMPPII  (3) 
HsPPII  100  42  44  11 
LnPPu  (1)  100  51  17 
LfnPPII  (2)  100  15 
LmPpii  (3)  100 
4.3.  Discussion 
Cysteine  peptidases  In  Leishmania  have  been  shown  to  play  an 
Important  role  In  parasite's  survival  and  pathogenicity  (Mottram  et  aL,  2004).  By 
database  mining  of  the  L  major  genomic  database.  using  the  human  cysteine 
PePtidase  of  clan  CF.  family  C13,  pyroglutamy!  pepbdase  I  (Dando  et  aL,  2003), 
a  single  Sequence  coding  for  a  PPI  in  L  rwjor  was  identified.  The  sequence  was 
amplirled  from  genomic  DNA  and  the  predicted  protein  contained  the  cysteine, 
histidine  and  glutamic  acid  catalytic  triad.  but  surprisingly  low  identity  with  other 
PPIS  from  different  organisms  (Table  4.3).  The  reason  for  this  is  unclear,  but 
mightSuggest  a  very  different  role  for  the  enzyme  in  L  major  compared  with  that 
In  humans.  In  humans.  the  enzyme  may  be  involved  in  the  cleavage  of  bloactive 
Peptides,  such  as  neuropeptides  (Dando  et  aL.  2003).  which  the  parasite  lacks.  It 
Is  unknown  what  may  be  the  L  m1or  PPI  natural  substrates,  but  this  would  be 
very  Informafive  on  the  role  that  the  enzyme  might  have  in  the  parasite.  Database 
searches  revealed  that  352  artnotated  proteins  start  with  Met-Gin  in  L  major,  and 
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can  potentially  be  pyroglutamyt-modified  after  cleavage  by  a  methionine 
arninopeptidase.  This  could  be  Investigated  by  a  proteomic  approach,  in  which  L. 
Imior  cell  lysates  would  be  treated  with  a  broad  substrate  specificity 
aminopeptidase.  In  order  to  degrade  unblocked  peptides,  and  compare  With  cell 
lYsates  fast  treated  with  PPI  before  treatment  with  the  same  aminopeptidase.  The 
difference  beh%*een  the  2  samples  would  theoretically  correspond  to  pGIu- 
modified  Peptides.  which  could  be  identified  by  mass-spectrometry. 
The  recombinant  L  major  PPI  was  produced  in  E.  coli,  and  about  4  mg 
of  soluble  enzyme  could  be  purified  from  a11  culture.  The  characteristics  of  the 
enzyme  conform  to  what  is  expected  for  a  marnmalian  PPI;  it  is  strictly  dependent 
On  reducing  agent  (Fig.  4.7).  it  has  an  alkaline  pH  optimum  (Fig.  4.10),  and  it  is 
active  as  a  nxxiorner  (Fig.  4.12).  The  very  high  pH  optimum  might  be  real  or 
artefactual  of  recombinant  expression.  as  it  is  unclear  what  biological  significance 
this  May  have.  The  PPI  did  not  have  a  signal  peptide  or  a  trans-membrane 
domain  predicted.  making  it  suggestive  the  enzyme  would  be  cytosolic,  as 
expected  for  the  other  PPIs.  The  localisation  of  the  PPI  in  L  major  is  investigated 
in  chapter  5.  The  free-living  prornastigotes  propagate  in  the  alimentary  tract  of 
the  sandfly.  primarily  in  the  midgut  where  the  pH  is  rather  alkaline  (7.0-9.0),  and 
the  nOn-MWe  arnastigotes  reside  in  phagolysosomes  of  mammalian 
macrOPhages.  whose  environment  is  acidic  (4.5-5.5),  but  the  intracellular  pH  is 
maintained  close  to  neutrality  (6.4-6.7)  at  all  times  (Zilberstein  et  aL.  1989).  It  is 
unclear  why  a  cytosok  enzyme  might  have  such  a  high  pH  optimum.  In  terms  of 
substrate  Specificity.  it  cleaves  preferentially  pGlu  synthetic  substrates,  but  can 
also  cleave  glutarnic  acid  as  a  N-terminal  residue  (Fig.  4.13),  which  is  unreported 
for  Marnfrialian  enzymes.  This  suggests  that  leishmanial  PPI  may  have  a  slightly 
different  conformation.  which  allows  Glu  to  bind  to  the  active  site  pocket. 
However.  it  cannot  be  excluded  that  this  activity  might  be  due  to  the  presence  of 
a  Small  amount  of  pGlu  In  the  Glu  substrate.  as  cyclisation  of  Glu  to  pGlu  is  also 
possible  (SchMing  et  at.  2004).  Activity  against  N-terminal  glutamine  may  be 
zero  (Fig.  4.14).  as  spontaneous  chemical  conversion  of  the  synthetic  substrate 
to  the  PGlu  derivative  would  Invalidate  the  assay.  The  recombinant  enzyme  is 
currently  being  tested  for  substrate  specificity  by  our  collaborators  (Juliano  and 
CD"wcfker3.  Sao  Paolo,  Brazil).  The  Kn  against  the  pGlu  substrate  falls  within  the 
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range  of  expected  Ka  values  reported  for  mammalian  PPIs  against  synthetic 
pGlu  substrate  (20  to  80  pt.  1)  (Mantle  et  aL.  1995.  Cummins  and  O'Connor,  1998; 
Dando  el  al..  2003).  and  not  the  range  for  the  bacterial  enzymes  (1180  to  250  tLM) 
(Le  Saux  el  aL,  1996;  Ito  et  aL.  2001).  The  inhibition  pattern  was  similar  to  the 
human  PPI  (Dando  et  aL.  2003);  L  major  PPI  was  inhibited  by  transition  metal 
ions  and  sylfhydr)i  bkx:  Wng  agents.  but  not  by  the  cysteine  peptidase  inhibitor 
E64  (rables  4A  and  4.5).  E64  is  a  potent  inhibitor  of  the  cysteine  peptidase  of 
the  clan  CA:  the  PPI  belongs  to  the  clan  CIF  and  possesses  very  few  common 
features  with  papain.  except  from  the  catalytic  mechanism  involving  an  active  site 
cYsteine  and  histidine.  The  clan  CIF  enzymes  are  not  produced  as  inactive 
Zymogens  that  require  activation,  as  it  is  the  case  for  the  clan  CA  enzymes,  but 
directly  as  mature  proteins.  The  L  rmlor  PPI  possesses  cysteine  residues, 
excluding  the  active  site.  %rhich  could  potentially  form  2  disulfide  bridges.  But  the 
POsitiOn  of  these  cysteine  residues  among  the  different  organisms  is  not 
cOnSereed.  making  the  presence  of  the  disuffide  bridges  less  likely  to  be 
important  for  activity. 
The  biochemical  characteristics  of  L  major  PPI  seemed  to  conform  to  the 
data  reported  for  the  marnmatian  PPIs,  and  this  is  consistent  with  the 
PhYlogenetic  anaWs  of  the  enzyme.  A  phylogenefic  tree  generated  using  the 
arignment  of  the  L  rwjor  PPI  Wth  various  PPs  from  different  organisms  (see 
Appendix  1)  showed  that  L  rwjor  PPI  is  more  closely  related  to  eukaryotic  PPIs 
than  bacterial  PPs  (Fog.  422). 
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FIG.  4.22.  Neighbour-joining  phylogenetic  tree  of  amino  acid  sequences  of 
pyroglutamyl  peptidases.  The  sequences  of  PPs  from  various  organisms  were  aligned  using 
Align  X  (Clustal  X,  Vector  NTI  program),  cut  to  the  same  amino  acid  length  (166)  and  insertions 
were  removed  manually.  The  bootstrapped  unrooted  phylogenetic  tree  was  generated  using  the 
MEGA  program  (Kumar  et  al.,  2001),  with  1000  bootstrap  replicates.  Eubacteria  are  on  dark  grey 
background,  Archeabacteria  are  on  light  grey  background,  and  Eukaryotes  are  on  white 
background.  L.  major  PPI  is  boxed.  The  scale  bar  indicates  the  number  of  estimated  amino  acid 
substitutions  per  site.  Abbreviations:  Cpe,  Clostridium  perfringens;  Spy,  Streptococcus  pyogenes; 
Sau,  Staphylococcus  aureus;  Tde,  Treponema  denticola;  Bam,  Bacillus  amyloliquefaciens,  Vvu, 
Vibrio  vulnificus,  Sce,  Streptomyces  ceolicor,  Rso,  Ralstonia  solanacearum;  Cvi, 
Chromobacterium  violaceum;  Pfl,  Pseudomonas  fluorescens;  Mtu,  Mycobacteriurn  tuberculosis; 
Pfu,  Pyrococcus  furiosis;  Tlit,  Thermococcus  litoralis;  Sso,  Sulfolobus  solfatanicus;  Ath, 
Arabidopsis  thaliana;  Cel,  Caenorhabditis  elegans;  Dme,  Drosophila  melanogaster,  Gga,  Gallus 
gallus;  Hs,  Homo  sapiens;  Xtr,  Xenopus  tropicalis;  Lin,  Leishmania  infantum;  Lmj,  Leishmania 
major,  Tb,  Trypanosoma  brucei;  Tc,  Trypanosoma  cruzi. 
165 
Eubacteria Chapter  4:  Expression  and  characterisation  of  recombinant 
pyroglutamyl  peptidase  /  of  L.  major 
By  active  site  mutagenesis,  the  catalytic  triad  cysteine-210,  histidine-234 
and  glutamic  acid-101,  predicted  for  a  PPI  enzyme  from  the  alignment  with  other 
PPls,  was  confirmed,  and  the  glutamic  acid-107  was  shown  possibly  to  play 
some  role  in  the  catalytic  reaction,  such  as  a  possible  substrate  stabilisation  in 
the  active  site  pocket,  without  being  essential  to  the  catalytic  reaction  (Table  4.6). 
The  presence  of  sequences  for  a  glutaminyl  cyclase  (QC)  were  analysed 
by  database  mining  using  the  human  enzyme  sequences.  One  potential  gene 
encoding  a  QC  was  detected,  with  very  little  sequence  identity  to  the  human 
enzyme.  The  L.  major  QC  had  a  predicted  trans-membrane  domain,  whereas  the 
human  enzyme  possesses  a  signal  peptide  for  localisation  to  the  secretory 
pathway  and  subsequent  modification  of  secreted  peptides  (Pohl  et  aL,  1991). 
This  suggests  a  very  different  local  isation/role  for  the  parasite's  QC,  if  Indeed  the 
protein  is  expressed  as  a  functional  enzyme  in  the  parasite.  As  5'  RACE  was 
successful,  mRNA  is  produced  for  the  enzyme,  but  this  is  not  indicative  of 
whether  or  not  the  enzyme  is  expressed,  as  the  sequence  may  be  part  of  a 
transcription  unit,  transcribed  as  a  polycistronic  pre-mRNA,  subsequently 
matured. 
The  L.  major  genomic  database  contains  3  potential  sequences  encoding 
metal  lo  peptidase  PPII  enzymes.  These  enzymes  all  contain  the  active  site 
residues  required  for  activity  but  only  2  of  the  predicted  proteins  show  good 
similarity  with  the  human  PPII  (42-44%  identity).  The  presence  of  sequences  for 
these  proteins  is  quite  surprising,  as  PPII  in  human  has  a  very  strong  specificity 
for  thyrotropin-releasing  hormones  (TRH),  thought  to  be  absent  in  parasites,  and 
it  would  unexpected  for  a  unicellular  organism  to  possess  enzymes  with  such 
degree  of  specificity.  The  clan  MA(E),  family  M1  of  metal  lo-aminopeptidases 
includes  a  whole  range  of  peptidases  cleaving  acidic,  neutral  or  basic  residues, 
and  it  could  be  that  the  L.  major  enzymes  with  PPII  similarities  just  happen  to 
share  the  features  classifying  them  in  this  clan,  without  being  able  to  cleave  a 
pGlu  residue  at  the  N-terminus.  The  presence  of  PPI,  QC  and  PPII  In  L.  major 
cell  extracts  is  assessed  in  chapter  5,  as  well  as  localisation  and  functional 
analysis  of  the  PPI. 
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Chapter  5 
Functional  study  of  the 
pyroglutamyl  peptidase  I  of  L.  major 
5.1.  Introduction 
It  was  shown  in  Chapter  4  that  L.  major  possesses  a  single  gene  encoding 
pyroglutamyl  peptidase  I  (PPI),  3  potential  genes  for  pyroglutamyl  peptidases  11 
(PPII),  and  I  potential  gene  for  a  glutaminyl  cyclase  (QC).  Functional 
recombinant  expression  of  the  PPI  of  L.  major  in  E.  coli  was  successful.  Tho 
presence  of  such  an  enzyme  in  L.  major  is  very  intriguing,  as  very  few  PPIs  of 
mammals  have  been  fully  characterised  so  far  and  a  definitive  physiological  rolo 
has  yet  to  be  attributed.  Bacterial  PPs  have  been  widely  used  for  unblocking  of 
the  N-terminus  of  proteins  prior  to  N-terminal  sequencing,  but,  as  with  tho 
mammalian  PPIs,  the  physiological  function  of  bacterial  PPs  is  still  unknown.  Tho 
leishmanial  enzyme  may  be  involved  in  protein  metabolism,  as  reported  for 
bacteria  (Awade  et  aL,  1994;  Ito  et  aL,  2001),  although  it  is  unclear  if  L.  major  Is 
able  to  produce  its  own  pGlu-modified  peptides,  as  the  gene  encoding  for  a  QC  Is 
only  putative.  Therefore,  it  would  be  of  interest  to  determine  the  enzyme's  natural 
substrate(s),  and  if  it  interacts  with  proteins  in  the  insect  vector  or  the  mammalian 
host,  and  consequently  contribute  to  the  parasite's  pathogenicity.  If  so,  tho 
parasite's  PPI  could  be  a  new  drug  target. 
In  order  to  investigate  the  function  of  the  PPI  in  the  parasite,  the  first  aim 
was  to  generate  gene  deletion  lines,  where  the  PPI  gene  would  be  replaced  by 
selectable  markers,  and  lines  over-expressing  PPI.  These  approaches  would 
give  information  on  whether  the  modification  in  PPI  expression  affected  the 
survival  of  the  parasite  in  vitro,  metacyclogenesis  and  infectivity  to  mice. 
Generation  of  PPI  knock-out  mutants  would  also  facilitate  study  of  whether  other 
PP  activities  are  present  in  L.  major  (for  instance  PPII  activities),  and  therefore,  if 
the  genes  encoding  putative  PPIls  are  expressed.  In  addition,  testing  the  effects 
of  pGlu-modified  peptides  such  as  gomesin  on  the  different  cell  lines  should  give 
insight  into  the  role  of  PPI  in  the  host-parasite  interaction,  and  whether  the 
enzyme  might  confer  protection  against  pGlu-modified  peptides  from  the  host  or 
the  insect  vector. 
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It  was  also  intended  to  carry  out  immuno-localisation  studies  to  investigate 
the  enzyme's  location  and  also  look  for  secretion. 
5.2.  Results 
5.2.1.  Over-expression  of  LmPPI  in  L.  major  promastigotes 
5.2.1.1.  Over-expression 
The  sequence  encoding  PPI  of  L.  major,  was  amplified  from  genomic 
DNA  and  cloned  into  the  derivative  of  the  pXG  vector  pGL102,  containing  a 
selectable  marker  (Neo  gene  from  transposon  Tn5  encoding  an  aminoglycosido 
3'-phosphotransferase)  for  use  with  neomycin,  for  over-expression  of  a  N- 
terminally  His-tagged  protein  in  the  parasites.  The  sequence  encoding  Ppl,  In 
which  the  active  site  cysteine  had  been  changed  to  an  alanine,  was  cloned  In  the 
same  way.  Both  were  transfected  into  L.  major  promastigotes.  As  a  control,  the 
empty  pGL1  02  vector  was  transfected  into  L.  major  promastigotes,  to  check  that 
the  over-expression  of  the  neomycin  resistance  gene  did  not  have  a  detrimental 
effect  on  the  parasite's  growth  or  survival.  All,  vectors  were  transfected  for 
expression  as  episomes  (free  plasmids),  andthe  maps  are  presented  In  Fig.  5.1. 
168 Chapter  5:  Functional  study  of  the  pyroglutamyl  peptidase  /  of  L.  major 
Ncol 
-ýno,  III 
'del 
LmPP 
Xmal 
Smal 
irnHI 
-,.  p  Ncol 
Ecc 
'del 
rnPP* 
-nHI 
-p 
E--jRl  tH 
Hinoill  (492ý 
amp 
Xmal 
smal 
arriHl 
Xm,  iI  (I  A6,  I) 
smal  (1366) 
liamfil  (1,  M) 
thild  111  (  1910  ) 
FIG.  5.1.  Constructs  for  over-expression  of  LmPPl  in  L.  major  promastigotos.  (A) 
Plasmid  for  over-expression  of  the  native  N-terminal  His-tagged  enzyme.  (B)  Plasillid  for  over- 
expression  of  the  active  site  cysteine  mutated  N-terminal  His-tagged  enzyme.  (C)  Empty  vector 
Neo,  neomycin  resistance  gene;  amp,  ampicillin  resistance  gene;  Lm,  L.  major. 
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5.2.1.2.  Analysis  of  over-expression 
Western  blotting  using  anti-LmPPI  antiserum  on  extracts  of  L.  major 
promastigotes  transfected  with  the  different  plasmids  revealed  high  over- 
expression  of  both  native  and  mutated  PPI  compared  to  control  cells  transfected 
with  the  empty  pGL102  vector  (Fig.  5.2).  A  major  protein  at  about  31  kDa,  the 
size  expected  for  the  N-terminal  His-tagged  PPI,  could  be  detected  in 
promastigotes  transfected  with  the  pGL102LmPPI  and  pGL102LmPPI*  plasmid, 
Over-expression  of  the  2  enzymes  (native  and  mutated)  seemed  to  be  at 
approximately  the  same  level.  No  protein  could  be  detected  in  the  pellet  fraction 
of  cell  lysates,  proving  that  the  enzyme  is  not  membrane-associated  (results  not 
shown).  The  acellular  fraction  of  cultures  of  the  different  cell  lines  was  TCA 
precipitated  and  the  equivalent  of  5  ml  of  medium  was  analysed  by  western  blot 
using  anti-LmPPI  antibodies,  but  no  signal  could  be  detected  (results  not  shown). 
This  suggests  that  the  over-expressed  enzymes  are  not  released  into  the 
extracellular  environment. 
Control  PPI*  PPI 
31  kDa  LA  *1**.  10 
FIG.  5.2.  Western  blot  analysis  of  the  over-expression  of  the  pyroglutamyl  poptidase 
I  (PPI)  of  L.  major  in  L.  major  promastigotes.  The  anti-PPI  of  L.  majot  antiscruni  raised  in  tot 
was  used  at  a  dilution  of  1.500  (v/v),  and  the  anti-rat  antibody  was  used  at  1:  1500  (v/v).  Tho 
membrane  was  exposed  for  3  min.  L.  major  promastigotes  were  grown  in  HOMEM  media 
supplemented  with  10%  (v/v)  HI-FBS  and  50  ýtg/ml  neomycin.  The  supernatant  extract  of  5x1O'  L. 
major  stationary  phase  promastigotes  was  loaded  in  each  lane.  Lane  control,  supernatant  of  cell 
lysate  of  cells  transfected  with  the  pGL102  empty  vector;  lane  PPI*,  supernatant  of  cell  lysate  of 
cells  transfected  with  the  plasmid  for  over-expression  of  the  active  site  cysteine  mutated  PPI.  lane 
PPI,  supernatant  of  cell  lysate  of  cells  transfected  with  the  plasmid  for  over-expression  of  the 
native  PPI, 
The  PPI  activities  present  in  the  different  fractions  of  cell  lystates  were 
investigated  using  the  substrate  pGlu-PNA,  and  the  activity  of  the  over- 
expression  lines  was  compared  to  the  control  cells  transfected  with  the  empty 
pGL102  vector.  The  PPI  activity  was  exclusively  associated  with  the  soluble 
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fraction  of  cell  lysate,  and  the  supernatant  of  cells  over-expressing  the  dead 
mutant  of  PPI  had  very  similar  activity  to  control  cells.  However,  the  supernatant 
of  cells  over-expressing  the  active  enzyme  had  about  7  times  greater  activity 
than  the  control  (Table  5.1). 
TABLE.  5.1.  Comparison  of  the  activity  towards  pGlu-PNA  of  L.  major 
promastigotes  over-expressing  native  PPI,  the  active  site  cysteine  mutant  of  the  enzyme, 
or  the  empty  vector.  Cells  were  grown  in  presence  of  50  pg/ml  of  neomycin.  The  equivalent  of 
8X1  07  stationary  phase  cells  were  tested  per  assay.  Assays  were  in  50  mM  HEPES  pH  8.0,2  mM 
TCEP,  I  mM  EDTA,  200  pM  pGlu-PNA,  at  3211C.  Measurements  were  continuous  for  10  min 
(excitation  320  nm,  emission  410  nm).  Activity  is  represented  in  comparison  with  the  control. 
Plasmid 
transfected  pGL102  empty  pGL102LMPPI*  pGLI02LmPPI 
Cell  lysate 
fraction  Pellet  Supematant  Pellet  Supematant  Pellet  Supematant 
Comparative 
<0.05  1  <0.005  1.2  10.3  <0.05  7  12 
activity 
The  dependence  of  the  over-expression  '6n'neomycin  concentration  was 
tested  by  growing  the  cell  lines  in  the  presence  of  different  concentrations  of  tho 
selection  drug.  The  supernatant  of  cell  lysates'was'  analysed  by  western-blot 
using  anti-LmPPI  antibodies,  but  no  difference  could  be  detected  In  tho 
expression  after  1  growth  cycle  (1  passage)  in  t_h,  e  different  neomycin 
concentrations  (Fig.  5.3),  suggesting  either  that  the  accumulation  of  episomes  is 
a  slow  process  and  several  cycles  of  growths  would  be  necessary  to  observe  a 
difference,  or  that  the  cells  reached  the  maximum  level  of  expression  tolerable 
even  at  the  lowest  neomycin  concentrations. 
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FIG.  5.3.  Dependence  of  the  over-expression  of  the  native  LrnPPl  in  L.  major 
promastigotes  cultures  on  the  amount  of  selection  drug.  The  anti-PPI  of  L.  major  antisertim 
raised  in  rat  was  used  at  a  dilution  of  1:  500  (v/v),  and  the  anti-rat  antibody  was  used  at  1:  1500 
(v/v).  The  membrane  was  exposed  for  3  min.  The  supernatant  Of  5X107  L.  major  cell  lysate  was 
loaded  per  lane.  Lane  1,  supernatant  of  cell  lysate  of  cells  grown  with  50  pg/ml  neomycin,  lane  2, 
supernatant  of  cell  lysate  of  cells  grown  with  100  pg/ml  neornycin;  lane  3,  supernatant  of  cell 
lysate  of  cells  grown  with  150  pg/ml  neornycin. 
To  test  whether  the  enzyme  was  released  into  the  extracellular  milieu, 
supernatants  of  cultures  of  the  different  cell  lines  were  TCA  precipitated  and  the 
equivalent  of  1  ml  was  loaded  on  a  SDS-PAGE  gel  and  used  for  western  blot 
analysis,  using  anti-PPI  antibodies.  No  signal  could  be  detected  in  any  of  the 
supernatants  of  cultures.  Furthermore,  100  [tI  of  crude  supernatant  of  cultures  of 
each  line  was  assayed  for  activity  towards  200  ýM  pGlu-IMA.  No  activity  coum 
be  detected  'in  any  case  (less  than  10  pU/ml  were  detected,  which  corresponds 
to  the  maximum  level  of  activity  detected  with  buffer  and  substrate  alone).  Thi's 
was  indicative  that  either  the  PPI  was  released  into  the  supernatant  of  culture  at 
a  level  that  was  not  detectable,  or  was  not  released  at  all. 
5.2.1.3.  Phenotype  analysis  of  PPI  over-expressing  cell  lines 
5.2.1.3.1.  Morphology  and  growth 
The  over-expression  of  the  PPI  in  L.  major  promastigotes  did  not  result  in 
any  difference  detectable  at  the  morphological  level.  In  terms  of  growth,  all  cell 
lines  were  able  to  multiply,  though  the  cells  transfected  with  the  empty  pGL102 
vector  grew  significantly  faster  from  day  3  to  day  6  and  the  final  cell  density 
higher  (about  1.5  fold  higher)  (Fig.  5.4).  The  cells  over-expressing  the  dead 
mutant  enzyme  grew  at  similar  rates  as  the  cells  over-expressing  the  active 
enzyme  but  reached  a  slightly  higher  density  (1.6  x  107/Ml  compared  to  1.3  x 
107/Ml  ).  Thus,  the  decrease  of  the  growth  rate  might  be  related  to  the  over- 
expression,  whereas  the  final  density  may  be  influenced  by  the  active  enzyme 
over-expressed. 
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FIG.  5.4.  Growth  curve  of  L.  major  pr9mastigote  cell  lines  over-expressing  the 
native  LmPPI,  the  active  site  cysteine  mutant  of  the  enzyme  and  the  empty  vector.  Cells 
were  grown  with  50  pglml  of  neomycin  and  counted  at  regular  intervals.  pGL102LmPPI,  cells 
expressing  the  native  PPI;  pGL102LmPPI*,  cells  over-expmssing  the  active  site  cysteine  mutant; 
pGL102,  cells  transfected  with  the  empty  vector.  Results  are  the  means  ±  SD  from  3  Independent 
experiments.  The  cells  transfected  with  the  empty  pGL102  vector  grew  significantly  faster  from 
day  3  to  day  6  compared  to  the  2  other  cell  lines  (P<0.05)  and  the'  cells  transfected  with  the 
pGLI  02LmPPI*  plasmid  grew  significantly  faster  than  the  cells  transfected  with  the  pGL1  02LmPPI 
plasmid  from  day  4  to  day  7  (P<0.05),  except  on  day  5. 
5.2.1.3.2.  Differentiation  to  metacyclic  promastigotes 
It  was  interesting  to  determine  if  there  was  a  difference  in  the  kinetics  of 
formation  of  infective  metacyclic  promastigotes  in  the  different  cultures. 
Metacyclic  promastigotes  were  separated  from  the  procyclic  promastigotes  using 
the  peanut  agglutinin  method  (Sacks  et  al.,  1985).  The  method  is  based  on  the 
observation  that  concentrations  of  peanut  adglutinin  necessary  to'agglutinate'the 
totality  of  log-phase  Leishmania  promastigotes  do  not,  agglutinate  metacyclic 
promastigotes.  The  difference  in  agglutination  is  due  to  developmental  regulation 
of  surface  lipophosphoglycans,  shed  by  procyclic  pr  omastigotes,  'and  acquisition  I 
of  new  carbohydrate  determinants  during  metacyclogenesis'(Saý6ks  and  da  Silva, 
1987).  It  was  shown  that  the  number  of  metacyclic'pr6mastigotes'in  the  culture  of 
cells  over-expressing  the  active  enzyme  increased  significantly  IM,  ore  slowly  than 
in  the  2  other  cultures  (Fig.  5.5),  though  these 
'metacyclic 
pro'mastigotes  were 
morphologically  identical  to  wild  type  cells.  The  measurements  were  taken  In 
duplicate  from  the  time  point  at  which  the  cells  entered  stationary  phase  of 
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growth  (day  4  after  initiation  of  the  cultures  at  106/ml).  'It  seemed  that  the  protein 
over-expression  was  not  responsible  for  this  slow  conversion,  as  the'cells  over- 
expressing  the  PPI  dead  mutant  produced  the  same'  number  of,  metacyclic 
promastigotes  as  the  control  cells.  Thus  it  seemed  that'over-expression  of  the 
active  PPI  resulted  in  slower  metacyclogenesis.  - 
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FIG.  5.5.  Production  of  metacyclic  promastigotes  in  L.  major.  Cells  were  grown  with 
50  pg/ml  of  neomycin  and  metacyclic  proportions  were  assessed.  using  peanut  agglutinin 
agglutination  at  regular  time  intervals.  pGLI02LmPPI,  cells  expressing  r  the  native  PPI; 
pGL102LmPPI*,  cells  over-expressing  the  active  site  cysteine  mutant;  pGLI02,  cells  transfected 
with  the  empty  vector.  Results  are  the  means  ±  SE  from  2  independent  measurements. 
pGLI02LmPPl  transfected  cells  produced  significantly  less  metacyclic  promastigotes  from  day  3 
compared  to  the  2  other  cell  lines  (P<0.05,  P<0.03  at  day  10). 
5.2.1.3.3.  In  vitro  infectivity  to  macrophages 
Infection  in  vitro  was  assessed  using  peritOneal  macrophages,  with 
stationary  phase  promastigotes  and  purified  metacYcl,  ic  promastigotes.  Infection 
with  stationary  phase  promastigotes  over-expressing  the  active  PPI  showed  a 
significantly  lower  level  of  infection  compared  -to  the  promastigotes  over- 
expressing  the  dead  PPI  or  the  empty  episome  (about  2  times  less)  (Fig.  5.6). 
But  when  the  macrophages  were  infected  with  purified  metacyclic  promastigotes, 
the  infections  rates  observed  with  the  different  cell  lines  were  very  similar  (all 
-around  40%).  The  culture  of  cells  over-expressing  the  active  PPI  contained  about 
2  times  fewer  metacyclic  promastigotes  compared  to  the  other  2,  lines,  Which  may, 
explain  the  lower  level  of  infection  when  total  populations  of.  promasticlotes  were 
used.  Using  a  ratio  of  metacyclic  promastigotes  of  0.51,  the  maximum  infection 
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rate  expected  would  be  around  50%,  which  fits  well  with  the  results  obtained;  and 
when  using  promastigotes  at  a  2:  1  ratio,  the  infection  expected  would  be  around 
2  times  the  percentage  of  metacyclic  promastigotes  in  the  culture.  In  this  case, 
the  infection  rates  obtained  are  slightly  higher;  this  may  be  due  to  loss  of  some 
macrophages  during  the  washing  steps.  Comparing  the  percentages  of 
metacyclic  promastigotes  in  the  different  cultures,  a  2-fold  lower  infection  rate 
would  be  expected  with  the  line  over-expression  the  active  PPI,  which  is  the 
case.  So  the  over-expression  of  the  active  PPI  seems  to  hinder  the  production  of 
metacyclic  promastigotes.  but  the  metacyclic  promastigotes  produced  are 
infective  for  macrophages. 
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FIG.  5.6.  In  vitro  macrophage  infection  by  L.  major  stationary  phase 
promastigotes  or  purified  metacyclic  promastigotes.  Promastigotes  were  infected  at  a  ratio  of 
2:  1,  metacyclic  promastigotes  at  a  ratio  of  0.5.1.  Percentages  on  the  bars  correspond  to  the 
percentage  of  metacyclic  promastigotes  in  the  stationary  phase  culture.  Incubations  were  for  6 
days.  pGL102LmPPI,  cells  expressing  the  native  PPI;  pGL102LmPPI*,  cells  over-expressing  the 
active  site  cysteine  mutant,  pGL102,  cells  transfected  with  the  empty  vector.  Results  are  the 
means  -- 
SD  from  3  independent  experiments.  The  infection  rates  obtained  using  pGL102LmPPI 
transfected  promastigotes  were  significantly  lower  than  the  ones  obtained  with  the  2  others  Cell 
lines  (P<0.004),  whereas  the  infection  rates  obtained  with  pGL102LmPPI*  and  pGL102 
transfected  promastigotes  were  not  significantly  different  from  each  other  (P>0.05).  Infection  rates 
obtained  with  metacyclic  promastigotes  from  the  different  lines  were  similar  (P>0.05). 
5.2.1.3.4.  In  vivo  infectivity  in  mice 
5x  10  :ý  stationary  phase  promastigotes  of  the  cell  lines  transfected  with 
the  pGL102LmPPI,  pGL102LmPPI*  or  pGL102  plasmids  were  inoculated  into  the 
footpad  of  BALB/c  mice.  The  evolution  of  the  infection  was  assessed  by 
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measurement  of  the  footpad  widths  over  time.  The  results  showed  that  cells  over- 
expressing  the  dead  mutant  were  infecting  as  well  as  the  cells  transfected  with 
the  empty  vector,  whereas  the  cells  over-expressing  the  active  enzyme  showed  a 
delay  in  infection  of  5  weeks  (Fig.  5.7).  The  over-expression  was  via  an  episomal 
plasmid,  and  the  selection  for  neomycin  resistance  was  not  Possible,  during  the 
experiment,  thus  it  was  expected  the  plasmid  would  probably  be  slowly  lost  over 
time.  Whether  this  process  would  take  5  weeks  to  occur  and  so  the  later  growth 
c)f  the  lesions  correlated  with  loss  of  the  over-expression  of  PPI'is  unknown.  To 
test  if  the  level  of  PPI  activity  might  be  related  to  the  size  of  lesions  formed, 
amastigotes  from  lesions  of  different  sizes  were  extracted  from  different  mice 
from  this  group.  The  cells  were  grown  to  stationary  phase  in  medium  without 
neomycin  to  mimic  the  conditions  in  the  mice,  and  PPI  activity  in  the  supernatant 
of  cell  lysates  was  measured  using  pGlu-PNA.  Interestingly, 
_ 
the  parasites 
extracted  from  the  smallest  lesions  (mouse  1)  presented  the  highest  level  of  PPI 
activity  (Table  5.2).  The  parasites  that  had  formed  lesions  of  the  same  size  as  of 
the  control  cells  (mouse  2)  at  the  time  of  termination  of  the  experiment,  showed  a 
very  similar  level  of  PPI  activity. 
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FIG.  5.7.  Mice  Infectivity  of  L  major  cell  lines.  5x1  05  cells  resuspended  in  20  lAl  of 
PBS  were  infected  into  one  footpad  of  BALBIC  mice.  Measurements  of  the  width  of  the  footpads 
were  taken  at  regular  intervals.  pGL102LmPPI,  cells  expressing  the  native  PPI;  pGLI02LmPPI*, 
cells  over-expressing  the  active  site  cysteine  mutant;  pGL102,  cells  transfected  with  the  empty 
vector.  Results  are  the  means  ±  SID  from  6  mice.  The  lesions 
^ 
provoked  by  pGLI02LmPpl 
transfected  cells  were  significantly  smaller  from  week  2  compared  to  the  2  other  cells  lines 
(P<0.0001),  and  the  lesions  provoked  by  pGL102  transfected  cells  were  only  significantly  bigger 
than  the  ones  provoked  by  pGL1  02LMPPI*  transfected  cells  from  week  2  to  4  (P<0.02). 
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TABLE.  5.2.  Comparison  between  Infected  mice  footpad  sizes  and  PPI  activity  of 
promastigotes  generated  from  extracted  amastigotes.  At  the  termination  time  of  the  mice 
infectivity  experiment  L  major  amastigotes  from  2  of  the  6  mice  infected  with  the.  L.  major  cell 
line  over-expressing  the  native  PPI  of  L  major,  and  from  1  of  the  6  mice  infected  with  cells 
transfected  with  the  empty  pGL102  vector  were  taken  from  the  footpad  lesions  and  grown  in 
medium  without  neomycin.  The  PPI  activity  in  the  supernatants  of  cell  lysates  were  measured  In, 
50  mM  HEPES  pH  8.0,2  mM  TCEP,  1  mM  EDTA,  200  ýLM  pGlu-PNA,  continuously  for  5  min  at 
32"G  (excitation  320  nm,  emission  410  nm).  8xl  07  cell  equivalents  were  used  per  assay.  Activity 
is  represented  in  comparison  to  activity  in  control.  pGL102LmPPI  (mouse  1),  cells  expressing  the 
native  PPI  and  extracted  from  the  footpad  of  the  mouse  with  the  smallest  footpad  size  from  the 
group;  pGL102LmPPI  (mouse  2),  cells  expressing  the  native  PPI  and  extracted  from  the  footpad 
c)f  the  mouse  with  the  biggest  footpad  size  from  the  group;  pGL102,  cells  transfected  with  the 
empty  vector. 
Cell  line  pGL102LmPPI  pGL102LmPPI  pGL102  (mouse  1)  (mouse  2) 
Duration  of  mice 
footpad  10  10  6  infection 
(w  eks)  - 
Size  of  footpad 
at  end  of  2.40  4.20  4.50 
experiment 
(mm) 
Comparative  PPI 
activity  In  2  03 
supernatant  of  . 
cell  lysate  I  I 
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5.2.2.  Knock-out  of  LmPPI  gene  in  L.  major  pronnastigotes 
5.2.2.1.  Analysis  of  knock-out 
Using  5'  and  3'  specific  flanks  to  the  PPI,  a  plasmid  was  designed  for 
gene  knock-out  (Fig.  5.8).  The  selection  markers  used  for  the  first  allele  knock- 
out  was  the  blasticidin  S  resistance  gene,  and  the  selection  marker  used  for  the 
second  allele  knock-out  was  the  hygromicin  B  resistance  gene.  Two  knock-out 
lines  were  generated  from  independent  sequential  transfection  events  (lines 
KOPPa  and  KOPPb). 
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FIG.  5.8.  Construct  for  gene  knock-out  of  the  pyroglutamyl  peptidase  I  (PPI)  of  L. 
major.  Schematic  representation  of  the  plasmid  resulting  from  the  cloning  of  the  sequences  for 
the  5'  and  3'  flanks  of  the  PPI  of  L.  major  in  pGL345  (HYG)  or  pGL842  (BSD)  for  gene 
replacement  of  the  PPI.  amp,  ampicillin  resistance  gene-,  BSD,  blasticidin  resistance  gene-,  HYG, 
hygromycin  resistance  gene. 
Gene  replacement  was  first  confirmed  by  PCR  (Fig.  5.913)  (a  scheme  of 
the  locus  and  the  position  of  the  primers  used  is  shown  on  Fig.  5.9A).  A  single 
DNA  fragment  at  -1.4  kb  corresponding  to  the  wild  type  PPI  gene  was  amplified 
from  the  wild  type  cells.  With  the  single  allele  knock-out  line,  2  DNA  fragments 
were  amplified;  one  at  -1.4  kb  corresponding  to  the  wild  type  PPI,  and  one  at 
-3.2  kb  corresponding  to  the  blasticidin  resistance  gene.  In  the  knock-out  lines,  2 
DNA  fragments  were  amplified;  one  at  -3.2  kb  corresponding  the  blasticidin 
resistance  gene,  and  one  at  -4  kb  corresponding  to  the  hygromycin  resistance 
gene. 
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FIG.  5.9.  L.  major  PPI  gene  knock-out  confirmation  by  PCR.  (A)  Schematic 
representation  of  the  PPI  gene  locus  on  chromosome  34  and  the  result  of  the  PP/  gene 
replacement.  Block  arrows  indicate  ORFs.  Small  arrows  indicate  position  Of  PCR  primers.  1: 
checkKOPPFor;  2:  checkKOPPRev  (see  Table  2.1).  The  predicted  sizes  of  fragments  amplified 
by  PCIR  are  indicated.  LmPPI,  L.  major  pyroglutamyl  pepticlase  gene-,  DHFR,  dihydrofolate 
reductase  gene;  BSD,  blasticidin  resistance  gene;  HYG,  hygromycin  resistance  gene.  (B)  PCR 
analysis.  PCR  was  performed  on  genomic  DNA  with  primers  1  and  2  and  using  the  Long 
Template  PCR  System  (Roche)  and  10  pl  were  run  on  a1%  (w/v)  agarose  gel.  Lane  1,  wild  type; 
lane  2,  single  allele  knock-out  (11  allele  replaced  with  BSD  gene);  lane  3,  double  PP/  gene  knock- 
out,  clone  KOPPa;  lane  4,  double  PPI  gene  knock-out,  clone  KOPPb.  Clones  KOPPa  and  b  were 
generated  from  independent  first  and  second  allele  replacements.  The  positions  of  the  molecular 
size  markers  in  bp  are  shown  on  the  left  of  the  figure. 
Knock-out  cells  lines  were  also  confirmed  by  Southern-blot,  using  the  5' 
flank  sequence  as  a  probe  (Fig.  5.10).  On  the  wild  type  cells,  a  single  DNA 
fragment  at  -3  kb  corresponding  to  the  wild  type  PPI  gene  was  detected.  On  the 
single  allele  knock-out  line,  2  DNA  fragments  were  detected;  one  at  -3  kb 
corresponding  to  the  wild  type  PPI,  and  one  at  -3.7  kb  corresponding  the 
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blasticidin  resistance  gene  insertion.  In  the  knock-out  lines,  2  DNA  fragments 
were  detected;  one  at  -3.7  kb  corresponding  the  blasticidin  resistance  gene 
insertion,  and  one  at  -4.3  kb  corresponding  to  the  hygromycin  resistance  gene 
insertion. 
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FIG.  5.10.  L.  major  PPI  gene  knock-out  confirmation  by  Southern  blot.  (A)  Schematic 
representation  of  the  PPI  gene  locus  on  chromosome  34  and  the  result  of  the  PPI  gene 
replacement.  Arrows  indicate  ORFs.  The  predicted  sizes  of  the  BarnHIISnial  fragments  detected 
by  Southern  blot  using  the  5'flank  as  a  probe  are  indicated.  LmPPI,  L.  major  pyroglutamyl 
peptidase  gene;  DHFR,  dihydrofolate  reductase  gene;  BSD,  blasticidin  resistance  gene-,  HYG, 
hygromycin  resistance  gene.  (B)  Southern  blot  analysis.  Genomic  DNA  was  digested  with  BamHI 
and  Smal,  run  on  a  1%  (w/v)  agarose  gel,  blotted  on  nylon  membrane  and  hybridised  with  32p_ 
labelled  5'flank  sequence.  Lane  1,  wild  type;  lane  2,  single  allele  knock-out  (1  allele  replaced  with 
BSD  gene);  lane  3,  double  PP/  gene  knock-out,  clone  KOPPa;  lane  4,  double  PPI  gene  knock- 
out,  clone  KOPPb.  Clones  KOPPa  and  b  were  generated  from  independent  first  and  second  allele 
replacements.  Blot  was  exposed  for  8  days.  The  positions  of  the  molecular  size  markers  (bp)  are 
shown  on  the  left  of  the  figure. 
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The  PPI  activity  present  in  the  different  fractions  of  cell  lysates  was 
measured  using  the  substrate  pGlu-PNA,  and  the  activity  of  knock-out  lines  was 
compared  to  the  wild  type  cells.  PPI  activity  was  totally  absent  from  the  knock-out 
lines  compared  to  the  wild  type  cells  (Table  5.3). 
TABLE.  5.3.  Comparison  of  the  activity  towards  pGlu-PNA  of  L.  major  wild  type  and 
knock-out  cell  lines  for  the  PPI.  The  equivalent  of  8xi  07  cells  were  tested  per  assay.  Assays 
were  in  50  mM  HEPES  pH  8.0,2  mM  TCEP,  1  mM  EDTA,  200  [tM  pGlu-PNA,  at  3211C. 
Measurements  were  continuous  for  10  min  (excitation  320  nm,  emission  410  nm). 
Cell  line  KOPPa  KOPPb  Wild  type 
Cell  lysate 
fraction  Pellet  Supematant  Pellet  Supematant  Pellet  Supematant 
Activity 
(Pull  01  <5  <5  <5  <5  <5  100  ±  20 
cells) 
5.2.2.2.  Phenotype  analysis  of  PPI  knock-out  cell  lines 
5.2.2.2.1.  Morphology  and  growth 
Promastigotes  of  PPI  knock-out  lines  of  L.  major  did  not  show  any 
difference  detectable  at  the  morphological  level  compared  to  wild  type  cells.  In 
terms  of  growth,  all  cell  lines  multiplied  at  the  same  rate  and  reached  the  same 
final  density  as  the  wild  type  parasites  (Fig.  5.11).  Thus,  the  knock-out  of  PPI  did 
not  influence  the  growth  of  promastigotes  in  vitro. 
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FIG.  5.11.  Growth  of  L.  major  wild  type  and  PPI  knock-out  line  as  promastigotes. 
Cells  were  grown  without  selection  drug  and  counted  at  regular  intervals.  KOPPa  and  KOPPb 
correspond  to  2  different  cell  lines  obtained  from  individual  gene  knock-out  events;  PPI  knock- 
out  cell  lines;  wt,  wild  type  cells.  Results  are  the  means  ±  SID  from  3  independent  experiments. 
5.2.2.2.2.  Conversion  to  metacyclic  promastigotes 
The  percentage  of  metacyclic  promastigotes  in  the  populations  were 
determined  from  the  time  point  at  which  the  cells  entered  stationary  phase  of 
growth  (day  4  after  initiation  of  cultures  at  106  cells/ml).  There  did  not  appear  to 
be  a  difference  either  in  the  morphology,  or  the  kinetics  of  formation  of  metacylic 
promastigotes  over  time  between  the  knock-out  cell  lines  and  wild  type  cells  (Fig. 
5.12).  Thus,  the  knock-out  of  the  PPI  did  not  influence  the  conversion. 
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FIG.  5.12.  Metacyclogenesis  In  L.  major  wild  type  and  PPI  knock-out  cell  lines. 
Cells  were  grown  to  stationary  phase  and  metacyclic  promastigotes  proportions  were  assessed 
using  the  peanut  agglutinin  agglutination  test  at  regular  time  intervals.  wt,  wild  type',  KOPPa  and 
KOPPb  correspond  to  2  different  cell  lines  obtained  from  individual  gene  knock-out  events. 
Results  are  the  means  ±  SE  from  2  independent  measurements. 
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5.2.2.2.3.  In  vitro  infectivity  in  macrophages 
Infectivity  in  vitro  towards  peritoneal  macrophages  was  assessed,  using 
stationary  phase  promastigotes  and  purified  metacyclic  promastigotes. 
Prornastigotes  and  purified  metacyclic  promastigotes  from  wild  type  and  the  2 
independent  knock-out  lines  resulted  in  infection  rates  that  were  very  similar,  of 
about  60%  and  40%  respectively  (Fig.  5.13).  The  numbers  of  metacyclics  in  the 
different  promastigote  cultures  were  very  similar,  so  these  results  suggest  that 
the  knock-out  of  the  PPI  did  not  affect  infectivity  in  vitro. 
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FIG.  5.13.  In  vitro  macrophage  infection  by  L.  major  stationary  phase 
promastigotes  or  purified  metacyclic  promastigotes  of  wild  type  or  PPI  knock-out  cell 
lines.  Promastigotes  were  infected  at  a  ratio  of  2:  1,  metacyclic  promastigotes  at  a  ratio  of  0.5:  1. 
Percentages  on  the  bars  correspond  to  the  percentage  of  metacyclic  promastigotes  in  the 
stationary  phase  cultures.  Incubations  were  for  6  days.  WT,  wild  type;  KOPPa  and  KOPPb 
correspond  to  2  different  cell  lines  obtained  from  individual  gene  knock-out  events.  Results  are 
the  means  ±  SID  from  3  independent  experiments.  The  different  cells  lines  did  not  induce 
significantly  different  infection  levels  (P>0.05). 
5.2.2.2.4.  In  vivo  infectivity  in  mice 
Lesions  resulting  from  inoculation  of  mice  footpads  with  5x  105 
promastigotes  of  the  2  knock-out  cells  lines  grew  more  slowly  than  those  of  wild 
type  parasites,  showing  a  delay  of  about  2-3  weeks.  Subsequent  growth  was  also 
somewhat  slower  than  the  lesions  caused  by  wild  type  parasites  (Fig.  5.14).  The 
proportions  of  metacyclic  promastigotes  in  the  populations  of  promastigotes  used 
to  infect  were  determined  and  it  was  shown  that  while  wild  type  culture  contained 
12%  metacyclic  promastigotes,  the  PIPI  knock-out  lines  contained  6%.  It  was 
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unclear  if  the  difference  in  growth  of  the  lesions  was  due  to  the  difference  in 
numbers  of  metacyclic:  promastigotes  injected  into  the  footpads,  to  difference  in 
infectivity  of  the  metacyclic  promastigotes  in  the  different  cultures,  or  to  a 
difference  in  virulence  of  the  amastigotes  of  the  different  lines.  Therefore  the 
experiment  was  repeated  using  the  same  number  of  metacyclic:  promastigotes 
per  injection  for  all  lines.  In  this  case,  the  infection  rates  observed  for  all  3  lines 
(wild  type  and  2  lines  of  knock-out)  were  the  same  (Fig.  5.15).  So  it  seemed  that 
the  knock-out  of  the  PPI  gene  did  not  have  an  effect  on  infectivity  to  mice,  and 
that  the  delay  in  infectivity  observed  in  the  case  of  mice  infection  with  PPI  knock- 
out  promastigotes  may  have  been  due  to  a  difference  in  metacyclic 
promastigotes  numbers  compared  to  the  wild  type  line,  as  it  was  suppressed 
when  the  same  number  of  metacyclic  promastigotes  was  infected  for  each  lines. 
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FIG.  5.14.  Mice  Infectivity  of  L.  major  PPI  knock-out  and  wild  type  cell  lines.  5x1  05 
cells  resuspended  in  20  Id  of  PBS  were  infected  into  one  footpad  of  BALB/c  mice.  Six  mice  per 
cell  line  were  infected.  Measurements  of  the  width  of  the  footpads  were  taken  at  regular  intervals. 
KOPP,  knock-out  cell  lines  for  the  PPI;  wt,  wild  type  cells.  KOPPa  and  KOPPb  correspond  to  2 
different  cell  lines  obtained  from  individual  gene  knock-out  events.  Results  are  the  means  ±  SD 
from  6  mice.  The  infections  generated  by  wild  type  parasite  were  significantly  greater  than  the  2 
others  from  week  1  (P=0.0002),  and  the  infections  generated  by  the  2  individual  knock-out  lines 
were  only  significantly  different  from  each  other  at  week  4  (P=0.005)  and  week  5  (P=0.0017). 
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FIG.  5.15.  Mice  infectivity  of  L.  major  PPI  knock-out  and  wild  type  purified 
metacyclic  promastigotes.  105  purified  metacyclic  promastigotes  resuspended  in  20  pl  of  PBS 
were  infected  into  one  footpad  of  BALB/C  mice.  Four  mice  per  cell  line  were  infected. 
Measurements  of  the  width  of  the  footpads  were  taken  at  regular  intervals.  KOPP,  knock-out  cell 
lines  for  the  PPI;  wt,  wild  type  cells.  KOPPa  and  KOPPb  correspond  to  2  different  cell  lines 
obtained  from  individual  gene  knock-out  events.  Results  are  the  means  ±  SD  from  6  mice.  The 
infections  generated  by  the  different  cell  lines  were  not  significantly  different  (P>0.05). 
5.2.3.  PPI  locallsation  in  L.  major  promastigotes 
Immunolocalisation  studies  using  the  anti-LmPPI  antiserum  on  L.  major 
promastigote  cell  lines  (knock-out  for  the  PPI  gene,  wild  type  and  over- 
expressing  the  PPI  enzyme)  showed  the  enzyme  may  be  cytosolic  (Fig.  5.16). 
The  staining  was  not  associated  with  the  nucleus,  and  was  diffuse  throughout  the 
cytoplasm. 
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FIG.  5.16,  immunolocallestion  of  the  LmPPl  In  L.  major  promastigot"  using  anti- 
LmPP1  angswurn  raised  In  rat.  The  secondary  antibody  was  the  Alexa  FluorS  568  goat  anti-rat 
IgG  (Molecular  Probes)  at  a  dilution  of  1:  500  (v/v).  Blue  staining  corresponds  to  DAR  staining  of 
nucleus  and  kinetoplast;  red  staining  corresponds  to  PPI  localisation.  From  top  to  bottom,  pictures 
are:  differential  Interference  contrast  (DIC),  DAPI,  Alexa  FluorS  568  and  merged.  Wild  type:  L. 
major  wild  type;  KOPPa:  L.  mi*or  cell  line  having  both  alleles  for  the  PPI  gene  removed; 
pGL102LmPPI:  L  major  call  line  over-expressing  the  active  PPI  of  L.  major.  (A)  Anti-LmPPI 
antiserum  was  used  at  1:  500  (vtv).  (B)  No  Incubation  with  anti-LmPPI  antiserum,  wild  type  cells. 
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5.2-4.  Effect  of  the  natural  antimicrobial  peptide  gomesin  on  L.  major 
Gomesin  and  gomesin  analogues  were  kindly  provided  by  Dr  Antonio  de 
Miranda  (Sao  Paolo,  Brazil).  Gomesin  is  an  18-residue  cysteine-rich  peptide  from 
the  hemolymph  of  the  spider  Acanthoscurria  gomesiana,  carrying  2  disulfide 
bridges,  a  N-terminal  pGlu  and  a  C-terminal  a-amidation,  which  showed 
leishmanicidal  properties  (Silva  et  aL,  2000).  The  primary  amino  acid  structure  of 
gornesin  is  ZCRRLCYKQRCVTYCRGR*  (using  the  single  letter  amino  acid  code, 
were  Z  stands  for  pyroglutarnate  and  the  asterisk  indicates  a  C-terminal  cc-amide) 
(Silva  et  aL,  2000).  The  gomesin  analogues  were  [Ala']-gomesin,  where  the  N- 
terminal  pyroglutarnate  was  replaced  by  an  alanine,  and  Ac-[Alal]-gomesin, 
where  the  N-terminal  pyroglutarnate  was  replaced  by  an  acetylated  alanine. 
The  IC50  (inhibitor  concentration  required  to  reduce  by  50%  the  response 
obtained  with  untreated  cells)  of  gomesin  towards  wild  type,  PPI  over-expression 
or  PPI  knock-out  L.  major  cell  lines  at  the  same  culture  phase  (day  3  of  stationary 
phase,  day  I  being  the  day  cells  enter  stationary  phase)  were  all  similar  (around 
5  IN),  suggesting  the  over-expression  of  PPI  did  not  have  a  favourable  effect  on 
parasite  survival  in  the  conditions  tested  in  vitro  (Fig.  5.17).  The  N-terminal 
blocking  of  gomesin  was  not  essential  to  the  activity  of  the  peptide,  as  the 
unblocked  [Ala']-gomesin  was  still  toxic  to  L.  major  stationary  cells.  However, 
[Ala']-gomesin  showed  reduced  toxicity  (3-fold  reduction,  IC50  of  about  15  PM) 
towards  all  L.  major  cell  lines  tested  (Fig.  5.17).  The  replacement  of  the  N- 
terminal  pGlu  by  an  acetyl-alanine  slightly  decreased  the  toxicity  of  gomesin  (1.2 
to  1.5-fold,  IC50  of  about  7  pt%  but  not  as  much  as  unblocking  of  the  N-terminus. 
So  it  seems  that  the  pGlu  modification  plays  a  role,  but  is  not  essential  to 
gomesin's  toxicity.  Interestingly,  the  IC50S  of  the  different  compounds  towards  late 
log-phase  L.  major  promastigotes  (wild  type,  PPI  over-expressing  and  PPI  knock- 
out  cell  lines)  were  about  5-fold  lower  than  the  IC50  towards  stationary  phase 
promastigotes  at  day  3  of  stationary  phase  (data  for  wild  type  cells  are  shown  on 
Fig.  5.18).  The'  wild  type  culture  contained  about  15-20%  metacyclics 
promastigotes  at,  day  3  of  stationary  phase  (see  Fig.  5.13).  The  decreased 
susceptibility  of  stationary  phase  promastigotes  compared  to  log-phase 
promastigotes  was  probably  due  to  surface  remodelling  during  stationary  phase 
and  transformation  to  metacyclic  forms  (Sacks  and  da  Silva,  1987). 
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Fig.  5.17.  IC50  of  gomesin  and  gomesin  analogues  on  L.  major  cell  lines.  5x  10'ý 
stationary  phase  L.  major  promastigotes  (day  3  of  stationary  phase)  were  incubated  with  various 
concentrations  of  gomesin  (Silva  et  al.,  2000)  or  gomesin  analogues.  After  1h  incubation  at  250C, 
MTT  was  added  to  a  final  concentration  of  1  mg/ml.  The  samples  were  incubated  for  a  further  1h 
at  250C,  before  the  absorbance  at  620  nrn  was  read  in  a  microtiter  plate  reader.  wt,  L.  major  wild 
type;  pGL102LmPPI,  L.  major  cell  line  over-expressing  the  LmPPI;  KOPPa,  PP/  knock-out  L. 
major  cell  line.  [Ala']-gomesin,  the  N-terminal  pyroglutarnate  of  gomesin  was  replaced  by  an 
alanine;  Ac-[Alal]-gomesin,  the  N-terminal  pyroglutarnate  of  gomesin  was  replaced  by  an 
acetylated  alanine.  Values  are  the  means  ±  SID  of  3  independent  experiments.  The  ICý,,  Js  of  each 
compound  towards  the  different  cell  lines  were  not  statistically  different  from  each  other  (PAA), 
but  the  IC50S  of  the  3  compounds  towards  the  same  cell  lines  were  statistically  different  from  each 
other  (P<0.025). 
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Fig.  5.18.  Dependence  of  the  IC50  of  gomesin  on  L.  major  culture  phase.  5x  10'ý  wild 
type  late  log  or  stationary  phase  L.  major  Promastigotes  were  incubated  with  various 
concentrations  of  gomesin  (Silva  et  al.,  2000)  or  gomesin  analogues.  After  1h  incubation  at  250C, 
MTT  was  added  to  a  final  concentration  of  1  mg/ml.  The  samples  were  incubated  for  a  further  1h 
at  251C,  before  the  absorbance  at  620  nm  was  read  in  a  microtiter  plate  reader.  [Ala']-gomesin, 
the  N-terminal  residue  is  an  alanine;  Ac-[Alal]-gomesin,  the  N-terminal  residue  is  an  acetylated 
alanine.  Values  are  single  measurements  or  means  ±  SID  of  3  independent  experiments. 
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5.2.5.  Glutaminyl  cyclase  (QC)  and  PPII  activities 
In  order  to  determine  if  L.  major  possesses  a  QC  activity,  polyclonal 
antibodies  reactive  against  QC  of  L.  major  had  been  raised  in  rat  (see  Chapter 
4).  The  antibodies  were  used  on  western  blots  of  L.  major  promastigote  cells 
lysates,  but  no  protein  could  be  detected  at  the  size  predicted  for  the  full  length 
QC  (98  kDa)  and  many  other  proteins  could  be  detected  with  similar  intensities, 
suggesting  the  antiserurn  produced  was  of  poor  specificity  (results  not  shown). 
Measurement  of  the  enzyme  activity  of  QC  relies  on  the  use  of  an  indirect  assay, 
using  the  QC  as  a  primary  enzyme  for  cyclisation  of  the  H-Gln  substrate,  followed 
by  cleavage  of  the  cyclised  substrate  (pGlu)  by  PPI  (Chikuma  et  al.,  2004; 
Schilling  et  al.,  2002).  But  as  shown  in  Chapter  4,  spontaneous  cyclisation  of  H- 
GIn  substrate  does  occur,  making  the-  measurement  of  any  QC  activity 
problematic.  These  fluorometric  assays  do  not  permit  one  to  distinguish  the 
signal  generated  from  spontaneously  generated  pGlu  substrate  from  that  of  the 
enzymatically  produced  pGlu  substrate  (Chikuma  et  al.,  2004).  Precise 
quantification  of  pGlu  formed  from  the  H-Gln  substrate  in  presence  or  absence  of 
QC  requires  HPLC  analysis,  and  this  was  not  attempted.  Thus,  it  is  still  unknown 
if  L.  major  possesses  its  own  QC  activity  and  is  able  to  produce  pGlu-modified 
peptides. 
The  generation  of  knock-out  cells  lines  for  PPI  provided  a  good  means  to 
study  the  presence  of  other  PP  activities.  It  was  shown  that  under  the  assay 
conditions  for  PPI  activity,  no  activity  could  be  detected  against  pGlu-PNA  in  the 
knock-out  cell  line  promastigote  extracts  (Table  5.3).  The  same  assays  as 
described  in  Table  5.3  were  performed  in  a  buffer  composed  of  50  mM  Tris/HCI 
pH  8.0,  which  is  a  buffer  that  has  been  shown  to  be  appropriate  for  the 
measurement  of  QC  activity  (Czekay  and  Bauer,  1993).  No  activity  could  be 
detected  under  these  conditions  against  the  pGlu-PNA  substrate,  suggesting  the 
level  of  PPII  activity  was  too  low  for  detection  or  the  enzyme  was  absent  from  the 
cells. 
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5.3.  Discussion 
The  presence  of  a  pyroglutamyl  peptidase  I  (PPI)  sequence  in  L.  major  is 
most  intriguing,  as  one  presumed  role  of  PPI  is  to  inactivate  bioactive  peptides, 
such  as  neuropeptides  in  human,  which  the  parasite  apparently  lacks.  However, 
this  study  has  shown  that  the  parasite  indeed  possesses  such  a  PPI  activity 
(Table  5.1)  and  that  the  PPI  is  the  major,  if  not  the  only  PP  activity  in  L.  major 
promastigotes.  The  anti-QC  antiserum  of  L.  major  was  found  to  be  poorly 
specific,  and  the  absence  of  an  easy  straightforward  assay  for  the  QC  activity 
meant  that  I  was  unable  to  determine  if  L.  major  is indeed  able  to  produce  its  own 
pGlu-modified  peptides. 
Over-expression  of  the  PPI  in  L.  majorwas  successfully  achieved  using  an 
episomal  vector,  and  an  increase  of  5-9  fold  in  activity  in  the  cell  extract  against 
the  pGlu  substrate  could  be  detected  in  the  cells  over-expressing  the  active 
enzyme.  The  activity  was  exclusively  associated  with  the  soluble  fraction  of  cell 
lysates,  which  would  be  consistent  with  the  enzyme  being  cytosolic,  and  no  PPI 
protein  nor  PPI  activity  could  be  detected  in  the  supernatant  of  culture,  being 
suggestive  that  the  enzyme  is  not  released.  Immunolocalisation  study  of  the  PPI 
in  L.  major  promastigotes  showed  the  enzyme  is  cytosolic  and  is  not  found 
associated  with  a  particular  organelle  in  the  cell  (Fig.  5.16),  which  coincides  with 
what  was  found  for  other  PPIs  in  different  organisms  (Mantle  et  a/.,  1991). 
The  over-expression  of  the  active  PPI  in  L.  major  promastigote  did  not 
seem  to  influence  much  the  growth  of  the  parasite,  though  lower  cell  density  was 
reached  at  stationary  stage  (Fig.  5.4).  A  difference  was  detected  in  the  ability  of 
the  parasite  to  transform  to  infective  metacyclic  promastigotes  at  stationary  phase 
of  growth,  (Fig  5.5),  though  the  morphology  of  the  metacyclics  promastigotes 
produced  was  identical  to  that  of  wild  type  cells.  The  over-expression  of  the  active 
PPI  seemed  to  render  the  rate  of  production  of  metacyclic  promastigotes  very 
slow,  whereas 
' 
over-expression  of  the  dead  PPI  and  the  empty  episome  resulted 
in  cell  lines  with  comparable  metacyclogenesis  rates.  Both  formed  about  3-fold 
more  metacyclic  promastigotes  by  10  days  . than  did  the  cells  over-expressing  the 
active  PPI.  In  terms  of  infectivity  to  macrophages  in  vitro,  the  cells  over- 
expressing 
' 
the  active  PPI  showed  a2  times  lower  infectivity  rate  when  total 
promastigotes,  were  used,  but  no  difference  when  purified  metacyclic 
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promastigotes  were  used  (Fig.  5.6).  The  lower  infection  rate  may  be  explained  by 
the  lower  number  of  metacyclics  present  in  the  promastigote  culture,  and  though 
the  over-expressing  line  (for  the  active  PPI)  does  not  produce  as  many 
metacyclic  promastigotes  as  the  control  lines,  these  metacyclic  promastigotes  are 
as  infective  for  macrophages  as  metacyclics  purified  from  the  cells  over- 
expressing  the  dead  PPI  or  the  empty  episome.  In  vivo,  the  cells  over-expressing 
the  active  PPI  showed  a5  weeks  delay  in  infection  of  mice  footpads,  whereas 
cells  over-expressing  the  dead  PPI  showed  the  same  pattern  of  infection  as  the 
cells  over-expressing  only  the  selection  marker  (Fig.  5.7).  It  was  unclear  if  the 
delay  in  infection  might  correlate  with  the  amount  of  PPI  activity  present  in  cells, 
which  would  indicate  that  over-expression  of  the  PPI  in  an  active  form  is 
detrimental  to  infection  and  that  the  lesion  growth  with  this  line  was  due  to  slow 
loss  of  the  episome  in  the  absence  of  the  selection  drug  in  the  mice.  An 
alternative  possible  explanation  is  that  the  number  of  metacyclic  promastigotes 
injected  differed,  being  significantly  lower  in  the  culture  of  cells  over-expressing 
the  active  PPI,  though  the  5  week  delay  in  infection  observed  is  longer  than  what 
would  be  anticipated;  a2  week  delay  was  observed  when  5x  104  as  opposed  to 
5x  105  promastigotes  were  injected  (Susan  Baillie,  personal  communication).  So 
these  results  would  suggest  that  to  explain  a5  week  delay  the  number  of 
infective  metacyclics  promastigotes  in  the  culture  of  cells  over-expressing  the 
active  PPI  at  the  time  of  infection  would  have  to  be  more  than  10-fold  decreased 
compared  to  the  other  cultures.  Based  on  the  data  in  Fig.  5.5,  this  was  not  the 
case  as  the  number  of  metacyclics  promastigotes  was  at  the  most  4-fold 
decreased  in  the  PPI  over-expressing  cell  line  compared  to  the  other  2  lines  in 
cultures  at  the  same  phase  of  growth,  and  cultures  at  the  same  stage  of  growth 
were  used  for  mice  infections.  It  would  be  very  interesting  to  analyse  the  effect  of 
infecting  the  same  number  of  metacyclic  promastigotes  for  the  different  cell  lines 
in  the  mice. 
The  results  in  vivo  differ  slightly  from  the  results  in  vitro,  but  this  is  not 
unexpected  as  with  the  in  vitro  studies  only  the  ability  to  infect  isolated 
macrophages  is  tested,  whereas  with  the  in  vivo  investigations,  the  host's 
immune  response  may  have  an  influence  on  how  the  parasites  infect  (Liew  et  a/., 
1990;  Alexander  and  Russell,  1992).  As  an  example,  the  targeted  gene  disruption 
of  the  CPB  gene  array  of  L.  mexicana,  encoding  for  cathepsin  L-like  enzymes, 
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resulted  in  a  >80%  decreased  infectivity  to  macrophages  compared  to  wild-type 
parasites,  but  lesions  in  mice,  though  smaller  than  those  induced  by  wild  type 
parasites,  still  occurred  (Mottram  et  al.,  1996). 
Two  individual  knock-out  cell  lines  for  the  PPI  were  successfully 
produced  (Fig.  5.9  and  5.10).  The  absence  of  PPI  activity  did  not  result  in  a 
difference  in  morphology  or  growth  compared  to  the  wild  type  cells  (Fig.  5.11) 
and  metacyclic  promastigotes  were  formed  at  the  same  rate  in  stationary  phase 
cultures  of  the  knock-out  line  compared  to  the  cultures  of  wild  type  parasites  (Fig. 
5.12).  The  maximum  proportion  of  metacyclic  promastigotes  seemed  to  also 
depend  on  the  time  the  parasites  had  been  maintained  in  culture,  the  cells  freshly 
transformed  from  amastigotes  giving  higher  numbers  of  metacyclic  promastigotes 
(in  this  case,  wild  type,  and  knock-out  lines  have  been  maintained  in  culture  for  2 
weeks,  whereas  the  over-expression  lines  had  been  kept  for  16  weeks).  In  vitro 
infection  in  macrophages  showed  both  wild  type  and  knock-out  lines  were 
generating  the  same  levels  of  infection  (Fig.  5.13).  In  vivo  infection  in  mice  using 
the  same  number  of  promastigotes  (but  about  half  the  number  of  metacyclic 
promastigotes  in  the  knock-out  lines  compared  to  the  wild  type)  showed  a  delay 
in  infection  of  about  3-4  weeks  in  the  knock-out  lines  (Fig.  5.14).  To  test  if  this 
delay  was  due  to  the  different  number  of  metacyclic  promastigotes  infected  or 
difference  of  infectivity  of  the  metacyclic  promastigotes,  the  same  number  of 
metacyclic  promastigotes  was  injected  for  knock-out  and  wild  type  lines.  In  this 
case,  the  infection  rates  for  all  lines  were  comparable,  indicating  the  metacyclic 
promastigotes  produced  in  the  PPI  knock-out  lines  were  as  infective  to  mice  as 
the  wild  type  parasites  (Fig.  5.15). 
So  it  appears  that  the  over-expression  rather  than  the  knock-out  of  the 
PPI  activity  is  detrimental  to  the  parasites,  in  terms  of  infectivity  in  mice.  It  is  still 
unclear  what  may  be  the  significance  of  the  presence  of  such  an  enzyme  in  L. 
major. 
Upon  microbial  infection,  the  mammalian  host  has  at  its  disposal  various 
mechanisms  to  kill  the  pathogen.  The  first  barrier  involves  the  innate  immune 
system,  machinery  present  in  all  other  animals  and  also  plants  and  mainly 
composed  of  peptides  with  antimicrobial  activity.  These  peptides  are  cationic 
potent  antibiotics  of  15-45  amino  acids,  active  against  a  wide  range  of  organisms, 
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including  bacteria,  fungi  (Tang  et  a/.,  2002),  viruses,  protozoa  (Aley  et  al.,  1994; 
Lugli  et  al.,  2004),  and  tumour  cells. 
The  peptides  are  classified  in  different  families,  depending  on  their 
structure.  In  human,  there  are  2  main  families:  the  defensins,  divided  in  the  2 
classes  a-  and  P-defensins,  and  the  cathelicidins.  Many  of  the  P-defensins  and 
the  pro-mature  human  cathelicidin  carry  a  N-terminal  pGlu  modification  (Selsted 
et  al.,  1993;  Andersson  et  al.,  2002;  Sahl  et  al.,  2004).  Defensins  are  peptides 
with  3  disulfide  bonds  and  a  flat  dimeric  P-sheet  structure,  with  a  difference  in 
disulfide  bridges  pattern  between  the  (x-  and  P-class,  whereas  cathelicidins  are 
linear  peptides  free  of  cysteines  and  with  a  (x-helical  and  amphipatic  solution 
structure.  Other  antimicrobial  peptides  that  occur,  but  are  less  widespread,  have 
a  bias  in  certain  amino  acids,  like  proline,  arginine,  tryptophane  or  histidine 
(Boman,  2003).  a-defensins  are  produced  by  neutrophils  in  a  constitutive 
manner,  while  P-defensins  are  inducible  and  produced  in  neutrophils, 
macrophages  and  epithelial  cells,  where  they  act  as  anti-microbial  agents 
(Hoover  et  al.,  2001).  The  disulfide  bridges  are  essential  to  the  activity  (Torres 
and  Kuchel,  2004)  and  their  mechanism  of  action  relies  initially  on  electrostatic 
interaction  of  the  cationic  poles  of  the  peptide  with  negatively  charged  moieties 
on  the  target  cell  surface;  the  peptide  is  then  inserted  into  the  phospholipid 
bilayer,  and  diffusion  of  the  peptides  in  the  membrane  eventually  promotes  the 
formation  of  pores,  provoking  cell  lysis  (Boman,  2003).  Cathelicidin  production  is 
induced  in  the  epithelium  following  epithelial  wounding  and  infectious  challenge 
(Schaller-Bals,  et  al.,  2002).  In  human,  the  only  cathelicidin,  hCAP-18,  is 
produced  as  a  19  kDa  pre-pro-peptide,  with  a  conserved  cathelin-like  sequence 
in  the  pro-domain  and  a  variable  antimicrobial  C-terminal  sequence  (Gennaro  et 
al.,  1998).  Cathelin  is  a  12  kDa  peptide  isolated  from  porcine  neutrophils,  that 
shares  similarities  with  the  cystatin  superfamily  of  cysteine  peptidases  inhibitors 
(Scocchi  et  al.,  1997).  Two  distinct  activities  have  been  attributed  to  the  pro- 
domain;  a  role  of  inhibition  of  bacterial  growth,  and  a  role  of  inhibition  of  cysteine 
peptidase-mediated  tissue  damage  (Zaiou  et  al.,  2003).  The  C-terminal  fragment, 
namely  LL-37,  is  thought  to  provoke  cell  lysis  using  a  similar  mechanism  to  the 
defensins  (Sahl  et  al.,  2004).  The  pro-mature  precursor  is  targeted  to  granules  for 
storage,  and  upon  activation,  the  content of  the  granules  is  released  or  delivered 
to  phagolysosomes  (Sorensen  et  al.,  2001).  But  hCAP-1  8  is  not  processed  to  the 
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active  LL-37  form  in  the  phagolysosomes.  The  main  function  of  hCAP-18  seems 
to  be  extracellular,  where  LL-37  is  formed  and  acts  as  a  chemotactic  agent  for 
neutrophils,  monocytes  and  T  cells;  LL-37  seems  therefore  to  be  an  important 
mediator  of  the  extracellular  immune  activity  (Sorensen  et  al.,  2001). 
So  how  might  the  PPI  activity  in  L.  major  act  on  these  compounds?  First, 
as  the  activity  of  the  defensins  is  mainly  due  to  the  arrangement  of  disulfide 
bridges,  and  for  LL-37  to  the  amphipatic  properties,  it  is  unlikely  the  pGlu 
modification  at  the  N-terminus  of  some  of  these  compounds  might  play  a  role  in 
the  activity,  but  rather  in  the  stabilisation  of  these  compounds.  Furthermore,  the 
LL-37  compound  is  most  probably  not  active  in  the  phagolysosomes,  but  present 
as  the  inactive  hCAP-1  8  precursor. 
On  hypothesis  is  that  the  PPI  might  protect  L.  major  from  pGlu-modified 
natural  peptides  from  the  host,  by  either  cleaving  off  the  pGlu  residue  essential 
for  the  activity  of  the  peptide,  or  destabilising  the  peptides  by  making  them  prone 
to  exopeptidase  degradation,  one  would  expect  an  increase  in  the  infectivity 
when  the  active  PPI  is  over-expressed,  which  is  not  the  case  here.  In  the  case  of 
hCAP-18,  the  cleavage  of  the  N-terminal  pGlu  might  destabilise  the  protein  and 
make  it  more  likely  to  be  processed  to  its  active  LL-37  form  in  the 
phagolysosomes.  Although  release  of  PPI  activity  from  amastigote  cells  was  not 
tested,  the  PPI  enzyme  did  not  seem  to  be  released  from  the  parasite  cell  in 
promastigote  cultures,  and  would  therefore  have  to  act  on  internalised 
compounds.  PPI  seems  to  be  the  main,  if  not  the  only,  PP  activity  present  in  L. 
major  but  the  expression  of  other  PP  activities,  such  as  PPII,  in  the  amastigote 
stage  cannot  be  excluded. 
A  way  by  which  Leishmania  has  been  shown  to  evade  the  immune 
response  from  the  host  is  to  promote  phagocytosis  by  macrophages  and  so  avoid 
humoral  immunoglobulin  mediated  response.  The  presence  of 
lipophosphoglycans  (LPS)  on  the  parasite  cell  surface  makes  it  rather  resistant  to 
acid  hydrolases  released  from  the  lysosomes  upon  fusion  with  the  phagosome 
(Desjardins,  2003).  Resistance  to  Leishmania  has  been  shown  to  rely  on  the 
development  of  CD4+  Thl  cells,  which  promote  an  effective  cellular  mediated 
immune  response,  by  increasing  the  release  of  the  cytokine  IFN-y,  which 
promotes  macrophage  activation  and  parasite  killing  (Jones  et  al.,  1998).  On  the 
contrary,  susceptibility  to  Leishmania  infection  is  characterised  by  a  mainly  Th2 
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response,  promoting  the  release  of  IL-4,  which  stimulates  the  production  of 
immunoglobulins,  ineffective  against  phagocytosed  parasites.  Adaptive  immunity 
relies  on  the  degradation  of  the  pathogen  proteins  into  peptides,  which  can  be 
presented  on  the  surface  on  the  macrophage  as  antigens  in  conjunction  with 
MHC-I  or  -11  molecules,  and  trigger  a  cell  mediated  immune  response.  It  is 
unclear  though  why  the  over-expression  of  the  active  PPI  enzyme  may  lead  to 
decreased  infectivity  compared  to  over-expression  of  the  inactive  PPI,  and  the 
results  of  the  experiments  in  vivo  cannot  therefore  be  clearly  explained  by  an 
increase  in  antigenicity  when  the  enzyme  is  over-expressed  in  the  parasite  in  its 
active  form,  unless  major  structural  perturbation  has  occurred  in  the  mutant 
enzyme.  Furthermore,  the  PPI  enzyme  is  not  secreted,  and  immune  response 
would  have  to  be  triggered  by  released  PPI  from  dead  cells.  It  would  be 
interesting  to  determine  if  indeed  there  is  a  difference  in  the  immune  response 
generated  with  the  different  cell  lines  in  the  mice. 
Another  hypothesis  is  that  the  over-expression  of  the  active  PPI  may 
perturbate  some  essential  functions  in  the  parasite,  such  as  formation  of  infective 
metacyclic  promastigotes  and  infectivity  of  these  cells.  The  presence  of  a 
glutaminyl  cyclase  could  not  be  determined  in  the  promastigote  form  of  L.  major, 
due  to  lack  of  assay  for  the  enzyme.  The  gene  seemed  to  be  expressed,  but  no 
evidence  of  the  expression  of  the  protein  could  be  found.  Again  it  cannot  be  ruled 
out  that  the  cyclase  might  be  expressed  in  the  promastigote  form  or/and  in  the 
amastigote  form.  As  the  over-expression  -of  active  PPI  seemed  to  impair  the 
formation  of  metacyclic  promastigotes,  important  regulatory  proteins,  which  might 
carry  a  pGlu  modification  may  be  excessively  degraded  and  perturb  the  normal 
progression  to  metacyclic  form.  Also,  there  might  be  a  perturbation  of  the  signals 
involved  in  the  modulation  of  the  immune  response  in  the  host,  in  the  hypothesis 
pGlu-modified  peptides  might  be  involved.  So  the  over-expression  of  the  active 
PPI  might  influence  the  composition  of  pGlu  modified  peptides  in  the  parasite 
more  than  in  the  hosts,  hence  the  relevance  of  trying  to  determine  what  are  the 
natural  substrates  of  PPI  of  L.  major,  and  if  indeed  they  might  play  a  role  in  the 
parasite's  infectivity.  Mass-spectrometry  approaches,  involving  the  complete  N- 
terminal  degradation  of  whole  cells  peptide  extracts  from  wild-type  and  PPI 
knock-out  lines,  should  allow  the  isolation  of  the  totality  of  N-terminal  modified 
peptides,  and  the  subsequent  unblocking  using  the  PPI  would  allow  selection  of 
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all  modified  peptides  except  the  ones  carrying  the  N-terminal  pGlu.  By  proteomic 
analysis  on  2-dimensions  (2-D)  gels  of  the  different  treated  extracts,  N-terminally 
pGlu-modified  proteins  might  be  isolated  and  identified.  This  would  identify  the 
natural  substrates  of  PPI  in  the  parasites,  and  if  the  parasites  are  indeed  able  to 
generate  pGlu-modified  peptides  on  their  own. 
Another  possible  explanation  might  be  that  the  over-expression  of  the 
active  PPI  may  perturb  the  parasite  cell  in  a  non-specific  way,  as  a  result  of 
excessive  processing  by  the  PPI.  A  complete  analysis  of  the  substrate  specificity 
may  give  an  insight  on  what  other  residues  might  be  susceptible  to  cleavage  by 
the  enzyme,  especially  in  conditions  where  the  enzyme  is  used  in  excess.  The 
over-expression  of  the  active  enzyme  may  have  some  detrimental  effect  on  the 
cell,  not  only  specific  to  the  cleavage  of  pGlu  residues  on  the  proteins,  but  also  to 
other  possible  non-specific  cleavage  of  proteins. 
Could  it  be  that  the  enzyme  might  have  a  more  important  role  in  the  insect 
vector9  The  genome  of  the  Plasmodium  vector,  the  mosquito  Anopheles  gambia, 
has  been  extensively  searched  for  the  presence  of  anti-microbial  peptides.  Four 
defensins  and  4  cecropin  genes  have  been  shown  to  be  induced  in  the  insect 
vector  by  a  malaria  infection  (Christophides  et  al.,  2002).  But  none  of  these 
compounds  carry  a  pGlu  modification  at  the  N-terminus.  A  defensin-like 
antimicrobial  peptide  was  isolated  from  the  hemolymph  of  the  sandfly 
Phlebotomus  duboscqi,  a  vector  of  Leishmania.  The  peptide  showed  anti- 
parasite  properties  on  L.  major,  and  its  expression  was  induced  by  L.  major 
infection  in  the  insect  (Boulanger  et  al.,  2004).  The  peptide was  synthesised  as  a 
pre-pro-peptide,  the  sequence  of  the  pro-peptide  starting  with  a  glutamic  acid, 
which  could  potentially  be  cyclised  to  pGlu.  Gomesin,  the  antimicrobial  peptide 
from  the  spider  Acanthoscurria  gomesiana,  which  showed  leishmanicidal 
properties,  is  an  18-residue  cysteine-rich  peptide,  carrying  2  disulfide  bridges  and 
a  N-terminal  pGlu  (Silva  et  a/.,  2000).  The  IC50  of  gomesin  towards  wild  type,  PPI 
over-expression  or  PPI  knock-out  L.  major  cell  lines  were  all  similar,  suggesting 
the  over-expression  of  PPI  did  not  have  a  favourable  effect  on  parasite  survival  in 
the  conditions  tested  in  vitro  (Fig.  5.17).  This  suggests  a  different 
compartmentation  between  the  site  of  action  of  gomesin  and  the  localisation  of 
PPI  in  L.  major  promastigotes.  This  is  consistent  with  the  fact  that  cysteine-rich 
antimicrobial  peptides  promote  the  formation  of  pores  into  the  parasite's 
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membrane,  provoking  cell  lysis  (Boman,  2003),  and  that  PPI  is  a  cytosolic 
enzyme  that  is  not  released  by  L.  major  promastigotes.  The  N-terminal  blocking 
of  gomesin  was  not  essential  to  the  activity  of  the  peptide,  but  the  unblocked 
[Ala']-gomesin  showed  reduced  toxicity  (3-fold  reduction)  towards  all  L.  major  cell 
lines  tested  (Fig.  5.17).  The  replacement  of  the  N-terminal  pGlu  by  an  acetyl- 
alanine  also  decreased  the  toxicity  of  gomesin  (about  1.2-1.5-fold,  Fig.  5.17).  So 
it  seems  that  the  N-terminal  blocking  of  gomesin  is  not  essential  to  the  peptide 
toxicity,  and  that  the  toxic  activity  of  gomesin  mainly  relies  upon  features  that  are 
independent  from  this  N-terminal  blocking.  However,  the  N-terminal  pGlu 
modification,  or  N-terminal  blocking  by  acetylation,  is  favourable  to  the 
leishmanicidal  activity  of  gomesin,  probably  by  increasing  the  peptide's  stability. 
The  leishmanial  PPI  might  play  a  role  in  the  protection  against  pGlu-modified 
peptides  in  the  sandfly  vector,  provided  PPI  can  act  on  these  peptides.  The  study 
of  the  propagation  of  PPI  knock-out  and  over-expressing  cell  lines  in  the  insect 
vector  would  be  of  high  interest. 
So  in  conclusion,  no  phenotype  could  be  observed  in  the  PPI  knock-out 
cell  lines,  but  an  impairment  in  the  production  of  metacyclic  promastigotes  and 
infectivity  in  vivo  could  be  observed  with  the  active  PPI  over-expressing  lines. 
What  significance  could  this  have  in  terms  of  therapy?  The  over-expression  of 
PPI  is  not  likely  to  occur  in  the  field,  nor  can  the  induction  of  such  over- 
expression  be  easily  achieved.  Many  naturally  occurring  anti-microbial  peptides, 
in  mammals  and  insect,  carry a  pGlu  modification  at  the  N-terminus,  but  also  an 
amidation  at  the  C-terminus  (Silva  et  aL,  2000),  which  is  not  thought  to  play  a 
role  in  the  activity  of  the  peptides.  Post-transcriptional  modifications  are  more 
likely  to  stabilise  the  compounds.  Whether  the  cleavage  of  such  modification  in 
the  wild  may  impair  their  efficiency  in  a  significant  way,  is  unknown.  The 
mechanism  by  which  an  intracellular  enzyme,  not  secreted,  may  influence  the 
effect  of  the  extracellular  peptides,  thought  to  provoke  membrane 
destabilisation  of  the  microbial  agent,  is  unclear.  The  over-expression  of  the 
active  PPI  might  influence  the  composition  of  pGlu-modified  peptides  in  the 
parasite  more  than  in  the  hosts,  provided  L.  major  is  able  to  catalyse  the  N- 
terminal  glutamic  acid  cyclisation.  Thus,  a  gene  khock-out  of  the  glutaminyl 
cyclase  might  be  more  informative.  If  indeed  pGlu  modified  peptides  are  among 
regulatory  peptides  that  participate  in  metacyclogenesis  or  infectivity  in  vivo,  the 
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absence  of  cyclisation  may  have  some  detrimental  effect  on  the  parasite.  Very 
low  sequence  similarity  was  detected  between  the  putative  glutaminyl  cyclase 
of  L.  major  and  the  human  enzyme  (11  %),  which  could  potentially  make  the 
design  of  specific  inhibitors  to  the  L.  major  glutaminyl  cyclase  possible.  This 
may  be  more  realistic  in  terms  of  therapy.  But  no  reports  has  been  made 
previously  on  pyroglutamyl  peptidases  in  parasites,  and  no  biological  function 
has  been  attributed  to  the  PP  in  bacteria  yet,  though  they  have  been  known  for 
almost  30  years  (Exterkate,  1977).  Hopefully  the  years  to  come  will  bring  more 
knowledge  in  this  field  and  provide  insight  into  the  roles  of  PPs. 
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226 Appendix  1 
Alignment  of  the  edited  pyroglutamyl  peptidase  sequences  for 
generation  for  the  phylogenetic  tree  (Fig.  4.22) 
1 
AthPPI  (1)  FKKFHGVAEMPTEKMANNLKDVNGCTVLETAGQGALýA'-ý1,  YQI,  I,  Q!,  AVN'I'Ki-:  ý;  ý;  ý,  "I  IWV11F,;  VGAT  IHITV 
BamPPI  (1) 
W 
VLLTZFDPFGGETVIPSWEAVKRLNAAEPASIVSEQVPTVFYKSLAVLREAIKKIIQPI)I  I  ICVGQA(;  GRM 
CelPPI  (1)  VVVT'IFGPFRGFEEMPSSIIIDELTGISGVDLELHKITVAYEDVSKKVPELWNF:  IIKPI)LVIII1,  GAIII'Vi-:  K 
,  ' 
CpePPI  (1)  ,  IGQA(,  GRl- 
VLITý1,  FDPFGGESIMPAI,  EAVKMIPNIEGAQVIKLEIPTVFRKSLEKIEEKIEEINPI)ýVI.  l 
CvippI  (1)  VLLT6qFEPFGGETVMPSWEAARQLDTIAGARVHARLLPCEFGAALDELYRQLDAI,  RPI)VA  I  AVGýW;  GRP 
DmePPI  (1)  WFGPFLGHAVMASWEAVKLLPHDGIYDLEKRLVSVEYGAVDEAVAEIWKRQ)NPý'LVIIIVGVý;  (',  VAK  IVVS 
GgaPPI  (1) 
W 
VSRQEFGPFRQYLVISSWEAVKELSGLGNIDLRIMQLPVVYQKAKEQIVRIW'FI'1,11P  I  LTVIIVGI  A!,  AKA 
HsPPI  (1)  VVVT*EFGPFGEHTVMASWIAVQELEGLGDVDLHVYEIPVEYQTVQRLIPALWEKIISPQLVVIIVGV!;  ("MAT 
LinPPI  (1)  VFITTWYGPFATVFVMPSý;  )I  ALRVVMRYTLDVSVTTVAAYFEKVEREIADI  I  AEIIGA  I  LI,  CIII,  GVlINTTG 
LmjPPI  (1)  YGPFATVKVMPS,  ')I)IALRVAVRYTLDVSVTSVAAYFEKVERDTADI  IAI-:  11(;  AILI,  ('111,  GVIIN'l"I'G  VFIT469 
MtUppI  (1) 
, 
WP,  %Q'-TAEELDTIAGATVISRIVPNI'FFESIAAAQQAIAEIEPALVIMI, 
Gl-:  YIIGR:;  VLVTT,,  FGPYG%"ri'VM 
Pflppi  (1)  . 
VLI,  TZFEPFDQD  PVMPSWEAVIRQLDQLGSVK1  VAR  R  LPCAFATAGECLTRI,  I  DE  IJ  I  PAMV  I  ATGI,  G  PGR:: 
PfUPPI  (1)  VL%'TEFEPFGGI,:  KII,  7WP'1'1-:  RIAKDLDKIGDAQVFGRVLPVVFGKAKEVLEK'rLEI-:  IKPI)IiýllIVGIAIIGRý; 
RsoPPI  (1)  VLITVWIEPFESLýlý-,  'MPS'ý,  'DIARALDRIDGATLVARQLPCVFGRANRELVAAIEA'I'QP!;  LVI.  AI,  GlA!;  GR:: 
SauPPI  (1)  ILVTZFAPFDN,  ýl)IIPSWLý:  AVTQLEIIGTHTIDKLKLPTI,;  FKKVDTIINK'rLA,  ")NIIYI)VVI,  AiG(.  )A(;  GRN 
ScePPI  (1)  VLITVFAPFGGI.:  I,  'V2PSeýQ,  ýASLVAPPAGLAVTAAELPCVFGESLDALRDAIRAI)NPI)LVI,  ('I.  G(,  )A(;  GRI, 
SpyppI  (1)  ILI,  'TEFI)PFGGý:  ý,  IMP;  ',  I,  I--AIKKLPTIHGAEIKCIEVPTVFQKSADVLQQtilESI-*QPI)AVI.  ('IG(-)A(;  GRI 
SSOPPI  (1)  VLLFEFEPFLEYý:  1-:  '. TýPSL.,  'QLIVEALNSTLEEVKGVILPVEYEKIEDLIVTKIRI,,  MKPIL'1'1,  (;  IGVAI,  GRA 
TbPPI  (1)  LYlrhVWYGPFLE%"I'E'IPS;,,,  ýIAQSVAVHHELI)VNLEAVSKYFNRLNESV'I'AliLEA'I'liPVLI,  VNVGI,  li!;  FI.:  Fý 
TcPPI  (1)  TWPSAMIGESVSVHYELEVGLEAVSAYFDGI,  EGALAQHMEI)NIII)VL1,1,111GI,  ll:;  Iý1-:  1-:  LYMTZFGPFKS1'1'Vi 
TdePPI  (1)  .  ILVTEFDPFGGI-:  ýýIMPAL,  ETIKLLPEILGAKIIKLEIPTVICKSVAKIKDMIEKENPI)VVI.!;  IGý)A(,  NRA 
TliPPI  (1)  VLITZFFPFGGI)L;  FZP'1'1.:  QIAKYFDQIGNAMVYGRVLPVSVKRATIELKRYliEEIKPI-:  IVINI,  Gli%l"1'%"", 
VVUPPI  (1)  VLL  FEPFGGHs11  !,  G 
. 
WTPSI,  ELVKQMAALPQVEIIGCEVPVVRYQAIETVLQAVE'I'IIQPI)LVI,  Mlafý)A'  RC  ;  I 
XtrPPI  (1)  FGPFGEYITVMASWVAVQELGGLGEVDLHIYEIPVEYQTVQRLIPALRKKIiFPI<VIVII%'G%'ý:  (;  ýl,  \1  V  , 
71  1-1(1 
AthPPI  (71)  K  FA  I  MQQAVNT  IE  FRC  PDE  LGWKPQN  LIP  IV  PSGSTVRKTNLPVE  E  IT  KALE  KING  FEV  III) 
BamPPI  (71)  QITPGRVAINLEDARIPDNEGNQPVGEDISQGGPAAYWT(,  LPIKRIVEEIKKFGlrjl,,  'I'ý"I'ATFI.  ',  SNI(! 
CelPPI  (71)  ý.  ý!  )Ip,  :i  TIKFMQQAFSVNGYCSNDVNGCTPADNKTSCSSi4ETLVSCINCI)I.  'I,  V'FKVTEK(';  ý\1,  I)i; 
CpePPI  (71) 
l 
GVTPMRVAINMDDARIEDNEGNQPIDISIYEDGESAYFSNLPIKAMVKI.:  MVDNGII,;  ý.  ý-iI  D"'INH, 
CvippI  (71)  lil  -  . Al  DIAVJRVAINV  DARFPDNAGRQPIDEPVVANGPAAYFA'I'LP  I  KAI  VAGLRERC(;  IJ,,  'f-)::  ll 
DmePPI  (71)  . 
f  ý 
CVYIMKLAYNYIIKFRRAI)NDKKLANGTCELPNNANVLKTELDVDKIVAVVNENCAI)(",  'liýýtlý  1ý  I 
GcgaPPI  (71) 
HsPPI  (71) 
IIIL§QCGKNTKGYEEMDACGFHPEGGCCMI,  NGPI.  'F,  IES'rTNMKTIWKNISVEGII)'I'I  1,14,10 
TVT'  KCG  , II  HNTKC3YKGLDNCRFCPGSQCCvý,,  I)Gpi, 
'SjI)SjlDMDAVCKRVTTI, 
GI,  D%'ý;  1,1.1 
LinPPI  (71) 
LmjPPI  (71) 
4,  LIRVIIVQGYNEASVPDVDGKVLNGHEPIVý: 
D(,  VT(,  AVTKNEVTI):  ',  I)ADRKDMAMi,,  'ýiý';, 
LICVMVQGCNESSVPDVDGKV 
'  '  '  LNGHEPIVL4,  AVTNNEVTl;  ADTDRKDMAM  I,  FF  (I  I)GV  I 
MtUppI  (71) 
Pflppi  (71) 
MI  TVIR  LAQNVN  RYG  I,  ADCAGRVLVG  E  PTD  PAC  PVAYHATVPVRAMV  LAMIR  KAG  V  1,1,  ý "  It  ,, '\  rI  1ý'SN  I  I! 
DISVSRVAININDARIPDNLGE 
't 
PfUPPI  (71) 
QPIDTAVVAI)GPAAFF'I"I'LPIKAMVKAVRE 
I- 
AGN  I  A,  ',  l(.  )  I 
AISIMRIAVNAIDARIIIDNEGKKIEDEPIVIIGAP'I'AYI; 
'  '  "I'LIP  I  KK  I  MKK  LHERG  I  PAI 
RSOPPI  (71)  ,  ,  ELS  VIRVAINVI  DARI  PDNAGNQPVDvPVVADG  ,  '  l 
SauPPI  (71) 
PAAyF!,  [,  ;  LP  I  KA  I  ViiALRAAGI,  Vl  .  AITPaRVAINIDDARIPDNDDP'QPIDQAIIII  INW,  S11N  AP(;  Ný:  Arr  1  I)GAI'AYI  -'ý;  NLPVKAMT  GI  *  (71)  ScePPI 
1  Q  ,  Q  ,  GVTVIRVGINVDDARII)DNAGGQPIDEPVVIII)G  Nii' 
ý. 
'ý'  '  -  '  '  '  '  '  ' 
SpyppI  (71) 
71) 
g  PAAYI  I  ,  ,  Iltj!  ý;  ]  VAAMREAG,!  \  Afr  LPVKA( 
GLTPMRVAINQDDARI[IDNEGNQPID'FPIRADGKAAYF 
!;  TLPIKAMVAAlIiQAGI,, 
ý)I-;  ý  IllArri"fill 
KIT  PIK  I  AI  N  '1 
SSOPPI  (  Y  KYSREGDNAGK  KYKG  ,  EK  I  DPLGQI)(,,  I  FTN  I  PV  1-:  1)  1,  Vl)],  I,  NENG  Iv1,  1  ýý:  Aj:;  IZSN;  ýý 
TbPPI  (71)  VLRIIVRAFNELGNPII)DI,  J,  -'[,  PL,  STCKDSAFVKGCK  1,  E71-1-FAL  I  EFI,  NA  I  ERNG!;  N,  )l  III  I 
TcPPI  (71) 
ý, 
KMRIaVCGYNEI,  GSPIL)ý,,  sIPMDVCI,  ESMLVRGCI  "I 
TdePPI  (71) 
TliPPI  (71) 
DISVaR'G'NIDDCRIPDNEGNQPIDEPVVKDGPAAYI-'V'I'LPIKAivl.  -I<vKA(.,,  K  I  ffit4l  I  N1  1'ý  l,  I  '. 
.ý  NIT%73RIAVNl  IDkRIIIDNI)GYQPIDEKIEFL)APIAYMA'I'LPVI  '  '  ' 
:,  II 
VvUppI  (71) 
XtrPPI  (71) 
N"  ý  ýAII  K  I  I,  RDNG  I 
AITPORVAINLI)DYRII-'DNAGIIQPVDEPIIAI'GPAAyý'  -  ';  TLPVKAITfIALQQAGIý)I,  k  W;  AjTF,,  'SNm 
AVT  LJIKCGHNT  IX,  YQýl  I  ZNC  E  FCPGTQCCV  EGG  PI-x,  mIý;  vIDI  DTVCK  R; 
I 
1PA-Sw  3:  1  1 
227 141 
AthPPI  (141) 
BamPPI  (141) 
CelPPI  (141) 
CpePPI  (141) 
CvippI  (140) 
DmePPI  (141) 
GqaPPI  (141) 
HsPPI  (141) 
LinPPI  (141) 
LmjPPI  (141) 
MtUPPI  (141) 
PflppI  (141) 
PfUPPI  (141) 
RsoPPI  (141) 
SauPPI  (141) 
ScePPI  (141) 
SPYPPI  (141) 
SSOPPI  (141) 
TbPPI  (141) 
TcPPI  (141) 
TdePPI  (141) 
TliPPI  (141) 
VVUPPI  (141) 
XtrPPI  (141) 
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Multiple  alignment  of  pyroglutamyl  peptidases  from  various  organisms  (edited 
sequences).  The  Align  X  (Vector  NTI)  program  was  used.  Identical  residues  are  on  block 
background;  conservative  residues  are  on  grey  background.  Cpe,  Clostridiurn  perfringeos 
(GenBank  Accession  No.:  NP  562341);  Spy,  Streptococcus  pyogenes  (NP  268785):  Sau, 
Staphylococcus  aureus  (NP  375809);  Tcle,  Treponema  denticola  (NP  970791)ý  Barn,  Bacillus 
amyloliquefaciens  (JX0244),  Vvu,  Vibrio  vulnificus  (NP  936141),  Sce,  Streptomyces  ceolicor  (NP 
624759);  Rso,  Ralstonia  solanacearum  (NP  520286);  Cvi,  ChromobacteriLI171  violaceum  (NP 
902846);  Pfl,  Pseudomonas  fluorescens  (A55583);  Mtu,  Mycobacterium  tuberculosis  (NP 
334743);  Pfu,  Pyrococcus  furiosis  (NP  579028);  Tlit,  Thermococcus  litoralis  (CAA74299);  Sso, 
Sulfolobus  solfatanicus  (NP  343028);  Ath,  Arabidopsis  thaliana  (NP  173758);  Cel,  Caenorhabdifis 
elegans  (NP  492491);  Dme,  Drosophila  melanogaster  (NP  730035);  Gga,  Gallus  gallus  (NP 
418244);  Hs,  Homo  sapiens  (NP  060182);  Xtr,  Xenopus  tropicalis  (AAH75524);  Lin,  Leishniallia 
infanturn  (GeneDB  CIDS'.  LinJ34.1440)-  Lmj,  Leishmania  major  (GeneDB  CIDS:  LmjF34.200ft  Tb, 
Trypanosoma  brucei  (GeneDB  CIDS:  ýb04.1 
H  19.1350).  Tc,  Trypanosoma  cruzi  (GeneDB  CIDS: 
TcOO.  1047053506635.60). 
jtr  c  228 